← Back to OpenPV
Causality assessment

Drug–Adverse Event Causality Assessment

453 written assessments and a 24-row extended scan

Your pair not here? Sponsor an assessment from $9 — an AI research agent drafts the Bradford Hill card, every citation is machine-verified, and the page publishes for everyone. Or use the free case worksheet.

How this list was built, and how to read a card
How this list was built. OpenPV flags disproportionality signals (PRR/ROR) across roughly 3,600 drugs — about 1.3 million drug–reaction pairs in total. An initial pass hand-picked six textbook-famous examples. This revision widened the net: a systematic scan kept only signal-flagged pairs with at least 30 reports and PRR ≥ 5 (loosened from "famous enough to already know" to "statistically real and large enough to investigate"), after excluding obviously administrative, lab-monitoring, or vague MedDRA terms. That scan surfaces roughly 136,000 candidate pairs — the overwhelming majority of them circular (a drug's own indication or named syndrome reported back as its "reaction"), confounded, or otherwise not independently meaningful. The 453 pairs below are the ones, drawn from that wider pool, with an established regulatory history (an FDA label warning, a REMS program, a market withdrawal, or a black-box warning added or removed) independent of this site's own statistics — so each causality grade reflects published literature and regulatory action, with this dataset's own PRR/ROR/report counts shown for context, not as the basis for the grade. A disproportionality signal alone is never sufficient to establish causation, and loosening the statistical threshold did not loosen the evidentiary bar for inclusion. A second batch of 20 full write-ups was added later, then a third batch of 20, then a fourth batch of 100, then a fifth batch of 100, then a sixth batch of 100, and most recently a seventh batch of 100.
Bradford Hill viewpoints. Each card below carries a Bradford Hill table scoring Sir Austin Bradford Hill's nine classic 1965 viewpoints for judging causation from an observed association: temporality (the only one Hill considered strictly necessary), strength, consistency, specificity, biological gradient, plausibility, coherence, experiment, and analogy. These tables are this page's own qualitative read of the literature cited in each card, not a computed or citation-gated output. This site's vaccine evidence dossiers (see evidence-dossiers/) run a separate, far more rigorous process for a smaller set of vaccine–event pairs: a 68-node evidence matrix where every node is backed by a logged PubMed query, a timestamped run date, and per-citation machine classification (supports / refutes / ambiguous), with the Hill table and claim matrix computed from that node data rather than hand-set. Nothing on this page has been through that pipeline. Hill's own framework is explicit that these are "viewpoints," not a checklist that adds up to proof — and that framing applies doubly here, where the grading is editorial.
Trial evidence (ClinicalTrials.gov). FAERS and VAERS-style passive reports never carry a denominator or a comparator arm — a report count alone can't say whether an event is more common on the drug than off it. Where a relevant trial has posted results on ClinicalTrials.gov (required for most Phase 2+ drug trials registered since 2008, under FDAAA 801), this page now pulls the actual per-arm event table from that trial's structured Results/AdverseEvents data via the public API: real enrollment counts, real affected-vs-at-risk numbers, by arm. This was run for the original 13 full write-ups and, later, for a second batch of 20, a third batch of 20, a fourth batch of 100, a fifth batch of 100, a sixth batch of 100, and a seventh batch of 100. It found usable data for 5; for 3 (metoclopramide, clozapine, ciprofloxacin) no trial in the top search results captured the relevant term at all — itself informative, since tardive dyskinesia, agranulocytosis, and tendon rupture are each either slow to develop (months–years of exposure) or too rare to show up in a typical trial's size and follow-up window, which is exactly why they were caught by post-marketing surveillance instead. The other 2 (ranitidine, thalidomide) were not searched, because neither signal is something a trial's adverse-event table could show in principle: ranitidine's cancer signal is a manufacturing contaminant unrelated to the drug's own pharmacology, and thalidomide's hCG pairing is a monitoring-protocol artifact, not a biological effect of the drug at all. The second batch of 20 was run the same way: 7 of them returned a usable per-arm trial table (denosumab/ONJ, drospirenone/DVT, capecitabine/hand-foot syndrome, risperidone/weight gain, docetaxel/alopecia, rituximab/infection, and warfarin/INR); the remainder were searched with no relevant term, were not applicable in principle (slow-growing tumors; a device "foreign body" term), or were not separately searched. Coverage here is a pilot across these 453 pairs, not a claim about ClinicalTrials.gov coverage for the other ~3,600 drugs in this dataset. The fourth batch of 100 full write-ups was searched the same way and returned usable per-arm trial tables for 17 of them, and the fifth batch of 100 returned usable per-arm trial tables for 59 of them, and the sixth batch of 100 returned usable per-arm trial tables for 37 of them, and the seventh batch of 100 returned usable per-arm trial tables for 37 of them, and the seventh batch of 100 returned usable per-arm trial tables for 37 of them, and the seventh batch of 100 returned usable per-arm trial tables for 37 of them. Where an earlier batch has no table, the search found no relevant term, or the event was not something a trial table could show. The seventh batch of 100 does not yet include a ClinicalTrials.gov per-arm table.
Causality: well established

Metoclopramide ↔ Tardive dyskinesia

Open this assessment on its own page →

n=13,206 co-reports · PRR 335.0 · ROR 441.6 Dyskinesia (related term): n=2,561 · PRR 25.8

Reporting over time (stimulated-reporting check)

2004: 1 reports (0.16% of the drug's reports)2005: 12 reports (1.88% of the drug's reports)2006: 4 reports (0.66% of the drug's reports)2007: 14 reports (2.44% of the drug's reports)2008: 19 reports (2.59% of the drug's reports)2009: 18 reports (1.98% of the drug's reports)2010: 606 reports (35.21% of the drug's reports)2011: 7,370 reports (79.37% of the drug's reports)2012: 4,593 reports (73.04% of the drug's reports)2013: 426 reports (23.88% of the drug's reports)2014: 37 reports (2.59% of the drug's reports)2015: 21 reports (1.21% of the drug's reports)2016: 10 reports (0.50% of the drug's reports)2017: 7 reports (0.41% of the drug's reports)2018: 1 reports (0.04% of the drug's reports)2019: 9 reports (0.29% of the drug's reports)2020: 9 reports (0.30% of the drug's reports)2021: 6 reports (0.18% of the drug's reports)2022: 20 reports (0.63% of the drug's reports)2023: 10 reports (0.35% of the drug's reports)2024: 9 reports (0.35% of the drug's reports)2025: 3 reports (0.12% of the drug's reports)FDA boxed warning for tardive dyskinesia (2009)05081114172023

Reporting spiked in 2010, 2011, 2012, 2013 — 91% of all 13,205 reports arrived in two years (2011–2012). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Dashed lines: 2009 — FDA boxed warning for tardive dyskinesia

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

This is the single largest PRR among the pairs on this page, and the underlying mechanism is textbook: metoclopramide is a dopamine D2-receptor antagonist, the same pharmacological class responsible for antipsychotic-induced tardive dyskinesia. FDA's 2009 boxed-warning decision followed continued spontaneous reports concentrated in patients who had taken the drug for more than 3 months, and published analyses since have identified metoclopramide as the single most common cause of drug-induced movement disorders overall — not just among gastric-motility agents, but across all drug classes. Risk rises sharply with treatment duration and cumulative dose, which is why the boxed warning specifically limits use beyond 12 weeks except in rare cases. This is one of the best mechanistically-understood adverse drug reactions in this dataset — a predictable, class-wide, dose/duration-dependent effect, not merely a statistical coincidence.

Regulatory basis: FDA boxed warning (2009), metoclopramide prescribing information.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOnset after months–years of cumulative dosing, consistent with the mechanism
StrengthmetPRR 335, one of the largest on this page
ConsistencymetReplicated across decades, same pattern as other D2 antagonists
SpecificitypartialNot unique to metoclopramide — shared across the D2-antagonist class
Biological gradientmetRisk rises with treatment duration/cumulative dose
PlausibilitymetD2 receptor antagonism — same mechanism as antipsychotic-induced TD
CoherencemetFits established class pharmacology
Experimentpartial12-week duration limit (boxed warning) functions as a real-world exposure-reduction intervention; not an RCT
AnalogymetDirect analogy to antipsychotic-induced tardive dyskinesia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top 15 search hits for metoclopramide captured tardive dyskinesia or a related extrapyramidal term as a tracked adverse event. Consistent with the mechanism: TD typically takes months of cumulative dosing to emerge, longer than most registered trials run or enroll enough patients to catch — which is exactly why this signal was identified through decades of post-marketing surveillance, not a trial.
Causality: well established

Clozapine ↔ Agranulocytosis / severe neutropenia

Open this assessment on its own page →

Agranulocytosis: n=2,074 · PRR 21.1 · ROR 21.5 Neutropenia: n=18,898 · PRR 27.1 · ROR 31.8

Reporting over time (stimulated-reporting check)

2004: 41 reports (2.40% of the drug's reports)2005: 37 reports (2.33% of the drug's reports)2006: 68 reports (2.78% of the drug's reports)2007: 24 reports (2.60% of the drug's reports)2008: 23 reports (2.47% of the drug's reports)2009: 33 reports (1.65% of the drug's reports)2010: 38 reports (1.32% of the drug's reports)2011: 99 reports (1.76% of the drug's reports)2012: 102 reports (2.44% of the drug's reports)2013: 41 reports (1.36% of the drug's reports)2014: 42 reports (1.24% of the drug's reports)2015: 68 reports (1.63% of the drug's reports)2016: 137 reports (3.02% of the drug's reports)2017: 148 reports (2.03% of the drug's reports)2018: 201 reports (2.95% of the drug's reports)2019: 179 reports (2.40% of the drug's reports)2020: 66 reports (0.82% of the drug's reports)2021: 75 reports (1.02% of the drug's reports)2022: 67 reports (0.48% of the drug's reports)2023: 339 reports (2.58% of the drug's reports)2024: 85 reports (0.73% of the drug's reports)2025: 134 reports (1.62% of the drug's reports)05081114172023

No reporting spike: the pair's share of the drug's reports is fairly stable over time (busiest two years hold 21% of 2,047 reports), so stimulated reporting is unlikely to explain the signal.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

Clozapine-induced agranulocytosis is arguably the most consequential single adverse-drug-reaction discovery in modern psychiatry: it is the reason clozapine, despite being one of the most effective antipsychotics for treatment-resistant schizophrenia, can only be dispensed in the U.S. through a mandatory REMS program requiring regular absolute neutrophil count (ANC) monitoring for the life of the prescription — weekly for the first 6 months, biweekly for the next 6, then monthly if counts stay in range. Reported incidence is 1–2% of patients, overwhelmingly concentrated in the first 6 months of therapy, which is itself a form of temporal and dose-independent specificity (the event is a sudden, often zero-count crash, not a gradual dose-related decline). The mechanism remains formally unresolved — proposed as an idiosyncratic, likely immune-mediated toxic effect on bone marrow myeloid precursors or their progenitors — but the monitoring program's mandatory, indefinite existence is itself regulators' institutional verdict that the causal link is settled, not merely a statistical association.

Regulatory basis: Clozapine REMS program (mandatory ANC monitoring); clozapine prescribing information.

Bradford Hill viewpointStatusNote
Temporality (necessary)metRisk overwhelmingly concentrated in the first 6 months — a well-characterized window
StrengthmetPRR 21–27
ConsistencymetReplicated across countries and registries for decades
SpecificitymetRisk is unusually high for clozapine among antipsychotics specifically
Biological gradientpartialIdiosyncratic reaction; not clearly dose-dependent the way the TD example above is
PlausibilitymetProposed immune-mediated bone-marrow toxicity mechanism
CoherencemetConsistent with a myeloid-toxicity pattern
ExperimentmetMandatory ANC monitoring (REMS) demonstrably reduces fatal outcomes — a real-world intervention
AnalogypartialOther drugs (older antipsychotics, antithyroid agents) also cause agranulocytosis, but at lower rates

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top 15 search hits for clozapine captured agranulocytosis or neutropenia at a usable rate. Not surprising: this is exactly the signal the mandatory ANC-monitoring REMS program exists to catch in ongoing real-world use, not something most individual registered trials are sized or designed to surface in their own AE tables.
Causality: well established

Ciprofloxacin (fluoroquinolones) ↔ Tendon rupture / tendinitis

Open this assessment on its own page →

Tendon rupture: n=1,254 · PRR 25.8 · ROR 26.2 Tendonitis: n=2,198 · PRR 37.7 · ROR 38.6

Reporting over time (stimulated-reporting check)

2004: 6 reports (0.61% of the drug's reports)2005: 9 reports (0.85% of the drug's reports)2006: 21 reports (1.67% of the drug's reports)2007: 24 reports (1.96% of the drug's reports)2008: 72 reports (4.14% of the drug's reports)2009: 41 reports (2.23% of the drug's reports)2010: 82 reports (3.76% of the drug's reports)2011: 139 reports (4.28% of the drug's reports)2012: 55 reports (1.86% of the drug's reports)2013: 39 reports (1.25% of the drug's reports)2014: 36 reports (1.04% of the drug's reports)2015: 74 reports (1.55% of the drug's reports)2016: 94 reports (1.38% of the drug's reports)2017: 62 reports (1.13% of the drug's reports)2018: 105 reports (1.33% of the drug's reports)2019: 109 reports (1.15% of the drug's reports)2020: 45 reports (0.65% of the drug's reports)2021: 60 reports (0.96% of the drug's reports)2022: 27 reports (0.56% of the drug's reports)2023: 48 reports (0.94% of the drug's reports)2024: 46 reports (0.97% of the drug's reports)2025: 49 reports (1.18% of the drug's reports)FDA boxed warning, tendinitis/tendon rupture (2008)FDA strengthens fluoroquinolone warnings (2016)05081114172023

Reporting spiked in 2008, 2010, 2011 — 18% of all 1,243 reports arrived in two years (2010–2011). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Dashed lines: 2008 — FDA boxed warning, tendinitis/tendon rupture; 2016 — FDA strengthens fluoroquinolone warnings

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

Fluoroquinolone-associated tendinopathy, most notoriously Achilles tendon rupture, carries an FDA boxed warning since 2008 that applies class-wide, not just to ciprofloxacin. This is one of the more mechanistically dense entries on this page: at least five distinct pathways have been proposed and partly confirmed in vitro, not just one. Ciprofloxacin upregulates matrix metalloproteinase-3 in tendon-derived cells while suppressing tenocyte proliferation and migration (via reduced FAK phosphorylation), directly degrading and under-replacing collagen. Separately, fluoroquinolones chelate magnesium and iron, cofactors tendon cells need to hydroxylate proline residues during collagen maturation — chelation leaves collagen fibers under-cross-linked and mechanically weaker, the same chelation chemistry responsible for the well-known interaction with magnesium-containing antacids. A third pathway implicates fluoroquinolone-driven reactive oxygen species production in tenocyte mitochondria. Clinical risk factors are well replicated across independent studies: age over 60, concurrent corticosteroid use, and solid-organ transplant history all multiply risk. This is a case where a drug class effect was identified, mechanistically investigated from multiple independent angles, and confirmed beyond spontaneous reports alone.

Regulatory basis: FDA boxed warning for tendinitis/tendon rupture (2008); fluoroquinolone class labeling, with further systemic safety-label restrictions added in 2016. Mechanism review: PMC4080593.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOnset typically within days to weeks of exposure
StrengthmetPRR 26–38
ConsistencymetClass-wide, replicated across multiple countries
SpecificitypartialClass effect, not unique to ciprofloxacin
Biological gradientpartialRisk factors (age, steroids, transplant) modify risk; no clean dose-response shown
PlausibilitymetMagnesium chelation / MMP activation, with supporting in-vitro and animal evidence
CoherencemetFits the broader fluoroquinolone connective-tissue toxicity pattern
Experimentnot establishedNo RCT withdrawal/rechallenge data
AnalogymetAnalogous to other fluoroquinolone connective-tissue signals (e.g. aortic dissection)

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top 15 search hits for ciprofloxacin captured tendon rupture or tendinitis. Consistent with the mechanism described above: the known risk factors (age over 60, concurrent steroids, transplant history) concentrate the real risk in an older, comorbid population not well represented in many registered trials, and the event is idiosyncratic enough that large real-world exposure, not a typical trial's size, is what caught it.
Causality: well established

Ranitidine (Zantac) ↔ Cancer (breast, prostate, bladder, colorectal, renal)

Open this assessment on its own page →

Breast cancer: n=24,854 · PRR 37.9 Prostate cancer: n=22,252 · PRR 39.8 Colorectal cancer: n=17,674 · PRR 61.0 Bladder cancer: n=16,746 · PRR 41.3 Renal cancer: n=16,278 · PRR 53.9

Reporting over time (stimulated-reporting check)

2004: 0 reports (0.00% of the drug's reports)2005: 5 reports (0.42% of the drug's reports)2006: 3 reports (0.26% of the drug's reports)2007: 6 reports (0.71% of the drug's reports)2008: 1 reports (0.10% of the drug's reports)2009: 11 reports (0.75% of the drug's reports)2010: 4 reports (0.24% of the drug's reports)2011: 6 reports (0.33% of the drug's reports)2012: 12 reports (0.47% of the drug's reports)2013: 5 reports (0.20% of the drug's reports)2014: 81 reports (2.55% of the drug's reports)2015: 11 reports (0.25% of the drug's reports)2016: 14 reports (0.27% of the drug's reports)2017: 13 reports (0.25% of the drug's reports)2018: 13 reports (0.17% of the drug's reports)2019: 25 reports (0.26% of the drug's reports)2020: 2,816 reports (13.59% of the drug's reports)2021: 36,472 reports (37.51% of the drug's reports)2022: 7,421 reports (40.34% of the drug's reports)2023: 155 reports (1.92% of the drug's reports)2024: 16 reports (1.26% of the drug's reports)2025: 15 reports (1.46% of the drug's reports)FDA NDMA contamination alert (2019)FDA requests market withdrawal (2020)05081114172023

Reporting spiked in 2014, 2020, 2021, 2022, 2023 — 93% of all 47,105 reports arrived in two years (2021–2022). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Dashed lines: 2019 — FDA NDMA contamination alert; 2020 — FDA requests market withdrawal

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

This is the clearest "mechanism, not mystery" entry on this page. Ranitidine itself is not believed to cause cancer; the problem was contamination. In 2019–2020, independent and FDA laboratory testing found that ranitidine can degrade — especially under heat or over time in storage — into NDMA (N-nitrosodimethylamine), a compound classified as a probable human carcinogen based on animal studies. The elevated cancer signals across multiple unrelated organ systems in this dataset (breast, prostate, colorectal, bladder, renal all flagged independently) is exactly the pattern a systemic carcinogen contaminant would produce, rather than the organ-specific pattern a drug's own pharmacology usually leaves. FDA requested market withdrawal of all ranitidine products in the U.S. in April 2020. This is a textbook example of a real, serious, and ultimately regulatory-confirmed signal — but the causal agent was a manufacturing/stability impurity, not ranitidine's intended pharmacological action.

Regulatory basis: FDA market withdrawal request for all ranitidine products (April 2020), citing NDMA contamination.

Bradford Hill viewpointStatusNote
Temporality (necessary)metLong-term use before diagnosis fits carcinogen-latency expectations
StrengthpartialEach organ-specific PRR (38–61) is moderate alone; the real strength is the cross-organ pattern
ConsistencymetReplicated across 5 independent organ sites in this dataset
Specificitynot establishedDeliberately so: the carcinogen is a contaminant, not ranitidine's own pharmacology — a multi-organ pattern is the expected signature of a contaminant, not a specific drug effect
Biological gradientmetFDA found contamination increased with storage time and heat
PlausibilitymetNDMA is an IARC/EPA-classified probable carcinogen; degradation chemistry independently confirmed
CoherencemetMulti-organ pattern coheres with systemic contaminant exposure, not with H2-blocker pharmacology
ExperimentmetMarket withdrawal (2020) is the real-world exposure-removal intervention
AnalogymetAnalogous to other nitrosamine-contamination recalls in the same period (valsartan, metformin ER)

This page's own qualitative read, not an automated/citation-gated assessment.

Not searched in ClinicalTrials.gov. A contaminant's cancer risk isn't a property of ranitidine's own pharmacology that a drug trial's AE table could ever have been designed to detect — it would only show up if a trial happened to use contaminated stock and ran long enough to catch a cancer signal, which is not how carcinogen exposures are identified or how this one actually was identified (lab testing of the product itself).
Causality: well established

Oxycodone ↔ Drug dependence / withdrawal syndrome

Open this assessment on its own page →

Drug dependence: n=100,436 · PRR 158.4 · ROR 295.3 Drug withdrawal syndrome: n=36,964 · PRR 69.3

Reporting over time (stimulated-reporting check)

2004: 650 reports (17.09% of the drug's reports)2005: 694 reports (21.96% of the drug's reports)2006: 176 reports (10.82% of the drug's reports)2007: 659 reports (26.27% of the drug's reports)2008: 154 reports (9.45% of the drug's reports)2009: 94 reports (5.54% of the drug's reports)2010: 95 reports (3.25% of the drug's reports)2011: 112 reports (4.06% of the drug's reports)2012: 62 reports (2.06% of the drug's reports)2013: 88 reports (3.12% of the drug's reports)2014: 137 reports (3.75% of the drug's reports)2015: 170 reports (3.36% of the drug's reports)2016: 280 reports (4.52% of the drug's reports)2017: 275 reports (3.68% of the drug's reports)2018: 1,231 reports (4.34% of the drug's reports)2019: 415 reports (6.94% of the drug's reports)2020: 16,989 reports (66.42% of the drug's reports)2021: 46,526 reports (86.13% of the drug's reports)2022: 29,807 reports (85.43% of the drug's reports)2023: 1,034 reports (17.07% of the drug's reports)2024: 277 reports (5.59% of the drug's reports)2025: 382 reports (7.18% of the drug's reports)05081114172023

Reporting spiked in 2004, 2005, 2007, 2020, 2021, 2022, 2023 — 76% of all 100,307 reports arrived in two years (2021–2022). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

The largest report volume of any pair on this page, and the least scientifically contested: oxycodone is a full mu-opioid receptor agonist, and physical dependence and withdrawal on cessation are expected, dose- and duration-related pharmacological effects of that mechanism, not an idiosyncratic reaction. This pair is included less because it is surprising and more because its sheer scale in this dataset (over 100,000 co-reports) is itself a public-health data point, central to the opioid-crisis regulatory response, including REMS requirements for opioid analgesics and prescribing-guideline changes from CDC.

Regulatory basis: opioid analgesic REMS program; CDC clinical practice guideline for prescribing opioids.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDependence develops over the course of exposure, before withdrawal is observed on cessation
StrengthmetPRR 158
ConsistencymetReplicated across every opioid in the class
SpecificitypartialOpioid class effect, not specific to oxycodone
Biological gradientmetTextbook dose/duration dependence
PlausibilitymetMu-opioid receptor mechanism, among the best-characterized in pharmacology
CoherencemetFits the entire opioid pharmacology literature
ExperimentmetReduced prescribing volume demonstrably reduces new dependence at the population level
AnalogymetDirect analogy across the entire opioid class

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top 15 search hits for oxycodone tracked dependence or withdrawal syndrome as a formal adverse-event term. Most registered oxycodone trials are short-duration analgesia studies not designed or powered to capture dependence, which develops over sustained use — the evidence base for this pairing is epidemiological and clinical (prescribing-pattern and REMS data), not trial AE tables.
Causality: well established

Risperidone ↔ Gynaecomastia

Open this assessment on its own page →

n=24,650 · PRR 614.0 · ROR 754.5

Reporting over time (stimulated-reporting check)

2004: 4 reports (0.18% of the drug's reports)2005: 2 reports (0.09% of the drug's reports)2006: 10 reports (0.38% of the drug's reports)2007: 8 reports (0.33% of the drug's reports)2008: 9 reports (0.36% of the drug's reports)2009: 6 reports (0.14% of the drug's reports)2010: 13 reports (0.32% of the drug's reports)2011: 24 reports (0.58% of the drug's reports)2012: 36 reports (0.87% of the drug's reports)2013: 68 reports (2.03% of the drug's reports)2014: 949 reports (21.31% of the drug's reports)2015: 6,394 reports (41.84% of the drug's reports)2016: 6,150 reports (42.60% of the drug's reports)2017: 6,494 reports (47.18% of the drug's reports)2018: 858 reports (11.82% of the drug's reports)2019: 1,670 reports (20.60% of the drug's reports)2020: 797 reports (12.35% of the drug's reports)2021: 241 reports (4.59% of the drug's reports)2022: 205 reports (3.57% of the drug's reports)2023: 254 reports (4.77% of the drug's reports)2024: 220 reports (3.90% of the drug's reports)2025: 196 reports (3.83% of the drug's reports)05081114172023

Reporting spiked in 2014, 2015, 2016, 2017, 2018, 2019, 2020 — 51% of all 24,608 reports arrived in two years (2016–2017). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

One of the largest PRR values on this page that is not circular or a coding artifact. Risperidone raises prolactin more than most other second-generation antipsychotics because, unlike many of its peers, it does not readily cross back out of the pituitary once it blocks dopamine D2 receptors there. Elevated prolactin drives breast tissue growth in males (gynecomastia) and galactorrhea in both sexes. This dose-related, mechanistically direct, and well-replicated across independent case series and the prescribing information itself.

Regulatory basis: risperidone prescribing information (hyperprolactinemia warning).

Bradford Hill viewpointStatusNote
Temporality (necessary)metDevelops over weeks–months of exposure
StrengthmetPRR 614, one of the largest non-circular pairs on this page
ConsistencymetReplicated across many independent case series
SpecificitymetNotably higher than most other second-generation antipsychotics
Biological gradientmetCorrelates with serum prolactin level
PlausibilitymetRisperidone's limited blood–brain-barrier efflux keeps pituitary D2 blockade high — a well-described PK mechanism
CoherencemetFits known antipsychotic prolactin pharmacology
ExperimentpartialSwitching to a prolactin-sparing agent reduces symptoms in practice; not a dedicated RCT
AnalogymetDirect analogy to other prolactin-raising antipsychotics, at lower magnitude

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — relapse-prevention comparison trial (NCT00216476), N=711, 3 arms

Event (precursor lab finding)Risperidone LAI (n=329)Quetiapine (n=337)Aripiprazole (n=45)
Hyperprolactinaemia43 (13.1%)5 (1.5%)0 (0%)

The trial term is hyperprolactinaemia (the lab/mechanistic precursor), not gynaecomastia itself (the downstream clinical consequence this card's FAERS numbers track) — but the pattern directly confirms the mechanism: risperidone raised prolactin in roughly 1 in 8 patients, nearly 9× quetiapine's rate and far above aripiprazole's. View on ClinicalTrials.gov →

Causality: well established

TNF-inhibitors (adalimumab) ↔ Drug-induced lupus

Open this assessment on its own page →

Adalimumab ↔ Systemic lupus erythematosus: n=13,702 · PRR 18.4

Reporting over time (stimulated-reporting check)

2004: 9 reports (0.15% of the drug's reports)2005: 8 reports (0.15% of the drug's reports)2006: 4 reports (0.27% of the drug's reports)2007: 7 reports (0.18% of the drug's reports)2008: 33 reports (0.27% of the drug's reports)2009: 17 reports (0.09% of the drug's reports)2010: 21 reports (0.23% of the drug's reports)2011: 56 reports (0.29% of the drug's reports)2012: 76 reports (0.28% of the drug's reports)2013: 72 reports (0.30% of the drug's reports)2014: 108 reports (0.22% of the drug's reports)2015: 126 reports (0.24% of the drug's reports)2016: 126 reports (0.15% of the drug's reports)2017: 136 reports (0.37% of the drug's reports)2018: 113 reports (0.27% of the drug's reports)2019: 113 reports (0.25% of the drug's reports)2020: 124 reports (0.26% of the drug's reports)2021: 140 reports (0.36% of the drug's reports)2022: 227 reports (0.29% of the drug's reports)2023: 198 reports (0.48% of the drug's reports)2024: 335 reports (1.24% of the drug's reports)2025: 289 reports (1.37% of the drug's reports)05081114172023

Reporting spiked in 2024, 2025 — 27% of all 2,338 reports arrived in two years (2024–2025). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

TNF-alpha inhibitors (adalimumab, infliximab, etanercept) are well documented in the rheumatology literature to induce a lupus-like syndrome, with clinically evident cases in roughly 0.2% of treated patients across the class — strikingly close to this dataset's own trial-derived rate for adalimumab specifically (see the trial box below). Published reviews put infliximab and etanercept ahead of adalimumab in how often they trigger antinuclear/anti-dsDNA antibody formation, so adalimumab is, if anything, a conservative example of a class-wide effect rather than its worst case. Onset is typically around 11 months into therapy (joint and skin manifestations predominate: malar/annular rash, arthralgia, sometimes myositis), and symptoms resolve over three weeks to six months after the drug is stopped — a real dechallenge pattern, not instant, but documented. This is a recognized, labeled class effect, not specific to adalimumab.

Regulatory basis: TNF-inhibitor class labeling (autoimmunity/lupus-like reactions warning). Anti-TNF-α-induced lupus, review: PMC6852950.

Bradford Hill viewpointStatusNote
Temporality (necessary)metTypically emerges after months of therapy
StrengthpartialPRR 18.4, moderate
ConsistencymetReplicated class-wide (adalimumab, infliximab, etanercept)
SpecificitypartialClass effect
Biological gradientnot establishedNo clear dose-response demonstrated
PlausibilitymetAnti-dsDNA / anti-histone antibody induction is documented
CoherencemetFits known TNF-inhibitor immunology
ExperimentmetSymptoms resolve after stopping the drug (dechallenge) — the most direct evidence on this page short of a trial
AnalogymetClassic "drug-induced lupus" category shared with older drugs (hydralazine, procainamide)

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — long-term Humira registry (NCT00524537), N=5,025

EventAdalimumab (n=5,025)
Lupus-like syndrome (any)11 (0.22%)
Systemic lupus erythematosus9 (0.18%)
Cutaneous lupus erythematosus1 (0.02%)

A single-arm long-term registry (no placebo comparator), but with a real denominator across 5,025 patients — direct evidence the event genuinely occurs at a low but non-zero, quantifiable rate under real-world adalimumab use, independent of FAERS's passive-report counting. View on ClinicalTrials.gov →

Causality: well established

Erythropoiesis-stimulating agents (darbepoetin alfa) ↔ Mortality / cardiovascular risk

Open this assessment on its own page →

Darbepoetin alfa ↔ Death: n=16,130 · PRR 7.5 · ROR 10.2

Reporting over time (stimulated-reporting check)

2004: 6 reports (1.20% of the drug's reports)2005: 7 reports (1.10% of the drug's reports)2006: 21 reports (2.25% of the drug's reports)2007: 42 reports (4.49% of the drug's reports)2008: 21 reports (2.44% of the drug's reports)2009: 31 reports (3.39% of the drug's reports)2010: 57 reports (6.10% of the drug's reports)2011: 88 reports (8.22% of the drug's reports)2012: 527 reports (31.33% of the drug's reports)2013: 387 reports (25.20% of the drug's reports)2014: 3,547 reports (61.67% of the drug's reports)2015: 2,851 reports (44.19% of the drug's reports)2016: 2,855 reports (41.70% of the drug's reports)2017: 2,623 reports (37.14% of the drug's reports)2018: 1,228 reports (27.83% of the drug's reports)2019: 62 reports (4.08% of the drug's reports)2020: 132 reports (7.86% of the drug's reports)2021: 138 reports (8.65% of the drug's reports)2022: 165 reports (10.25% of the drug's reports)2023: 435 reports (18.41% of the drug's reports)2024: 356 reports (17.84% of the drug's reports)2025: 286 reports (19.94% of the drug's reports)05081114172023

Reporting spiked in 2012, 2014, 2015, 2016, 2017, 2018 — 40% of all 15,865 reports arrived in two years (2014–2015). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

Unlike most entries on this page, the darbepoetin/death signal is backed by dedicated randomized controlled trials, not just spontaneous reports. The CHOIR trial (hemoglobin targets in chronic kidney disease, NEJM 2006) and the TREAT trial (darbepoetin alfa specifically, NEJM 2009) both found that targeting higher hemoglobin levels with an ESA increased cardiovascular events (including stroke, in TREAT) without a clear survival benefit, and ESAs also carry a labeled warning about shortened survival and faster tumor progression when used in certain cancer patients. FDA added a boxed warning and, for a period, required participation in a dedicated REMS program (ESA APPRISE) before this evolved into label-based risk communication. The raw "Death" PT in FAERS is non-specific, but the underlying causal story here is unusually well controlled compared to most of this page.

Regulatory basis: FDA boxed warning for ESAs; Pfeffer MA, et al. (TREAT). N Engl J Med. 2009;361(21):2019–2032; Singh AK, et al. (CHOIR). N Engl J Med. 2006;355(20):2085–2098.

Bradford Hill viewpointStatusNote
Temporality (necessary)metEstablished by prospective randomized-trial design, not just spontaneous-report timing
StrengthmetStatistically significant within randomized trials — the gold-standard strength tier
ConsistencymetReplicated independently across CHOIR and TREAT
SpecificitypartialEffect concentrated in the higher-hemoglobin-target strategy, not ESA exposure alone
Biological gradientmetRisk tracked with hemoglobin target/dose achieved
PlausibilitymetThrombosis/vascular mechanism proposed for higher-hemoglobin-driven events
CoherencemetFits known hematologic/vascular physiology
ExperimentmetThis is the experiment — the strongest evidence tier on this entire page
AnalogypartialLoosely analogous to other "more aggressive lab-value target = more harm" trial findings (e.g. tight glycemic control)

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — TREAT (NCT00093015), N=4,038, placebo-controlled

Serious eventDarbepoetin alfa (n=2,004)Placebo (n=2,019)
Death (all-cause)3938
Haemorrhagic stroke41
Ischaemic stroke64
Sudden death / sudden cardiac death1313

This refines the prose above: in TREAT's own numbers, all-cause death was essentially identical between arms (39 vs. 38 of ~2,000) — the trial's real finding was concentrated in stroke risk (haemorrhagic stroke 4× more common on darbepoetin), not raw mortality. The FAERS "Death" PT at the top of this card is a blunter instrument than this trial's cause-specific breakdown. View on ClinicalTrials.gov →

Causality: well established

Nirmatrelvir/ritonavir (Paxlovid) ↔ COVID-19 recurrence ("Paxlovid rebound")

Open this assessment on its own page →

Disease recurrence: n=20,103 · PRR 285.7 · ROR 455.4 COVID-19: n=22,815 · PRR 57.6

Reporting over time (stimulated-reporting check)

2004: 0 reports (0.00% of the drug's reports)2005: 0 reports (0.00% of the drug's reports)2006: 0 reports (0.00% of the drug's reports)2007: 0 reports (0.00% of the drug's reports)2008: 0 reports (0.00% of the drug's reports)2009: 0 reports (0.00% of the drug's reports)2010: 0 reports (0.00% of the drug's reports)2011: 0 reports (0.00% of the drug's reports)2012: 0 reports (0.00% of the drug's reports)2013: 0 reports (0.00% of the drug's reports)2014: 0 reports (0.00% of the drug's reports)2015: 0 reports (0.00% of the drug's reports)2016: 0 reports (0.00% of the drug's reports)2017: 0 reports (0.00% of the drug's reports)2018: 0 reports (0.00% of the drug's reports)2019: 0 reports (0.00% of the drug's reports)2020: 0 reports (0.00% of the drug's reports)2021: 0 reports (0.00% of the drug's reports)2022: 10,190 reports (37.70% of the drug's reports)2023: 5,540 reports (38.42% of the drug's reports)2024: 3,782 reports (41.83% of the drug's reports)2025: 577 reports (22.12% of the drug's reports)05081114172023

No reporting spike: the pair's share of the drug's reports is fairly stable over time (busiest two years hold 78% of 20,089 reports), so stimulated reporting is unlikely to explain the signal.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

"Paxlovid rebound" — recurrence of COVID-19 symptoms or a positive test 2–8 days after finishing a 5-day nirmatrelvir/ritonavir course, sometimes after testing negative in between — became widely enough recognized that CDC issued a Health Alert Network advisory about it in May 2022. The leading mechanistic explanation is that the drug's antiviral course may be short relative to the time needed to fully clear virus in some patients, allowing a viral (and symptomatic) rebound once the drug is stopped, rather than true reinfection. It is included here as a genuinely well-publicized, real, and mechanistically plausible phenomenon, though the precise frequency and whether it differs meaningfully from the "rebound" some untreated COVID-19 cases also show is still an active area of study.

Regulatory basis: CDC Health Alert Network Advisory 467 (May 24, 2022): rebound reported 2–8 days after recovery, median duration 3 days, not attributed to reinfection or resistance.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDefined 2–8 day post-course window
StrengthmetPRR 285.7 for "disease recurrence"
ConsistencymetWidely replicated; prompted an independent CDC advisory
Specificitynot establishedThe proposed mechanism isn't unique to this drug — likely reflects short antiviral-course length generally
Biological gradientnot establishedNot clearly dose/duration related beyond the fixed 5-day course
PlausibilitymetShort antiviral course relative to viral clearance kinetics is a coherent, published hypothesis
CoherencepartialSome rebound also occurs in untreated patients, complicating a clean causal story
Experimentnot establishedNo RCT designed specifically to test rebound causally
AnalogymetAnalogous to rebound phenomena described with other short-course antivirals

This page's own qualitative read, not an automated/citation-gated assessment.

⚠ Trial evidence found, but doesn't capture rebound — EPIC-HR (NCT04960202), N=2,091

Serious eventNirmatrelvir/ritonavir (n=1,038)Placebo (n=1,053)
COVID-19 (new/recurrent diagnosis)27
COVID-19 pneumonia736

This is a genuine negative result for the specific rebound claim, not a confirmation. EPIC-HR, the pivotal registration trial, shows fewer COVID-19 and pneumonia events on drug than placebo, exactly as expected for an effective antiviral — it doesn't surface a rebound signal at all. That's consistent with the history: rebound was identified afterward, in real-world post-marketing use, not in this trial. It illustrates a real limit of trial AE tables: they can only surface what the trial was watching for, and nobody was specifically coding "symptom rebound 5–10 days after a negative test" as a term when EPIC-HR ran. View on ClinicalTrials.gov →

Signal detected, later overturned by randomized trial

Varenicline (Chantix) ↔ Suicidal ideation / depression

Open this assessment on its own page →

Suicidal ideation: n=218 · PRR 8.3 · ROR 8.5 Depression: n=361 · PRR 5.5 · ROR 5.8

Reporting over time (stimulated-reporting check)

2004: 0 reports (0.00% of the drug's reports)2005: 0 reports (0.00% of the drug's reports)2006: 0 reports (0.00% of the drug's reports)2007: 213 reports (6.77% of the drug's reports)2008: 728 reports (13.04% of the drug's reports)2009: 254 reports (12.53% of the drug's reports)2010: 1,217 reports (4.04% of the drug's reports)2011: 727 reports (11.29% of the drug's reports)2012: 374 reports (5.34% of the drug's reports)2013: 105 reports (3.15% of the drug's reports)2014: 107 reports (2.97% of the drug's reports)2015: 64 reports (2.78% of the drug's reports)2016: 81 reports (3.26% of the drug's reports)2017: 73 reports (2.99% of the drug's reports)2018: 85 reports (3.66% of the drug's reports)2019: 68 reports (2.62% of the drug's reports)2020: 33 reports (1.79% of the drug's reports)2021: 21 reports (1.72% of the drug's reports)2022: 12 reports (1.07% of the drug's reports)2023: 7 reports (1.56% of the drug's reports)2024: 9 reports (2.41% of the drug's reports)2025: 10 reports (1.62% of the drug's reports)FDA boxed warning, neuropsychiatric events (2009)boxed warning removed after EAGLES trial (2016)05081114172023

Reporting spiked in 2008, 2009, 2011 — 46% of all 4,188 reports arrived in two years (2010–2011). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Dashed lines: 2009 — FDA boxed warning, neuropsychiatric events; 2016 — boxed warning removed after EAGLES trial

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

This is the most instructive case on this page precisely because the story has two acts. In 2009, after a wave of post-marketing reports of neuropsychiatric events, FDA added a boxed warning to varenicline for suicidal thoughts and behavior — the kind of signal disproportionality data like this would have supported at the time. But FDA also required the manufacturer to run a large, purpose-built randomized controlled trial (EAGLES, published in The Lancet, 2016) directly comparing varenicline, bupropion, nicotine patch, and placebo for neuropsychiatric safety. EAGLES found no statistically significant increase in moderate-to-severe neuropsychiatric events for varenicline versus placebo, and FDA removed the boxed warning in December 2016. The spontaneous-report signal was real and worth investigating; the controlled trial it motivated did not confirm a causal drug effect at the magnitude first feared. This is the clearest example in this dataset of why a disproportionality signal is a prompt for better-controlled study, not a verdict on its own.

Regulatory basis: FDA boxed warning added 2009, removed December 2016, following the EAGLES trial (Anthenelli RM, et al. Lancet. 2016;387(10037):2507–2520).

Bradford Hill viewpointStatusNote
Temporality (necessary)metMet in the original spontaneous reports
StrengthpartialPRR 5.5–8.3, modest
Consistencynot establishedThe EAGLES RCT did not replicate the signal
Specificitynot established—
Biological gradientnot established—
PlausibilitypartialNicotinic receptor/CNS mechanism proposed but not confirmed
Coherencenot establishedDoesn't fit the larger randomized-trial picture
Experimentnot establishedThe actual experiment (EAGLES) returned a null result — the whole point of this entry
Analogynot established—

Almost every viewpoint looked "met" from spontaneous reports alone in 2009; the actual experiment is what changed the picture. This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — EAGLES (NCT01456936), N=8,058, 4 arms

Serious eventVarenicline (n=2,016)Bupropion (n=2,006)NRT patch (n=2,022)Placebo (n=2,014)
Depression1110
Suicidal ideation2103
Suicide attempt0211
Completed suicide0001
Suicidal behaviour0001

Varenicline's counts are not higher than placebo for any of these five terms — for several, placebo is higher. This is the primary source underneath the "EAGLES found no significant increase" claim in the prose above, not a secondary summary of it. View on ClinicalTrials.gov →

Contested / confounded by indication

Isotretinoin (Accutane) ↔ Depression / suicidal ideation

Open this assessment on its own page →

Depression: n=5,803 · PRR 11.1 · ROR 12.4 Suicidal ideation: n=2,146 · PRR 10.2 · ROR 10.6 Completed suicide: n=264 · PRR 1.3 (not a flagged signal)

Reporting over time (stimulated-reporting check)

2004: 127 reports (12.78% of the drug's reports)2005: 103 reports (9.48% of the drug's reports)2006: 126 reports (10.18% of the drug's reports)2007: 105 reports (8.66% of the drug's reports)2008: 119 reports (7.66% of the drug's reports)2009: 141 reports (12.59% of the drug's reports)2010: 336 reports (21.04% of the drug's reports)2011: 1,136 reports (31.83% of the drug's reports)2012: 1,037 reports (30.51% of the drug's reports)2013: 245 reports (17.39% of the drug's reports)2014: 146 reports (8.12% of the drug's reports)2015: 192 reports (7.75% of the drug's reports)2016: 176 reports (10.12% of the drug's reports)2017: 226 reports (8.88% of the drug's reports)2018: 100 reports (8.73% of the drug's reports)2019: 88 reports (7.32% of the drug's reports)2020: 122 reports (6.60% of the drug's reports)2021: 174 reports (7.00% of the drug's reports)2022: 256 reports (7.45% of the drug's reports)2023: 241 reports (6.90% of the drug's reports)2024: 256 reports (5.84% of the drug's reports)2025: 246 reports (6.46% of the drug's reports)05081114172023

Reporting spiked in 2011, 2012 — 38% of all 5,698 reports arrived in two years (2011–2012). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

Isotretinoin carries a prominent psychiatric warning on its U.S. label, and individual case reports of depression and suicidal ideation following treatment are well documented and plausible (isotretinoin affects retinoid signaling pathways implicated in mood regulation). But the two largest cohort studies on this question directly disagree with each other, and that disagreement is the real story. Jick et al. (2000) followed 7,195 Saskatchewan isotretinoin users and 13,700 acne patients on oral antibiotics (plus a smaller UK cohort), comparing depression/psychosis diagnoses before vs. after exposure, and found relative risks around 1.0 — no detectable excess. Sundström et al., a Swedish registry cohort of 5,756 isotretinoin patients, found the opposite framing of the same question: the standardized incidence ratio for attempted suicide was already elevated in the year before treatment started (SIR 1.57 for all attempts), not just during or after it — the single clearest documented instance of the confounding-by-indication pattern this grade is built on (people with the most psychologically distressing acne are the ones referred for isotretinoin in the first place). Note also that completed suicide specifically is not a flagged signal in this dataset (PRR 1.3), which argues against the most severe form of the proposed association, even while the milder mood-symptom signals remain flagged. This page grades it as genuinely contested rather than established in either direction.

Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol. 2000;136(10):1231–1236. PMID 11030769. Sundström A, et al. Association of suicide attempts with acne and treatment with isotretinoin. BMJ. 2010;341:c5812.

Bradford Hill viewpointStatusNote
Temporality (necessary)partialMixed — several studies find depression risk highest before treatment starts
StrengthpartialPRR 10–11, modest
Consistencynot establishedPublished cohort studies disagree with each other
Specificitynot establishedDepression is also elevated in acne patients not on isotretinoin
Biological gradientnot establishedNo consistent dose-response shown
PlausibilitypartialRetinoid-signaling/mood hypothesis proposed, not confirmed
CoherencepartialA competing hypothesis (disease severity, not drug) fits the same data equally well
Experimentnot establishedNo clean dechallenge/rechallenge trial data
Analogynot established—

This page's own qualitative read, not an automated/citation-gated assessment.

✗ A ClinicalTrials.gov search for isotretinoin depression/suicidality data returned only a false-positive match (an unrelated pediatric oncology trial's "depressed level of consciousness," a sedation term, not psychiatric depression) and no genuine isotretinoin psychiatric-outcome trial with posted results in the top hits. Consistent with the contested grade above: isotretinoin's own pivotal trials predate FDAAA 801's 2008 results-reporting requirement, and most published depression/suicidality data for this drug comes from post-marketing cohort studies, not trial AE tables.
Monitoring-protocol artifact, not a drug effect

Thalidomide ↔ Abnormal/increased blood hCG

Open this assessment on its own page →

hCG increased: n=113 · PRR 633.2 hCG abnormal: n=16 · PRR 503.0

Reporting over time (stimulated-reporting check)

2004: 22 reports (0.50% of the drug's reports)2005: 18 reports (0.42% of the drug's reports)2006: 10 reports (1.24% of the drug's reports)2007: 12 reports (1.56% of the drug's reports)2008: 24 reports (1.19% of the drug's reports)2009: 15 reports (1.53% of the drug's reports)2010: 10 reports (1.11% of the drug's reports)2011: 2 reports (0.21% of the drug's reports)2012: 0 reports (0.00% of the drug's reports)2013: 0 reports (0.00% of the drug's reports)2014: 0 reports (0.00% of the drug's reports)2015: 0 reports (0.00% of the drug's reports)2016: 0 reports (0.00% of the drug's reports)2017: 0 reports (0.00% of the drug's reports)2018: 0 reports (0.00% of the drug's reports)2019: 0 reports (0.00% of the drug's reports)2020: 0 reports (0.00% of the drug's reports)2021: 0 reports (0.00% of the drug's reports)2022: 0 reports (0.00% of the drug's reports)2023: 0 reports (0.00% of the drug's reports)2024: 0 reports (0.00% of the drug's reports)2025: 0 reports (0.00% of the drug's reports)05081114172023

No reporting spike: the pair's share of the drug's reports is fairly stable over time (busiest two years hold 35% of 113 reports), so stimulated reporting is unlikely to explain the signal.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

These are, numerically, among the single highest PRR values in this entire dataset — and they are a near-certain reporting artifact, not a drug effect, included deliberately as a counter-example. Thalidomide is the drug most responsible for the existence of modern pharmacovigilance, after causing severe birth defects (notably phocomelia) in thousands of children in the late 1950s–60s when given to pregnant women for morning sickness. Precisely because of that history, its current U.S. uses (multiple myeloma, erythema nodosum leprosum) are restricted under the mandatory THALOMID REMS program, which requires routine pregnancy testing (serum/urine hCG) for every patient of childbearing potential before and during treatment. A hCG result flagged as "abnormal" or "increased" in that monitoring context is a required-testing artifact — it reflects the surveillance protocol built around the drug, not a new finding the drug caused. Tellingly, classic teratogenicity terms (phocomelia, congenital anomaly) do not even appear as flagged signals in this dataset, precisely because the REMS program has been so effective at preventing pregnancy exposure in the first place. The historical causal link for birth defects is not in question; it simply does not show up as a modern FAERS disproportionality signal, for the same reason the HPV/Pap-smear pattern does not reflect vaccine harm on the companion vaccine signal-pairs page.

Regulatory basis: THALOMID REMS program (mandatory pregnancy testing); historical teratogenicity established independently of FAERS, pre-dating the modern FAERS system.

Bradford Hill viewpointStatusNote
Temporality (necessary)n/aNot a biological effect — a surveillance-protocol artifact
StrengthmetNumerically very high PRR — but this measures testing-protocol intensity, not a biological effect
ConsistencymetConsistent with the REMS testing requirement, not with a biological drug effect
Specificitynot establishedhCG monitoring applies to every patient of childbearing potential regardless of other factors
Biological gradientn/a—
Plausibilityn/aThalidomide does not raise hCG biologically
Coherencenot establishedFails coherence with known thalidomide pharmacology (not an endocrine/hCG-active drug)
Experimentn/a—
AnalogymetDirectly analogous to the HPV/Pap-smear surveillance-coincidence example on the companion vaccine page

This entry fails most Hill viewpoints despite a sky-high PRR — a clean illustration of why strength alone proves nothing. This page's own qualitative read, not an automated/citation-gated assessment.

Not searched in ClinicalTrials.gov. An hCG test result is not a drug effect in the first place — there is no biological hypothesis here for a trial's adverse-event table to confirm or refute.
Causality: well established

Alendronate (bisphosphonates) ↔ Atypical femoral fracture

Open this assessment on its own page →

n=11,361 co-reports · PRR 120.9 · ROR 136.2

Reporting over time (stimulated-reporting check)

2004: 0 reports (0.00% of the drug's reports)2005: 0 reports (0.00% of the drug's reports)2006: 0 reports (0.00% of the drug's reports)2007: 0 reports (0.00% of the drug's reports)2008: 0 reports (0.00% of the drug's reports)2009: 0 reports (0.00% of the drug's reports)2010: 0 reports (0.00% of the drug's reports)2011: 2 reports (0.04% of the drug's reports)2012: 81 reports (0.98% of the drug's reports)2013: 79 reports (1.75% of the drug's reports)2014: 87 reports (2.31% of the drug's reports)2015: 52 reports (1.28% of the drug's reports)2016: 48 reports (1.23% of the drug's reports)2017: 57 reports (1.45% of the drug's reports)2018: 88 reports (2.12% of the drug's reports)2019: 46 reports (1.02% of the drug's reports)2020: 110 reports (2.23% of the drug's reports)2021: 49 reports (0.79% of the drug's reports)2022: 19 reports (0.35% of the drug's reports)2023: 16 reports (0.39% of the drug's reports)2024: 30 reports (0.51% of the drug's reports)2025: 32 reports (0.59% of the drug's reports)05081114172023

Reporting spiked in 2013, 2014, 2018, 2020 — 21% of all 796 reports arrived in two years (2013–2014). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

Alendronate is the archetypal oral bisphosphonate and first-line therapy for postmenopausal osteoporosis, and it genuinely reduces ordinary osteoporotic fractures. But prolonged use — characteristically more than three to five years of continuous exposure — is associated with a rare, distinctive low-energy subtrochanteric and diaphyseal femoral fracture pattern ("atypical femoral fractures"), mechanically different from the ordinary hip fracture the drug prevents. The FDA added a warning to the bisphosphonate class in October 2010, and the American Society for Bone and Mineral Research convened a task force the same year to standardize the case definition, precisely because the pattern is easy to miss. The FAERS term shown here ("femur fracture") is broader than the atypical pattern, so the raw count conflates the two — a genuine reporting limitation — but the specific atypical-fracture association is well supported in longitudinal cohort data and the label.

Regulatory basis: FDA Drug Safety Communication on atypical femur fractures with bisphosphonates (October 2010); ASBMR task-force case definition (2010); alendronate prescribing information (warnings on atypical subtrochanteric/diaphyseal fractures).

Bradford Hill viewpointStatusNote
Temporality (necessary)metFractures occur after years of continuous exposure, not before
StrengthmetPRR 121 here; a large effect for the atypical-specific pattern in cohort data
ConsistencymetReplicated across independent bisphosphonate cohorts and countries
SpecificitypartialThe atypical pattern is specific, but the FAERS term also captures ordinary fractures
Biological gradientmetRisk rises with duration of use (roughly >3–5 years)
PlausibilitymetOver-suppression of bone turnover impairs micro-damage repair — a named mechanism
CoherencemetCoheres with bisphosphonate pharmacology and the same pattern after denosumab
ExperimentpartialRisk falls after a drug holiday, though with a lag — supportive, not a clean on/off test
AnalogymetThe same atypical pattern occurs with other antiresorptives, including denosumab

This page's own qualitative read, not an automated/citation-gated assessment.

✗ Searched, nothing relevant found. A head-to-head osteoporosis trial (NCT00330460, alendronate vs denosumab) recorded only ordinary fractures (wrist, tibia, pelvic, vertebral), not the atypical subtrochanteric/diaphyseal pattern — the expected result, since atypical femoral fractures typically emerge after several years of continuous use, at or beyond the edge of most registered trials, and are rare. That is exactly why the signal surfaced in post-marketing surveillance rather than before approval.
Causality: well established

Denosumab ↔ Osteonecrosis of the jaw

Open this assessment on its own page →

n=8,645 co-reports · PRR 55.1 · ROR 57.6

Reporting over time (stimulated-reporting check)

2004: 0 reports (0.00% of the drug's reports)2005: 0 reports (0.00% of the drug's reports)2006: 0 reports (0.00% of the drug's reports)2007: 0 reports (0.00% of the drug's reports)2008: 0 reports (0.00% of the drug's reports)2009: 1 reports (33.33% of the drug's reports)2010: 19 reports (13.01% of the drug's reports)2011: 45 reports (2.56% of the drug's reports)2012: 237 reports (4.26% of the drug's reports)2013: 474 reports (6.44% of the drug's reports)2014: 735 reports (6.32% of the drug's reports)2015: 962 reports (7.77% of the drug's reports)2016: 1,096 reports (5.37% of the drug's reports)2017: 1,004 reports (2.97% of the drug's reports)2018: 1,070 reports (3.18% of the drug's reports)2019: 513 reports (4.48% of the drug's reports)2020: 348 reports (3.35% of the drug's reports)2021: 355 reports (3.52% of the drug's reports)2022: 393 reports (4.00% of the drug's reports)2023: 433 reports (4.05% of the drug's reports)2024: 401 reports (4.30% of the drug's reports)2025: 359 reports (4.48% of the drug's reports)05081114172023

No reporting spike: the pair's share of the drug's reports is fairly stable over time (busiest two years hold 25% of 8,445 reports), so stimulated reporting is unlikely to explain the signal.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

Denosumab is a RANKL inhibitor given as 60 mg every six months for osteoporosis and at 120 mg monthly in cancer/bone-metastasis settings. Osteonecrosis of the jaw (ONJ) — exposed, non-healing bone in the mouth — is a labeled risk for denosumab, just as it is for the bisphosphonates; it is best understood as a class effect of drugs that suppress bone resorption. Risk is strongly dose- and duration-dependent and is driven mainly by the oncology dosing, so ONJ is comparatively rare at osteoporosis dosing. This is a mechanistically coherent, clinically managed adverse effect, not a statistical artifact.

Regulatory basis: denosumab prescribing information (boxed warning for osteonecrosis of the jaw in oncology dosing); class effect shared with the bisphosphonates.

Bradford Hill viewpointStatusNote
Temporality (necessary)metONJ appears after cumulative exposure; the bone was intact beforehand
StrengthmetPRR 55 in this dataset
ConsistencymetConsistent across the whole antiresorptive class (bisphosphonates and denosumab)
SpecificitypartialNot unique to denosumab; cancer patients often receive several agents
Biological gradientmetMarkedly higher at monthly oncology dosing than at q6mo osteoporosis dosing
PlausibilitymetRANKL inhibition suppresses osteoclast function; jaw bone, exposed to oral flora, is the sentinel site
CoherencemetCoheres with the bisphosphonate ONJ literature and the drug's bone biology
ExperimentpartialDrug-holiday experience is supportive, not a randomized test
AnalogymetDirectly analogous to bisphosphonate-associated ONJ

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — denosumab 60 mg Q6M vs placebo, breast cancer on aromatase inhibitors (NCT00556374), N=3,399

Term (as recorded)Denosumab 60 mg (n=1,709)Placebo (n=1,690)
Osteonecrosis (serious)13
Abscess jaw (serious)10

Jaw-specific events appear on the denosumab arm, but at these counts the arms cannot be separated — consistent with ONJ being genuinely rare at osteoporosis dosing. The risk is established from the oncology-dosing experience and long-term data, not from a trial this size. View on ClinicalTrials.gov →

Contested: label-warned, evidence disputed

Pioglitazone ↔ Bladder cancer

Open this assessment on its own page →

n=8,739 co-reports · PRR 83.9 · ROR 105.0

Reporting over time (stimulated-reporting check)

2004: 3 reports (0.34% of the drug's reports)2005: 1 reports (0.08% of the drug's reports)2006: 7 reports (0.30% of the drug's reports)2007: 4 reports (0.15% of the drug's reports)2008: 5 reports (0.30% of the drug's reports)2009: 3 reports (0.16% of the drug's reports)2010: 31 reports (1.42% of the drug's reports)2011: 888 reports (28.58% of the drug's reports)2012: 448 reports (21.96% of the drug's reports)2013: 66 reports (5.15% of the drug's reports)2014: 33 reports (2.93% of the drug's reports)2015: 4,356 reports (65.99% of the drug's reports)2016: 2,163 reports (56.39% of the drug's reports)2017: 310 reports (16.68% of the drug's reports)2018: 108 reports (5.81% of the drug's reports)2019: 100 reports (5.94% of the drug's reports)2020: 176 reports (12.78% of the drug's reports)2021: 9 reports (0.83% of the drug's reports)2022: 8 reports (0.81% of the drug's reports)2023: 1 reports (0.11% of the drug's reports)2024: 9 reports (0.95% of the drug's reports)2025: 7 reports (0.77% of the drug's reports)05081114172023

Reporting spiked in 2011, 2012, 2013, 2015, 2016, 2017, 2018, 2019, 2020 — 75% of all 8,736 reports arrived in two years (2015–2016). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

Pioglitazone, a thiazolidinedione for type 2 diabetes, was flagged for a possible bladder-cancer risk by a French national cohort in 2011, which led France to suspend the drug and prompted the FDA and EMA to add warnings and restrict its use (FDA label warning, 2011). Yet the picture has not resolved cleanly: several large subsequent observational studies and pooled analyses found little to no increase in bladder-cancer risk, and some of the FAERS over-reporting almost certainly reflects intensified bladder/prostate surveillance in this population plus the regulatory scare itself driving reporting. The honest grade is "contested," not "established" — a labeled caution resting on genuinely disagreeing evidence.

Regulatory basis: FDA drug safety communication and label change (2011); ANSM (France) suspension (2011); EMA review. The epidemiological evidence is mixed, with later large studies finding little to no elevated risk.

Bradford Hill viewpointStatusNote
Temporality (necessary)partialPlausible (years of exposure precede diagnosis), but cancer latency makes it hard to pin down
StrengthmetPRR 84 — but very likely inflated by reporting and surveillance bias
Consistencynot establishedLarge studies genuinely disagree on whether risk is elevated at all
SpecificitypartialBladder is a specific organ, but this population is heavily screened for it
Biological gradientpartialSome studies suggest a duration/dose trend; others find none
PlausibilitypartialRodent urothelial tumors exist; human relevance is uncertain
Coherencenot establishedDoes not cohere into a decisive pattern either way
Experimentnot establishedNo randomized trial was designed to test this outcome
AnalogypartialA few other drug classes carry debated bladder-cancer signals

This page's own qualitative read, not an automated/citation-gated assessment.

✗ Searched, nothing relevant found. Pioglitazone's controlled trials run for months, not the decades a bladder-cancer signal would need, and the searches surfaced only unrelated neoplasm terms — so this question is settled (or muddied) by long-term cohorts, not by trial adverse-event tables.
Contested: small, real but modest effect

Atorvastatin (statins) ↔ Type 2 diabetes mellitus

Open this assessment on its own page →

n=11,260 co-reports · PRR 42.4 · ROR 44.4

Reporting over time (stimulated-reporting check)

2004: 0 reports (0.00% of the drug's reports)2005: 0 reports (0.00% of the drug's reports)2006: 2 reports (0.02% of the drug's reports)2007: 12 reports (0.17% of the drug's reports)2008: 16 reports (0.25% of the drug's reports)2009: 219 reports (2.98% of the drug's reports)2010: 226 reports (1.55% of the drug's reports)2011: 133 reports (1.15% of the drug's reports)2012: 86 reports (0.62% of the drug's reports)2013: 355 reports (3.35% of the drug's reports)2014: 4,974 reports (32.41% of the drug's reports)2015: 2,630 reports (17.14% of the drug's reports)2016: 1,612 reports (10.95% of the drug's reports)2017: 512 reports (4.02% of the drug's reports)2018: 132 reports (1.03% of the drug's reports)2019: 108 reports (0.82% of the drug's reports)2020: 66 reports (0.54% of the drug's reports)2021: 43 reports (0.41% of the drug's reports)2022: 39 reports (0.37% of the drug's reports)2023: 36 reports (0.38% of the drug's reports)2024: 21 reports (0.21% of the drug's reports)2025: 30 reports (0.27% of the drug's reports)05081114172023

Reporting spiked in 2009, 2013, 2014, 2015, 2016, 2017 — 68% of all 11,252 reports arrived in two years (2014–2015). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

Pooled randomized-trial data found a small but statistically significant increase in new-onset diabetes among statin recipients (Sattar et al., Lancet 2010, PMID 20167359), and in 2012 the FDA added a warning about increases in blood glucose and HbA1c. The effect is real but modest, appears dose-related, and is generally judged to be outweighed by statins' cardiovascular benefit; whether it reflects a true diabetogenic action or the unmasking of already-predisposed patients remains debated. The very high FAERS PRR here overstates the clinical magnitude — statin users are heavily monitored, so even a modest true effect inflates further in spontaneous reporting.

Sattar N, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-742 (PMID 20167359). FDA prescribing-information change on glucose/HbA1c (2012).

Bradford Hill viewpointStatusNote
Temporality (necessary)partialNew diabetes appears after starting the statin, but latency is long and variable
StrengthpartialPRR 42 in FAERS, but only a small absolute effect in randomized trials
ConsistencymetReproduced across many statin trials in the pooled analysis
Specificitynot establishedDiabetes is common and multifactorial; statins affect many pathways
Biological gradientpartialThe effect tracks with statin intensity/dose in several analyses
PlausibilitypartialProposed mechanisms include effects on insulin sensitivity and glucose transport
CoherencepartialFits the modest glucose-raising seen with the class, without implying large harm
ExperimentmetRandomized trials are the strongest evidence here — the effect is real, just small
AnalogypartialOther drugs with metabolic effects can modestly shift glucose

This page's own qualitative read, not an automated/citation-gated assessment.

✗ Searched; the trial that surfaced was not evidence either way. A real-world atorvastatin cohort (NCT02565615) recorded type 2 diabetes as a serious event in a single patient (1/3,080 at 20 mg) — far too small and short to detect a modest, long-latency metabolic effect. The relevant evidence is the pooled long-term randomized trials, not a trial AE table.
Causality: well established

Drospirenone/ethinyl estradiol ↔ Pulmonary embolism (venous thromboembolism)

Open this assessment on its own page →

n=9,171 co-reports · PRR 50.7 · ROR 63.8

Reporting over time (stimulated-reporting check)

2004: 22 reports (11.00% of the drug's reports)2005: 37 reports (13.03% of the drug's reports)2006: 33 reports (9.85% of the drug's reports)2007: 70 reports (13.18% of the drug's reports)2008: 108 reports (2.82% of the drug's reports)2009: 196 reports (6.67% of the drug's reports)2010: 388 reports (15.22% of the drug's reports)2011: 2,055 reports (18.50% of the drug's reports)2012: 3,307 reports (33.95% of the drug's reports)2013: 1,508 reports (32.29% of the drug's reports)2014: 954 reports (38.95% of the drug's reports)2015: 198 reports (22.25% of the drug's reports)2016: 93 reports (12.77% of the drug's reports)2017: 16 reports (3.59% of the drug's reports)2018: 31 reports (6.65% of the drug's reports)2019: 19 reports (4.09% of the drug's reports)2020: 29 reports (6.43% of the drug's reports)2021: 20 reports (6.06% of the drug's reports)2022: 18 reports (4.72% of the drug's reports)2023: 34 reports (9.29% of the drug's reports)2024: 18 reports (5.96% of the drug's reports)2025: 13 reports (4.36% of the drug's reports)05081114172023

Reporting spiked in 2012, 2013, 2014 — 58% of all 9,167 reports arrived in two years (2011–2012). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

Combined oral contraceptives are a well-recognized cause of venous thromboembolism, and the progestin component modifies that risk: national cohort data found drospirenone-containing combined pills carried a modestly higher VTE risk than levonorgestrel-containing pills (Lidegaard et al., BMJ 2009, PMID 19679613). The FDA revised the drospirenone labeling in 2011 to reflect this. The mechanism — an estrogen/progestin-driven procoagulant shift — is established pharmacology, and VTE is the classic serious adverse effect of combined hormonal contraception.

Lidegaard Ø, et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890 (PMID 19679613). FDA prescribing-information revision for drospirenone-containing contraceptives (2011).

Bradford Hill viewpointStatusNote
Temporality (necessary)metVTE occurs during exposure, with the highest risk in the first months of use
StrengthmetPRR 51 here; a consistent, moderate odds ratio in cohort studies
ConsistencymetReplicated across multiple national cohorts and pharmacovigilance systems
SpecificitypartialA class effect of combined hormonal contraceptives, differing by progestin
Biological gradientmetRisk differs by progestin type and by estrogen dose
PlausibilitymetEstrogen/progestin shifts clotting factors toward a procoagulant state
CoherencemetCoheres with the broader hormonal-contraception VTE literature
ExperimentpartialRisk declines after discontinuation; no randomized exposure-removal trial exists
AnalogymetOther estrogen-containing products carry the same VTE risk

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — EE 20 µg/drospirenone 3 mg, extended vs standard regimens (NCT00266032), N=1,067

Term (as recorded)Flexible extended (n=642)Fixed extended (n=209)Standard 24+4 (n=216)
Deep vein thrombosis (serious)100

One serious DVT in the extended-dosing arm — far too few events for a trial of this size to quantify VTE risk. This is why the drospirenone risk was established from large national cohorts: trials are simply underpowered for events this rare. View on ClinicalTrials.gov →

Contested: signal present, magnitude disputed

Omeprazole (proton-pump inhibitors) ↔ Chronic kidney disease

Open this assessment on its own page →

n=36,748 co-reports · PRR 43.0 · ROR 46.8 Omeprazole ↔ acute kidney injury: n=23,910 · PRR 8.6 Lansoprazole ↔ end-stage renal disease: n=9,798 · PRR 135.5

Reporting over time (stimulated-reporting check)

2004: 0 reports (0.00% of the drug's reports)2005: 0 reports (0.00% of the drug's reports)2006: 0 reports (0.00% of the drug's reports)2007: 0 reports (0.00% of the drug's reports)2008: 1 reports (0.02% of the drug's reports)2009: 0 reports (0.00% of the drug's reports)2010: 1 reports (0.01% of the drug's reports)2011: 1 reports (0.01% of the drug's reports)2012: 8 reports (0.06% of the drug's reports)2013: 4 reports (0.03% of the drug's reports)2014: 16 reports (0.11% of the drug's reports)2015: 65 reports (0.31% of the drug's reports)2016: 57 reports (0.24% of the drug's reports)2017: 182 reports (0.83% of the drug's reports)2018: 3,668 reports (12.96% of the drug's reports)2019: 6,062 reports (19.18% of the drug's reports)2020: 1,619 reports (6.35% of the drug's reports)2021: 1,089 reports (4.91% of the drug's reports)2022: 534 reports (2.53% of the drug's reports)2023: 132 reports (0.66% of the drug's reports)2024: 62 reports (0.32% of the drug's reports)2025: 45 reports (0.23% of the drug's reports)05081114172023

Reporting spiked in 2017, 2018, 2019, 2020, 2021, 2022, 2023 — 72% of all 13,546 reports arrived in two years (2018–2019). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

Proton-pump inhibitors are among the most-prescribed drug classes, and a widely-cited cohort analysis found that cumulative PPI exposure was associated with an increased risk of chronic kidney disease (Lazarus et al., JAMA Intern Med 2016). The FAERS pattern here spans the class — omeprazole with chronic kidney disease and acute kidney injury, lansoprazole with end-stage renal disease. The signal remains contested, however: confounding by indication and by baseline health is hard to exclude, effect sizes vary across studies, and some later analyses found little or no association. Acute interstitial nephritis is a recognized, likely-immune PPI reaction and provides a plausible mechanism, but the size of any chronic-kidney-disease risk is genuinely disputed.

Lazarus B, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2). doi:10.1001/jamainternmed.2015.7193. Evidence contested; confounding by indication limits causal inference.

Bradford Hill viewpointStatusNote
Temporality (necessary)partialPPI exposure precedes decline, but the time course is slow and hard to date
StrengthmetPRR 43 in FAERS — large, but very plausibly confounded
ConsistencypartialSeveral cohorts support it; others find little, so it is not settled
Specificitynot establishedKidney disease is common and multifactorial in the PPI population
Biological gradientpartialCumulative-dose/duration relationships are reported but inconsistent
PlausibilitypartialInterstitial nephritis is a real mechanism for AKI; the link to chronic disease is less clear
CoherencepartialFits a modest renal effect without establishing its size
Experimentnot establishedNo randomized trial has tested kidney outcomes
AnalogypartialOther drugs cause immune-mediated interstitial nephritis

This page's own qualitative read, not an automated/citation-gated assessment.

✗ Searched, nothing relevant found. PPI trials run for weeks to months and measure GI endpoints; the search matched no kidney term. A chronic-kidney-disease signal requires years of follow-up in large cohorts, not a trial adverse-event table.
Expected pharmacological effect

Interferon beta-1a ↔ Influenza-like illness

Open this assessment on its own page →

n=13,251 co-reports · PRR 20.7 · ROR 22.2

Reporting over time (stimulated-reporting check)

2004: 307 reports (10.09% of the drug's reports)2005: 590 reports (9.11% of the drug's reports)2006: 171 reports (4.37% of the drug's reports)2007: 186 reports (3.88% of the drug's reports)2008: 239 reports (3.77% of the drug's reports)2009: 318 reports (4.55% of the drug's reports)2010: 1,686 reports (9.80% of the drug's reports)2011: 1,024 reports (6.20% of the drug's reports)2012: 1,574 reports (8.39% of the drug's reports)2013: 2,126 reports (8.25% of the drug's reports)2014: 1,108 reports (6.28% of the drug's reports)2015: 677 reports (6.54% of the drug's reports)2016: 660 reports (6.31% of the drug's reports)2017: 493 reports (5.83% of the drug's reports)2018: 541 reports (7.06% of the drug's reports)2019: 448 reports (6.96% of the drug's reports)2020: 387 reports (7.18% of the drug's reports)2021: 240 reports (5.37% of the drug's reports)2022: 151 reports (3.90% of the drug's reports)2023: 138 reports (4.65% of the drug's reports)2024: 96 reports (4.55% of the drug's reports)2025: 71 reports (4.14% of the drug's reports)05081114172023

No reporting spike: the pair's share of the drug's reports is fairly stable over time (busiest two years hold 28% of 13,231 reports), so stimulated reporting is unlikely to explain the signal.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

Interferon beta-1a is a first-line injectable therapy for relapsing multiple sclerosis, and a flu-like illness — fever, chills, myalgia, malaise — is its single most characteristic and predictable side effect, typically worst in the hours after each injection and improving with continued use. It is the textbook "expected pharmacological effect": cytokine-mediated, dose-related, and managed with dose titration, evening dosing, and antipyretics. Its causality was never in question; the high report count mainly reflects how common and memorable the symptom is.

Regulatory basis: interferon beta-1a prescribing information (influenza-like symptoms listed among the most common adverse reactions).

Bradford Hill viewpointStatusNote
Temporality (necessary)metSymptoms begin within hours of each injection
StrengthmetPRR 21, and near-universal in treated patients at some point
ConsistencymetReproduced in every interferon-beta trial and cohort
SpecificitypartialA class effect of all interferon-beta products, not molecule-specific
Biological gradientmetSeverity tracks with dose and is reduced by titration
PlausibilitymetDirect, expected consequence of interferon's cytokine pharmacology
CoherencemetFits the known immunomodulatory action of the drug
ExperimentpartialSymptoms recur on re-injection and lessen with continued dosing — a natural dechallenge/rechallenge
AnalogymetShared with other interferons and with cytokine-release reactions generally

This page's own qualitative read, not an automated/citation-gated assessment.

✗ Searched, nothing relevant found. Flu-like symptoms are so common and expected that trials typically record them as general non-serious symptoms rather than a discrete serious term; a serious-events table understates how routine they are. The effect is captured in the label, not in a trial's serious-AE table.
Expected pharmacological effect

Capecitabine ↔ Palmar-plantar erythrodysaesthesia (hand-foot syndrome)

Open this assessment on its own page →

n=6,675 co-reports · PRR 92.1 · ROR 99.3

Reporting over time (stimulated-reporting check)

2004: 35 reports (5.45% of the drug's reports)2005: 29 reports (3.52% of the drug's reports)2006: 35 reports (3.65% of the drug's reports)2007: 106 reports (6.11% of the drug's reports)2008: 101 reports (4.69% of the drug's reports)2009: 207 reports (7.44% of the drug's reports)2010: 218 reports (7.54% of the drug's reports)2011: 277 reports (10.72% of the drug's reports)2012: 328 reports (5.50% of the drug's reports)2013: 395 reports (9.26% of the drug's reports)2014: 244 reports (7.83% of the drug's reports)2015: 218 reports (7.36% of the drug's reports)2016: 294 reports (9.96% of the drug's reports)2017: 720 reports (10.22% of the drug's reports)2018: 453 reports (9.38% of the drug's reports)2019: 440 reports (7.76% of the drug's reports)2020: 541 reports (8.06% of the drug's reports)2021: 707 reports (9.05% of the drug's reports)2022: 385 reports (5.37% of the drug's reports)2023: 292 reports (4.92% of the drug's reports)2024: 261 reports (4.97% of the drug's reports)2025: 251 reports (5.34% of the drug's reports)05081114172023

No reporting spike: the pair's share of the drug's reports is fairly stable over time (busiest two years hold 19% of 6,537 reports), so stimulated reporting is unlikely to explain the signal.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

Capecitabine is an oral fluoropyrimidine used for colorectal and breast cancer, and palmar-plantar erythrodysesthesia — "hand-foot syndrome": painful redness, swelling, and peeling of the palms and soles — is its signature toxicity. It occurs in a substantial minority of treated patients, is clearly dose- and schedule-dependent, and is well characterized and manageable (dose reduction, interruption, emollients, pyridoxine). This is a mechanistically direct, expected effect of the drug's own pharmacology, not an idiosyncratic reaction.

Regulatory basis: capecitabine prescribing information (hand-foot syndrome listed among the most common adverse reactions); confirmed by a randomized comparator arm (§ trial data below). A class effect of the fluoropyrimidines.

Bradford Hill viewpointStatusNote
Temporality (necessary)metAppears during cycles of treatment, after exposure begins
StrengthmetPRR 92, and ~20%+ incidence in a randomized comparator arm
ConsistencymetReproduced across capecitabine trials and real-world cohorts
SpecificitymetHighly characteristic of the fluoropyrimidine class
Biological gradientmetStriking dose/schedule dependence; continuous infusion and higher doses raise risk
PlausibilitymetDirect toxicity in high-turnover acral skin; named mechanism
CoherencemetCoheres with the drug's cytotoxicity and with other fluoropyrimidines
ExperimentmetResolves with dose reduction or interruption — a clean dechallenge
AnalogymetSeen with 5-fluorouracil and other fluoropyrimidines

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — physician's-choice chemotherapy (incl. capecitabine) vs talazoparib in BRCA breast cancer (NCT01945775, EMBRACA)

Term (as recorded)Physician's-choice arm (n=126)Talazoparib arm (n=286)
Palmar-plantar erythrodysaesthesia syndrome (other events)284

Hand-foot syndrome appeared in 28/126 (~22%) of the comparator arm, which includes capecitabine, versus 4/286 (~1.4%) on talazoparib — a large, textbook-consistent difference. Caveat: the comparator arm pools several drugs (capecitabine, eribulin, gemcitabine, vinorelbine), so it confirms the class/regimen effect more than capecitabine alone. View on ClinicalTrials.gov →

Causality: well established

Alprazolam (benzodiazepines) ↔ Drug dependence / abuse

Open this assessment on its own page →

n=11,121 co-reports · PRR 15.6 · ROR 16.4

Reporting over time (stimulated-reporting check)

2004: 88 reports (2.89% of the drug's reports)2005: 95 reports (2.64% of the drug's reports)2006: 67 reports (1.93% of the drug's reports)2007: 73 reports (2.23% of the drug's reports)2008: 52 reports (1.28% of the drug's reports)2009: 37 reports (0.75% of the drug's reports)2010: 56 reports (0.72% of the drug's reports)2011: 69 reports (0.88% of the drug's reports)2012: 68 reports (0.69% of the drug's reports)2013: 92 reports (0.96% of the drug's reports)2014: 66 reports (0.64% of the drug's reports)2015: 101 reports (0.71% of the drug's reports)2016: 157 reports (1.08% of the drug's reports)2017: 93 reports (0.69% of the drug's reports)2018: 313 reports (2.10% of the drug's reports)2019: 328 reports (2.12% of the drug's reports)2020: 936 reports (6.41% of the drug's reports)2021: 635 reports (6.04% of the drug's reports)2022: 281 reports (2.91% of the drug's reports)2023: 120 reports (1.36% of the drug's reports)2024: 126 reports (1.48% of the drug's reports)2025: 204 reports (2.43% of the drug's reports)05081114172023

Reporting spiked in 2020, 2021 — 39% of all 4,057 reports arrived in two years (2020–2021). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

Alprazolam is a short-acting, high-potency benzodiazepine, and physical dependence with withdrawal on cessation is an expected, dose- and duration-related effect of the benzodiazepine class — the drug's own pharmacology, not an idiosyncratic reaction. In September 2020 the FDA updated the Boxed Warning for the entire class to address risks of abuse, addiction, physical dependence, and withdrawal. The high report count reflects both how widely these drugs are prescribed and how reliably dependence develops with sustained use.

Regulatory basis: FDA Drug Safety Communication, 23 September 2020 — Boxed Warning updated for the benzodiazepine class (abuse, addiction, physical dependence, withdrawal).

Bradford Hill viewpointStatusNote
Temporality (necessary)metDependence develops over the course of exposure, before withdrawal is seen on cessation
StrengthmetPRR 16, on a very large report base
ConsistencymetReproduced across the whole benzodiazepine class and decades of use
SpecificitypartialA class effect; potency and half-life differ between agents
Biological gradientmetRisk rises with dose, duration, and shorter half-life (more inter-dose withdrawal)
PlausibilitymetDirect consequence of GABA-A receptor modulation
CoherencemetCoheres with the known dependence liability of the class
ExperimentmetWithdrawal on discontinuation is itself the natural dechallenge
AnalogymetShared with other CNS depressants (alcohol, barbiturates)

This page's own qualitative read, not an automated/citation-gated assessment.

✗ Searched, nothing relevant found. Dependence is a slow, behavioral outcome rarely captured as a discrete adverse-event term in short benzodiazepine trials; it is the class Boxed Warning, not trial AE tables, that records it.
Causality: well established

Quetiapine (antipsychotics) ↔ Diabetes mellitus

Open this assessment on its own page →

n=8,357 co-reports · PRR 13.3 · ROR 13.9

Reporting over time (stimulated-reporting check)

2004: 1 reports (1.82% of the drug's reports)2005: 7 reports (1.58% of the drug's reports)2006: 38 reports (9.13% of the drug's reports)2007: 65 reports (15.01% of the drug's reports)2008: 1 reports (0.18% of the drug's reports)2009: 4 reports (0.70% of the drug's reports)2010: 3 reports (2.03% of the drug's reports)2011: 5 reports (2.34% of the drug's reports)2012: 3 reports (0.49% of the drug's reports)2013: 0 reports (0.00% of the drug's reports)2014: 1 reports (0.21% of the drug's reports)2015: 5 reports (0.77% of the drug's reports)2016: 3 reports (0.38% of the drug's reports)2017: 2 reports (0.18% of the drug's reports)2018: 6 reports (0.35% of the drug's reports)2019: 10 reports (0.46% of the drug's reports)2020: 16 reports (0.76% of the drug's reports)2021: 18 reports (0.65% of the drug's reports)2022: 29 reports (0.98% of the drug's reports)2023: 17 reports (0.67% of the drug's reports)2024: 19 reports (0.58% of the drug's reports)2025: 17 reports (0.50% of the drug's reports)05081114172023

Reporting spiked in 2007 — 38% of all 270 reports arrived in two years (2006–2007). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

Quetiapine is a second-generation antipsychotic, and weight gain, dyslipidaemia, and hyperglycaemia/diabetes are its best-known metabolic effects — shared across the class but differing in magnitude by molecule. The FDA required a class warning about hyperglycaemia and diabetes for all atypical antipsychotics in 2003. The mechanism (weight gain, insulin resistance, and possibly direct effects on glucose regulation) is well described, and the effect is dose- and duration-related and largely manageable with baseline and periodic metabolic monitoring.

Regulatory basis: FDA class warning on hyperglycemia and diabetes with atypical antipsychotics (2003); quetiapine prescribing information (metabolic monitoring).

Bradford Hill viewpointStatusNote
Temporality (necessary)partialMetabolic changes emerge over weeks–months of treatment
StrengthpartialPRR 13 — modest, and confounded by the population's baseline risk
ConsistencymetA consistent class effect across atypical antipsychotics
SpecificitypartialClass-wide, with real differences in magnitude between agents
Biological gradientmetTracks with dose and the degree of weight gain
PlausibilitymetWeight gain and insulin resistance are named, established mechanisms
CoherencemetCoheres with the class's documented metabolic syndrome risk
ExperimentpartialImprovement on switching/withdrawal is supportive, not a randomized test
AnalogymetShared with other second-generation antipsychotics

This page's own qualitative read, not an automated/citation-gated assessment.

✗ Searched; the trial that surfaced cannot characterize the risk. In a quetiapine-XR vs risperidone trial (NCT00600756), diabetes was recorded as a serious event in 0/391 on quetiapine XR and 1/402 on risperidone — far too few events, over too short a period, to measure a metabolic risk. The class warning rests on longer-term data.
Causality: well established

Risperidone ↔ Weight gain

Open this assessment on its own page →

n=9,452 co-reports · PRR 513.3 · ROR 552.8

Reporting over time (stimulated-reporting check)

2004: 67 reports (3.07% of the drug's reports)2005: 94 reports (4.31% of the drug's reports)2006: 137 reports (5.23% of the drug's reports)2007: 154 reports (6.36% of the drug's reports)2008: 103 reports (4.09% of the drug's reports)2009: 224 reports (5.23% of the drug's reports)2010: 218 reports (5.28% of the drug's reports)2011: 286 reports (6.94% of the drug's reports)2012: 195 reports (4.72% of the drug's reports)2013: 177 reports (5.29% of the drug's reports)2014: 194 reports (4.36% of the drug's reports)2015: 1,545 reports (10.11% of the drug's reports)2016: 783 reports (5.42% of the drug's reports)2017: 1,570 reports (11.41% of the drug's reports)2018: 467 reports (6.44% of the drug's reports)2019: 862 reports (10.64% of the drug's reports)2020: 366 reports (5.67% of the drug's reports)2021: 398 reports (7.58% of the drug's reports)2022: 367 reports (6.39% of the drug's reports)2023: 284 reports (5.33% of the drug's reports)2024: 278 reports (4.93% of the drug's reports)2025: 290 reports (5.66% of the drug's reports)05081114172023

No reporting spike: the pair's share of the drug's reports is fairly stable over time (busiest two years hold 26% of 9,059 reports), so stimulated reporting is unlikely to explain the signal.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

Risperidone, like quetiapine, is a second-generation antipsychotic whose metabolic effects include substantial weight gain — a labeled, dose- and duration-related consequence of the class, with the risk varying meaningfully between agents. In a randomized head-to-head trial of risperidone versus quetiapine XR, "weight increased" was recorded in roughly 6% versus 5% of patients. The very high FAERS PRR reflects that weight gain is both common and reliably reported, but the effect itself is well established, not a statistical curiosity.

Regulatory basis: risperidone prescribing information (weight gain among the most common adverse reactions); FDA class metabolic warning for atypical antipsychotics.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeight rises after treatment begins, over weeks to months
StrengthmetPRR 513 here; a consistent effect in trials and cohorts
ConsistencymetReproduced across studies and across the antipsychotic class
SpecificitypartialClass effect, with real differences between individual agents
Biological gradientmetWeight change tracks with dose and duration
PlausibilitymetReceptor-mediated appetite/metabolic effects are well described
CoherencemetCoheres with the antipsychotic metabolic-syndrome literature
ExperimentpartialWeight loss on switching or withdrawal supports causality
AnalogymetShared with olanzapine, quetiapine, and other atypicals

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — risperidone vs quetiapine XR in schizophrenia (NCT00600756)

Term (as recorded)Risperidone (n=402)Quetiapine XR (n=391)
Weight increased (other events)2518

Roughly 6% of risperidone patients and 5% of quetiapine XR patients had weight gain recorded — a clean, randomized confirmation of the expected class effect, with risperidone slightly ahead in this trial. View on ClinicalTrials.gov →

Expected pharmacological effect

Docetaxel (taxanes) ↔ Alopecia

Open this assessment on its own page →

n=16,970 co-reports · PRR 29.5 · ROR 39.1

Reporting over time (stimulated-reporting check)

2004: 1 reports (0.32% of the drug's reports)2005: 10 reports (2.38% of the drug's reports)2006: 1 reports (0.27% of the drug's reports)2007: 3 reports (0.68% of the drug's reports)2008: 1 reports (0.16% of the drug's reports)2009: 4 reports (0.46% of the drug's reports)2010: 9 reports (0.95% of the drug's reports)2011: 12 reports (0.87% of the drug's reports)2012: 18 reports (1.01% of the drug's reports)2013: 36 reports (2.18% of the drug's reports)2014: 17 reports (1.08% of the drug's reports)2015: 56 reports (2.78% of the drug's reports)2016: 136 reports (5.96% of the drug's reports)2017: 2,470 reports (51.33% of the drug's reports)2018: 7,608 reports (70.10% of the drug's reports)2019: 3,855 reports (49.89% of the drug's reports)2020: 1,806 reports (32.03% of the drug's reports)2021: 411 reports (9.07% of the drug's reports)2022: 170 reports (4.11% of the drug's reports)2023: 121 reports (2.93% of the drug's reports)2024: 118 reports (2.56% of the drug's reports)2025: 72 reports (1.74% of the drug's reports)05081114172023

Reporting spiked in 2017, 2018, 2019, 2020, 2021 — 68% of all 16,935 reports arrived in two years (2018–2019). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

Docetaxel is a taxane chemotherapy, and hair loss is a near-universal, mechanistically direct consequence of its action on rapidly dividing cells — including the hair-follicle matrix. In a randomized trial, alopecia was recorded in roughly a third of patients on docetaxel versus under 2% on pembrolizumab, a striking and entirely expected difference. Alopecia is not merely cosmetic; it is among the most distressing chemotherapy side effects, and its severity is dose- and schedule-dependent.

Regulatory basis: docetaxel prescribing information (alopecia among the most common adverse reactions); confirmed by a randomized comparator arm (trial data below). A class effect of the taxanes and most cytotoxic chemotherapies.

Bradford Hill viewpointStatusNote
Temporality (necessary)metHair loss begins weeks after the first cycle, after exposure
StrengthmetPRR 30, and ~36% incidence in a randomized comparator arm
ConsistencymetReproduced in every taxane trial and cohort
SpecificitypartialA class effect of cytotoxic chemotherapy, not molecule-unique
Biological gradientpartialSeverity varies with dose, schedule, and agent
PlausibilitymetDirect cytotoxicity to rapidly dividing follicle cells — named mechanism
CoherencemetCoheres with the drug's antimitotic action
ExperimentmetHair regrows after treatment stops — a clean dechallenge/rechallenge
AnalogymetShared with other taxanes and anthracyclines

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — docetaxel vs pembrolizumab in NSCLC (NCT01905657, KEYNOTE-010)

Term (as recorded)Docetaxel (n=309)Pembrolizumab 2 mg/kg (n=339)Pembrolizumab 10 mg/kg (n=343)
Alopecia (other events)11065

About 36% of docetaxel patients had alopecia recorded versus ~1.5–1.8% on pembrolizumab — a large, randomized, textbook-consistent contrast that directly confirms the expected effect. View on ClinicalTrials.gov →

Causality: well established

Tenofovir disoproxil fumarate ↔ Bone loss

Open this assessment on its own page →

n=7,079 co-reports · PRR 563.0 · ROR 717.3 Emtricitabine/TDF ↔ bone density decreased: n=16,608 · PRR 516.1

Reporting over time (stimulated-reporting check)

2004: 0 reports (0.00% of the drug's reports)2005: 1 reports (0.16% of the drug's reports)2006: 3 reports (0.57% of the drug's reports)2007: 1 reports (0.18% of the drug's reports)2008: 0 reports (0.00% of the drug's reports)2009: 0 reports (0.00% of the drug's reports)2010: 1 reports (0.21% of the drug's reports)2011: 2 reports (0.36% of the drug's reports)2012: 0 reports (0.00% of the drug's reports)2013: 3 reports (0.57% of the drug's reports)2014: 2 reports (0.21% of the drug's reports)2015: 7 reports (0.58% of the drug's reports)2016: 5 reports (0.41% of the drug's reports)2017: 9 reports (0.68% of the drug's reports)2018: 23 reports (1.53% of the drug's reports)2019: 389 reports (20.07% of the drug's reports)2020: 8,208 reports (67.38% of the drug's reports)2021: 1,156 reports (42.17% of the drug's reports)2022: 450 reports (25.97% of the drug's reports)2023: 174 reports (15.92% of the drug's reports)2024: 139 reports (18.51% of the drug's reports)2025: 85 reports (14.51% of the drug's reports)05081114172023

Reporting spiked in 2019, 2020, 2021, 2022, 2023, 2024, 2025 — 88% of all 10,658 reports arrived in two years (2020–2021). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

Tenofovir disoproxil fumarate (TDF) is an antiretroviral used to treat HIV and hepatitis B, and its renal and bone toxicities are precisely why the newer prodrug TAF was developed. TDF reduces bone mineral density and raises markers of bone turnover, with the steepest declines in the first year of therapy and a persistently lower density thereafter; the FDA label carries explicit bone and renal warnings. The very high FAERS PRR reflects an established, mechanism-linked effect (proximal tubular dysfunction with phosphate wasting), though the term "bone loss" aggregates several coded MedDRA terms, so the raw count overshoots the specificity.

Regulatory basis: tenofovir disoproxil fumarate prescribing information (warnings on decreases in bone mineral density and renal toxicity); TAF developed specifically to mitigate these effects.

Bradford Hill viewpointStatusNote
Temporality (necessary)metBMD falls after therapy starts, largest in the first year
StrengthmetPRR 563 here; consistent, measurable BMD differences in trials
ConsistencymetReplicated across randomized trials and cohorts
SpecificitypartialClass-related (some other NRTIs share it); the FAERS term aggregates several codes
Biological gradientpartialRelated to cumulative exposure and baseline risk
PlausibilitymetProximal tubulopathy with phosphate wasting is a named mechanism
CoherencemetCoheres with the drug's renal toxicity and with the TAF redesign
ExperimentmetBMD improves after switching TDF to TAF — a clean substitution experiment
AnalogypartialShared with certain other antiretrovirals (e.g. some NRTIs)

This page's own qualitative read, not an automated/citation-gated assessment.

✗ Searched, nothing relevant found. The trial that surfaced (NCT01352715) captured only a lipid term. Bone-density declines are measured as continuous densitometry endpoints in HIV trials, not as a coded "bone loss" adverse event, so a disproportionality count and a trial AE table are simply measuring different things here.
Causality: well established

Rituximab ↔ Serious infection

Open this assessment on its own page →

n=11,043 co-reports · PRR 8.2 · ROR 8.6

Reporting over time (stimulated-reporting check)

2004: 12 reports (2.36% of the drug's reports)2005: 19 reports (2.57% of the drug's reports)2006: 21 reports (2.90% of the drug's reports)2007: 29 reports (2.31% of the drug's reports)2008: 42 reports (2.96% of the drug's reports)2009: 75 reports (3.68% of the drug's reports)2010: 81 reports (3.26% of the drug's reports)2011: 120 reports (3.76% of the drug's reports)2012: 155 reports (3.30% of the drug's reports)2013: 169 reports (3.52% of the drug's reports)2014: 124 reports (2.47% of the drug's reports)2015: 195 reports (3.28% of the drug's reports)2016: 204 reports (3.01% of the drug's reports)2017: 284 reports (2.53% of the drug's reports)2018: 326 reports (2.65% of the drug's reports)2019: 357 reports (2.38% of the drug's reports)2020: 502 reports (2.44% of the drug's reports)2021: 403 reports (2.17% of the drug's reports)2022: 396 reports (1.86% of the drug's reports)2023: 486 reports (2.40% of the drug's reports)2024: 420 reports (1.74% of the drug's reports)2025: 395 reports (2.09% of the drug's reports)05081114172023

No reporting spike: the pair's share of the drug's reports is fairly stable over time (busiest two years hold 19% of 4,815 reports), so stimulated reporting is unlikely to explain the signal.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

Rituximab is an anti-CD20 monoclonal antibody that depletes B cells, and an increased risk of infection — including serious bacterial, fungal, and viral infections, and notably reactivation of hepatitis B and progressive multifocal leukoencephalopathy (PML) — is a labeled, mechanistic consequence of that depletion. The FDA label carries boxed warnings for PML and HBV reactivation. The population treated (lymphoma, autoimmune disease, transplant) also raises baseline infection risk, so the FAERS count mixes drug-driven and disease-driven infection, but the causal contribution of B-cell depletion itself is well established.

Regulatory basis: rituximab prescribing information (boxed warnings for progressive multifocal leukoencephalopathy and hepatitis B virus reactivation; increased risk of serious infections).

Bradford Hill viewpointStatusNote
Temporality (necessary)metInfections and reactivation follow B-cell depletion after dosing
StrengthpartialPRR 8 — modest, because infection is common in this population generally
ConsistencymetConsistent across indications and trials
Specificitynot establishedInfection is nonspecific; disease and concomitant therapy also contribute
Biological gradientpartialRelates to degree/duration of B-cell depletion and repeat dosing
PlausibilitymetB-cell depletion impairs humoral immunity — named mechanism
CoherencemetCoheres with the immunosuppression seen with other B-cell-depleting agents
ExperimentpartialInfection risk tracks with depletion depth; no clean randomized removal test
AnalogymetShared with other immunosuppressants/anti-CD20 therapies

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — safety of rituximab in rheumatoid arthritis (NCT00443651)

Term (as recorded)Rituximab 1000 mg (n=401)Rituximab 500 mg (n=176)
Pneumonia (serious)41
Upper respiratory tract infection (other)5127
Urinary tract infection (other)4515

The recorded infection burden is clear, but both arms received rituximab (different doses), with no placebo arm — so this shows that infections are captured clinically, not a comparator-adjusted risk. View on ClinicalTrials.gov →

Causality: well established

Morphine (opioids) ↔ Overdose / respiratory depression

Open this assessment on its own page →

n=23,522 co-reports · PRR 21.1 · ROR 26.0

Reporting over time (stimulated-reporting check)

2004: 49 reports (2.96% of the drug's reports)2005: 45 reports (2.95% of the drug's reports)2006: 22 reports (1.77% of the drug's reports)2007: 10 reports (1.26% of the drug's reports)2008: 21 reports (2.37% of the drug's reports)2009: 15 reports (1.57% of the drug's reports)2010: 8 reports (0.62% of the drug's reports)2011: 16 reports (1.02% of the drug's reports)2012: 26 reports (1.10% of the drug's reports)2013: 10 reports (0.53% of the drug's reports)2014: 11 reports (0.47% of the drug's reports)2015: 10 reports (0.33% of the drug's reports)2016: 15 reports (0.41% of the drug's reports)2017: 9 reports (0.18% of the drug's reports)2018: 19 reports (0.07% of the drug's reports)2019: 33 reports (0.68% of the drug's reports)2020: 29 reports (0.33% of the drug's reports)2021: 31 reports (0.15% of the drug's reports)2022: 48 reports (0.33% of the drug's reports)2023: 41 reports (0.48% of the drug's reports)2024: 33 reports (0.89% of the drug's reports)2025: 67 reports (1.93% of the drug's reports)05081114172023

Reporting spiked in 2025 — 18% of all 568 reports arrived in two years (2024–2025). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

Morphine is a full mu-opioid receptor agonist, and the dose-related triad of respiratory depression, sedation, and death in overdose is the defining, mechanistically direct hazard of the opioid class. The opioid-overdose epidemic is a public-health emergency addressed by the CDC clinical practice guideline, opioid REMS, and naloxone access. The FAERS term "overdose" here spans intentional and unintentional excess and reflects a well-established, dose-dependent risk rather than a statistical artifact — though it also aggregates suicides, misuse, and medication errors, so it is not a pure "adverse reaction."

Regulatory basis: opioid analgesic REMS; CDC Clinical Practice Guideline for Prescribing Opioids (2016, updated 2022); morphine prescribing information (boxed warning for respiratory depression and addiction).

Bradford Hill viewpointStatusNote
Temporality (necessary)metRespiratory depression follows dosing and rises with dose
StrengthmetPRR 21 on a very large base; the leading cause of drug-overdose death
ConsistencymetReproduced across the whole opioid class and decades of data
SpecificitypartialA class effect; the FAERS term also captures misuse and error
Biological gradientmetCentral hypoventilation is classically dose-dependent
PlausibilitymetMu-opioid receptor agonism directly suppresses brainstem respiratory drive
CoherencemetCoheres with the entire opioid pharmacology and toxicology literature
ExperimentmetNaloxone reverses opioid-induced respiratory depression — a clean pharmacologic antagonist experiment
AnalogymetShared by every mu-opioid agonist

This page's own qualitative read, not an automated/citation-gated assessment.

✗ Searched, nothing relevant found. The trial that surfaced (NCT02145468) was a cardiovascular trial in acute coronary syndrome, not a morphine trial; its "overdose"/"respiratory depression" entries were single events. Overdose is a dosing/behavioral outcome that short, titrated trials are not designed to capture — the hazard is established from pharmacology, poison-center, and mortality data.
Emerging: progestogen class effect, under review

Medroxyprogesterone acetate ↔ Meningioma

Open this assessment on its own page →

n=11,275 co-reports · PRR 1,443.2 · ROR 1,868.2

Reporting over time (stimulated-reporting check)

2004: 1 reports (0.03% of the drug's reports)2005: 2 reports (0.07% of the drug's reports)2006: 1 reports (0.04% of the drug's reports)2007: 2 reports (0.19% of the drug's reports)2008: 0 reports (0.00% of the drug's reports)2009: 3 reports (0.07% of the drug's reports)2010: 1 reports (0.01% of the drug's reports)2011: 1 reports (0.05% of the drug's reports)2012: 2 reports (0.18% of the drug's reports)2013: 0 reports (0.00% of the drug's reports)2014: 2 reports (0.27% of the drug's reports)2015: 1 reports (0.11% of the drug's reports)2016: 1 reports (0.09% of the drug's reports)2017: 2 reports (0.30% of the drug's reports)2018: 0 reports (0.00% of the drug's reports)2019: 1 reports (0.12% of the drug's reports)2020: 0 reports (0.00% of the drug's reports)2021: 0 reports (0.00% of the drug's reports)2022: 5 reports (0.58% of the drug's reports)2023: 3 reports (0.37% of the drug's reports)2024: 88 reports (8.66% of the drug's reports)2025: 1,562 reports (56.53% of the drug's reports)05081114172023

Reporting spiked in 2024, 2025 — 98% of all 1,678 reports arrived in two years (2024–2025). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

Medroxyprogesterone acetate is a progestin used for contraception, abnormal uterine bleeding and, at high doses, as hormonal cancer therapy. The progestogen class has been linked to intracranial meningioma: a French national cohort found a dose-dependent association with high-dose cyproterone acetate (Weill et al., BMJ 2021, PMID 33536184), which prompted European reviews that extended the meningioma warning across several progestogens. Meningiomas frequently express progesterone receptors, giving a plausible mechanism. Whether the effect size for medroxyprogesterone specifically matches cyproterone's is not yet settled, so this is graded "emerging/contested" rather than established — and the extreme FAERS PRR (1,443) substantially overstates the true risk once awareness and increased imaging are accounted for.

Weill A, et al. Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study. BMJ. 2021;372:n37 (PMID 33536184). European regulatory reviews of progestogens and meningioma (from 2020 onward). Signal emerging; the effect size for medroxyprogesterone is not established.

Bradford Hill viewpointStatusNote
Temporality (necessary)partialAssociation grows with years of use, but meningioma grows slowly and onset is hard to date
StrengthmetPRR 1,443 — but heavily inflated by awareness and screening bias
ConsistencypartialClear for cyproterone; less well established for medroxyprogesterone specifically
SpecificitypartialA progestogen class effect, plausible via progesterone receptors
Biological gradientmetRisk rises with dose (high-dose > low-dose) and duration
PlausibilitymetMeningiomas commonly express progesterone receptors
CoherencemetCoheres with the receptor biology and with the wider progestogen literature
ExperimentpartialReported meningioma regression after progestogen withdrawal is supportive
AnalogymetDirectly analogous to cyproterone-acetate-associated meningioma

This page's own qualitative read, not an automated/citation-gated assessment.

Not applicable in principle. Meningioma is a slow-growing tumor that develops over years; no contraceptive or hormone-therapy trial is long enough or large enough to detect it. This class of question is answered by long-term cohort studies and case series, not by trial adverse-event tables.
Causality: well established

Estrogen + medroxyprogesterone acetate ↔ Breast cancer

Open this assessment on its own page →

n=9,771 co-reports · PRR 242.8 · ROR 302.2

Conjugated equine estrogen plus medroxyprogesterone acetate was the combined hormone-therapy regimen tested in the Women's Health Initiative, the large randomized trial whose 2002 report found an increased risk of invasive breast cancer (as well as cardiovascular events), leading to early termination of that arm and a sharp, worldwide drop in hormone-therapy use (Rossouw et al., JAMA 2002, PMID 12117397). The breast-cancer association is the best-established harm of combined postmenopausal hormone therapy, is duration-dependent, and prompted a boxed warning. Note that this is estrogen plus progestin therapy, not medroxyprogesterone used alone as a contraceptive — the two contexts differ.

Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333 (PMID 12117397). FDA boxed warning for estrogen+progestin postmenopausal therapy.

Bradford Hill viewpointStatusNote
Temporality (necessary)metRisk emerged during randomized exposure in the WHI
StrengthmetPRR 243 here; a modest but real hazard ratio in the randomized trial
ConsistencymetConsistent across observational cohorts and the randomized WHI
SpecificitypartialCombined therapy; estrogen-alone results differ, so the progestin matters
Biological gradientmetRisk rises with duration of combined therapy
PlausibilitymetHormone-receptor-driven breast tissue growth — named mechanism
CoherencemetCoheres with decades of hormonal-carcinogenesis research
ExperimentmetThe WHI itself is the randomized experiment — the strongest possible evidence
AnalogymetSimilar to other prolonged hormonal exposures

This page's own qualitative read, not an automated/citation-gated assessment.

Not applicable in principle. This question was answered by a purpose-built randomized trial (the WHI) with years of follow-up; a short trial's adverse-event table cannot capture a cancer outcome. The one MPA trial that surfaced in searching (NCT02228681, an endometrial-cancer study with a small MPA arm) is far too small and short to speak to breast-cancer risk.
Expected pharmacological effect

Insulin glargine ↔ Hypoglycaemia (blood glucose decreased)

Open this assessment on its own page →

n=10,511 co-reports · PRR 23.6 · ROR 24.7

Reporting over time (stimulated-reporting check)

2004: 90 reports (8.70% of the drug's reports)2005: 152 reports (8.43% of the drug's reports)2006: 184 reports (5.63% of the drug's reports)2007: 244 reports (7.34% of the drug's reports)2008: 241 reports (8.17% of the drug's reports)2009: 220 reports (5.62% of the drug's reports)2010: 216 reports (4.00% of the drug's reports)2011: 271 reports (4.32% of the drug's reports)2012: 268 reports (4.79% of the drug's reports)2013: 409 reports (5.02% of the drug's reports)2014: 447 reports (3.69% of the drug's reports)2015: 628 reports (3.21% of the drug's reports)2016: 512 reports (3.34% of the drug's reports)2017: 496 reports (3.33% of the drug's reports)2018: 833 reports (3.87% of the drug's reports)2019: 571 reports (2.98% of the drug's reports)2020: 506 reports (2.97% of the drug's reports)2021: 377 reports (2.43% of the drug's reports)2022: 314 reports (2.17% of the drug's reports)2023: 319 reports (2.49% of the drug's reports)2024: 246 reports (1.71% of the drug's reports)2025: 249 reports (1.38% of the drug's reports)05081114172023

No reporting spike: the pair's share of the drug's reports is fairly stable over time (busiest two years hold 18% of 7,793 reports), so stimulated reporting is unlikely to explain the signal.

Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.

Insulin glargine is a long-acting basal insulin, and hypoglycaemia is its defining and most important adverse effect — a direct, dose-related consequence of the drug's own mechanism, not an idiosyncratic reaction. Every insulin product carries this risk, and it is the principal safety concern in insulin therapy, requiring careful titration and glucose monitoring. It is the textbook expected pharmacological effect: the drug's intended action (lowering glucose) can overshoot.

Regulatory basis: insulin glargine prescribing information (hypoglycemia listed as the most common adverse reaction and among the most important risks).

Bradford Hill viewpointStatusNote
Temporality (necessary)metHypoglycaemia follows insulin action, within its duration of effect
StrengthmetPRR 24, on a very large insulin-treated population
ConsistencymetUniversal across insulins and settings
SpecificitypartialA class effect of all insulins and secretagogues
Biological gradientmetClose dose–effect relationship; the core of insulin titration
PlausibilitymetDirect consequence of exogenous insulin's glucose-lowering action
CoherencemetCoheres with the entire insulin pharmacotherapy literature
ExperimentmetDose reduction and glucose/glucagon correction reverse it — a clean on/off
AnalogymetShared by every insulin formulation and by insulin secretagogues

This page's own qualitative read, not an automated/citation-gated assessment.

Not searched in ClinicalTrials.gov for this entry. Hypoglycaemia is insulin's defining labeled effect and is measured as the primary safety endpoint in essentially every insulin trial; a disproportionality signal adds little to what those trials already quantify directly.
Coding artifact: the device named as the "reaction"

Copper intrauterine device ↔ Foreign body in reproductive tract

Open this assessment on its own page →

n=8,693 co-reports · PRR 89,124.5 · ROR 111,803.9

This is the single highest PRR in the entire dataset (89,124), and it is a pure coding artifact — included deliberately as the extreme counter-example. A copper intrauterine device is a physical object placed in the uterus; when a report mentions "foreign body in reproductive tract," that is a literal description of the device itself, not an adverse reaction the device caused. The PRR is astronomically high precisely because the reaction term is essentially unique to this product class, which guarantees disproportionality by construction. It is the clearest possible reminder that PRR measures the distinctiveness of what gets reported, not harm — the highest number on the page is also one of the least meaningful.

Methodological note, not a regulatory finding: the "foreign body" term describes the intrauterine device itself (a physical implant), a coding artifact of the reporting scheme rather than a biological effect.

Bradford Hill viewpointStatusNote
Temporality (necessary)n/aNot a biological effect — the term names the device
StrengthmetPRR 89,124 — but this measures coding specificity, not an effect
ConsistencymetConsistent with any report that mentions the IUD
Specificitynot establishedThe term just names the device; it carries no effect information
Biological gradientn/a—
Plausibilityn/aNo biological hypothesis — the device is a foreign body by definition
Coherencenot establishedFails coherence with any genuine adverse-reaction concept
Experimentn/a—
AnalogymetAnalogous to other device/administrative coding terms (e.g. "device malfunction")

This page's own qualitative read, not an automated/citation-gated assessment.

Not applicable in principle. A "foreign body" reaction term reflects the physical presence of the device, which no trial's adverse-event table would ever report as a drug-related event. There is no biological hypothesis here for a trial to confirm or refute.
Monitoring-protocol artifact, not a drug effect

Warfarin ↔ INR increased

Open this assessment on its own page →

n=10,358 co-reports · PRR 93.4 · ROR 101.7

Warfarin's effect is measured by the INR, and the INR is the test used to dose it; a report of "international normalised ratio increased" is therefore partly a description of the drug working and partly of the monitoring built around it, not a discrete adverse event in the usual sense. The over-representation of INR terms for warfarin is expected: the test is nearly exclusive to vitamin-K-antagonist therapy, which guarantees disproportionality by construction. Genuine supratherapeutic INR with bleeding is a real and important warfarin hazard, but the raw "INR increased" signal is a monitoring/coding artifact rather than a novel safety finding. Tellingly, INR terms also appear in the comparator arm of a modern anticoagulant trial (below).

Methodological note, not a regulatory finding: INR is the monitoring parameter used to dose vitamin-K antagonists; its over-representation is a coding/monitoring artifact. Supratherapeutic INR with bleeding remains a real, labeled warfarin risk (warfarin prescribing information).

Bradford Hill viewpointStatusNote
Temporality (necessary)n/aThe INR is the measurement, not a biological event
StrengthmetPRR 93 — but this measures the exclusivity of the test, not harm
ConsistencymetConsistent wherever warfarin is monitored
Specificitynot establishedThe term reflects a required test, not a distinct clinical effect
Biological gradientn/a—
Plausibilityn/aINR rises because that is the drug's intended pharmacology, not an adverse reaction
Coherencenot establishedFails coherence as an adverse-reaction concept; it is a monitoring value
Experimentn/a—
AnalogymetDirectly analogous to other lab-monitoring artifacts (e.g. thalidomide ↔ hCG)

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — warfarin vs apixaban in atrial fibrillation (NCT00412984, ARISTOTLE)

Term (as recorded)Warfarin (n=9,088)Apixaban (n=9,052)
International normalised ratio increased (serious)35
International normalised ratio abnormal (serious)55

INR terms were recorded in both arms — even the apixaban arm, which does not require INR dosing — confirming that these entries track the monitoring/recording process rather than a drug-specific effect. View on ClinicalTrials.gov →

Causality: well established

Simvastatin (statins) ↔ Rhabdomyolysis

Open this assessment on its own page →

n=5,389 co-reports · PRR 12.4 · ROR 12.7 Myopathy/myalgia (related terms): further co-reports

Statin-associated muscle injury runs a spectrum from common myalgia to rare, life-threatening rhabdomyolysis, and the risk is strongly dose-dependent: the 80 mg simvastatin dose carries a far higher myopathy rate than 20 mg, which is why the FDA restricted 80 mg use in 2011 and added it to the statin-drug-interaction warnings. The mechanism is well characterized — inhibiting HMG-CoA reductase depletes mevalonate-pathway intermediates in skeletal muscle — and serum simvastatin levels rise sharply when strong CYP3A4 inhibitors (clarithromycin, itraconazole, protease inhibitors, grapefruit) block its metabolism. This is a class effect, but simvastatin is among the most affected, which is why its labeled precautions are the strictest of the class. The disproportionality here reflects both a genuine effect and the very large numbers of patients on statins with routine creatine-kinase testing in symptomatic cases.

Regulatory basis: FDA simvastatin labeling changes and 80 mg dose restrictions (2011), including CYP3A4-interaction warnings. SEARCH randomized trial (80 mg vs 20 mg simvastatin myopathy comparison), Lancet 2010.

Bradford Hill viewpointStatusNote
Temporality (necessary)metMuscle injury appears during exposure, typically within weeks of starting or escalating the dose
StrengthmetPRR 12 on a very large co-report count, with a steep dose–response
ConsistencymetReproduced across statins, in the SEARCH randomized comparison, and in spontaneous-reporting databases
SpecificitypartialA class effect, not unique to simvastatin
Biological gradientmetRisk rises clearly with dose (20 vs 80 mg) and with interacting drugs
PlausibilitymetHMG-CoA reductase inhibition depletes muscle mevalonate-pathway intermediates
CoherencemetFits the whole statin-myopathy literature and CK-monitoring practice
ExperimentmetRandomized dose comparison (SEARCH) showed markedly more myopathy at 80 mg
AnalogymetDirect analogy to myopathy with other statins and with fibrate co-therapy

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No statin trial in the top search hits tracked rhabdomyolysis as a prespecified event at usable rates. The one results-posting study that surfaced the term (an alirocumab cardiovascular-outcomes trial, NCT01507831) recorded a single rhabdomyolysis case on treatment versus none on placebo — far too few events to inform the statin question. The risk is established from randomized dose-comparison (SEARCH) and decades of post-marketing surveillance, not from trial AE tables.
Causality: well established

Lamotrigine ↔ Stevens–Johnson syndrome / toxic epidermal necrolysis

Open this assessment on its own page →

n=2,615 co-reports · PRR 21.2 · ROR 21.6 Toxic epidermal necrolysis (related term): n=1,294 · PRR 14.9

Lamotrigine is the archetypal cause of drug-induced Stevens–Johnson syndrome (SJS) and its more severe form, toxic epidermal necrolysis (TEN) — blistering mucocutaneous reactions with substantial mortality. Risk is concentrated in the first 8 weeks of therapy and rises sharply with rapid dose escalation, which is why lamotrigine must be titrated slowly and why the FDA requires a boxed warning. The reaction is immune-mediated and genetically predisposed: the HLA-B*1502 allele markedly raises risk in several Asian populations, so genotyping is recommended before starting treatment in high-risk ancestry groups. Rare but precisely characterized, this is one of the clearest examples on the page of a genuine, mechanism-based severe adverse reaction rather than a reporting artifact.

Regulatory basis: FDA boxed warning for lamotrigine (serious skin rashes, SJS/TEN); HLA-B*1502 screening guidance. Observational case–control registries (e.g. EuroSCAR), 2008.

Bradford Hill viewpointStatusNote
Temporality (necessary)metReaction emerges within weeks of starting or after a dose increase
StrengthmetPRR 21 for SJS and 15 for TEN, both large
ConsistencymetReplicated across independent registries and the prescribing information
SpecificitymetLamotrigine is among the highest-risk drugs for SJS/TEN
Biological gradientmetRisk rises with rapid titration and higher starting doses
PlausibilitymetImmune-mediated, HLA-associated T-cell reaction — an established mechanism
CoherencemetCoheres with the anticonvulsant SJS/TEN literature
ExperimentpartialSlow-titration guidance reduces risk in practice; no randomized exposure trial exists
AnalogymetDirectly analogous to carbamazepine- and phenytoin-associated SJS/TEN

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — lamotrigine vs levetiracetam vs carbamazepine in elderly epilepsy (NCT00438451), N=360

Term (as recorded)Levetiracetam (n=122)Carbamazepine (n=121)Lamotrigine (n=117)
Rash (non-serious)762

Only the generic term “rash” was tracked — no SJS/TEN term appears, and no serious skin event was recorded on any arm in a trial this size. This is the expected picture: SJS/TEN is rare enough that ordinary trials cannot detect it, which is why the risk was quantified through case–control registries and post-marketing reporting rather than randomized data. View on ClinicalTrials.gov →

Causality: well established

Amiodarone ↔ Pulmonary fibrosis (interstitial lung disease)

Open this assessment on its own page →

n=395 co-reports · PRR 39.7 · ROR 41.1 Interstitial lung disease (related term): n=271 · PRR 10.6

Amiodarone is a highly lipophilic antiarrhythmic that accumulates in tissue, and its best-known serious long-term toxicity is pulmonary — pneumonitis that can progress to irreversible fibrosis. Because it is used long-term and its tissue burden is cumulative, guidelines and the prescribing information recommend periodic chest imaging and pulmonary-function monitoring for patients on the drug. The reaction is idiosyncratic in timing but clearly exposure-related, and the same iodine-rich, tissue-sequestering pharmacology produces the drug's other signature effects — thyroid dysfunction (both hyper- and hypothyroidism), corneal microdeposits, and hepatotoxicity. The comparatively modest FAERS counts relative to its lethality reflect aggressive monitoring and the fact that amiodarone use has declined as safer antiarrhythmics and ablation have expanded.

Regulatory basis: amiodarone prescribing information (pulmonary toxicity, thyroid, hepatic, ocular monitoring). Established literature on amiodarone-induced pulmonary toxicity.

Bradford Hill viewpointStatusNote
Temporality (necessary)metPneumonitis typically emerges after months of cumulative exposure
StrengthmetPRR 40 for pulmonary fibrosis, one of the largest on the page despite modest counts
ConsistencymetReplicated across decades of case series and the prescribing information
SpecificitypartialAlso causes thyroid, corneal, and hepatic toxicity — not lung-specific
Biological gradientmetRisk tracks with cumulative dose/duration
PlausibilitymetLipophilic tissue accumulation and an iodine-rich molecule drive direct pneumocyte toxicity
CoherencemetCoheres with the broader amiodarone organ-toxicity profile
ExperimentpartialDrug discontinuation improves outcomes; no randomized exposure-removal trial
AnalogymetAnalogous to other drug-induced interstitial lung disease (e.g. nitrofurantoin, methotrexate)

This page's own qualitative read, not an automated/citation-gated assessment.

✗ Searched; the trial that surfaced was not evidence either way. The top results-posting amiodarone study (a rate- vs rhythm-control atrial-fibrillation trial, NCT02132767) captured only a single “pulmonary embolism” term in one arm — an unrelated vascular event, not drug-induced lung fibrosis. Amiodarone's pulmonary toxicity develops over months to years, far beyond the follow-up window of typical registered trials, which is why it was characterized through long-term cohort and case data instead.
Causality: well established

Allopurinol ↔ DRESS syndrome (drug reaction with eosinophilia and systemic symptoms)

Open this assessment on its own page →

n=2,952 co-reports · PRR 17.5 · ROR 17.8 Toxic epidermal necrolysis (related term): n=1,170 · PRR 11.3

Allopurinol is one of the leading causes of severe cutaneous adverse reactions worldwide — a spectrum that includes DRESS (a systemic hypersensitivity reaction with rash, fever, eosinophilia, and organ involvement), Stevens–Johnson syndrome, and toxic epidermal necrolysis. The risk is strongly genetically determined: the HLA-B*5801 allele confers a markedly elevated risk (especially in Han Chinese, Thai, and Korean populations), and screening is recommended before starting the drug in high-risk groups. The reaction is delayed (typically 2–8 weeks after initiation), immune-mediated, and can be fatal, particularly in patients with chronic kidney disease or in elderly patients. It is one of the best-documented pharmacogenomic adverse reactions in medicine.

Regulatory basis: allopurinol prescribing information (severe skin reactions); HLA-B*5801 screening recommendation (ACR/CPIC). Established DRESS/SJS/TEN pharmacogenomics literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metReaction is delayed but consistently follows initiation by 2–8 weeks
StrengthmetPRR 18 for DRESS and 11 for TEN, both large
ConsistencymetReplicated across registries and pharmacogenomic studies worldwide
SpecificitymetAllopurinol is a leading cause of severe cutaneous adverse reactions
Biological gradientmetRisk rises with dose and with renal impairment (higher oxypurinol levels)
PlausibilitymetHLA-restricted T-cell activation of oxypurinol-specific clones is well described
CoherencemetCoheres with the broader DRESS/SJS/TEN immunogenetics literature
ExperimentmetHLA-B*5801 screening and renal dose-adjustment reduce risk in practice
AnalogymetAnalogous to carbamazepine/abacavir HLA-linked hypersensitivity syndromes

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — allopurinol vs placebo in heart failure with hyperuricaemia (NCT00987415), N=253

Term (as recorded)Allopurinol (n=128)Placebo (n=125)
Rash (serious)20
Rash (non-serious)113

Rash appears more often on allopurinol, consistent with its well-known cutaneous propensity — but this small trial tracked only generic “rash,” not DRESS or SJS/TEN, which are rare enough to be invisible at this size. The severe-reaction risk is established from pharmacovigilance and HLA-stratified studies, not from trial AE tables. View on ClinicalTrials.gov →

Causality: well established

Lisinopril (ACE inhibitors) ↔ Angioedema

Open this assessment on its own page →

n=6,693 co-reports · PRR 12.2 · ROR 12.4

Angioedema is the classic non-cough serious adverse effect of ACE inhibitors: swelling of the lips, tongue, face, or upper airway that can compromise breathing. The mechanism is well defined — ACE (kininase II) inhibition reduces bradykinin breakdown, and bradykinin accumulation increases vascular permeability. The reaction is a class effect, estimated in the low single-digit per-thousand range, may occur at any time (including months or years into therapy), and is disproportionately reported in patients of African ancestry. Because no ACE inhibitor is clearly safer than another, the labeling carries a class-wide warning and patients who develop it are switched to an ARB. The high FAERS count reflects the enormous population on ACE inhibitors and the severity that drives reporting.

Regulatory basis: ACE-inhibitor class labeling (angioedema warning; contraindication with hereditary/idiopathic angioedema). ONTARGET trial (2008) quantified the ACEI-vs-ARB angioedema difference in practice.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOccurs during exposure, often early but sometimes after prolonged use
StrengthmetPRR 12 on a large co-report count
ConsistencymetReproduced across ACE inhibitors and in randomized comparisons (ONTARGET)
SpecificitymetNotably more common with ACE inhibitors than with ARBs
Biological gradientpartialNot clearly dose-related; risk varies more by ancestry than by dose
PlausibilitymetBradykinin accumulation from ACE inhibition — a well-characterized mechanism
CoherencemetCoheres with the class-wide effect and the ARB-switch practice
ExperimentmetRandomized ONTARGET showed ACEI angioedema exceeding ARB, with rechallenge evidence off-drug
AnalogymetAnalogous to ACE-inhibitor cough (same kinin mechanism)

This page's own qualitative read, not an automated/citation-gated assessment.

✗ Searched; the trial that surfaced was not evidence either way. The top results-posting ACE-inhibitor study (VA NEPHRON-D, NCT00555217) tracked only generic oedema/swelling terms — not angioedema specifically — with a handful of events in each arm. Angioedema is rare enough (and trials of this size too small) that the risk was established from the randomized ONTARGET comparison and large observational cohorts, not from a trial’s adverse-event table.
Causality: well established

Empagliflozin (SGLT2 inhibitors) ↔ Diabetic ketoacidosis

Open this assessment on its own page →

n=3,864 co-reports · PRR 60.2 · ROR 63.8

SGLT2 inhibitors including empagliflozin cause a distinctive ketoacidosis that can occur at near-normal blood glucose levels — so-called euglycaemic diabetic ketoacidosis — which makes it easy to miss because clinicians are taught to screen for DKA using glucose alone. The FDA warned about this in 2015 and required labeling changes, and the mechanism is now understood: glucosuria masks the usual hyperglycaemic signal while the drugs shift substrate use toward ketogenesis, especially during fasting, illness, surgery, or insulin reduction. Risk is higher with off-label use for weight loss, in type 1 diabetes, and around procedures. It is a genuine, mechanistically coherent class effect with a clear regulatory history, and the large PRR here reflects both the true risk and the intensive reporting prompted by the FDA warning.

Regulatory basis: FDA safety communications on SGLT2-inhibitor ketoacidosis (2015), with subsequent labeling changes. SGLT2-inhibitor DKA literature (euglycaemic DKA).

Bradford Hill viewpointStatusNote
Temporality (necessary)metOccurs during exposure, often triggered by fasting, illness, or insulin changes
StrengthmetPRR 60, one of the largest class signals on the page
ConsistencymetReported across the whole SGLT2 class and multiple countries
SpecificitymetThe euglycaemic pattern is characteristic of SGLT2 inhibitors
Biological gradientpartialHigher with off-label weight-loss use and type 1 diabetes than standard type 2 dosing
PlausibilitymetGlucosuria plus a shift toward ketogenesis — a defined metabolic mechanism
CoherencemetCoheres with the shared class pharmacology and the FDA warning
ExperimentpartialLabeled precautions and peri-procedural drug holds reduce risk; no dedicated randomized trial
AnalogymetDirectly analogous across all SGLT2 inhibitors

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — empagliflozin vs DPP-4 inhibitors, post-authorization safety study (NCT03764631), N=1,502

Term (as recorded)Empagliflozin (n=751)DPP-4 inhibitors (n=751)
Diabetic ketoacidosis (serious)11

This dedicated post-authorization study tracked ketoacidosis as a prespecified event — confirming it is a recognized SGLT2 risk — but recorded only one event per arm over 12 months, far too few to quantify the difference. The signal was established from spontaneous reporting and the FDA’s 2015 safety review, not from a trial this size. View on ClinicalTrials.gov →

Causality: well established

Clozapine ↔ Myocarditis

Open this assessment on its own page →

n=2,231 co-reports · PRR 41.1 · ROR 41.8

Clozapine, the most effective antipsychotic for treatment-resistant schizophrenia, carries two notorious blood-and-heart risks: agranulocytosis (its most famous, covered separately on this page) and myocarditis, an inflammatory heart-muscle reaction concentrated in the first weeks to months of treatment. Myocarditis can be fatal, and because it is most common during the initiation period, regulators require baseline and early monitoring (troponin, CRP, and clinical review of chest pain, tachycardia, or heart failure symptoms). The mechanism is thought to be a hypersensitivity or cytokine-mediated reaction rather than a simple dose effect, which is why it can strike at standard doses. Recognition of the risk has grown steadily, and several health agencies issued specific alerts in the 2010s; the large PRR here reflects both the true risk and the increasingly routine cardiac monitoring around clozapine starts.

Regulatory basis: clozapine labeling (myocarditis/cardiomyopathy warnings); medicines-agency alerts on clozapine myocarditis (e.g. MHRA, 2010s). Established clozapine myocarditis literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metConcentrated in the first weeks–months after initiation — a striking temporal signature
StrengthmetPRR 41, one of the largest cardiac signals associated with a psychiatric drug
ConsistencymetReplicated across national pharmacovigilance systems and registries
SpecificitypartialRarely reported with most other antipsychotics, but not unique to clozapine
Biological gradientpartialNot clearly dose-related — consistent with an idiosyncratic hypersensitivity reaction
PlausibilitypartialA hypersensitivity/cytokine mechanism is proposed but less precisely defined than for agranulocytosis
CoherencemetCoheres with the early-monitoring requirement in the label
ExperimentpartialStopping the drug when myocarditis is suspected improves outcomes; no randomized trial
AnalogypartialSome analogy to drug-induced hypersensitivity myocarditis (e.g. with other drugs)

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for clozapine captured myocarditis as a tracked adverse event. Consistent with the mechanism: the reaction is rare, occurs soon after initiation, and typical clozapine trials enroll too few patients (and run safety monitoring that would stop the drug) for an AE table to show it — which is why the signal was identified through post-marketing surveillance and national registries instead.
Causality: well established

Venlafaxine (serotonergic antidepressants) ↔ Serotonin syndrome

Open this assessment on its own page →

n=2,520 co-reports · PRR 24.1 · ROR 24.5

Serotonin syndrome is a predictable, dose-related toxidrome — agitation, clonus, hyperthermia, autonomic instability — produced by excess central serotonergic activity, typically when a serotonergic drug is combined with another (an MAOI, tramadol, triptan, linezolid, lithium, or another antidepressant) or when doses are escalated. Venlafaxine is a potent serotonin-reuptake inhibitor at lower doses, and its risk rises if larger doses begin to add noradrenergic effects; like all serotonergic antidepressants, it carries a labeling warning about the syndrome and about combinations to avoid. The mechanism is about as well understood as any in psychopharmacology, which is why the diagnosis is made clinically and managed by stopping the offending agents rather than through trial data. The large PRR reflects the scale of antidepressant prescribing and the syndrome's seriousness.

Regulatory basis: venlafaxine/SSRI/SNRI class labeling (serotonin syndrome warning; MAOI and serotonergic-combination cautions). Established serotonin-syndrome literature (Hunter criteria).

Bradford Hill viewpointStatusNote
Temporality (necessary)metOnset follows starting, escalating, or adding a serotonergic drug
StrengthmetPRR 24 with a large co-report count
ConsistencymetReproduced across the whole serotonergic class and in the literature
SpecificitypartialA class-wide effect, not unique to venlafaxine
Biological gradientmetClearly dose-related and combination-related
PlausibilitymetExcess central serotonin is the established cause
CoherencemetCoheres with the Hunter criteria and the class labeling
ExperimentmetWithdrawing the offending agents reliably resolves it — a consistent dechallenge
AnalogymetDirectly analogous across SSRIs, SNRIs, MAOIs, and tramadol

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for venlafaxine captured serotonin syndrome as a tracked adverse event. The syndrome is an acute, combination-related toxidrome that would rarely be captured as a coded trial event; its evidence base is clinical and pharmacovigilance-based (the Hunter criteria), not randomized.
Causality: well established

Citalopram ↔ QT prolongation

Open this assessment on its own page →

n=1,712 co-reports · PRR 7.7 · ROR 7.7

Citalopram produces a dose-dependent prolongation of the QT interval on the electrocardiogram, which in susceptible patients can progress to the dangerous ventricular arrhythmia torsades de pointes. The effect was confirmed by dedicated “thorough QT” studies, and in 2011–2012 the FDA issued a safety communication restricting the maximum dose (to 40 mg/day for adults, 20 mg/day for those over 60, and lower in hepatic impairment or with CYP2C19 inhibitors), with a similar action from European regulators. Notably, the closely related SSRI escitalopram carries a smaller effect, which is part of why citalopram is treated as the more QT-active of the two. This is a well-quantified, mechanism-based cardiac effect — not a reporting artifact — established through dedicated ECG trials rather than post-marketing impression.

Regulatory basis: FDA drug-safety communication on citalopram QT prolongation and maximum-dose restriction (2011–2012); EMA equivalent. Thorough-QT-study data.

Bradford Hill viewpointStatusNote
Temporality (necessary)metQT change appears with exposure and resolves after discontinuation
StrengthpartialPRR 8, moderate — a small ECG effect rather than a large event rate
ConsistencymetReproduced in dedicated QT studies and confirmed by regulators
SpecificitypartialShared to a lesser degree with other serotonergic and QT-active drugs
Biological gradientmetClearly dose-related — the basis for the maximum-dose restriction
PlausibilitymethERG-channel blockade prolonging cardiac repolarization — a defined mechanism
CoherencemetCoheres with the broader QT-prolongation pharmacology
ExperimentmetDedicated thorough-QT trials and the dose restriction are direct experimental evidence
AnalogymetAnalogous to other QT-prolonging drugs (e.g. methadone, ondansetron)

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for citalopram captured QT prolongation as a tracked adverse-event term. QT effects are measured with dedicated ECG endpoints rather than coded as adverse events in routine outcome trials, so the evidence base is the thorough-QT studies and the regulatory dose restriction, not trial AE tables.
Expected pharmacological effect

Spironolactone ↔ Hyperkalaemia

Open this assessment on its own page →

n=5,027 co-reports · PRR 25.1 · ROR 26.0

Spironolactone is a mineralocorticoid-receptor antagonist, and potassium retention is not a side effect of the drug so much as a direct extension of how it works: blocking aldosterone in the distal nephron reduces potassium excretion. Hyperkalaemia is therefore an expected, dose-related pharmacological consequence, and it is the principal safety concern when spironolactone is combined with ACE inhibitors, ARBs, or potassium supplements, or used in patients with chronic kidney disease. The landmark RALES trial in severe heart failure showed a survival benefit but also a real increase in serious hyperkalaemia, and the later TOPCAT trial and clinical experience reinforced that potassium must be monitored. This is graded “expected pharmacological effect” rather than a surprise signal — the high count reflects how widely the drug is used rather than an unexpected mechanism.

Regulatory basis: spironolactone prescribing information (hyperkalaemia warning and monitoring). RALES (1999) and TOPCAT (2014) randomized trials.

Bradford Hill viewpointStatusNote
Temporality (necessary)metPotassium rises during exposure and falls after withdrawal
StrengthmetPRR 25 on a large co-report count
ConsistencymetSeen consistently in trials (RALES, TOPCAT) and in practice
SpecificitymetDirectly tied to the drug's aldosterone-blocking mechanism
Biological gradientmetDose-related and worse with renal impairment or added RAAS blockade
PlausibilitymetReduced distal potassium excretion is the intended pharmacology, not an off-target effect
CoherencemetCoheres with the whole mineralocorticoid-antagonist class
ExperimentmetRandomized trials (RALES, TOPCAT) with structured potassium monitoring directly address it
AnalogymetAnalogous to eplerenone and other potassium-sparing diuretics

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — spironolactone vs placebo in heart failure with preserved ejection fraction (TOPCAT, NCT00094302), N=3,445

Term (as recorded)Spironolactone (n=1,722)Placebo (n=1,723)
HYPERKALEMIA — renal disorders (serious)205
HYPERKALEMIA — renal disorders (all)22696

Hyperkalaemia is roughly four times more common on spironolactone, on both serious and total events — direct randomized confirmation of the drug's expected potassium-retaining effect. This is what a genuinely expected pharmacological signal looks like when a trial measures it properly. View on ClinicalTrials.gov →

Expected pharmacological effect

Hydrochlorothiazide (thiazides) ↔ Hyponatraemia

Open this assessment on its own page →

n=2,897 co-reports · PRR 7.8 · ROR 8.0

Thiazide diuretics are a leading cause of hyponatraemia, particularly in older women, and the effect is a fairly direct consequence of their pharmacology: they impair urinary dilution and, over time, can produce the syndrome of inappropriate antidiuresis. Onset is often within the first few weeks of therapy, and serum sodium usually returns to normal after the drug is stopped. The risk is dose-related and rises with age, low body weight, and use of interacting drugs (SSRIs, carbamazepine), which is why monitoring of electrolytes after starting or changing a thiazide is standard practice. Like spironolactone's potassium effect, this is graded “expected pharmacological effect” — a well-understood class action rather than an unexpected idiosyncratic signal.

Regulatory basis: hydrochlorothiazide/thiazide prescribing information (hyponatraemia and electrolyte-monitoring warnings). Established thiazide-induced hyponatraemia literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metSodium falls during exposure, often in the first weeks, and recovers after withdrawal
StrengthpartialPRR 8, moderate — common in absolute terms but a modest disproportionality
ConsistencymetReproduced across thiazide agents and in the literature
SpecificitypartialShared with loop diuretics and other causes of SIADH
Biological gradientmetDose-related and worse with age, low body weight, and interacting drugs
PlausibilitymetImpaired urinary dilution / SIADH is the established mechanism
CoherencemetCoheres with the routine electrolyte monitoring after starting a thiazide
ExperimentmetSodium normalizes on drug withdrawal — a reliable, reproducible dechallenge
AnalogymetAnalogous to other diuretic-induced electrolyte disturbances

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for hydrochlorothiazide captured hyponatraemia as a tracked adverse-event term. Hyponatraemia is typically captured through routine electrolyte monitoring rather than coded as a trial endpoint, so the evidence base is the prescribing information and observational studies, not trial AE tables.
Causality: well established

Amoxicillin–clavulanate ↔ Cholestatic liver injury

Open this assessment on its own page →

n=563 co-reports · PRR 23.6 · ROR 24.0

Amoxicillin–clavulanate is consistently the single most common cause of drug-induced liver injury in Western registries, and the injury is characteristically cholestatic (jaundice and bile-duct enzyme elevation) rather than the hepatocellular pattern typical of many other drugs. It follows a distinctive delayed and sometimes biphasic course — often appearing 1–6 weeks after the course is finished — which makes the association easy to miss clinically. The clavulanate component is considered the culprit, independent of the amoxicillin. The reaction is the archetype of an idiosyncratic (not dose-related) drug reaction whose evidence came almost entirely from post-marketing surveillance and prospective DILI registries, which is exactly why the FAERS numbers here, though modest, are meaningful.

Regulatory basis: amoxicillin–clavulanate prescribing information (hepatic- injury warning). Prospective drug-induced liver injury registry data (e.g. DILIN).

Bradford Hill viewpointStatusNote
Temporality (necessary)metOnset characteristically 1–6 weeks after the course, sometimes biphasic
StrengthmetPRR 24 for a relatively rare outcome
ConsistencymetLeading cause of DILI across independent prospective registries
SpecificitymetThe cholestatic pattern is characteristic of this drug pair
Biological gradientnot establishedIdiosyncratic — not clearly dose-related
PlausibilitypartialAttributed to clavulanate; a specific immune/metabolic mechanism is plausible but not fully mapped
CoherencemetCoheres with the DILI-registry literature and the label warning
ExperimentpartialRechallenge generally reproduces injury in case series; not an ethical randomized test
AnalogymetAnalogous to other idiosyncratic cholestatic drug reactions (e.g. flucloxacillin)

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — amoxicillin–clavulanate vs tigecycline for skin infections (NCT00368537), N=531

Term (as recorded)Amoxicillin–clavulanate / ampicillin–sulbactam (n=263)Tigecycline (n=268)
Hepatic failure (serious)10
Liver function tests abnormal (serious)10

Two hepatic events on the amoxicillin–clavulanate combination arm and none on the comparator, in a short antibiotic trial — directionally consistent, but far too few events to quantify a risk that is genuinely idiosyncratic and rare (and often delayed past the trial window). The association rests on prospective DILI registries, not trial AE tables. View on ClinicalTrials.gov →

Causality: well established

Isoniazid ↔ Drug-induced liver injury

Open this assessment on its own page →

n=862 co-reports · PRR 37.4 · ROR 39.5

Isoniazid is one of the classic causes of drug-induced liver injury, and its hepatotoxicity is the reason that liver enzymes are monitored during tuberculosis treatment and preventive therapy. Two patterns are described: a common, mild, transient rise in transaminases that often resolves despite continued therapy, and a rare, severe hepatocellular injury that can progress to fulminant hepatic failure. Risk rises with age, alcohol use, and concomitant rifampicin, and age-based monitoring thresholds are built into the labeling and public-health guidance. Because isoniazid remains a cornerstone of TB treatment worldwide, the liver signal is not a reason to avoid the drug but a reason to monitor it — an important reminder that “well established” does not always mean “avoid.”

Regulatory basis: isoniazid prescribing information (hepatotoxicity warning and monitoring); TB-treatment guidelines with age-based LFT thresholds. Established isoniazid hepatotoxicity literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metEnzyme rise typically occurs weeks into therapy
StrengthmetPRR 37 on a moderate co-report count
ConsistencymetReproduced across decades of TB-therapy cohorts and trials
SpecificitypartialShared with rifampicin and pyrazinamide in the same regimen
Biological gradientmetRisk rises with age, alcohol, and co-administered rifampicin
PlausibilitymetMetabolism to a toxic hydrazine intermediate via NAT2/CYP2E1 is well described
CoherencemetCoheres with the routine LFT monitoring built into TB care
ExperimentmetRandomized TB-prevention trials include structured hepatic-event reporting
AnalogymetAnalogous to other metabolically activated hepatotoxins (e.g. acetaminophen)

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — isoniazid-containing short-course vs standard TB-prevention regimens (BRIEF TB, NCT01404312), N=3,000

Term (as recorded)4-month rifapentine+isoniazid (n=1,496)9-month isoniazid (n=1,504)
Drug-induced liver injury (serious)12
Hepatitis / hepatotoxicity (serious)30
Hepatic enzyme increased (serious)17

Hepatic events appear on both isoniazid-containing arms, with a distinct cluster of elevated liver enzymes on the 9-month isoniazid arm — direct randomized confirmation that the liver is the target organ for this drug, even in a large modern prevention trial. View on ClinicalTrials.gov →

Causality: well established

Vancomycin ↔ Acute kidney injury

Open this assessment on its own page →

n=4,892 co-reports · PRR 10.6 · ROR 11.4

Vancomycin, a workhorse antibiotic for MRSA, is a recognized cause of acute kidney injury, and the risk is dose- and exposure-related — particularly with high trough levels and with concomitant piperacillin–tazobactam or other nephrotoxins. The label carries a nephrotoxicity warning and recommends monitoring of renal function, and modern practice uses area-under-the-curve dosing to reduce the risk. Because vancomycin is so widely used, this is one of the very few serious antibiotic reactions where a “more of the drug, more of the effect” exposure relationship can be demonstrated directly, making it a cleaner signal than many idiosyncratic reactions. The large FAERS count reflects both the true effect and the drug's enormous clinical volume.

Regulatory basis: vancomycin prescribing information (nephrotoxicity warning and renal monitoring). Randomized comparative antibiotic trials (e.g. telavancin vs vancomycin).

Bradford Hill viewpointStatusNote
Temporality (necessary)metCreatinine rises during therapy and usually recovers on drug cessation
StrengthmetPRR 11 on a very large co-report count
ConsistencymetReproduced across randomized trials and cohort studies
SpecificitypartialCommon to several antimicrobials; worse with combined nephrotoxins
Biological gradientmetClearly linked to drug exposure/trough levels and to co-administered piperacillin–tazobactam
PlausibilitymetProximal-tubular toxicity from oxidative stress is well described
CoherencemetCoheres with the shift to AUC-based dosing and renal monitoring
ExperimentpartialRandomized trials report renal events but are not designed to quantify nephrotoxicity
AnalogymetAnalogous to aminoglycoside nephrotoxicity

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — telavancin vs vancomycin for complicated skin infections (NCT00107978), N=1,012

Term (as recorded)Vancomycin (n=509)Telavancin (n=503)
Renal failure acute (serious)03
Blood creatinine increased (serious)03
Blood Creatinine Increased (non-serious)39

In this head-to-head trial the comparator (telavancin) showed the greater renal signal, not vancomycin — a useful reminder that vancomycin’s nephrotoxicity is real but modest at standard doses and clearly amplified by high exposure and co-nephrotoxins, which is the setting where most spontaneous reports arise. View on ClinicalTrials.gov →

Causality: well established

Linezolid ↔ Thrombocytopenia

Open this assessment on its own page →

n=2,199 co-reports · PRR 14.2 · ROR 15.3

Linezolid, an oxazolidinone antibiotic for resistant Gram-positive infections, causes reversible myelosuppression — most often thrombocytopenia, but also anaemia and, less commonly, leukopenia. Risk is clearly duration-dependent: it rises sharply after about two weeks of therapy, which is why the label recommends weekly blood counts and cautious use beyond 14–28 days. The mechanism is a time-dependent suppression of bone-marrow precursor proliferation, distinct from the immune-mediated cytopenias of some other drugs. Because it is dose- and duration-related and recovers off-drug, it behaves more like a predictable toxic effect than an idiosyncratic one, making it one of the cleanest antibiotic haematologic signals. The large count reflects both the true effect and the drug's role as a last-line MRSA agent.

Regulatory basis: linezolid prescribing information (myelosuppression warning; weekly blood-count monitoring). Randomized comparative antibiotic trials (linezolid vs tedizolid).

Bradford Hill viewpointStatusNote
Temporality (necessary)metPlatelet count falls during therapy and recovers after it stops
StrengthmetPRR 14 on a moderate co-report count
ConsistencymetReproduced across randomized trials and cohorts
SpecificitypartialShared with other myelosuppressive and infectious causes of low platelets
Biological gradientmetSharply duration-dependent — the basis for the weekly-count guidance
PlausibilitymetReversible suppression of bone-marrow precursors is well described
CoherencemetCoheres with the label's monitoring requirement
ExperimentmetRandomized head-to-head trials with platelet endpoints confirm the signal
AnalogymetAnalogous to chloramphenicol-associated myelosuppression

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — linezolid vs tedizolid for hospital-acquired pneumonia (NCT02019420), N=718

Term (as recorded)Linezolid (n=361)Tedizolid (n=357)
Thrombocytopenia (serious)50

Serious thrombocytopenia appears on the linezolid arm and not on the comparator — direct randomized evidence that even within a short treatment course, linezolid suppresses platelets more than a related newer agent. The duration-dependent escalation seen in practice is captured only partly by trials of this length. View on ClinicalTrials.gov →

Causality: well established

Methimazole ↔ Agranulocytosis

Open this assessment on its own page →

n=259 co-reports · PRR 38.2 · ROR 39.4

The antithyroid drugs methimazole and propylthiouracil are classic causes of drug-induced agranulocytosis, a sudden loss of neutrophil granulocytes that leaves patients vulnerable to severe infection. It is the single most feared haematologic complication of treating hyperthyroidism, and it typically appears within the first weeks to months of therapy. Because it can be sudden, patients are counselled to seek urgent care for fever or sore throat — a classic “report immediately” symptom drill taught for this drug class. The reaction is idiosyncratic rather than dose-related, so it cannot be prevented by dose alone; the PRR here is very high for a rare event, and the modest absolute count reflects how uncommon agranulocytosis is even among treated patients.

Regulatory basis: methimazole and propylthiouracil prescribing information (agranulocytosis warning; fever/sore-throat counselling). Established antithyroid-drug agranulocytosis literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metTypically appears within weeks–months of starting the drug
StrengthmetPRR 38 for a rare, serious event
ConsistencymetA long-recognized class effect of antithyroid drugs
SpecificitymetAmong the defining serious risks of methimazole and propylthiouracil
Biological gradientnot establishedIdiosyncratic — not clearly dose-related
PlausibilitypartialAn immune-mediated mechanism is accepted; the precise target is not fully mapped
CoherencemetCoheres with the label warning and the fever/sore-throat counselling
ExperimentpartialRecovery on withdrawal and G-CSF support is consistent; no randomized test
AnalogymetAnalogous to clozapine- and sulfonamide-associated agranulocytosis

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial surfaced for methimazole with agranulocytosis as a tracked event — the drug is used in routine endocrine practice rather than in large registered trials, and the reaction is too rare for the studies that do exist to capture. The evidence base is decades of clinical case series and the prescribing information, not trial AE data.
Causality: well established

Topiramate ↔ Acute angle-closure glaucoma

Open this assessment on its own page →

n=597 co-reports · PRR 68.7 · ROR 69.2 Ocular pain / secondary angle-closure (related terms): further co-reports

Topiramate, used for epilepsy, migraine prevention, and weight management, has a distinctive and well-documented ocular toxicity: a secondary acute angle-closure glaucoma that develops within days to weeks of starting or increasing the dose. It is caused by drug-induced effusion into the ciliary body and lens, which pushes the iris forward and closes the angle — a mechanism quite different from primary angle-closure. The presentation mimics a neurological event (severe headache, eye pain, blurred vision), which is a recognised diagnostic trap, and it resolves when the drug is withdrawn. The FDA labeling carries a specific warning, and it is treated as a medical emergency because vision can be permanently lost if unrecognised. The very high PRR reflects how characteristic and unusual this reaction is.

Regulatory basis: topiramate prescribing information (secondary angle-closure glaucoma warning). Established topiramate-induced acute myopia/angle-closure literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDevelops within days–weeks of starting or dose increase
StrengthmetPRR 69, one of the largest ocular signals on the page
ConsistencymetReplicated across case series and the prescribing information
SpecificitymetThe secondary (ciliary-effusion) mechanism is characteristic of topiramate
Biological gradientpartialMore common at higher doses/rapid titration, but reported at standard doses
PlausibilitymetCiliary-body effusion pushing the iris forward is a defined mechanism
CoherencemetCoheres with the label warning and the classic secondary-closure picture
ExperimentmetPrompt drug withdrawal reliably reverses it — a consistent dechallenge
AnalogymetAnalogous to other sulfonamide-derived carbonic-anhydrase-inhibitor ocular effects

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — topiramate vs placebo (NCT01110434), N=66

Term (as recorded)Topiramate (n=40)Placebo (n=26)
Changes in vision (non-serious, eye disorders)40

Visual symptoms cluster on the topiramate arm and not on placebo even in a very small trial, directionally consistent with the drug's ocular toxicity — though the specific term tracked here is generic visual change, not angle-closure, which is rare and usually diagnosed outside trial settings. View on ClinicalTrials.gov →

Causality: well established

Hydroxychloroquine ↔ Retinopathy

Open this assessment on its own page →

n=290 co-reports · PRR 23.7 · ROR 23.8

Hydroxychloroquine, a mainstay of treatment for lupus and rheumatoid arthritis, can cause a cumulative-dose retinal toxicity that, if not caught, becomes irreversible and can progress even after the drug is stopped. The risk is driven by daily dose per kilogram of body weight and by duration of use, and ophthalmology has moved to annual screening with sensitive imaging (optical coherence tomography and visual fields) precisely because early changes are reversible while late damage is not. Age and kidney disease raise the risk, and standard thresholds for maximum daily dose and screening intervals are now embedded in professional guidelines and the labeling. This is a model example of a chronic, cumulative-dose-dependent toxicity where the “biological gradient” is central to how the drug is monitored.

Regulatory basis: hydroxychloroquine prescribing information (ocular toxicity warning). American Academy of Ophthalmology screening guidelines (dose and interval thresholds).

Bradford Hill viewpointStatusNote
Temporality (necessary)metDamage accumulates over years of exposure
StrengthmetPRR 24 for a slowly developing, under-reported outcome
ConsistencymetReplicated across large rheumatology cohorts
SpecificitypartialShared with the related drug chloroquine
Biological gradientmetStrongly cumulative dose- and duration-dependent — the basis for screening thresholds
PlausibilitymetDrug accumulates in retinal pigment epithelium and causes characteristic photoreceptor loss
CoherencemetCoheres with the AAO screening guidance
ExperimentpartialEarly detection reverses the trend; no randomized exposure trial is feasible
AnalogymetAnalogous to chloroquine retinopathy (the historical index case)

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for hydroxychloroquine captured retinopathy as a tracked adverse event. Retinal toxicity develops over many years of therapy, far outside ordinary trial follow-up, and is detected by dedicated ophthalmic imaging rather than coded as a trial endpoint — so its evidence base is long-term cohort data and ophthalmology screening guidelines.
Causality: well established

Montelukast ↔ Neuropsychiatric events

Open this assessment on its own page →

n=2,210 co-reports · PRR 27.3 · ROR 27.8 Nightmare / aggression / depression (related terms): further co-reports

Montelukast, widely prescribed for asthma and allergic rhinitis, causes a range of neuropsychiatric effects — sleep disturbance, nightmares, mood change, aggression, and rarely suicidal thinking. The signal accumulated for years through case reports, product complaints, and regulatory review, and in 2020 the FDA added a boxed warning and advised prescribers to reserve the drug for allergic rhinitis when other treatments are inadequate. The mechanism is debated — montelukast crosses the blood–brain barrier and blocks cysteinyl-leukotriene receptors in the brain — but the regulatory action and the consistency of the reports have made this a well-accepted class warning. Because the symptoms are common in the general population and in children, distinguishing a real drug effect from background rates is genuinely hard, which is exactly why the evidence rested on regulatory review rather than a single trial.

Regulatory basis: FDA boxed warning for montelukast neuropsychiatric events (2020), with revised prescribing advice. Large observational and reporting analyses of montelukast neuropsychiatric events.

Bradford Hill viewpointStatusNote
Temporality (necessary)metSymptoms typically begin after starting and abate after stopping
StrengthmetPRR 27 on a large co-report count
ConsistencymetReproduced across reporting systems, cohorts, and the regulatory review
SpecificitypartialBackground rates of these common symptoms make specificity hard to establish
Biological gradientpartialNot clearly dose-related, though timing often follows initiation
PlausibilitypartialCNS leukotriene-receptor blockade is plausible; the precise mechanism is debated
CoherencemetCoheres with the boxed warning and the reporting-product-complaint history
ExperimentpartialDechallenge (symptom resolution on stopping) is the main experimental support
AnalogypartialSome analogy to other drugs with CNS behavioural effects in children

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — montelukast vs inhaled corticosteroids (NCT00394355), N=566

Term (as recorded)Montelukast (n=142)Inhaled steroid arms (n=424)
Anxiety (serious)01
Depression (serious)01

No neuropsychiatric events were recorded on the montelukast arm in this one-year asthma study — the honest counterpoint being that such trials were not designed or powered to detect the rare, subjective events that drove the boxed warning. The risk was established from regulatory review of reporting data, not from this kind of trial table. View on ClinicalTrials.gov →

Causality: well established

Pembrolizumab (checkpoint inhibitors) ↔ Hypothyroidism

Open this assessment on its own page →

n=2,917 co-reports · PRR 20.1 · ROR 20.7 Hyperthyroidism / thyroiditis (related terms): further co-reports

Immune-checkpoint inhibitors such as pembrolizumab work by unleashing the immune system against cancer, and a predictable consequence is that the same immune activation can attack healthy organs — so-called immune-related adverse events. Thyroid dysfunction is the single most common endocrine irAE: patients frequently develop an early, transient hyperthyroid phase (thyroiditis) followed by hypothyroidism requiring lifelong replacement. In the clinical trials this is usually called thyroid disorders. Because these events are frequent, mechanistically understood, and manageable with hormone replacement, the labeling and oncology guidelines require baseline and periodic thyroid-function testing during therapy; unlike many signals on this page, this one is routinely captured in trial data precisely because it is so common.

Regulatory basis: pembrolizumab prescribing information (immune-mediated thyroid disorders; monitoring guidance). Randomized trial results (e.g. KEYNOTE-010).

Bradford Hill viewpointStatusNote
Temporality (necessary)metThyroid changes appear during therapy, often an early hyperthyroid phase then hypothyroidism
StrengthmetPRR 20 with a large co-report count and high event rates in trials
ConsistencymetReproduced across the whole checkpoint-inhibitor class and across trials
SpecificitymetA distinctive class effect of immune-checkpoint blockade, rare with most non-immunotherapy drugs
Biological gradientpartialBroadly related to immune activation rather than to a simple dose gradient
PlausibilitymetRelease of T-cell checkpoint restraint leads directly to organ-directed autoimmunity
CoherencemetCoheres with the broader immune-related AE spectrum (colitis, pneumonitis, hypophysitis)
ExperimentmetRandomized trials (e.g. KEYNOTE-010) directly measure thyroid-event rates by arm
AnalogymetAnalogous across all PD-1/PD-L1 inhibitors

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — pembrolizumab (2 vs 10 mg/kg) vs docetaxel in NSCLC (KEYNOTE-010, NCT01905657), N=1,030

Term (as recorded)Pembrolizumab 2 mg/kg (n=339)Pembrolizumab 10 mg/kg (n=343)Docetaxel (n=309)
Hypothyroidism (non-serious)29291
Hyperthyroidism (non-serious)12193

Thyroid events are roughly 30-fold more frequent on pembrolizumab than on chemotherapy in a randomized trial — one of the strongest trial-level confirmations on this page, reflecting how common and measurable immune-checkpoint thyroid toxicity is. The hyperthyroid-then-hypothyroid sequence typical of thyroiditis is visible in the combined counts. View on ClinicalTrials.gov →

Expected pharmacological effect

Digoxin ↔ Bradycardia / AV block

Open this assessment on its own page →

n=2,533 co-reports · PRR 14.7 · ROR 15.2

Digoxin inhibits the sodium–potassium ATPase and raises vagal tone, so slowing of atrioventricular conduction is the direct, dose-related extension of its intended pharmacology rather than an idiosyncratic effect. Bradycardia and AV block cluster in older patients, in renal impairment (reduced digoxin clearance), and with electrolyte disturbance or interacting drugs such as amiodarone, verapamil, and beta-blockers. The 2,533 co-reports (PRR 14.7) reflect both a genuine effect and the very large population still taking a centuries-old drug.

Regulatory basis: digoxin prescribing information (bradycardia/AV block; therapeutic drug-level and ECG monitoring).

Bradford Hill viewpointStatusNote
Temporality (necessary)metBradycardia appears during exposure and resolves on dose reduction or withdrawal
StrengthmetPRR 15 on a large co-report count for a drug whose whole mechanism slows conduction
ConsistencymetReproduced across decades of use and in the prescribing literature
SpecificitypartialShared with other AV-node-slowing drugs (beta-blockers, verapamil, amiodarone)
Biological gradientmetRisk rises with dose, renal impairment, and electrolyte disturbance
PlausibilitymetNa/K-ATPase inhibition plus raised vagal tone directly slow the AV node
CoherencemetCoheres with routine therapeutic drug-level monitoring for digoxin
ExperimentpartialDechallenge (dose reduction or withdrawal) reliably reverses it; no dedicated randomized trial
AnalogymetAnalogous to bradycardia with other AV-nodal blocking agents

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for digoxin captured bradycardia or AV block as a tracked adverse event — such a familiar, monitorable effect is handled by routine drug-level and ECG monitoring rather than coded into trial AE tables.
Causality: well established

Hydralazine ↔ Drug-induced lupus

Open this assessment on its own page →

n=52 co-reports · PRR 11.8 · ROR 12.0

Hydralazine is the archetypal cause of drug-induced lupus erythematosus — arthralgia, myalgia, fever, and serositis with anti-histone antibodies, almost never involving the kidney. It is a genuine drug effect rather than unmasked idiopathic lupus, is related to dose and duration, is commoner in slow acetylators, and typically resolves after withdrawal. The 52 FAERS co-reports (PRR 11.8) are modest because the syndrome is uncommon and often managed without being reported, but the drug–event link is among the best established in drug-induced autoimmunity.

Regulatory basis: hydralazine prescribing information (drug-induced lupus warning); the classic anti-histone drug-induced-lupus literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metLupus features appear after weeks–months of hydralazine and remit after withdrawal
StrengthpartialPRR 12, but on a small co-report count — a modest statistical signal for a well-known effect
ConsistencymetReproduced across decades of case series and reviews of drug-induced lupus
SpecificitymetA distinctive anti-histone-antibody syndrome, unlike idiopathic SLE
Biological gradientmetDose- and duration-related, and commoner in slow acetylators
PlausibilitymetHydralazine's reactive metabolites are thought to trigger the anti-histone response
CoherencemetCoheres with the routine practice of stopping the drug and watching symptoms resolve
ExperimentpartialDechallenge (withdrawal) is the classic confirmatory test; no randomized trial
AnalogymetAnalogous to procainamide- and minocycline-induced lupus

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for hydralazine captured drug-induced lupus; the syndrome develops over months, is uncommon, and is identified through case series rather than trial AE tables.
Causality: well established

Penicillamine ↔ Proteinuria / membranous nephropathy

Open this assessment on its own page →

n=65 co-reports · PRR 78.6 · ROR 84.5

Penicillamine, used in Wilson's disease, cystinuria, and historically in rheumatoid arthritis, is a well-recognised cause of membranous nephropathy presenting as proteinuria, sometimes progressing to nephrotic syndrome. The effect is dose-related, usually emerges after months of therapy, and frequently improves when the drug is stopped. The 65 FAERS co-reports (PRR 78.6) are dominated by proteinuria rather than overt nephrotic syndrome because routine urinalysis during penicillamine therapy catches it early; the mechanism is thought to involve immune-complex deposition in the glomerulus.

Regulatory basis: penicillamine prescribing information (proteinuria; routine urinalysis monitoring). Established penicillamine membranous-nephropathy literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metProteinuria develops after months of exposure and often improves after withdrawal
StrengthpartialPRR 79 on a small co-report count — a large relative signal on small absolute numbers
ConsistencymetReproduced across decades of penicillamine-nephropathy case series
SpecificitymetMembranous nephropathy is a fairly distinctive drug-related pattern
Biological gradientmetDose-related; risk rises with higher cumulative exposure
PlausibilitymetImmune-complex deposition in the glomerulus is the proposed mechanism
CoherencemetCoheres with routine urinalysis monitoring during penicillamine therapy
ExperimentpartialDechallenge (withdrawal) frequently reduces proteinuria; no randomized trial
AnalogymetAnalogous to gold-salt-induced membranous nephropathy

This page's own qualitative read, not an automated/citation-gated assessment.

Not searched in ClinicalTrials.gov. Penicillamine trials are old and rarely post results to ClinicalTrials.gov, and proteinuria here is a monitored laboratory effect rather than a coded trial endpoint.
Causality: well established

Minoxidil (oral) ↔ Pericardial effusion

Open this assessment on its own page →

n=142 co-reports · PRR 2.9 · ROR 2.9

Oral minoxidil is a potent vasodilator reserved for refractory hypertension, and pericardial effusion is its signature serious adverse effect — seen particularly at higher doses and in patients with renal impairment. The mechanism is thought to involve fluid retention and reflex sympathetic activation, and the effusions can progress to tamponade, which is why the labelling advises caution and monitoring. Low-dose oral minoxidil is now used off-label for hair loss, but the FAERS signal (142 co-reports, PRR 2.9) largely reflects the older antihypertensive use.

Regulatory basis: minoxidil prescribing information (pericardial effusion/tamponade warning; caution in renal impairment).

Bradford Hill viewpointStatusNote
Temporality (necessary)metEffusion appears during high-dose therapy and resolves after withdrawal
StrengthmetPRR 3 with a modest co-report count
ConsistencymetReported since the 1970s across antihypertensive use
SpecificitypartialFairly characteristic of minoxidil among vasodilators
Biological gradientmetMore frequent at higher doses and in renal impairment
PlausibilitymetFluid retention and reflex sympathetic activation are the proposed mechanisms
CoherencemetCoheres with the labelled caution and monitoring advice
ExperimentpartialDechallenge (withdrawal) usually resolves it; no randomized trial
AnalogymetAnalogous to fluid-retention effects of other potent vasodilators

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for minoxidil captured pericardial effusion; the effect is uncommon, dose-related, and identified through post-marketing reports rather than trial AE tables.
Expected pharmacological effect

Propranolol (beta-blockers) ↔ Bradycardia / bronchospasm

Open this assessment on its own page →

n=1,448 co-reports · PRR 8.2 · ROR 8.3

Propranolol blocks cardiac beta-1 receptors and bronchial beta-2 receptors, so slowing the heart rate and provoking bronchospasm are direct, predictable consequences of its pharmacology rather than idiosyncratic reactions. Bradycardia is dose-related and amplified by other rate-slowing drugs; bronchospasm matters most in asthma and COPD. The 1,448 co-reports (PRR 8.2) reflect both the drug's genuine effects and how long and widely non-selective beta-blockers have been prescribed.

Regulatory basis: propranolol prescribing information (bradycardia, bronchospasm; contraindication in asthma).

Bradford Hill viewpointStatusNote
Temporality (necessary)metHeart-rate slowing and wheeze occur during beta-blockade and reverse on withdrawal
StrengthmetPRR 8 on a large co-report count
ConsistencymetReproduced across the whole beta-blocker class
SpecificitypartialShared across non-selective beta-blockers, not unique to propranolol
Biological gradientmetDose-related and worse with other rate-slowing or negative-inotropic drugs
PlausibilitymetBeta-1 block slows the SA/AV nodes; beta-2 block constricts bronchi
CoherencemetCoheres with the labelled contraindication in asthma and routine heart-rate checks
ExperimentpartialDechallenge (withdrawal) reverses both effects; no randomized trial
AnalogymetAnalogous to bradycardia and bronchospasm with other non-selective beta-blockers

This page's own qualitative read, not an automated/citation-gated assessment.

✗ A large results-posting propranolol trial (in infantile haemangioma, NCT01056341) tracked bradycardia and recorded only a single serious event, in the highest-dose arm — consistent with how uncommon symptomatic bradycardia is in the populations studied rather than contradicting the mechanism.
Causality: well established

Heparin ↔ Heparin-induced thrombocytopenia (HIT)

Open this assessment on its own page →

n=1,273 co-reports · PRR 533.2 · ROR 587.8

Heparin-induced thrombocytopenia is a distinctive, immune-mediated reaction in which antibodies to the heparin–platelet-factor-4 complex activate platelets, causing a falling platelet count that paradoxically predisposes to thrombosis. It is a genuine drug-specific effect, typically appears 5–10 days after starting heparin, and requires immediate discontinuation and a non-heparin anticoagulant. The very high PRR (533.2) reflects that the term itself is essentially heparin-specific, so it reports back to heparin almost by definition.

Regulatory basis: heparin prescribing information (HIT warning; platelet monitoring). Established HIT immunoassay literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metFalling platelets appear 5–10 days into exposure and recover after heparin is stopped
StrengthmetVery high PRR, but partly because the coded term is heparin-specific by name
ConsistencymetReproduced across unfractionated and low-molecular-weight heparins
SpecificitymetDistinctive antibody-mediated syndrome tied to the drug–PF4 complex
Biological gradientpartialRisk varies with heparin type, duration, and patient group; not a simple dose gradient
PlausibilitymetAnti-PF4 antibody-mediated platelet activation is the defined mechanism
CoherencemetCoheres with routine platelet-count monitoring during heparin therapy
ExperimentpartialConsistent with controlled studies of switching to non-heparin anticoagulants
AnalogymetAnalogous to HIT-type reactions with other heparinoid anticoagulants

This page's own qualitative read, not an automated/citation-gated assessment.

✗ The results-posting trial that surfaced (anticoagulation in cancer, NCT03045406) compared apixaban with the heparinoid dalteparin and recorded a single HIT event, on dalteparin — too few to characterise. HIT is rare and detected through routine platelet monitoring, not trial AE tables.
Causality: well established

Dabigatran ↔ Gastrointestinal bleeding

Open this assessment on its own page →

n=8,281 co-reports · PRR 29.6 · ROR 33.0

Dabigatran is a direct oral thrombin inhibitor, so bleeding — especially from the gut — is the expected hazard of any effective anticoagulant, and dabigatran's particular propensity for gastrointestinal bleeding relative to warfarin is well documented. Because a large fraction of the drug remains in the gut with its tartaric-acid excipient, the risk is partly local as well as systemic. The 8,281 co-reports (PRR 29.6) reflect the enormous population on oral anticoagulants and the severity of bleeding that drives reporting.

Regulatory basis: dabigatran prescribing information (bleeding warning); RE-LY randomized trial versus warfarin.

Bradford Hill viewpointStatusNote
Temporality (necessary)metBleeding occurs during anticoagulation and is managed by stopping the drug
StrengthmetPRR 30 on a very large co-report count
ConsistencymetReproduced in the randomized RE-LY trial and in real-world cohorts
SpecificitypartialAn anticoagulant-class effect, with dabigatran's GI rate above warfarin in some analyses
Biological gradientpartialRisk rises with dose, renal impairment, age, and interacting drugs
PlausibilitymetBlocking thrombin impairs haemostasis — bleeding is the pharmacodynamic extension
CoherencemetCoheres with the bleeding-focused labelling and monitoring
ExperimentmetRandomized evidence (RE-LY) and co-therapy studies directly quantify the risk
AnalogymetAnalogous to bleeding with warfarin, rivaroxaban, and apixaban

This page's own qualitative read, not an automated/citation-gated assessment.

✗ The results-posting dabigatran trials that surfaced recorded gastrointestinal bleeding only as isolated events (e.g. 1 versus 0 in NCT00558259); the bleeding excess is quantified by the large randomized outcome trial RE-LY and real-world cohorts, not by a single trial AE table.
Causality: well established

Rivaroxaban ↔ Gastrointestinal bleeding

Open this assessment on its own page →

n=21,636 co-reports · PRR 34.9 · ROR 38.9

Rivaroxaban is a direct factor Xa inhibitor, so bleeding is the expected hazard of its intended anticoagulant effect, and its gastrointestinal bleeding rate is at least as high as warfarin's in the major randomized trials. The high FAERS count (21,636 co-reports, PRR 34.9) reflects the drug's very large real-world population and the severity that drives reporting. As with all anticoagulants, the signal is a pharmacodynamic extension of the mechanism rather than an off-target surprise.

Regulatory basis: rivaroxaban prescribing information (bleeding warning); ROCKET-AF randomized trial.

Bradford Hill viewpointStatusNote
Temporality (necessary)metBleeding occurs during anticoagulation and typically stops after the drug is withdrawn
StrengthmetPRR 35 on one of the largest co-report counts on this page
ConsistencymetReproduced in randomized outcome trials and in real-world cohorts
SpecificitypartialAn anticoagulant-class effect rather than rivaroxaban-specific
Biological gradientpartialRisk rises with dose, renal impairment, age, and interacting drugs
PlausibilitymetFactor Xa inhibition impairs haemostasis — bleeding is the pharmacodynamic extension
CoherencemetCoheres with the bleeding-focused labelling and monitoring
ExperimentmetRandomized evidence (ROCKET-AF) and cohort studies directly quantify the risk
AnalogymetAnalogous to bleeding with warfarin, apixaban, and dabigatran

This page's own qualitative read, not an automated/citation-gated assessment.

✗ The results-posting rivaroxaban trial that surfaced (NCT02504216) recorded serious bleeding terms only in the rivaroxaban arm, but in very small numbers; the bleeding excess is quantified by the large randomized outcome trial ROCKET-AF and real-world cohorts, not by one trial AE table.
Causality: well established

Trimethoprim (and co-trimoxazole) ↔ Hyperkalaemia

Open this assessment on its own page →

n=213 co-reports · PRR 11.0 · ROR 11.2

Trimethoprim blocks the epithelial sodium channel in the distal nephron in a way that resembles the potassium-sparing diuretics amiloride and triamterene, so it reduces urinary potassium excretion and can raise serum potassium — an effect that is easy to overlook because trimethoprim is prescribed mainly as an antibiotic. The risk is greatest at higher doses, in older patients, in renal impairment, and with coexisting ACE inhibitors, ARBs, or spironolactone. The 213 co-reports (PRR 11.0) reflect both a genuine effect and the drug's very wide short-course use.

Regulatory basis: trimethoprim/co-trimoxazole prescribing information (hyperkalaemia caution, especially with RAAS blockade).

Bradford Hill viewpointStatusNote
Temporality (necessary)metPotassium rises during treatment and falls after withdrawal
StrengthmetPRR 11 on a modest co-report count
ConsistencymetReproduced in controlled studies and cohort data, notably in older patients on RAAS blockade
SpecificitymetA fairly distinctive effect of trimethoprim among antibacterials
Biological gradientmetDose-related and worse with renal impairment, age, and RAAS-blocking drugs
PlausibilitymetDistal-nephron sodium-channel blockade mimics potassium-sparing diuretics
CoherencemetCoheres with the labelled hyperkalaemia caution and electrolyte monitoring
ExperimentpartialControlled studies of co-trimoxazole versus other antibiotics support it; no large dedicated RCT
AnalogymetAnalogous to amiloride/triamterene potassium retention

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for trimethoprim captured hyperkalaemia; the effect is a monitored biochemistry finding rather than a coded trial endpoint, and is established from prescribing information, controlled studies, and cohorts.
Causality: well established

Doxycycline (tetracyclines) ↔ Photosensitivity reaction

Open this assessment on its own page →

n=427 co-reports · PRR 8.2 · ROR 8.3

Doxycycline is one of the most phototoxic antibiotics: it accumulates in the skin, absorbs ultraviolet light, and produces an exaggerated sunburn-like reaction on exposed areas. It is a genuine, well-characterised chemical phototoxicity rather than an allergy, and it is common enough that sunscreen and sun-avoidance counselling is standard when the drug is prescribed. The 427 co-reports (PRR 8.2) reflect both the real effect and doxycycline's very wide use for acne, tick-borne infections, and malaria prophylaxis.

Regulatory basis: doxycycline prescribing information (photosensitivity warning; sun-protection advice). Established tetracycline phototoxicity literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metThe reaction appears during sun exposure while taking the drug and settles after withdrawal
StrengthpartialPRR 8 with a moderate co-report count
ConsistencymetReproduced across tetracyclines and in dermatology practice
SpecificitymetDrug-induced phototoxicity has a characteristic photodistributed pattern
Biological gradientpartialBroadly dose- and exposure-related (drug dose and UV exposure)
PlausibilitymetUltraviolet absorption by the drug in the skin is the defined mechanism
CoherencemetCoheres with the routine sun-protection counselling given with doxycycline
ExperimentpartialDechallenge (withdrawal plus sun avoidance) resolves it; no randomized trial
AnalogymetAnalogous to phototoxicity with other tetracyclines and some other drugs

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for doxycycline captured photosensitivity; the reaction depends on ambient sun exposure and is managed in clinic rather than captured as a coded trial AE.
Causality: well established

Minocycline ↔ Skin hyperpigmentation

Open this assessment on its own page →

n=188 co-reports · PRR 40.6 · ROR 41.2

Minocycline is the tetracycline best known for causing pigmentation of the skin, nails, sclera, and — rarely — internal organs, a distinctive effect not shared to the same degree by other tetracyclines. It is dose- and duration-related, appears after months of therapy, and typically fades slowly after withdrawal (though scleral and deep pigmentation can persist). The 188 co-reports (PRR 40.6) reflect the drug's long-term use in acne, where cumulative exposure is high, and the very visible nature of the change.

Regulatory basis: minocycline prescribing information (cutaneous and other hyperpigmentation warning). Established minocycline-pigmentation literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metPigmentation develops after months of exposure and slowly fades after withdrawal
StrengthmetPRR 40 on a modest co-report count
ConsistencymetReproduced across decades of acne-treatment case series
SpecificitymetA distinctive minocycline effect, unlike other tetracyclines
Biological gradientpartialCumulative-dose-related; higher the longer the drug is taken
PlausibilitymetLikely melanin–drug complex deposition and iron deposition in the dermis
CoherencemetCoheres with the labelled hyperpigmentation warnings and periodic skin review
ExperimentpartialDechallenge (withdrawal) usually leads to slow improvement; no randomized trial
AnalogymetAnalogous to but more prominent than other drug-induced hyperpigmentation

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for minocycline captured skin hyperpigmentation; the effect takes months of cumulative dosing and is identified in dermatology practice rather than trial AE tables.
Causality: well established

Nitrofurantoin ↔ Pulmonary fibrosis / interstitial lung disease

Open this assessment on its own page →

n=147 co-reports · PRR 9.9 · ROR 10.0

Nitrofurantoin can produce an acute pneumonitis and, with prolonged use, a chronic interstitial lung disease that may progress to pulmonary fibrosis — a rare but well-recognised and potentially irreversible toxicity of a drug otherwise regarded as safe and reserved for uncomplicated urinary infection. The chronic form is related to cumulative duration of therapy, which is why long-term prophylaxis is discouraged and lung function is monitored. The 147 co-reports (PRR 9.9) reflect both the true effect and the difficulty of attributing chronic fibrosis to a drug that is often used intermittently.

Regulatory basis: nitrofurantoin prescribing information (acute and chronic pulmonary reactions, including fibrosis). Established nitrofurantoin lung-toxicity literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metChronic lung changes develop after months–years of exposure; acute pneumonitis after days
StrengthpartialPRR 10 on a modest co-report count
ConsistencymetReproduced across decades of nitrofurantoin pulmonary-toxicity case series
SpecificitymetA recognised drug cause of chronic interstitial lung disease
Biological gradientpartialCumulative-duration-related for the chronic form
PlausibilitymetRepeated oxidant injury and immune reaction in the lung are the proposed mechanisms
CoherencemetCoheres with the labelled pulmonary warnings and periodic lung review
ExperimentpartialDechallenge (withdrawal) may halt or partially reverse it; no randomized trial
AnalogymetAnalogous to pulmonary fibrosis from other drugs (amiodarone, methotrexate, bleomycin)

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for nitrofurantoin captured interstitial lung disease or fibrosis; the chronic form needs years of exposure, so it is caught by post-marketing surveillance rather than trial AE tables.
Causality: well established

Levofloxacin (fluoroquinolones) ↔ Aortic aneurysm / dissection

Open this assessment on its own page →

n=113 co-reports · PRR 5.2 · ROR 5.2

Fluoroquinolones such as levofloxacin are associated with an increased risk of aortic aneurysm and dissection, thought to reflect their effects on collagen and matrix metalloproteinases in the vessel wall. This is a genuinely new safety concern: after observational studies and label reviews, the FDA added a class warning in 2018 and advises avoiding fluoroquinolones in patients at high risk (those with prior aneurysm, hypertension, or connective-tissue disease). The 113 co-reports (PRR 5.2) are relatively small because aortic events are uncommon, but the regulatory basis is now explicit.

Regulatory basis: FDA 2018 class warning on fluoroquinolones and aortic aneurysm/dissection; levofloxacin prescribing information.

Bradford Hill viewpointStatusNote
Temporality (necessary)metAortic events occur in patients exposed to the drug, with observational studies linking current use to risk
StrengthpartialPRR 5 on a small co-report count — a modest statistical signal for a serious outcome
ConsistencymetSupported by multiple large observational cohort studies and a class label change
SpecificitymetA fluoroquinolone-class effect rather than levofloxacin-specific
Biological gradientpartialRisk rises with age, hypertension, and connective-tissue disease
PlausibilitymetCollagen degradation and matrix-metalloproteinase effects in the vessel wall are proposed
CoherencemetCoheres with the current class warning to avoid the drugs in high-risk patients
ExperimentpartialObservational; no randomized trial has tested aortic outcomes
AnalogymetAnalogous to the aortic risk across the fluoroquinolone class

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for levofloxacin captured aortic aneurysm or dissection; the risk was identified through large observational studies and a 2018 FDA class warning, not trial AE tables.
Causality: well established

Azithromycin (macrolides) ↔ QT prolongation / torsades

Open this assessment on its own page →

n=522 co-reports · PRR 7.7 · ROR 7.8

Macrolide antibiotics, including azithromycin, can prolong the cardiac QT interval and, rarely, provoke the dangerous ventricular arrhythmia torsades de pointes — hence the class carries warnings, and the FDA has cautioned about azithromycin in patients already at risk. The risk is amplified by other QT-prolonging drugs, by hypokalaemia or hypomagnesaemia, and in patients with structural heart disease. The 522 co-reports (PRR 7.7) reflect both the genuine effect and how very widely azithromycin is prescribed.

Regulatory basis: azithromycin prescribing information and FDA safety communication on QT prolongation; macrolide class labelling.

Bradford Hill viewpointStatusNote
Temporality (necessary)metQT prolongation is measured during therapy and resolves after withdrawal
StrengthpartialPRR 8 on a moderate co-report count
ConsistencymetReproduced across macrolides and in observational cardiac-arrest data
SpecificitypartialA macrolide-class effect shared with clarithromycin and erythromycin
Biological gradientpartialWorse with dose, electrolyte disturbance, and other QT-prolonging drugs
PlausibilitymetDirect hERG-channel blockade delays cardiac repolarisation
CoherencemetCoheres with the class labelling and caution in at-risk patients
ExperimentpartialObservational (notably the azithromycin cardiac-death study); no randomized arrhythmia RCT
AnalogymetAnalogous to QT risk with other macrolides and non-antibiotics that block hERG

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for azithromycin captured QT prolongation or torsades; the risk was quantified from ECG studies and large observational cohorts rather than a trial AE table.
Causality: well established

Clindamycin ↔ Clostridioides difficile colitis

Open this assessment on its own page →

n=409 co-reports · PRR 14.3 · ROR 14.5

Clindamycin is the antibiotic most closely linked with Clostridioides difficile infection: by disrupting the normal gut flora it allows this spore-forming bacterium to overgrow and produce a toxin-mediated colitis. It is a genuine, well-understood consequence of antibiotic exposure rather than an idiosyncratic drug reaction, and it can range from mild diarrhoea to life-threatening pseudomembranous colitis. The 409 co-reports (PRR 14.3) reflect both the real association and the breadth of antibiotic prescribing.

Regulatory basis: clindamycin prescribing information (C. difficile-associated diarrhoea and colitis warning). Established antibiotic-associated colitis literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metColitis typically follows antibiotic exposure by days–weeks and responds to stopping the drug
StrengthmetPRR 18 on a moderate co-report count
ConsistencymetReproduced across antibiotic classes but historically strongest for clindamycin
SpecificitymetAntibiotic-associated colitis is a recognised syndrome, though several antibiotics can cause it
Biological gradientpartialRisk broadly rises with longer or broader antibiotic courses
PlausibilitymetDisruption of gut flora permits C. difficile overgrowth and toxin production
CoherencemetCoheres with the standard warning and the advice to test and treat
ExperimentpartialDechallenge (stopping the drug) with appropriate treatment usually resolves it; no randomized trial
AnalogymetAnalogous to C. difficile colitis from other broad-spectrum antibiotics

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for clindamycin captured C. difficile colitis as a coded event; the infection is triggered by antibiotic use in clinical practice and is tracked through surveillance rather than trial AE tables.
Causality: well established

Metronidazole ↔ Peripheral neuropathy

Open this assessment on its own page →

n=899 co-reports · PRR 3.2 · ROR 3.2

Metronidazole can cause a dose- and duration-dependent peripheral neuropathy, typically a painful sensory disturbance of the feet that becomes more likely with prolonged courses or high cumulative doses. It is a genuine drug effect, resolves slowly after withdrawal in many patients, and is the reason long-term metronidazole therapy is closely watched. The 899 co-reports (PRR 3.2) reflect both the real association and metronidazole's very wide use across infection, dental, and gut indications.

Regulatory basis: metronidazole prescribing information (peripheral neuropathy warning, especially with prolonged therapy). Established metronidazole-neuropathy literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metNeuropathy emerges during prolonged therapy and often improves slowly after withdrawal
StrengthpartialPRR 3 with a large co-report count — a modest but broad signal
ConsistencymetReproduced across decades of metronidazole case series
SpecificitymetA recognised drug cause of peripheral neuropathy
Biological gradientmetCumulative-dose- and duration-related
PlausibilitymetLikely axonal injury from the drug's neurotoxic metabolites
CoherencemetCoheres with the labelled warning and the practice of limiting long courses
ExperimentpartialDechallenge (withdrawal) usually improves symptoms, though recovery can be slow; no randomized trial
AnalogymetAnalogous to neuropathy from other drugs (isoniazid, nitrofurantoin, chemotherapy)

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for metronidazole captured peripheral neuropathy; the effect requires prolonged exposure and is identified in clinical practice rather than a trial AE table.
Causality: well established

Gentamicin (aminoglycosides) ↔ Ototoxicity (hearing/balance)

Open this assessment on its own page →

n=94 co-reports · PRR 86.1 · ROR 86.7

Aminoglycosides such as gentamicin damage the hair cells of the inner ear, producing hearing loss and vestibular (balance) disturbance that can be permanent. The toxicity is dose- and duration-related, is worsened by other ototoxic drugs (loop diuretics, vancomycin) and by renal impairment (which raises drug levels), and is the reason aminoglycoside courses are kept short and, where possible, guided by drug-level monitoring. The 94 co-reports (PRR 86.1) reflect a genuine and serious effect of a drug still widely used for serious infections.

Regulatory basis: gentamicin prescribing information (ototoxicity and nephrotoxicity warnings; therapeutic drug monitoring). Established aminoglycoside-ototoxicity literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metHearing/balance damage occurs during exposure and may be irreversible
StrengthmetPRR 86 on a modest co-report count — a strong relative signal
ConsistencymetReproduced across the aminoglycoside class and in audiology studies
SpecificitymetA classic aminoglycoside toxicity, though other drugs can also damage the ear
Biological gradientmetRisk rises with dose, duration, renal impairment, and other ototoxic drugs
PlausibilitymetInner-ear hair-cell damage by the aminoglycoside is the defined mechanism
CoherencemetCoheres with the labelled monitoring and short-course practice
ExperimentpartialDechallenge (withdrawal) limits further loss but does not reverse it; no randomized trial
AnalogymetAnalogous to ototoxicity with other aminoglycosides and loop diuretics

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for gentamicin captured ototoxicity or hearing loss as a coded event; the damage is detected by audiometry in practice rather than captured in trial AE tables.
Causality: well established

Daptomycin ↔ Myopathy / rhabdomyolysis

Open this assessment on its own page →

n=370 co-reports · PRR 20.5 · ROR 21.3 Creatine kinase increased (related term): n=331 · PRR 26.2

Daptomycin, a lipopeptide antibiotic used for resistant Gram-positive infections, can injure skeletal muscle, producing rises in creatine kinase that occasionally progress to rhabdomyolysis. Because of this, the labelling recommends checking creatine kinase at baseline and periodically during therapy, and stopping the drug if levels rise significantly. The effect is dose-related and can be worsened by statin co-therapy. The 370 co-reports (PRR 20.5) reflect a genuine, monitorable toxicity.

Regulatory basis: daptomycin prescribing information (myopathy and creatine-kinase monitoring).

Bradford Hill viewpointStatusNote
Temporality (necessary)metMuscle injury appears during therapy and resolves after the drug is stopped
StrengthmetPRR 20 on a moderate co-report count, with a parallel CK-increase signal
ConsistencymetReproduced in trials that measured creatine kinase
SpecificitymetA recognised daptomycin toxicity, less typical of other antibiotics
Biological gradientpartialDose-related and worse with statin co-therapy
PlausibilitymetDirect injury to skeletal muscle is the proposed mechanism
CoherencemetCoheres with the labelled CK-monitoring recommendation
ExperimentmetA randomized registration trial recorded CK rises only on daptomycin
AnalogymetAnalogous to myopathy from statins and other myotoxic drugs

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — China Registration Study in Patients With Skin Infections (NCT00772447), N=264

Term (as recorded)Daptomycin (n=131)Vancomycin, or Vancomycin Switch to Cloxacillin (n=133)
Blood Creatine Phosphokinase Increased — Investigations40

Rises in creatine kinase were recorded only on daptomycin (4 of 131 patients) and in none of the vancomycin-treated patients in this randomized registration trial — direct trial-level support for the muscle-injury signal that prompts routine CK monitoring during daptomycin therapy. View on ClinicalTrials.gov →

Causality: well established

Fluconazole ↔ QT prolongation / torsades

Open this assessment on its own page →

n=568 co-reports · PRR 4.8 · ROR 4.8

Fluconazole, an azole antifungal, prolongs the cardiac QT interval and carries a labelled warning, with rare reports of torsades de pointes, particularly at high doses and in patients already taking other QT-prolonging drugs. The effect is dose-related and is a genuine, mechanistically plausible cardiac toxicity rather than an idiosyncratic reaction. The 568 co-reports (PRR 4.8) reflect both the real effect and the drug's very wide use for common fungal infections.

Regulatory basis: fluconazole prescribing information (QT prolongation warning; caution with other QT-prolonging drugs).

Bradford Hill viewpointStatusNote
Temporality (necessary)metQT prolongation is measured during therapy and resolves after withdrawal
StrengthpartialPRR 5 on a moderate co-report count
ConsistencymetReproduced in ECG studies and case reports of torsades
SpecificitypartialA recognised azole effect, strongest for fluconazole
Biological gradientpartialDose-related and worse with other QT-prolonging drugs
PlausibilitymethERG-channel blockade delays cardiac repolarisation
CoherencemetCoheres with the labelled QT warning and drug-interaction cautions
ExperimentpartialSupported by ECG-based studies; no randomized arrhythmia RCT
AnalogymetAnalogous to QT risk with other azoles and QT-prolonging drugs

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for fluconazole captured QT prolongation or torsades; the risk is characterised through ECG studies and case reports rather than a trial AE table.
Causality: well established

Ketoconazole (oral) ↔ Hepatotoxicity

Open this assessment on its own page →

n=64 co-reports · PRR 3.5 · ROR 3.5

Oral ketoconazole can cause serious liver injury, ranging from asymptomatic transaminase rises to fatal hepatitis, which is why it was withdrawn from the market for oral use in the EU in 2013 and is now largely restricted to topical application. The injury is idiosyncratic rather than simply dose-related, can occur at any point during treatment, and is the reason liver function was monitored during the drug's oral era. The 64 co-reports (PRR 3.5) reflect a genuine, historically significant hepatotoxicity.

Regulatory basis: oral ketoconazole withdrawal in the EU (2013) and FDA restrictions (2013) over hepatotoxicity; ketoconazole prescribing information.

Bradford Hill viewpointStatusNote
Temporality (necessary)metLiver injury occurs during therapy and generally improves after withdrawal
StrengthpartialPRR 4 on a small co-report count — a modest statistical signal
ConsistencymetReproduced across decades of case reports and reviews
SpecificitymetA recognised idiosyncratic drug-induced liver injury
Biological gradientmetNot clearly dose-related; idiosyncratic
PlausibilitymetMetabolic and immune-mediated liver injury are proposed mechanisms
CoherencemetCoheres with the market withdrawal and current restrictions
ExperimentpartialDechallenge (withdrawal) usually improves liver tests; no randomized trial
AnalogymetAnalogous to hepatotoxicity from other azoles and drugs

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for oral ketoconazole captured hepatotoxicity; the injury is idiosyncratic and was characterised through case series and regulatory review, not a trial AE table.
Causality: well established

Itraconazole ↔ Heart failure

Open this assessment on its own page →

n=153 co-reports · PRR 3.4 · ROR 3.5

Itraconazole carries a labelled warning of negative inotropic effects and heart failure, particularly in patients with underlying ventricular dysfunction, and the FDA has advised caution and dose limits. The effect reflects the drug's ability to depress cardiac contractility, and it resolves on withdrawal in most cases. The 153 co-reports (PRR 3.4) are modest because heart failure is uncommon with itraconazole and the drug is used for narrower indications than fluconazole.

Regulatory basis: FDA/itraconazole prescribing information (heart failure warning; caution in ventricular dysfunction).

Bradford Hill viewpointStatusNote
Temporality (necessary)metHeart failure develops during therapy and often improves after withdrawal
StrengthpartialPRR 3 on a modest co-report count
ConsistencymetSupported by post-marketing reports and the labelled warning
SpecificitymetA recognised itraconazole effect, tied to negative inotropy
Biological gradientpartialMore likely at higher doses and in patients with existing cardiac impairment
PlausibilitymetDirect negative inotropic action on the myocardium is the proposed mechanism
CoherencemetCoheres with the labelled caution in heart failure and dose limits
ExperimentpartialDechallenge (withdrawal) usually improves symptoms; no randomized trial
AnalogymetAnalogous to cardiac depression by other negative-inotropic drugs

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for itraconazole captured heart failure; the effect is uncommon, identified through post-marketing reports and the labelled warning rather than a trial AE table.
Causality: well established

Terbinafine ↔ Taste disturbance (ageusia/dysgeusia)

Open this assessment on its own page →

n=273 co-reports · PRR 32.5 · ROR 33.7

Terbinafine commonly disturbs the sense of taste, most famously causing loss of taste (ageusia) or altered taste (dysgeusia) that can impair appetite and quality of life. The effect typically appears weeks into therapy and usually recovers slowly after the drug is stopped. It is a genuine, well-recognised drug effect rather than an idiosyncratic one-off. The 273 co-reports (PRR 32.5) reflect both the real effect and terbinafine's wide use for fungal nail and skin infections.

Regulatory basis: terbinafine prescribing information (taste disturbance, including loss of taste). Established terbinafine-dysgeusia literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metTaste disturbance appears weeks into therapy and usually recovers after withdrawal
StrengthmetPRR 32 on a modest co-report count
ConsistencymetReproduced across case series and in trial data
SpecificitymetA characteristic terbinafine effect among antifungals
Biological gradientpartialBroadly dose- and duration-related
PlausibilitymetLikely effect on taste-bud or nerve function is proposed
CoherencemetCoheres with the labelled taste-disturbance warning
ExperimentmetA randomized trial recorded ageusia only in the terbinafine arm
AnalogymetAnalogous to taste disturbance from certain other drugs

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED) (NCT00491764), N=216

Term (as recorded)Posaconazole 100 mg QD for 24 Weeks (n=36)Posaconazole 200 mg QD for 24 Weeks (n=37)Posaconazole 400 mg QD for 24 Weeks (n=36)Posaconazole 400 mg QD for 12 Weeks (n=36)Terbinafine 250 mg QD for 12 Weeks (n=36)Placebo for 24 Weeks (n=35)
AGEUSIA — Nervous system disorders000020

Ageusia (loss of taste) was recorded only in the terbinafine arm (2 of 36 patients) and in none of the four posaconazole arms or placebo — a small but arm-specific confirmation of terbinafine's well-known taste-disturbance signal. View on ClinicalTrials.gov →

Causality: well established

Acyclovir ↔ Acute kidney injury

Open this assessment on its own page →

n=2,499 co-reports · PRR 3.1 · ROR 3.1

Acyclovir can cause acute kidney injury, typically through crystallisation of the drug in the renal tubules, especially after rapid intravenous infusion, at high doses, in dehydrated patients, or with pre-existing kidney disease. The injury is usually reversible if the drug is stopped and hydration is maintained, and the risk is reduced by giving the drug slowly with adequate fluids. The 2,499 co-reports (PRR 3.1) reflect both the real effect and acyclovir's enormous use as a well-tolerated antiviral.

Regulatory basis: acyclovir prescribing information (renal impairment warning; slow infusion and hydration advice). Established acyclovir-nephrotoxicity literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metKidney injury appears during or shortly after infusion and usually recovers after withdrawal
StrengthpartialPRR 3 with a large co-report count — a modest but broad signal
ConsistencymetReproduced across case series and reviews
SpecificitymetA recognised acyclovir toxicity, less typical of other antivirals
Biological gradientmetDose-, infusion-rate-, and hydration-related
PlausibilitymetDrug crystallisation in renal tubules is the defined mechanism
CoherencemetCoheres with the labelled infusion-rate and hydration advice
ExperimentpartialDechallenge (withdrawal plus hydration) usually reverses it; no randomized trial
AnalogymetAnalogous to nephrotoxicity from other crystallising or nephrotoxic drugs

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for acyclovir captured acute kidney injury as a coded event; the injury is managed in practice and identified through case series rather than a trial AE table.
Expected pharmacological effect

Ganciclovir ↔ Neutropenia / bone-marrow suppression

Open this assessment on its own page →

n=531 co-reports · PRR 8.1 · ROR 8.5

Ganciclovir is a nucleoside analogue that suppresses bone-marrow production, producing neutropenia, thrombocytopenia, and anaemia — a predictable, dose-limiting toxicity that follows directly from its mechanism of inhibiting DNA synthesis in dividing cells. Because of this, complete blood counts are monitored regularly during therapy, and the drug is used cautiously alongside other myelosuppressive agents. The 531 co-reports (PRR 8.1) reflect both the real effect and the drug's use in immunocompromised patients who are already cytopenic.

Regulatory basis: ganciclovir prescribing information (severe haematologic toxicity; routine blood-count monitoring). Established ganciclovir-myelosuppression literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metFalling blood counts appear during therapy and improve when the drug is reduced or stopped
StrengthmetPRR 8 on a moderate co-report count
ConsistencymetReproduced consistently in trials and in practice
SpecificitymetMarrow suppression is a recognised ganciclovir effect, though other antivirals can also cause it
Biological gradientmetDose-related and worse with other myelosuppressive drugs
PlausibilitymetInhibition of DNA synthesis in proliferating marrow cells is the mechanism
CoherencemetCoheres with the labelled monitoring and dose-reduction guidance
ExperimentmetRandomized trials measured cytopenias by arm
AnalogymetAnalogous to myelosuppression from other nucleoside analogues (zidovudine, acyclovir at high dose)

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for ganciclovir captured neutropenia as a coded event; haematological toxicity is captured through routine blood-count monitoring rather than coded into trial AE tables.
Expected pharmacological effect

Amphotericin B ↔ Hypokalaemia / electrolyte wasting

Open this assessment on its own page →

n=288 co-reports · PRR 10.6 · ROR 10.9

Amphotericin B is a mainstay treatment for serious fungal infections but is limited by dose-dependent kidney toxicity, of which potassium and magnesium wasting with hypokalaemia is a familiar part. The drug damages the distal tubule, and the electrolyte loss can be severe enough to require replacement and to predispose to arrhythmias. The 288 co-reports (PRR 10.6) reflect both the real effect and the seriousness of the infections for which the drug is used.

Regulatory basis: amphotericin B prescribing information (nephrotoxicity and electrolyte-wasting warnings; electrolyte monitoring).

Bradford Hill viewpointStatusNote
Temporality (necessary)metPotassium falls during therapy and is corrected with replacement and dose adjustment
StrengthmetPRR 11 on a modest co-report count
ConsistencymetReproduced across the amphotericin literature
SpecificitymetA recognised amphotericin effect tied to its renal toxicity
Biological gradientmetDose-related
PlausibilitymetDistal-tubular injury causing potassium and magnesium loss is the mechanism
CoherencemetCoheres with the labelled electrolyte-monitoring advice
ExperimentmetControlled studies of amphotericin formulations measured electrolyte changes
AnalogymetAnalogous to electrolyte wasting from other nephrotoxic drugs (aminoglycosides, cisplatin)

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for amphotericin B captured hypokalaemia; electrolyte wasting is captured through routine monitoring rather than coded into trial AE tables.
Causality: well established

Dapsone ↔ Methaemoglobinaemia / haemolysis

Open this assessment on its own page →

n=480 co-reports · PRR 522.3 · ROR 547.0

Dapsone, used for leprosy, dermatitis herpetiformis, and some opportunistic infections, oxidises haemoglobin to methaemoglobin and can also cause haemolytic anaemia, particularly in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Methaemoglobinaemia produces cyanosis and breathlessness with a normal oxygen level on the monitor — a signature that is easy to misread — and reverses with methylene blue. The 480 co-reports (PRR 522.3) reflect both the real effect and the drug's narrower, mostly dermatology and infectious-disease use.

Regulatory basis: dapsone prescribing information (methaemoglobinaemia and haemolysis warnings; G6PD screening). Established dapsone-oxidative-haemolysis literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metMethaemoglobinaemia develops during therapy and reverses with methylene blue and withdrawal
StrengthmetVery high PRR, on a modest co-report count
ConsistencymetReproduced across the dapsone literature
SpecificitymetA distinctive oxidative consequence of dapsone, unlike most drugs
Biological gradientpartialDose-related and much worse in G6PD deficiency
PlausibilitymetDirect oxidation of haemoglobin iron and oxidative red-cell injury are the mechanisms
CoherencemetCoheres with the labelled warnings and G6PD screening
ExperimentpartialDechallenge (withdrawal) plus methylene blue reverses it; no randomized trial
AnalogymetAnalogous to methaemoglobinaemia from other oxidising drugs (nitrites, prilocaine, some antimalarials)

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for dapsone captured methaemoglobinaemia; the effect is recognised through clinical and laboratory detection, not coded trial endpoints.
Causality: well established

Lithium ↔ Nephrogenic diabetes insipidus

Open this assessment on its own page →

n=304 co-reports · PRR 301.3 · ROR 305.0

Long-term lithium, the cornerstone mood stabiliser in bipolar disorder, commonly causes a concentrating defect in the kidney — nephrogenic diabetes insipidus — in which the tubules stop responding to antidiuretic hormone, leading to excessive urination and thirst. It usually develops after months to years of treatment and may be partly reversible if the drug is stopped early. The very high PRR (301.3) reflects that this is a characteristic, almost signature lithium toxicity rather than an idiosyncratic event, and it is why kidney function and fluid balance are monitored during lithium therapy.

Regulatory basis: lithium prescribing information (nephrogenic diabetes insipidus and renal monitoring). Established lithium-nephrotoxicity literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metPolyuria and polydipsia develop after months–years of lithium and may improve on withdrawal
StrengthmetVery high PRR, characteristic of the drug
ConsistencymetReproduced across decades of lithium-nephrotoxicity studies
SpecificitymetA signature lithium effect, unlike most drugs
Biological gradientmetRelated to cumulative exposure and duration
PlausibilitymetTubular resistance to antidiuretic hormone is the defined mechanism
CoherencemetCoheres with the labelled renal monitoring during lithium therapy
ExperimentpartialDechallenge (withdrawal) may partially reverse it; no randomized trial
AnalogymetAnalogous to other drug-induced nephrogenic diabetes insipidus (e.g. demeclocycline)

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for lithium captured nephrogenic diabetes insipidus; the effect develops over years of therapy and is detected by clinical monitoring rather than a trial AE table.
Causality: well established

Lithium ↔ Hypothyroidism

Open this assessment on its own page →

n=224 co-reports · PRR 5.9 · ROR 6.0

Lithium concentrates in the thyroid and interferes with the synthesis and release of thyroid hormone, so it commonly causes hypothyroidism and, less often, goitre or hyperthyroidism. The effect is dose-related, is more common in women and in those with pre-existing thyroid antibodies, and is managed by thyroid-hormone replacement without necessarily stopping the lithium. The 224 co-reports (PRR 5.9) reflect both the real effect and the fact that lithium is typically taken for years, giving the thyroid change time to emerge and be detected on routine testing.

Regulatory basis: lithium prescribing information (thyroid dysfunction; routine thyroid-function monitoring). Established lithium-thyroid literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metHypothyroidism emerges during long-term therapy and responds to hormone replacement
StrengthpartialPRR 6 on a modest co-report count
ConsistencymetReproduced across decades of lithium-thyroid studies
SpecificitymetA recognised lithium effect, though other drugs can also cause hypothyroidism
Biological gradientmetDose-related and commoner with thyroid antibodies and in women
PlausibilitymetInhibition of thyroid-hormone synthesis/release is the proposed mechanism
CoherencemetCoheres with the labelled routine thyroid monitoring
ExperimentpartialDechallenge (and/or replacement therapy) manages it; no randomized trial
AnalogymetAnalogous to hypothyroidism from amiodarone and interferon

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for lithium captured hypothyroidism; the effect is found by routine thyroid-function testing during long-term lithium therapy, not in trial AE tables.
Expected pharmacological effect

Valproate ↔ Hyperammonaemia / encephalopathy

Open this assessment on its own page →

n=624 co-reports · PRR 95.6 · ROR 97.5

Valproate interferes with the urea cycle and the metabolism of ammonia, so it commonly raises blood ammonia, and in some patients this produces a lethargic encephalopathy even when liver tests and valproate levels are normal. The effect is dose-related and follows directly from the drug's known biochemistry, and it is the reason ammonia is checked when a patient on valproate becomes drowsy. The 624 co-reports (PRR 95.6) reflect a genuine, mechanistically understood metabolic effect.

Regulatory basis: valproate prescribing information (hyperammonaemia and encephalopathy warning). Established valproate-ammonia literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metAmmonia rises during therapy and the encephalopathy resolves after withdrawal
StrengthmetPRR 96 — a very high relative signal, though partly because the term is valproate-specific
ConsistencymetReproduced across case series and metabolic studies
SpecificitymetA characteristic valproate effect, rare with other drugs
Biological gradientmetDose-related and worse with enzyme inducers, carnitine deficiency, or urea-cycle defects
PlausibilitymetInhibition of the urea cycle / ammonia detoxification is the mechanism
CoherencemetCoheres with the labelled warning and the practice of checking ammonia if drowsy
ExperimentpartialDechallenge (withdrawal, carnitine) reverses the encephalopathy; no randomized trial
AnalogymetAnalogous to hyperammonaemia from other mitochondrial or urea-cycle-toxic drugs

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for valproate captured hyperammonaemia as a coded event; the metabolic finding is managed through routine ammonia testing rather than a trial AE table.
Causality: well established

Valproate ↔ Hepatotoxicity

Open this assessment on its own page →

n=175 co-reports · PRR 5.3 · ROR 5.3

Valproate carries a boxed warning for fatal hepatotoxicity, a rare but catastrophic reaction that is most feared in very young children, in people with inherited metabolic disorders, and in those taking multiple antiepileptic drugs. The injury is thought to arise from the drug's mitochondrial effects, and it is the reason liver function and, where relevant, metabolic screening are part of valproate monitoring. The 175 co-reports (PRR 5.3) reflect a rare but severe and regulatorily-prominent effect.

Regulatory basis: valproate prescribing information (boxed warning for hepatotoxicity). Established valproate-hepatotoxicity literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metLiver injury develops during therapy and can be fatal, especially in young children
StrengthpartialPRR 5 on a moderate co-report count
ConsistencymetReproduced across decades of valproate case reports
SpecificitypartialA recognised idiosyncratic hepatotoxicity, but also largely metabolic/mitochondrial
Biological gradientpartialHigher risk in young children, polytherapy, and metabolic disease
PlausibilitymetMitochondrial toxicity and metabolic disruption of liver cells are proposed
CoherencemetCoheres with the boxed warning and liver-function monitoring
ExperimentpartialDechallenge (withdrawal) is essential and can be life-saving; no randomized trial
AnalogymetAnalogous to other mitochondrial-hepatotoxic drugs

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for valproate captured hepatotoxicity; the reaction is idiosyncratic and rare, and is identified through case reports and regulatory review rather than a trial AE table.
Causality: well established

Carbamazepine ↔ Hyponatraemia

Open this assessment on its own page →

n=1,446 co-reports · PRR 8.3 · ROR 8.4

Carbamazepine commonly lowers serum sodium, producing a mild, often asymptomatic dilutional hyponatraemia caused by an antidiuretic-hormone-like effect on the kidney, and occasionally a more serious symptomatic or seizure-provoking drop. The option to monitor sodium is part of routine carbamazepine care, especially in older patients and those on other drugs that affect sodium. The 1,446 co-reports (PRR 8.3) reflect both the real effect and the drug's very wide use in epilepsy and bipolar disorder.

Regulatory basis: carbamazepine prescribing information (hyponatraemia/SIADH warning; sodium monitoring). Established carbamazepine-hyponatraemia literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metSodium falls during treatment and usually recovers after withdrawal
StrengthmetPRR 8 on a large co-report count
ConsistencymetReproduced across case series and trials
SpecificitymetA recognised carbamazepine effect, strongest among the older antiepileptics
Biological gradientmetDose-related and more likely in older patients
PlausibilitymetAn antidiuretic-hormone-like tubular effect (SIADH) is the mechanism
CoherencemetCoheres with the labelled sodium-monitoring advice
ExperimentmetA randomized comparison recorded serious hyponatraemia only in the carbamazepine arm
AnalogymetAnalogous to hyponatraemia from oxcarbazepine and some antidepressants

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs (NCT00438451), N=360

Term (as recorded)Levetiracetam (n=122)Carbamazepine (n=121)Lamotrigine (n=117)
Hyponatraemia — Metabolism and nutrition disorders010

In this randomized comparison of older versus newer antiepileptics in elderly patients, serious hyponatraemia was recorded only in the carbamazepine arm (1 event versus 0 on levetiracetam and 0 on lamotrigine) — a small but arm-specific confirmation of carbamazepine's hyponatraemia signal. View on ClinicalTrials.gov →

Causality: well established

Carbamazepine ↔ Stevens–Johnson syndrome / TEN

Open this assessment on its own page →

n=920 co-reports · PRR 13.5 · ROR 13.7

Carbamazepine is a leading cause of Stevens–Johnson syndrome and toxic epidermal necrolysis, severe blistering skin reactions driven, in many Asian populations, by the HLA-B*15:02 genetic variant — which is why screening for that allele before starting the drug is now recommended in at-risk groups. The reaction is a genuine, genetically-predisposed drug hypersensitivity rather than a coincidence. The 920 co-reports (PRR 13.5) reflect both the severity that drives reporting and the drug's wide use in epilepsy, bipolar disorder, and trigeminal neuralgia.

Regulatory basis: carbamazepine prescribing information (boxed warning for SJS/TEN; HLA-B*15:02 screening). Established carbamazepine-HLA pharmacogenomics.

Bradford Hill viewpointStatusNote
Temporality (necessary)metSkin reaction appears early in therapy (usually within weeks) and is treated by withdrawal
StrengthmetPRR 14 on a large co-report count
ConsistencymetReproduced across populations and linked to HLA-B*15:02
SpecificitypartialShared with other aromatic antiepileptics (phenytoin, lamotrigine), a class pattern
Biological gradientpartialStrongly linked to genetic risk rather than a simple dose gradient
PlausibilitymetImmune-mediated keratinocyte death, often HLA-restricted, is the mechanism
CoherencemetCoheres with the boxed warning and pre-treatment genetic screening advice
ExperimentpartialDechallenge (immediate withdrawal) is essential and can be life-saving; no randomized trial
AnalogymetAnalogous to SJS/TEN from other aromatic antiepileptics and allopurinol

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for carbamazepine captured SJS/TEN; it is a rare, severe idiosyncratic reaction identified through case series and pharmacogenetic studies rather than a trial AE table.
Causality: well established

Phenytoin ↔ Stevens–Johnson syndrome / TEN

Open this assessment on its own page →

n=771 co-reports · PRR 36.2 · ROR 37.6

Phenytoin, an older antiepileptic also used in some cardiac and neurosurgical settings, is another leading cause of Stevens–Johnson syndrome and toxic epidermal necrolysis, with the same aromatic-antiepileptic, HLA-linked pattern seen with carbamazepine. The reaction usually appears within the first weeks of therapy and requires immediate withdrawal. The 771 co-reports (PRR 36.2) reflect both the severity of the reaction and the drug's continued use worldwide.

Regulatory basis: phenytoin prescribing information (SJS/TEN warning; HLA-B*15:02 caution). Established phenytoin-HLA pharmacogenomics.

Bradford Hill viewpointStatusNote
Temporality (necessary)metSkin reaction appears early in therapy and is managed by immediate withdrawal
StrengthmetPRR 36 on a large co-report count
ConsistencymetReproduced across populations and linked to HLA-B*15:02
SpecificitypartialShared with other aromatic antiepileptics, a class pattern
Biological gradientpartialLinked more to genetic risk than to a simple dose gradient
PlausibilitymetImmune-mediated keratinocyte death, often HLA-restricted, is the mechanism
CoherencemetCoheres with the labelled warnings and genetic-screening advice
ExperimentpartialDechallenge (immediate withdrawal) is essential and can be life-saving; no randomized trial
AnalogymetAnalogous to SJS/TEN from carbamazepine, lamotrigine, and allopurinol

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for phenytoin captured SJS/TEN; it is a rare, severe idiosyncratic reaction identified through case series and pharmacogenetics rather than a trial AE table.
Causality: well established

Haloperidol ↔ QT prolongation / torsades

Open this assessment on its own page →

n=653 co-reports · PRR 16.0 · ROR 16.4

Haloperidol, a first-generation antipsychotic widely used for agitation and delirium, prolongs the QT interval and carries a labelled warning for torsades de pointes, particularly with intravenous use or high doses. The risk is amplified by other QT-prolonging drugs and electrolyte disturbance, and it is why ECG monitoring is advised in at-risk patients. The 653 co-reports (PRR 16.0) reflect both the real effect and the drug's frequent use in acutely unwell patients.

Regulatory basis: haloperidol prescribing information (QT prolongation and torsades warning; ECG caution).

Bradford Hill viewpointStatusNote
Temporality (necessary)metQT prolongation is measured during therapy and resolves after withdrawal
StrengthmetPRR 16 on a moderate co-report count
ConsistencymetReproduced across ECG studies and trials
SpecificitypartialA recognised antipsychotic effect, strongest for some agents such as haloperidol
Biological gradientpartialWorse with dose, IV use, and electrolyte disturbance
PlausibilitymethERG-channel blockade delays cardiac repolarisation
CoherencemetCoheres with the labelled ECG-monitoring advice
ExperimentmetA randomized ICU trial recorded torsades by arm (rarely, but on haloperidol)
AnalogymetAnalogous to QT risk with other antipsychotics (thioridazine, ziprasidone)

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study (NCT01211522), N=566

Term (as recorded)Haloperidol (n=192)Ziprasidone (n=190)Placebo (n=184)
Torsades de pointes — Cardiac disorders211

In this randomized ICU trial, torsades de pointes occurred in 2 of 192 patients on haloperidol (about 1%), versus 1 on ziprasidone and 1 on placebo — a low absolute rate that nonetheless shows the event is recorded on haloperidol, which itself carries a QT/torsades warning. View on ClinicalTrials.gov →

Expected pharmacological effect

Olanzapine (antipsychotics) ↔ Weight gain / metabolic syndrome

Open this assessment on its own page →

n=6,832 co-reports · PRR 6.2 · ROR 6.5

Olanzapine is among the antipsychotics most strongly associated with weight gain and metabolic disturbance — effects that follow from its pharmacology (notably histamine and serotonin-receptor blockade) and that, over time, contribute to diabetes and cardiovascular risk. The weight gain occurs during treatment, is broadly dose-related, and is a leading reason patients stop the drug. The 6,832 co-reports (PRR 6.2) reflect both the real effect and the very large number of people taking atypical antipsychotics.

Regulatory basis: olanzapine prescribing information (weight gain, hyperglycaemia, and metabolic monitoring). Established antipsychotic metabolic-effects literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeight rises during treatment and can partly regress after switching or withdrawal
StrengthmetPRR 6 on a very large co-report count
ConsistencymetReproduced across antipsychotic trials and observational studies
SpecificitypartialA class effect, strongest for olanzapine and clozapine
Biological gradientpartialBroadly dose-related
PlausibilitymetAppetite/histamine and serotonin-receptor effects shift energy balance
CoherencemetCoheres with the labelled metabolic monitoring guidance
ExperimentmetA comparative study recorded weight gain several-fold more often on olanzapine
AnalogymetAnalogous to weight gain with clozapine and other atypical antipsychotics

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics (NCT00448630), N=328

Term (as recorded)Ziprasidone (n=57)Risperidone (n=64)Quetiapine (n=23)Olanzipine (n=60)Aripiprazole (n=50)Amisulpride (n=41)Other (n=33)
Weight gain — General disorders22112610

In this observational metabolic-syndrome study, weight gain was reported about six times more often on olanzapine (12 of 60 patients) than on any comparator antipsychotic (2/57 ziprasidone, 2/64 risperidone, 1/23 quetiapine) — a direct comparative confirmation of olanzapine's leading weight-gain liability. View on ClinicalTrials.gov →

Causality: well established

Sertraline (SSRIs) ↔ Upper gastrointestinal bleeding

Open this assessment on its own page →

n=361 co-reports · PRR 3.9 · ROR 3.9

SSRIs such as sertraline impair platelet serotonin uptake, and because platelets depend on serotonin for aggregation, this produces a modestly increased bleeding tendency — most clearly seen as upper gastrointestinal bleeding, especially when combined with NSAIDs, aspirin, or anticoagulants. The risk is a class effect, is not dose-specific in a simple way, and is an important drug-interaction consideration. The 361 co-reports (PRR 3.9) reflect both the real association and the enormous number of people taking SSRIs.

Regulatory basis: sertraline/SSRI labelling warnings on abnormal bleeding, especially with NSAIDs/anticoagulants. Established SSRI-GI-bleeding observational literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metBleeding occurs during treatment and resolves after withdrawal
StrengthpartialPRR 4 on a moderate co-report count
ConsistencymetReproduced across SSRI cohorts and case-control studies
SpecificitypartialA class effect across SSRIs, amplified by other bleeding-risk drugs
Biological gradientpartialRisk rises with age, and with NSAID, aspirin, or anticoagulant co-therapy
PlausibilitymetImpaired platelet serotonin uptake reduces platelet aggregation
CoherencemetCoheres with the labelled bleeding/interaction warnings
ExperimentpartialObservational; no randomized trial has tested bleeding outcomes
AnalogymetAnalogous to bleeding risk with other SSRIs and serotonin-reuptake-inhibiting drugs

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for sertraline captured gastrointestinal bleeding; the risk is small and was identified through large observational studies, not a trial AE table.
Causality: well established

Paroxetine (SSRIs) ↔ Discontinuation (withdrawal) syndrome

Open this assessment on its own page →

n=554 co-reports · PRR 3.9 · ROR 3.9

Paroxetine is the SSRI most likely to cause a discontinuation syndrome on stopping — dizziness, flu-like symptoms, irritability, and electric-shock-like sensations — largely because of its short half-life and lack of active metabolites. The syndrome is a genuine, predictable consequence of abruptly removing a drug the brain has adapted to, not a sign of addiction, and it is avoided by tapering. The 554 co-reports (PRR 3.9) reflect the drug's wide use and the vividness of the symptoms, which patients report readily.

Regulatory basis: paroxetine prescribing information (discontinuation-syndrome warning; tapering guidance).

Bradford Hill viewpointStatusNote
Temporality (necessary)metSymptoms appear when the drug is stopped and resolve on restarting or gradually tapering
StrengthmetPRR 7 on a moderate co-report count
ConsistencymetReproduced across SSRIs, strongest for paroxetine
SpecificitymetA class effect, most marked with short-half-life agents
Biological gradientpartialTied to the speed of discontinuation more than to daily dose
PlausibilitymetNeuroadaptation to serotonin-reuptake inhibition is the mechanism
CoherencemetCoheres with the labelled tapering guidance
ExperimentpartialDechallenge (taper/restart) reproducibly controls it; no randomized trial
AnalogymetAnalogous to discontinuation syndromes with venlafaxine and other SSRIs/SNRIs

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for paroxetine captured a structured discontinuation syndrome; it is identified through clinical reports and taper studies rather than a trial AE table.
Causality: well established

Bupropion ↔ Seizures

Open this assessment on its own page →

n=1,664 co-reports · PRR 7.0 · ROR 7.2

Bupropion lowers the seizure threshold, and this dose-related risk is why the immediate-release formulation was limited in dose and why the drug is avoided in people with epilepsy or eating disorders. Seizures are most likely at high doses, after rapid dose escalation, or when the drug is taken with other seizure-threshold-lowering agents. The 1,664 co-reports (PRR 7.0) reflect both the genuine effect and bupropion's wide use for depression and smoking cessation.

Regulatory basis: bupropion prescribing information (seizure warning; dose limits). Established bupropion-seizure literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metSeizures occur during treatment and risk falls after dose reduction or withdrawal
StrengthmetPRR 7 on a large co-report count
ConsistencymetReproduced in trials and overdose cohorts
SpecificitymetA recognised bupropion effect, less typical of other antidepressants
Biological gradientmetClearly dose-related, with higher risk at higher doses and on rapid escalation
PlausibilitymetReduced seizure threshold by the drug's mechanism is the basis
CoherencemetCoheres with the labelled dose limits and contraindications
ExperimentpartialDechallenge (withdrawal/dose reduction) lowers risk; no randomized trial
AnalogymetAnalogous to seizures from other seizure-threshold-lowering drugs (tramadol, tricyclics)

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for bupropion captured seizures as a coded event; the risk is characterised from trials, overdose data, and the labelled dose limits rather than a trial AE table.
Causality: well established

Trazodone ↔ Priapism

Open this assessment on its own page →

n=34 co-reports · PRR 13.3 · ROR 13.4

Trazodone is the antidepressant most associated with priapism, a prolonged, painful erection that is a urological emergency — an effect related to its alpha-adrenergic blocking action. It is uncommon but well recognised and can occur at therapeutic doses, so patients are warned to seek urgent help. The 34 co-reports (PRR 13.3) are small because priapism is rare and under-reported, but the association is distinctive and specific.

Regulatory basis: trazodone prescribing information (priapism warning). Established trazodone-priapism literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metPriapism occurs during treatment and is treated as an emergency by withdrawal and intervention
StrengthpartialPRR 13 on a small co-report count
ConsistencymetReproduced across decades of trazodone case reports
SpecificitymetA distinctive trazodone effect, unusual for other antidepressants
Biological gradientpartialNot clearly dose-related; can occur at therapeutic doses
PlausibilitymetAlpha-adrenergic blockade in penile vasculature is the proposed mechanism
CoherencemetCoheres with the labelled warning to seek urgent care
ExperimentpartialDechallenge (withdrawal) plus urological treatment resolves it; no randomized trial
AnalogymetAnalogous to priapism from some other alpha-blocking drugs

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for trazodone captured priapism; it is a rare emergency identified through case reports rather than a trial AE table.
Causality: well established

Donepezil (cholinesterase inhibitors) ↔ Bradycardia / syncope

Open this assessment on its own page →

n=1,014 co-reports · PRR 11.2 · ROR 11.5

Donepezil boosts acetylcholine by inhibiting cholinesterase, and because the vagus nerve uses acetylcholine to slow the heart, it can cause bradycardia, heart block, and syncope — effects that are easy to miss in older patients who may simply fall. This is why the drug's labelling cautions about heart-rate-lowering, and why clinicians watch for dizziness and falls. The 1,014 co-reports (PRR 11.2) reflect both the real effect and the very large, elderly population taking cholinesterase inhibitors.

Regulatory basis: donepezil prescribing information (bradycardia, heart block, and syncope cautions). Established cholinesterase-inhibitor bradycardia literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metBradycardia/syncope occur during treatment and resolve after withdrawal
StrengthmetPRR 11 on a large co-report count
ConsistencymetReproduced across cholinesterase inhibitors and in cohort studies
SpecificitymetA class effect of cholinesterase inhibitors
Biological gradientpartialRisk rises with dose and in patients with cardiac conduction disease
PlausibilitymetIncreased vagal (acetylcholine) tone slows the SA/AV nodes
CoherencemetCoheres with the labelled cardiac cautions and falls risk
ExperimentpartialDechallenge (withdrawal) reverses it; a large trial recorded bradycardia events by arm
AnalogymetAnalogous to bradycardia with other cholinesterase inhibitors

This page's own qualitative read, not an automated/citation-gated assessment.

✗ A large donepezil trial that posted results (NCT02079246) tracked bradycardia and syncope but recorded only single serious events, mostly in the active arm — too few to quantify, so the risk rests on the labelled caution and cohort studies rather than a trial AE table.
Causality: well established

Pramipexole (dopamine agonists) ↔ Impulse-control disorder

Open this assessment on its own page →

n=195 co-reports · PRR 144.0 · ROR 145.8

Dopamine agonists such as pramipexole can trigger striking impulse-control disorders — pathological gambling, compulsive shopping, hypersexuality, and binge eating — by over-stimulating the brain's reward circuitry. The effect is genuine, can appear at ordinary doses, and often resolves when the drug is reduced or stopped, and it is now the subject of explicit labelling after regulatory reviews in the 2010s. The very high PRR (144.0) reflects that the term is closely tied to this drug class.

Regulatory basis: pramipexole/ropinirole prescribing information (impulse-control disorders); EMA/FDA class reviews (2010s).

Bradford Hill viewpointStatusNote
Temporality (necessary)metBehaviours emerge during treatment and often resolve after dose reduction or withdrawal
StrengthmetVery high PRR, characteristic of dopamine agonists
ConsistencymetReproduced across the class and in cohort studies
SpecificitymetA distinctive dopamine-agonist effect, uncommon with other drugs
Biological gradientmetBroadly dose-related
PlausibilitymetDopamine-receptor over-stimulation of reward pathways is the mechanism
CoherencemetCoheres with the class labelling and patient warnings
ExperimentpartialDechallenge (dose reduction/withdrawal) usually reverses it; no randomized trial
AnalogymetAnalogous to impulse-control disorders with ropinirole and other dopamine agonists

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for pramipexole captured impulse-control disorder as a coded event; the behaviour is detected through clinical interview and case series rather than a trial AE table.
Causality: well established

Ropinirole (dopamine agonists) ↔ Impulse-control disorder

Open this assessment on its own page →

n=92 co-reports · PRR 64.2 · ROR 64.6

Like pramipexole, ropinirole can cause impulse-control disorders — pathological gambling, compulsive shopping or eating, and hypersexuality — through over-stimulation of dopamine reward pathways. The behaviours are genuine, can arise at therapeutic doses, and usually improve when the drug is withdrawn or reduced; the class carries explicit labelling. The very high PRR (64.2) again reflects how tightly this term maps to dopamine agonists.

Regulatory basis: ropinirole prescribing information (impulse-control disorders); EMA/FDA dopamine-agonist class reviews (2010s).

Bradford Hill viewpointStatusNote
Temporality (necessary)metBehaviours emerge during treatment and often resolve after dose reduction or withdrawal
StrengthmetVery high PRR, characteristic of dopamine agonists
ConsistencymetReproduced across the class and in cohort studies
SpecificitymetA distinctive dopamine-agonist effect, uncommon with other drugs
Biological gradientmetBroadly dose-related
PlausibilitymetDopamine-receptor over-stimulation of reward pathways is the mechanism
CoherencemetCoheres with the class labelling and patient warnings
ExperimentpartialDechallenge (dose reduction/withdrawal) usually reverses it; no randomized trial
AnalogymetAnalogous to impulse-control disorders with pramipexole and other dopamine agonists

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for ropinirole captured impulse-control disorder as a coded event; it is identified through clinical interview and case series rather than a trial AE table.
Causality: well established

Metformin ↔ Lactic acidosis

Open this assessment on its own page →

n=17,141 co-reports · PRR 67.6 · ROR 71.0

Metformin carries a boxed warning for lactic acidosis, a rare but potentially fatal accumulation of lactate that rises when the drug (which is cleared by the kidney) is used in renal impairment, in tissue hypoxia, or with excessive alcohol. The very high FAERS count (17,141 co-reports, PRR 67.6) reflects both the enormous population taking metformin and how severely the cases present, and it is why kidney function is checked and the drug withheld before contrast imaging or during acute illness.

Regulatory basis: metformin prescribing information (boxed warning for lactic acidosis; renal-function thresholds).

Bradford Hill viewpointStatusNote
Temporality (necessary)metLactate accumulates during treatment, especially in renal impairment or acute illness
StrengthmetPRR 68 — a very high relative signal on a very large co-report count
ConsistencymetReproduced across decades of metformin safety literature
SpecificitypartialA recognised metformin effect, though other biguanides share it
Biological gradientpartialRisk rises with impaired renal clearance, hypoxia, and alcohol
PlausibilitymetImpaired lactate clearance and mitochondrial effects are the mechanisms
CoherencemetCoheres with the boxed warning and renal-function monitoring
ExperimentpartialDechallenge (withdrawal) plus supportive care reverses it; no randomized trial
AnalogymetAnalogous to lactic acidosis with the older biguanide phenformin (withdrawn)

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for metformin captured lactic acidosis; it is a rare emergency identified through clinical surveillance and the boxed-warning evidence base rather than a trial AE table.
Expected pharmacological effect

Glipizide (sulfonylureas) ↔ Hypoglycaemia

Open this assessment on its own page →

n=1,332 co-reports · PRR 9.7 · ROR 9.9

Sulfonylureas such as glipizide work by forcing the pancreas to release insulin, so hypoglycaemia is a direct, predictable consequence of the mechanism rather than a side effect — and it is the main reason these drugs must be used carefully in older patients, in renal impairment, and around missed meals. Severe, prolonged hypoglycaemia is more likely with the longer-acting sulfonylureas. The 1,332 co-reports (PRR 9.7) reflect both the real effect and how widely sulfonylureas are still prescribed.

Regulatory basis: glipizide/sulfonylurea prescribing information (hypoglycaemia warning).

Bradford Hill viewpointStatusNote
Temporality (necessary)metBlood sugar falls during treatment and rises after withdrawal or food
StrengthmetPRR 10 on a large co-report count
ConsistencymetReproduced across the sulfonylurea class and in trials
SpecificitymetA class effect of insulin secretagogues
Biological gradientpartialRisk rises with dose, renal impairment, age, and missed meals
PlausibilitymetStimulation of insulin release regardless of glucose is the mechanism
CoherencemetCoheres with the labelled hypoglycaemia warning
ExperimentmetA randomized trial recorded markedly more hypoglycaemia on glipizide than on a comparator
AnalogymetAnalogous to hypoglycaemia with other sulfonylureas and insulin

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus (NCT00856284), N=2,620

Term (as recorded)Metformin + Alogliptin 12.5 mg (n=873)Metformin + Alogliptin 25 mg (n=878)Metformin + Glipizide (n=869)
Hypoglycaemia — Metabolism and nutrition disorders001
Hypoglycaemia — Metabolism and nutrition disorders18691

Hypoglycaemia was roughly five-fold more frequent on glipizide than on either comparator arm (91 versus 18 and 6 all-grade events) in this randomized diabetes trial — direct confirmation of the sulfonylurea's expected glucose-lowering hazard, with serious hypoglycaemia rare but slightly higher on glipizide. View on ClinicalTrials.gov →

Causality: well established

Propylthiouracil ↔ Hepatotoxicity / acute liver failure

Open this assessment on its own page →

n=46 co-reports · PRR 34.7 · ROR 35.5

Propylthiouracil, an antithyroid drug, carries a boxed warning for severe liver injury that can progress to acute liver failure and even require transplantation — a risk serious enough that its use is now largely limited to the first trimester of pregnancy and to thyroid storm, with methimazole preferred otherwise. The injury is idiosyncratic and can be sudden. The 46 co-reports (PRR 34.7) reflect a rare but regulatorily prominent and potentially fatal effect.

Regulatory basis: propylthiouracil prescribing information (boxed warning for hepatotoxicity/liver failure). Established propylthiouracil-hepatotoxicity literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metLiver injury develops during therapy and can be fulminant
StrengthmetPRR 35 on a small co-report count — a strong relative signal for a rare event
ConsistencymetReproduced across case series and pharmacovigilance analyses
SpecificitymetA distinctive propylthiouracil toxicity, less typical of methimazole
Biological gradientpartialLargely idiosyncratic rather than simply dose-related
PlausibilitymetImmune/metabolic hepatocellular injury is proposed
CoherencemetCoheres with the boxed warning and restricted-use recommendations
ExperimentpartialDechallenge (withdrawal) is essential and can be life-saving; no randomized trial
AnalogymetAnalogous to severe drug-induced liver injury from other drugs

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for propylthiouracil captured hepatotoxicity or liver failure; it is rare and idiosyncratic, identified through case series and regulatory review rather than a trial AE table.
Causality: well established

Corticosteroids (prednisolone) ↔ Avascular necrosis of bone

Open this assessment on its own page →

n=1,064 co-reports · PRR 3.8 · ROR 3.9

Systemic corticosteroids such as prednisolone are a leading cause of osteonecrosis (avascular necrosis), especially of the hip, and the risk rises with higher doses and longer courses — even short high-dose bursts have been implicated. The mechanism involves impaired blood supply and altered fat metabolism in bone. The 1,064 co-reports (PRR 3.8) are driven by the enormous number of patients who receive steroids for inflammatory and autoimmune conditions.

Regulatory basis: corticosteroid prescribing information (osteonecrosis, osteoporosis; monitoring advice). Established glucocorticoid-osteonecrosis literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOsteonecrosis typically appears months after starting or escalating steroids
StrengthpartialPRR 4 with a large co-report count — a modest but broad signal
ConsistencymetReproduced across decades of cohort and case series
SpecificitymetA recognised corticosteroid effect, not unique to prednisolone
Biological gradientpartialDose- and duration-related
PlausibilitymetImpaired bone blood supply and fat-metabolism changes are the mechanisms
CoherencemetCoheres with the labelled skeletal warnings and monitoring
ExperimentpartialDechallenge (steroid withdrawal) does not reverse established lesions; no randomized trial
AnalogymetAnalogous to osteonecrosis from other glucocorticoids and in transplant/immunosuppression

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for prednisolone captured osteonecrosis; it appears months after steroid exposure and is identified through imaging and cohort studies rather than a trial AE table.
Expected pharmacological effect

Corticosteroids (prednisolone) ↔ Hyperglycaemia / steroid diabetes

Open this assessment on its own page →

n=1,068 co-reports · PRR 3.5 · ROR 3.5

Glucocorticoids such as prednisolone raise blood glucose by increasing liver glucose output and reducing peripheral insulin sensitivity, so steroid-induced hyperglycaemia and even frank diabetes are expected, dose-related effects rather than surprises. The problem is greatest in people with existing diabetes, in the afternoon and evening with once-daily morning dosing, and during high-dose therapy. The 1,068 co-reports (PRR 3.5) reflect the very large number of patients receiving corticosteroids for inflammatory disease.

Regulatory basis: corticosteroid prescribing information (hyperglycaemia; glucose monitoring advice). Established glucocorticoid-induced hyperglycaemia literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metGlucose rises during steroid treatment and falls after withdrawal
StrengthmetPRR 4 with a large co-report count — a modest but broad signal
ConsistencymetReproduced across the corticosteroid literature
SpecificitymetA recognised corticosteroid effect, not unique to prednisolone
Biological gradientpartialDose-related and worse in existing diabetes
PlausibilitymetIncreased hepatic glucose output and insulin resistance are the mechanisms
CoherencemetCoheres with the labelled glucose-monitoring advice
ExperimentpartialDechallenge (steroid reduction/withdrawal) reverses it; no randomized trial
AnalogymetAnalogous to hyperglycaemia with other glucocorticoids and with some antipsychotics

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for prednisolone captured hyperglycaemia as a coded event; steroid hyperglycaemia is managed by glucose monitoring in practice rather than recorded as a trial AE.
Causality: well established

Zoledronic acid (bisphosphonates) ↔ Osteonecrosis of the jaw

Open this assessment on its own page →

n=2,708 co-reports · PRR 64.0 · ROR 68.6

Intravenous bisphosphonates such as zoledronic acid can cause osteonecrosis of the jaw, a painful, often persistent exposure of bone that occurs mainly in cancer patients receiving frequent high doses and is associated with dental procedures, poor oral hygiene, and steroid use. The risk is genuinely drug-related and is why dental review before starting therapy and attention to oral health are advised. The 2,708 co-reports (PRR 64.0) reflect the potency of zoledronic acid and its heavy use in oncology.

Regulatory basis: zoledronic acid prescribing information (osteonecrosis of the jaw warning; dental review advice). Established bisphosphonate-ONJ literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metJaw osteonecrosis appears during therapy, often after a dental event, and may not heal
StrengthmetPRR 64 on a large co-report count
ConsistencymetReproduced across bisphosphonate and denosumab studies
SpecificitymetA recognised antiresorptive-class effect
Biological gradientmetDose- and frequency-related; worse with steroid use and dental procedures
PlausibilitymetImpaired bone turnover in the jaw is the mechanism
CoherencemetCoheres with the labelled dental-review and oral-hygiene advice
ExperimentmetA randomized trial recorded osteonecrosis on zoledronic acid
AnalogymetAnalogous to ONJ with other bisphosphonates and denosumab

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement (NCT00869206), N=1,747

Term (as recorded)Arm I (Zoledronic Acid Every 4 Weeks) (n=879)Arm II (Zoledronic Acid Every 12 Weeks) (n=868)
Osteonecrosis — Musculoskeletal and connective tissue disorders44

Osteonecrosis was recorded in 4 of 879 patients on the every-4-weeks zoledronic-acid schedule and 4 of 868 on the every-12-weeks schedule. The trial had no untreated arm, so it shows ONJ occurs on the drug — the basis of the labelled risk — rather than quantifying the excess; notably, the less frequent schedule did not have fewer events. View on ClinicalTrials.gov →

Expected pharmacological effect

Cinacalcet ↔ Hypocalcaemia

Open this assessment on its own page →

n=273 co-reports · PRR 65.8 · ROR 69.8

Cinacalcet lowers parathyroid hormone by acting on the calcium-sensing receptor, and because it suppresses parathyroid hormone it also lowers serum calcium — so hypocalcaemia is a direct, dose-related consequence of how the drug works. It is the reason calcium levels are monitored when therapy starts or the dose changes, and why active vitamin D is sometimes needed. The 273 co-reports (PRR 65.8) reflect the drug's use in dialysis patients with secondary hyperparathyroidism, who are already at risk of calcium disturbance.

Regulatory basis: cinacalcet prescribing information (hypocalcaemia warning; calcium monitoring).

Bradford Hill viewpointStatusNote
Temporality (necessary)metCalcium falls during treatment and recovers with dose adjustment or withdrawal
StrengthmetVery high PRR, consistent with a drug whose whole action lowers PTH and calcium
ConsistencymetReproduced across the cinacalcet trial programme
SpecificitymetA direct consequence of the drug's calcimimetic mechanism
Biological gradientmetDose-related
PlausibilitymetCalcium-sensing-receptor activation suppresses PTH and lowers calcium
CoherencemetCoheres with the labelled calcium-monitoring guidance
ExperimentmetRandomized trials measured calcium by arm
AnalogymetAnalogous to hypocalcaemia from other calcimimetics

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for cinacalcet captured hypocalcaemia as a coded event; calcium changes are captured through routine laboratory monitoring rather than coded trial endpoints.
Causality: well established

Octreotide (somatostatin analogues) ↔ Gallstones (cholelithiasis)

Open this assessment on its own page →

n=68 co-reports · PRR 7.8 · ROR 7.9

Octreotide and other somatostatin analogues reduce gallbladder contractility and alter bile composition, so they promote the formation of gallstones or biliary sludge — a well-recognised effect that is usually asymptomatic but can cause biliary colic or pancreatitis. It is dose- and duration-related and is why periodic gallbladder imaging is considered during long-term therapy. The 68 co-reports (PRR 7.8) reflect the drug's use in acromegaly and neuroendocrine tumours, where treatment is often lifelong.

Regulatory basis: octreotide prescribing information (gallbladder/biliary adverse effects; periodic imaging advice). Established somatostatin-analogue cholelithiasis literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metStones/sludge form during long-term therapy
StrengthpartialPRR 8 on a small co-report count
ConsistencymetReproduced across somatostatin analogues and in imaging studies
SpecificitymetA recognised somatostatin-analogue effect
Biological gradientpartialDose- and duration-related
PlausibilitymetReduced gallbladder contractility and altered bile composition are the mechanisms
CoherencemetCoheres with the labelled advice to monitor the gallbladder
ExperimentpartialDechallenge (withdrawal) may slow progression but does not dissolve stones; no randomized trial
AnalogymetAnalogous to gallstones with other somatostatin analogues

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for octreotide captured cholelithiasis as a coded event; gallstones are found on routine imaging during long-term therapy rather than recorded in trial AE tables.
Causality: well established

Ondansetron (5-HT3 antagonists) ↔ QT prolongation / torsades

Open this assessment on its own page →

n=1,167 co-reports · PRR 6.4 · ROR 6.5

Ondansetron, a widely used anti-nausea drug, can prolong the cardiac QT interval and has been linked to rare torsades de pointes, particularly with intravenous doses or in patients with electrolyte disturbance or other QT-prolonging drugs. This led regulators to lower the maximum single intravenous dose. The effect is genuine and dose-related rather than idiosyncratic, and it is the reason ECG caution is advised in at-risk patients. The 1,167 co-reports (PRR 6.4) reflect ondansetron's very wide use in surgery, cancer care, and pregnancy.

Regulatory basis: ondansetron prescribing information and FDA dose-limit change (2012) over QT prolongation.

Bradford Hill viewpointStatusNote
Temporality (necessary)metQT prolongation is measured during treatment and resolves after the drug is cleared
StrengthmetPRR 6 on a large co-report count
ConsistencymetReproduced across ECG studies and case series
SpecificitypartialA class effect of 5-HT3 antagonists, strongest for some agents
Biological gradientpartialDose-related, especially with intravenous use
PlausibilitymethERG-channel blockade delays cardiac repolarisation
CoherencemetCoheres with the regulatory dose-limit change and ECG cautions
ExperimentpartialSupport from ECG studies; no randomized arrhythmia RCT
AnalogymetAnalogous to QT risk with other 5-HT3 antagonists and QT-prolonging drugs

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for ondansetron captured QT prolongation or torsades; the risk was characterised through ECG studies and the dose-limit regulatory action rather than a trial AE table.
Causality: well established

Azathioprine ↔ Bone-marrow suppression (pancytopenia)

Open this assessment on its own page →

n=1,126 co-reports · PRR 4.9 · ROR 5.0

Azathioprine suppresses the bone marrow, reducing white cells, platelets, and red cells, and this myelosuppression is dramatically worse in people who inherit low activity of the enzyme thiopurine methyltransferase (TPMT) — which is why testing for it and monitoring blood counts are recommended. The effect is a direct, dose-related consequence of the drug's antiproliferative action rather than an idiosyncratic reaction. The 1,126 co-reports (PRR 4.9) reflect azathioprine's widespread use in transplantation and autoimmune disease.

Regulatory basis: azathioprine prescribing information (myelosuppression warning; TPMT testing and blood-count monitoring).

Bradford Hill viewpointStatusNote
Temporality (necessary)metBlood counts fall during therapy and recover (with risk of infection/bleeding) when the drug is reduced or stopped
StrengthmetPRR 5 on a large co-report count
ConsistencymetReproduced across the thiopurine literature
SpecificitymetA recognised azathioprine effect, shared with mercaptopurine
Biological gradientmetDose-related and dramatically worse with low TPMT activity
PlausibilitymetInhibition of purine synthesis in proliferating marrow cells is the mechanism
CoherencemetCoheres with the labelled TPMT testing and blood-count monitoring
ExperimentpartialDechallenge (dose reduction/withdrawal) allows marrow recovery; no randomized trial
AnalogymetAnalogous to myelosuppression from other antimetabolites

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for azathioprine captured pancytopenia as a coded event; marrow suppression is captured through routine blood-count monitoring rather than coded trial endpoints.
Causality: well established

Methotrexate ↔ Hepatotoxicity

Open this assessment on its own page →

n=2,128 co-reports · PRR 5.2 · ROR 5.2

Methotrexate can cause liver injury, ranging from raised transaminases to fibrosis and, rarely, cirrhosis with long-term use — which is why liver enzymes are checked periodically, alcohol is discouraged, and cumulative dose is tracked. The injury is usually dose- and duration-related rather than idiosyncratic, and risk is higher in people with fatty liver, hepatitis, or heavy alcohol use. The 2,128 co-reports (PRR 5.2) reflect methotrexate's very wide use in rheumatoid arthritis, psoriasis, and cancer.

Regulatory basis: methotrexate prescribing information (hepatotoxicity warning; liver-enzyme monitoring). Established methotrexate-hepatotoxicity literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metLiver-enzyme rises occur during therapy and usually improve after withdrawal
StrengthmetPRR 5 on a very large co-report count
ConsistencymetReproduced across rheumatology and dermatology cohorts
SpecificitymetA recognised methotrexate effect, less typical of other DMARDs
Biological gradientpartialCumulative-dose- and duration-related
PlausibilitymetFolate antagonism and hepatic accumulation are the mechanisms
CoherencemetCoheres with the labelled liver-enzyme monitoring
ExperimentpartialA trial recorded transaminase rises in the methotrexate-containing arm
AnalogymetAnalogous to hepatotoxicity from other antimetabolites and leflunomide

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis (NCT01995201), N=744

Term (as recorded)Phase 1: Tocilizumab Monotherapy (n=74)Phase 1: Combination Therapy (n=327)Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) (n=89)Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) (n=90)Phase 2 Arm B: Participants With Low Disease Activity (n=95)Phase 2 Arm C: Moderate EULAR Response at Week 24 (n=67)Phase 2 Arm D: Non Responders (n=2)
Transaminases increased — Investigations13700000

Raised transaminases were recorded in 37 of 327 patients on the methotrexate-containing combination arm versus 1 of 74 on monotherapy in this trial — consistent with methotrexate's hepatotoxic signal, though the trial was not designed to compare liver toxicity directly. View on ClinicalTrials.gov →

Causality: well established

Methotrexate ↔ Pneumonitis / pulmonary fibrosis

Open this assessment on its own page →

n=3,464 co-reports · PRR 10.9 · ROR 11.0

Methotrexate can cause a hypersensitivity-type pneumonitis and, less often, chronic pulmonary fibrosis — a rare but serious effect that can occur at any dose and at any time during therapy, including the first months. It is the reason new breathlessness or dry cough in a patient on methotrexate is investigated promptly and the drug stopped. The 3,464 co-reports (PRR 10.9) reflect both the real effect and methotrexate's very large treated population.

Regulatory basis: methotrexate prescribing information (acute pneumonitis and pulmonary fibrosis warning). Established methotrexate-lung-toxicity literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metLung injury develops during therapy and may improve after withdrawal
StrengthmetPRR 11 on a large co-report count
ConsistencymetReproduced across rheumatology case series
SpecificitymetA recognised methotrexate effect, uncommon with most other drugs
Biological gradientpartialNot clearly dose-related; can occur early
PlausibilitymetAn immune/hypersensitivity reaction in the lung is the proposed mechanism
CoherencemetCoheres with the labelled advice to investigate new respiratory symptoms
ExperimentpartialDechallenge (withdrawal) is essential and often helps; no randomized trial
AnalogymetAnalogous to pneumonitis from other DMARDs (leflunomide, TNF inhibitors)

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for methotrexate captured drug-induced pneumonitis or pulmonary fibrosis as a coded event; the reaction is rare and identified in clinical practice rather than in trial AE tables.
Causality: well established

Leflunomide ↔ Hepatotoxicity

Open this assessment on its own page →

n=1,297 co-reports · PRR 10.7 · ROR 10.8

Leflunomide, a disease-modifying drug for rheumatoid and psoriatic arthritis, carries a boxed warning for severe liver injury, including fatal cases, and requires liver-enzyme monitoring and avoidance in people with pre-existing liver disease. The risk is higher when it is combined with methotrexate or other hepatotoxic drugs. The very high FAERS count (1,297 co-reports, PRR 10.7) reflects both the drug's real hepatotoxicity and how widely it has been prescribed.

Regulatory basis: leflunomide prescribing information (boxed warning for hepatotoxicity; liver-enzyme monitoring).

Bradford Hill viewpointStatusNote
Temporality (necessary)metLiver-enzyme rises occur during therapy and improve after withdrawal
StrengthmetPRR 11 on a very large co-report count
ConsistencymetReproduced in trials and post-marketing data
SpecificitymetA recognised leflunomide effect, stronger than most DMARDs
Biological gradientpartialDose-related and worse with pre-existing liver disease or methotrexate
PlausibilitymetDirect hepatocellular toxicity is the proposed mechanism
CoherencemetCoheres with the boxed warning and monitoring requirement
ExperimentpartialDechallenge (withdrawal, sometimes with cholestyramine washout) reverses it; no randomized trial
AnalogymetAnalogous to hepatotoxicity from methotrexate and other DMARDs

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for leflunomide captured hepatitis or hepatotoxicity as a coded event; liver toxicity is captured through routine enzyme monitoring rather than coded trial endpoints.
Causality: well established

Cyclophosphamide ↔ Haemorrhagic cystitis

Open this assessment on its own page →

n=1,125 co-reports · PRR 46.1 · ROR 46.4

Cyclophosphamide, an old but still essential chemotherapy and immunosuppressant, is broken down to acrolein, a metabolite that irritates the bladder lining and can cause haemorrhagic cystitis — a painful, sometimes severe bleeding from the bladder. The risk is dose-related and is greatly reduced by good hydration and by mesna, a drug that neutralises acrolein in the urine. The 1,125 co-reports (PRR 46.1) reflect both the real, mechanistically-defined effect and the drug's wide use in cancer and autoimmune disease.

Regulatory basis: cyclophosphamide prescribing information (haemorrhagic cystitis warning; hydration and mesna prophylaxis).

Bradford Hill viewpointStatusNote
Temporality (necessary)metBladder injury appears during or after therapy and is reduced by hydration/mesna
StrengthmetPRR 46 on a large co-report count
ConsistencymetReproduced across the oncology literature
SpecificitymetA distinctive cyclophosphamide effect via its acrolein metabolite
Biological gradientmetDose-related
PlausibilitymetAcrolein-induced bladder-mucosa injury is the defined mechanism
CoherencemetCoheres with the labelled hydration and mesna prophylaxis
ExperimentpartialDechallenge (stopping the drug) plus supportive care resolves it; no randomized trial
AnalogymetAnalogous to bladder toxicity from ifosfamide (same acrolein mechanism)

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for cyclophosphamide captured haemorrhagic cystitis as a coded event; the effect is managed with hydration/mesna in practice rather than recorded as a trial AE.
Causality: well established

Cyclosporine ↔ Nephrotoxicity

Open this assessment on its own page →

n=2,159 co-reports · PRR 5.0 · ROR 5.1

Cyclosporine, a cornerstone transplant immunosuppressant, narrows the blood vessels in the kidney and can cause both an acute, reversible rise in creatinine and a chronic, dose-related kidney damage over years of use. Because of this, drug levels and kidney function are monitored closely, and doses are kept as low as possible. The very high FAERS count (2,159 co-reports, PRR 5.0) reflects both the real, dose-dependent effect and the very large transplant population on calcineurin inhibitors.

Regulatory basis: cyclosporine prescribing information (nephrotoxicity warning; therapeutic drug and renal monitoring).

Bradford Hill viewpointStatusNote
Temporality (necessary)metKidney function worsens during therapy and may improve with dose reduction
StrengthmetPRR 5 on a very large co-report count
ConsistencymetReproduced across transplant medicine
SpecificitymetA calcineurin-inhibitor class effect
Biological gradientmetDose- and level-related
PlausibilitymetRenal vasoconstriction and chronic tubulointerstitial injury are the mechanisms
CoherencemetCoheres with the labelled drug-level and renal monitoring
ExperimentpartialDechallenge (dose reduction) often partly reverses it; no randomized trial
AnalogymetAnalogous to nephrotoxicity with tacrolimus

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for cyclosporine captured renal impairment as a coded event; kidney changes are captured through routine renal-function and drug-level monitoring rather than coded trial endpoints.
Causality: well established

Tacrolimus ↔ Nephrotoxicity

Open this assessment on its own page →

n=6,153 co-reports · PRR 5.6 · ROR 5.8

Tacrolimus, a calcineurin-inhibitor immunosuppressant used widely in transplantation, causes kidney injury in much the same way as cyclosporine — acute vasoconstriction and, over time, chronic damage — so its levels and kidney function are monitored closely and doses are minimised. The very high FAERS count (6,153 co-reports, PRR 5.6) reflects both the real effect and the drug's use in a very large transplant population.

Regulatory basis: tacrolimus prescribing information (nephrotoxicity warning; therapeutic drug and renal monitoring).

Bradford Hill viewpointStatusNote
Temporality (necessary)metKidney function worsens during therapy and can improve with dose reduction
StrengthmetPRR 6 on a very large co-report count
ConsistencymetReproduced across transplant medicine
SpecificitymetA calcineurin-inhibitor class effect
Biological gradientmetDose- and level-related
PlausibilitymetRenal vasoconstriction and chronic tubulointerstitial injury are the mechanisms
CoherencemetCoheres with the labelled drug-level and renal monitoring
ExperimentpartialDechallenge (dose reduction) often partly reverses it; no randomized trial
AnalogymetAnalogous to nephrotoxicity with cyclosporine

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for tacrolimus captured acute kidney injury as a coded event; kidney changes are captured through routine renal-function and drug-level monitoring rather than coded trial endpoints.
Expected pharmacological effect

Ribavirin ↔ Haemolytic anaemia

Open this assessment on its own page →

n=8,367 co-reports · PRR 15.0 · ROR 17.1

Ribavirin causes a predictable, dose-dependent breakdown of red blood cells, producing anaemia that is the main dose-limiting toxicity of hepatitis C treatment and can be severe enough to require dose reduction or a transfusion. The effect follows directly from the drug's mechanism and is monitored with regular blood counts. The very high FAERS count (8,367 co-reports, PRR 15.0) reflects both the real effect and the large number of patients treated for hepatitis C.

Regulatory basis: ribavirin prescribing information (haemolytic anaemia warning; blood-count monitoring). Established ribavirin-haemolysis literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metAnaemia develops during therapy and improves after dose reduction or withdrawal
StrengthmetPRR 15 on a very large co-report count
ConsistencymetReproduced across hepatitis C trials
SpecificitymetA recognised ribavirin effect, unlike most antivirals
Biological gradientmetDose-related
PlausibilitymetOxidative damage to red-cell membranes causes haemolysis
CoherencemetCoheres with the labelled blood-count monitoring
ExperimentmetA randomized trial recorded anaemia in all ribavirin-containing arms
AnalogymetAnalogous to haemolysis from other oxidative drugs (dapsone, primaquine)

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED) (NCT00705432), N=1,097

Term (as recorded)PEG + RBV (n=363)BOCEPREVIR + PEG + RBV - 24 WEEKS (n=368)BOCEPRIVIR + PEG + RBV - 44 WEEKS (n=366)
ANAEMIA — Blood and lymphatic system disorders134

All three arms of this hepatitis C trial received ribavirin, and anaemia was common in every one (107, 182 and 179 events) — consistent with ribavirin's dose-limiting haemolytic effect rather than a between-arm difference, since the arms differed in the protease inhibitor added, not in ribavirin. View on ClinicalTrials.gov →

Causality: well established

Ibuprofen (NSAIDs) ↔ Gastrointestinal bleeding

Open this assessment on its own page →

n=2,645 co-reports · PRR 2.5 · ROR 2.5

Ibuprofen and other non-steroidal anti-inflammatory drugs cause gastrointestinal bleeding by blocking the COX-1 enzyme that protects the stomach lining, and this is a genuine class effect whose risk rises with dose, age, and co-therapy with steroids, anticoagulants, or other NSAIDs. It is the reason NSAIDs carry prominent gastrointestinal warnings. The 2,645 co-reports (PRR 2.5) — a modest disproportionality on a huge co-report count — reflect how extremely widely ibuprofen is used.

Regulatory basis: ibuprofen/NSAID prescribing information (gastrointestinal bleeding and ulcer warnings). Established NSAID-gastrotoxicity literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metBleeding occurs during NSAID use and stops after withdrawal
StrengthpartialPRR 2.5 with a very large co-report count — common but not highly disproportionate
ConsistencymetReproduced across NSAIDs and in trials
SpecificitymetA class effect shared across non-selective NSAIDs
Biological gradientpartialDose-related and worse with age and interacting drugs
PlausibilitymetCOX-1 inhibition removes prostaglandin protection of the stomach lining
CoherencemetCoheres with the labelled gastrointestinal warnings
ExperimentmetRandomized and observational studies directly quantify the gastrotoxicity
AnalogymetAnalogous to GI bleeding with other NSAIDs, including the withdrawn rofecoxib

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for ibuprofen captured gastrointestinal bleeding as a coded event; the risk is established from randomized gastroprotection studies and large observational cohorts rather than a single trial AE table.
Causality: well established

Acetaminophen (paracetamol) ↔ Liver injury / hepatotoxicity

Open this assessment on its own page →

n=4,238 co-reports · PRR 9.8 · ROR 9.9

Acetaminophen causes liver injury when the normal detoxification pathway is overwhelmed — chiefly in overdose, but occasionally at near-therapeutic doses in people who fast, drink heavily, or take enzyme-inducing drugs. The toxic metabolite NAPQI depletes glutathione and damages liver cells, so early treatment with the antidote acetylcysteine is highly effective. The 4,238 co-reports (PRR 9.8) reflect acetaminophen's enormous worldwide use and the frequency of both deliberate and accidental overdose.

Regulatory basis: acetaminophen prescribing information (hepatotoxicity warning; maximum-dose guidance; acetylcysteine antidote). Established acetaminophen-hepatotoxicity literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metLiver injury follows overdose exposure and evolves over hours–days
StrengthmetPRR 10 on a large co-report count
ConsistencymetReproduced across decades of overdose literature
SpecificitymetA distinctive acetaminophen toxicity among analgesics
Biological gradientmetStrongly dose-related; near-therapeutic risk in susceptible patients
PlausibilitymetNAPQI metabolite overwhelming glutathione is the defined mechanism
CoherencemetCoheres with the antidote and maximum-dose guidance
ExperimentpartialDechallenge with acetylcysteine (antidote) is highly effective; no randomized trial
AnalogymetAnalogous to dose-dependent hepatotoxicity from other drugs metabolised to reactive species

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for acetaminophen captured liver injury as a coded event; the toxicity is established from overdose studies, the acetylcysteine antidote evidence base, and regulatory dose limits rather than a trial AE table.
Causality: well established

Tramadol ↔ Seizures

Open this assessment on its own page →

n=467 co-reports · PRR 2.3 · ROR 2.3

Tramadol lowers the seizure threshold, and this risk rises with higher doses, with rapid dose escalation, and when it is combined with other seizure-threshold-lowering drugs such as SSRIs, tricyclics, or antipsychotics. The effect is genuine and dose-related rather than idiosyncratic, and it is why tramadol is used cautiously in people with epilepsy. The 467 co-reports (PRR 2.3) reflect both the real effect and tramadol's wide prescription as an analgesic.

Regulatory basis: tramadol prescribing information (seizure risk; caution with other serotonergic or pro-convulsant drugs).

Bradford Hill viewpointStatusNote
Temporality (necessary)metSeizures occur during treatment and risk falls after dose reduction or withdrawal
StrengthpartialPRR 2.3 on a moderate co-report count — a modest but real signal
ConsistencymetReproduced across case series and observational data
SpecificitymetA recognised tramadol effect, less typical of other opioids
Biological gradientmetDose-related and worse with interacting drugs
PlausibilitymetMonoamine-reuptake inhibition and opioid effects are proposed
CoherencemetCoheres with the labelled seizure caution
ExperimentpartialDechallenge (dose reduction/withdrawal) lowers risk; no randomized trial
AnalogymetAnalogous to seizures from bupropion and tricyclic antidepressants

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for tramadol captured seizures as a coded event; the risk is characterised through case series and observational data rather than a trial AE table.
Expected pharmacological effect

Fentanyl (opioids) ↔ Respiratory depression

Open this assessment on its own page →

n=920 co-reports · PRR 17.3 · ROR 17.5

Fentanyl, a potent synthetic opioid, suppresses the brainstem's drive to breathe, so respiratory depression is the direct, dose-related consequence of opioid action and the mechanism behind most opioid fatalities. The risk is amplified by other sedatives (benzodiazepines, alcohol, gabapentinoids) and is why the drug carries boxed warnings and why naloxone is used to reverse it. The 920 co-reports (PRR 17.3) reflect both the real effect and the drug's use in anaesthesia, cancer pain, and (illicitly) as a cause of overdose.

Regulatory basis: fentanyl prescribing information (boxed warning for respiratory depression; naloxone reversal). Established opioid respiratory-depression literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metBreathing slows during opioid effect and is reversed by naloxone or withdrawal
StrengthmetPRR 17 on a moderate co-report count
ConsistencymetReproduced across opioids and in anaesthesia practice
SpecificitymetAn opioid-class effect, most dangerous with potent agents
Biological gradientpartialStrongly dose-related and worse with sedatives
PlausibilitymetMu-opioid-receptor suppression of the brainstem respiratory centre is the mechanism
CoherencemetCoheres with the boxed warning and naloxone reversal
ExperimentpartialDechallenge (naloxone) reliably reverses it; no randomized trial
AnalogymetAnalogous to respiratory depression with morphine, methadone, and other opioids

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for fentanyl captured respiratory depression as a coded event; the effect is managed in anaesthesia and identified through overdose data rather than a trial AE table.
Causality: well established

Methadone ↔ QT prolongation / torsades

Open this assessment on its own page →

n=862 co-reports · PRR 12.1 · ROR 12.3

Methadone prolongs the cardiac QT interval and can cause torsades de pointes, particularly at higher doses, when combined with other QT-prolonging drugs, or in patients with electrolyte disturbance. This is why ECG monitoring is advised during methadone initiation and dose increases for opioid-use disorder. The effect is a genuine, dose-related cardiac toxicity rather than an idiosyncratic one. The 862 co-reports (PRR 12.1) reflect the drug's wide use in addiction treatment and pain.

Regulatory basis: methadone prescribing information (QT prolongation and torsades warning; ECG monitoring advice).

Bradford Hill viewpointStatusNote
Temporality (necessary)metQT prolongation is measured during therapy and resolves after withdrawal
StrengthmetPRR 12 on a large co-report count
ConsistencymetReproduced across ECG studies and case series
SpecificitymetA recognised opioid effect, strongest for methadone
Biological gradientpartialDose-related, especially above ~100 mg/day
PlausibilitymethERG-channel blockade delays cardiac repolarisation
CoherencemetCoheres with the labelled ECG-monitoring advice
ExperimentpartialDechallenge (withdrawal/dose reduction) reverses it; no randomized trial
AnalogymetAnalogous to QT risk with other QT-prolonging opioids and drugs

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for methadone captured QT prolongation or torsades; the risk was characterised through ECG studies and the labelled monitoring advice rather than a trial AE table.
Causality: well established

Finasteride ↔ Sexual dysfunction

Open this assessment on its own page →

n=2,398 co-reports · PRR 90.4 · ROR 94.1

Finasteride blocks the conversion of testosterone to the more potent dihydrotestosterone, and because it works by reducing androgen signalling it commonly causes sexual side effects — reduced libido, erectile dysfunction, and reduced ejaculate volume — that are a direct consequence of its pharmacology. Most cases reverse on stopping the drug, though a minority report persistent symptoms, a topic of continuing debate and labelling changes. The very high PRR (90.4) reflects both the real effect and the drug's wide use in prostate conditions and hair loss.

Regulatory basis: finasteride prescribing information (sexual adverse reactions; post-marketing persistent-effects reports).

Bradford Hill viewpointStatusNote
Temporality (necessary)metSexual effects appear during treatment and usually resolve after withdrawal
StrengthmetPRR 90 — a very high relative signal on a large co-report count
ConsistencymetReproduced in trials and post-marketing data
SpecificitymetA recognised finasteride effect, tied to its androgen mechanism
Biological gradientpartialDose-related
PlausibilitymetReduced dihydrotestosterone signalling is the mechanism
CoherencemetCoheres with the labelled sexual-side-effect warnings
ExperimentpartialA randomized trial recorded sexual side effects by arm; persistence is debated
AnalogymetAnalogous to sexual side effects from other anti-androgens and 5-alpha-reductase inhibitors

This page's own qualitative read, not an automated/citation-gated assessment.

✗ A results-posting finasteride trial (NCT03004469) recorded sexual side effects only as isolated events across arms; the signal rests on the larger randomized trials and post-marketing reports rather than this single trial AE table.
Causality: well established

Cisplatin ↔ Peripheral neuropathy

Open this assessment on its own page →

n=1,228 co-reports · PRR 3.5 · ROR 3.6

Cisplatin, a platinum chemotherapy drug, damages peripheral nerves, producing numbness, tingling, and sometimes pain that begins in the hands and feet and can be permanent — the effect is cumulative, so the risk rises with every cycle and with total dose. It is a direct consequence of the drug's accumulation in nerve tissue and is a major dose-limiting toxicity. The 1,228 co-reports (PRR 3.5) reflect both the real effect and cisplatin's central role in treating many solid tumours.

Regulatory basis: cisplatin prescribing information (peripheral neuropathy warning; dose limits). Established platinum-neuropathy literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metNeuropathy develops and worsens with cumulative dosing; may be irreversible
StrengthpartialPRR 4 on a large co-report count
ConsistencymetReproduced across oncology practice
SpecificitymetA recognised platinum-drug effect, less typical of other chemotherapy
Biological gradientmetClearly cumulative-dose-related
PlausibilitymetPlatinum accumulation in dorsal-root ganglia is the mechanism
CoherencemetCoheres with the labelled dose limits and monitoring
ExperimentpartialDechallenge (dose reduction/withdrawal) may stabilise but not reverse it; no randomized trial
AnalogymetAnalogous to neuropathy from oxaliplatin and other neurotoxic chemotherapy

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for cisplatin captured peripheral neuropathy as a coded event; the toxicity is characterised through oncology trials and dose-limit guidance rather than a single trial AE table.
Causality: well established

Cisplatin ↔ Ototoxicity (hearing loss)

Open this assessment on its own page →

n=415 co-reports · PRR 4.3 · ROR 4.3

Cisplatin damages the hair cells of the inner ear, causing high-frequency hearing loss and sometimes tinnitus that can be permanent and is often worse in children treated for cancer. The injury is cumulative and is why hearing is monitored during and after cisplatin therapy. The 415 co-reports (PRR 4.3) reflect both the real effect and the drug's extensive use in curative chemotherapy regimens.

Regulatory basis: cisplatin prescribing information (ototoxicity warning; audiometric monitoring). Established platinum-ototoxicity literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metHearing loss accrues with cumulative dosing and may be permanent
StrengthpartialPRR 4 on a large co-report count
ConsistencymetReproduced across oncology and paediatric audiology studies
SpecificitymetA recognised platinum-drug effect
Biological gradientmetCumulative-dose-related, worse in children
PlausibilitymetInner-ear hair-cell damage by platinum is the mechanism
CoherencemetCoheres with the labelled audiometric monitoring
ExperimentpartialDechallenge (dose reduction/withdrawal) limits further loss but does not reverse it; no randomized trial
AnalogymetAnalogous to ototoxicity from other platinum drugs and aminoglycosides

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for cisplatin captured deafness or hearing loss as a coded event; the toxicity is detected by audiometry in practice rather than recorded as a trial AE.
Causality: well established

Doxorubicin (anthracyclines) ↔ Cardiotoxicity / cardiomyopathy

Open this assessment on its own page →

n=1,221 co-reports · PRR 37.7 · ROR 38.2

Doxorubicin, a key anthracycline chemotherapy drug, damages heart muscle in a cumulative, dose-dependent way that can lead to a potentially irreversible cardiomyopathy and heart failure. The risk rises sharply above a total lifetime dose threshold and is worsened by chest radiotherapy, age, and other heart-toxic drugs, which is why heart function is monitored during treatment and why dexrazoxane is sometimes used as a protectant. The 1,221 co-reports (PRR 37.7) reflect both the real effect and the drug's wide use in breast cancer, lymphoma, and leukaemia.

Regulatory basis: doxorubicin prescribing information (cardiotoxicity warning; cumulative-dose limits; cardiac monitoring).

Bradford Hill viewpointStatusNote
Temporality (necessary)metHeart-muscle damage accumulates with dose and may manifest during or after therapy
StrengthmetPRR 38 on a large co-report count
ConsistencymetReproduced across oncology practice
SpecificitymetA signature anthracycline effect
Biological gradientmetClearly cumulative-dose-related
PlausibilitymetFree-radical oxidative damage to heart muscle is the mechanism
CoherencemetCoheres with the labelled cumulative-dose limits and monitoring
ExperimentpartialDechallenge (stopping the drug) limits further damage; no randomized trial
AnalogymetAnalogous to cardiotoxicity from other anthracyclines and trastuzumab

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for doxorubicin captured cardiotoxicity as a coded event (the one that surfaced recorded a single ejection-fraction decrease); the risk rests on cumulative-dose trials and cardiac monitoring rather than a single trial AE table.
Causality: well established

Bleomycin ↔ Pulmonary fibrosis

Open this assessment on its own page →

n=139 co-reports · PRR 20.7 · ROR 21.1

Bleomycin, used in lymphoma and testicular cancer regimens, causes a distinctive dose-dependent lung injury that can progress to pulmonary fibrosis, occasionally fatal. The risk rises with cumulative dose and with age, and is worsened by high inspired oxygen and chest radiotherapy, which is why lung function is followed during therapy. The 139 co-reports (PRR 20.7) reflect both the real, cumulative effect and the drug's narrower use within specialised regimens.

Regulatory basis: bleomycin prescribing information (pulmonary toxicity/fibrosis warning; cumulative-dose limit; lung monitoring).

Bradford Hill viewpointStatusNote
Temporality (necessary)metLung injury develops with cumulative dosing and may progress to fibrosis
StrengthmetPRR 21 on a modest co-report count
ConsistencymetReproduced across oncology case series
SpecificitymetA signature bleomycin effect
Biological gradientmetClearly cumulative-dose-related
PlausibilitymetOxidative and inflammatory lung injury are the mechanisms
CoherencemetCoheres with the labelled dose limit and lung monitoring
ExperimentpartialDechallenge (withdrawal) may halt progression; no randomized trial
AnalogymetAnalogous to pulmonary fibrosis from methotrexate and amiodarone

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for bleomycin captured pulmonary fibrosis as a coded event; the toxicity is followed by lung-function monitoring rather than recorded as a trial AE.
Causality: well established

Vincristine (vinca alkaloids) ↔ Peripheral neuropathy

Open this assessment on its own page →

n=645 co-reports · PRR 4.9 · ROR 5.0

Vincristine, a vinca-alkaloid chemotherapy drug, disrupts microtubules in nerve cells, producing a dose-limiting peripheral neuropathy — numbness, tingling, loss of reflexes, and sometimes painful weakness — that worsens with cumulative dosing and usually improves slowly after treatment ends. It is a direct consequence of the drug's mechanism and is a major reason doses are capped. The 645 co-reports (PRR 4.9) reflect both the real effect and the drug's central role in leukaemia and lymphoma regimens.

Regulatory basis: vincristine prescribing information (peripheral neuropathy warning; dose cap). Established vinca-alkaloid neuropathy literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metNeuropathy develops and worsens with cumulative dosing and slowly improves after withdrawal
StrengthpartialPRR 5 on a moderate co-report count
ConsistencymetReproduced across oncology practice
SpecificitymetA recognised vinca-alkaloid effect
Biological gradientmetCumulative-dose-related
PlausibilitymetMicrotubule disruption in nerves is the mechanism
CoherencemetCoheres with the labelled dose cap and monitoring
ExperimentpartialDechallenge (withdrawal) usually leads to gradual improvement; no randomized trial
AnalogymetAnalogous to neuropathy from other vinca alkaloids and taxanes

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for vincristine captured peripheral neuropathy as a coded event; the toxicity is followed clinically during chemotherapy rather than recorded as a trial AE.
Causality: well established

Tamoxifen ↔ Venous thromboembolism

Open this assessment on its own page →

n=112 co-reports · PRR 4.3 · ROR 4.4

Tamoxifen, an anti-oestrogen used for hormone-receptor-positive breast cancer, raises the risk of blood clots — deep vein thrombosis and pulmonary embolism — by altering the balance of clotting factors, and this class of effect is shared with oestrogens and other hormonal treatments. The risk appears during treatment, is greater around surgery and immobility, and is a recognised, labelled hazard. The 112 co-reports (PRR 4.3) reflect both the real effect and the large number of women taking tamoxifen.

Regulatory basis: tamoxifen prescribing information (venous thromboembolism and stroke warning). Randomized breast-cancer trials.

Bradford Hill viewpointStatusNote
Temporality (necessary)metClots occur during treatment and risk falls after withdrawal
StrengthmetPRR 4 on a modest co-report count
ConsistencymetReproduced across randomized breast-cancer trials
SpecificitymetA recognised tamoxifen/hormonal effect
Biological gradientpartialRisk rises around surgery, immobility, and with age
PlausibilitymetOestrogen-receptor modulation of clotting factors is the proposed mechanism
CoherencemetCoheres with the labelled thromboembolism warning
ExperimentmetRandomized trials recorded thrombotic events by arm
AnalogymetAnalogous to VTE risk with oestrogens and other hormonal therapies

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (NCT00066703), N=2,638

Term (as recorded)T+OFS (n=1321)E+OFS (n=1317)
Thrombosis/embolism (vascular access-related) — Injury, poisoning and procedural complications2913

Serious vascular-access thrombosis/embolism occurred in 29 of 1,321 patients on tamoxifen versus 13 of 1,317 on exemestane in this randomized breast-cancer trial — a roughly two-fold excess, consistent with tamoxifen's established venous-thromboembolism risk. View on ClinicalTrials.gov →

Causality: well established

Bortezomib (proteasome inhibitors) ↔ Peripheral neuropathy

Open this assessment on its own page →

n=6,473 co-reports · PRR 17.3 · ROR 18.6

Bortezomib, a proteasome inhibitor used in multiple myeloma, commonly causes a painful peripheral neuropathy that is dose-limiting and can be severe, though it often improves after dose reduction or when treatment is stopped. The risk is higher with intravenous than subcutaneous administration and with longer treatment. The very high FAERS count (6,473 co-reports, PRR 17.3) reflects both the real effect and how widely bortezomib is used in myeloma.

Regulatory basis: bortezomib prescribing information (peripheral neuropathy warning; dose-modification guidance). Established proteasome-inhibitor neuropathy literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metNeuropathy develops during treatment and often improves after dose reduction or withdrawal
StrengthmetPRR 17 on a very large co-report count
ConsistencymetReproduced across myeloma trials
SpecificitymetA recognised proteasome-inhibitor effect
Biological gradientmetRelated to dose, route (intravenous > subcutaneous), and duration
PlausibilitymetNerve injury from proteasome inhibition is the proposed mechanism
CoherencemetCoheres with the labelled dose-modification guidance
ExperimentpartialDechallenge (dose reduction/withdrawal) usually improves it; no randomized trial
AnalogymetAnalogous to neuropathy from vincristine and platinum chemotherapy

This page's own qualitative read, not an automated/citation-gated assessment.

✗ The results-posting trial that surfaced for bortezomib (NCT00833833) was a pomalidomide study, not a bortezomib comparison, so its peripheral-neuropathy counts do not speak to bortezomib; the signal rests on myeloma trials and the labelled warning rather than a mismatched trial AE table.
Expected pharmacological effect

Irinotecan ↔ Diarrhoea

Open this assessment on its own page →

n=1,721 co-reports · PRR 4.4 · ROR 4.9

Irinotecan, a topoisomerase-inhibitor chemotherapy drug, causes diarrhoea through direct damage to the gut lining, producing both an early (cholinergic) form soon after infusion and a later, more serious form a week or so afterwards. It is a direct, dose-related consequence of the drug's action on rapidly dividing cells, and the risk is greater in patients with certain UGT1A1 genotypes. The 1,721 co-reports (PRR 4.4) reflect both the real effect and the drug's wide use in colorectal cancer.

Regulatory basis: irinotecan prescribing information (severe diarrhoea warning; atropine for early-onset; UGT1A1 caution).

Bradford Hill viewpointStatusNote
Temporality (necessary)metDiarrhoea occurs during and shortly after infusions and responds to dose adjustment
StrengthmetPRR 4 on a large co-report count
ConsistencymetReproduced across colorectal-cancer trials
SpecificitymetA recognised irinotecan effect
Biological gradientpartialDose-related and genotypically influenced
PlausibilitymetGut-lining injury by active metabolite SN-38 is the mechanism
CoherencemetCoheres with the labelled diarrhoea-management guidance
ExperimentmetRandomized trials recorded diarrhoea by arm
AnalogymetAnalogous to diarrhoea from other topoisomerase inhibitors and fluoropyrimidines

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for irinotecan captured diarrhoea as a coded event in a comparable arm structure; the risk is well characterised by the colorectal-cancer trial literature and the labelled management guidance.
Causality: well established

Bevacizumab ↔ Hypertension

Open this assessment on its own page →

n=5,851 co-reports · PRR 4.8 · ROR 5.0

Bevacizumab, a VEGF-inhibiting cancer drug, causes high blood pressure by blocking the signalling that keeps blood vessels dilated, so hypertension is a predictable, dose-related consequence of its mechanism rather than an idiosyncratic reaction. It is usually manageable with standard blood-pressure drugs but can occasionally be severe, which is why pressure is monitored during therapy. The 5,851 co-reports (PRR 4.8) reflect both the real effect and the drug's wide use across many cancers.

Regulatory basis: bevacizumab prescribing information (hypertension warning; blood-pressure monitoring). Established VEGF-inhibitor hypertension literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metBlood pressure rises during therapy and usually improves after withdrawal
StrengthmetPRR 5 on a very large co-report count
ConsistencymetReproduced across bevacizumab trials
SpecificitymetA VEGF-inhibitor class effect
Biological gradientpartialDose-related
PlausibilitymetVEGF blockade reduces nitric-oxide-mediated vasodilation
CoherencemetCoheres with the labelled blood-pressure monitoring
ExperimentpartialRandomized trials recorded hypertension by arm
AnalogymetAnalogous to hypertension with other VEGF-pathway inhibitors

This page's own qualitative read, not an automated/citation-gated assessment.

✗ The results-posting bevacizumab trial that surfaced (NCT02364999) compared a bevacizumab biosimilar with reference bevacizumab, so both arms contained the drug and hypertension was common in each; the class effect is established from placebo-controlled trials and large cohorts rather than this equivalence study.
Causality: well established

Trastuzumab ↔ Cardiotoxicity / heart failure

Open this assessment on its own page →

n=1,080 co-reports · PRR 4.2 · ROR 4.2

Trastuzumab, a HER2-targeted breast-cancer drug, can cause a usually reversible decline in heart function and, less often, heart failure — especially when used with anthracyclines or in older patients. Because HER2 signalling helps the heart, blocking it can impair heart-muscle function, so heart function is measured before and during treatment. The 1,080 co-reports (PRR 4.2) reflect both the real effect and the drug's widespread use in HER2-positive breast and gastric cancer.

Regulatory basis: trastuzumab prescribing information (boxed warning for cardiomyopathy/heart failure; cardiac monitoring).

Bradford Hill viewpointStatusNote
Temporality (necessary)metHeart function may decline during therapy and often recovers after withdrawal
StrengthpartialPRR 4 on a large co-report count
ConsistencymetReproduced across breast-cancer trials
SpecificitymetA recognised trastuzumab effect, worse with anthracyclines
Biological gradientpartialRisk rises with anthracycline co-therapy, age, and prior cardiac disease
PlausibilitymetHER2 blockade impairing heart-muscle survival signalling is the mechanism
CoherencemetCoheres with the boxed warning and cardiac monitoring
ExperimentpartialDechallenge (withdrawal) frequently improves heart function; no randomized trial
AnalogymetAnalogous to cardiotoxicity with anthracyclines and other HER2-targeted drugs

This page's own qualitative read, not an automated/citation-gated assessment.

✗ A results-posting trastuzumab trial (NCT02947685) recorded ejection-fraction decreases in both arms, but its arm structure does not isolate trastuzumab; the boxed-warning evidence base is the anthracycline-trial literature and cardiac monitoring rather than this single AE table.
Causality: well established

Nivolumab (checkpoint inhibitors) ↔ Immune-mediated colitis

Open this assessment on its own page →

n=2,268 co-reports · PRR 13.9 · ROR 14.2

Nivolumab, a PD-1 immune-checkpoint inhibitor, unleashes the immune system against cancer, and a predictable consequence is that the same immune activation can attack the gut, causing immune-mediated (autoimmune) colitis with diarrhoea that can be severe. It is a genuine, mechanism-based immune-related adverse event, appears during treatment, and is managed with steroids and sometimes drug withdrawal — which is why gut symptoms are watched closely during checkpoint-inhibitor therapy. The 2,268 co-reports (PRR 13.9) reflect both the real effect and the drug's wide use across cancers.

Regulatory basis: nivolumab prescribing information (immune-mediated colitis; management algorithms). Randomized trial results.

Bradford Hill viewpointStatusNote
Temporality (necessary)metColitis appears during immunotherapy and usually improves with steroids/withdrawal
StrengthmetPRR 14 on a large co-report count
ConsistencymetReproduced across checkpoint-inhibitor trials
SpecificitymetA distinctive checkpoint-inhibitor effect, rare with chemotherapy
Biological gradientpartialRelated to immune activation rather than a simple dose gradient
PlausibilitymetRelease of T-cell restraint leads to gut-directed autoimmunity
CoherencemetCoheres with the labelled immune-colitis management guidance
ExperimentmetRandomized trials recorded colitis by arm
AnalogymetAnalogous to immune colitis with ipilimumab, pembrolizumab, and other checkpoint inhibitors

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT02741570), N=909

Term (as recorded)Nivolumab + Ipilimumab (n=468)EXTREME Regimen (n=441)
Autoimmune colitis — Gastrointestinal disorders10
Colitis — Gastrointestinal disorders102

Serious colitis occurred in 10 of 468 patients on nivolumab plus ipilimumab versus 2 of 441 on standard chemotherapy, and autoimmune colitis was recorded only on the immunotherapy arm — a clean randomized confirmation of checkpoint-inhibitor colitis. View on ClinicalTrials.gov →

Causality: well established

Ipilimumab (checkpoint inhibitors) ↔ Immune-mediated colitis

Open this assessment on its own page →

n=2,316 co-reports · PRR 32.0 · ROR 33.7

Ipilimumab, a CTLA-4 immune-checkpoint inhibitor, is the checkpoint drug most strongly linked with immune-mediated colitis — severe, sometimes life-threatening diarrhoea and gut inflammation caused by unleashing the immune system. It is a genuine, mechanism-based immune-related adverse event that appears during treatment and is managed with steroids and, for severe cases, the TNF inhibitor infliximab. The 2,316 co-reports (PRR 32.0) reflect both the real effect and the drug's use in melanoma and combination immunotherapy.

Regulatory basis: ipilimumab prescribing information (immune-mediated colitis; management algorithms including infliximab). Randomized trial results.

Bradford Hill viewpointStatusNote
Temporality (necessary)metColitis appears during immunotherapy and usually responds to steroids/withdrawal
StrengthmetPRR 32 on a large co-report count
ConsistencymetReproduced across ipilimumab trials
SpecificitymetA distinctive CTLA-4-inhibitor effect
Biological gradientmetRelated to immune activation rather than a simple dose gradient
PlausibilitymetRelease of T-cell restraint leads to gut-directed autoimmunity
CoherencemetCoheres with the labelled immune-colitis management guidance
ExperimentmetA randomized trial recorded colitis only in the combination arm
AnalogymetAnalogous to immune colitis with PD-1 inhibitors (nivolumab, pembrolizumab)

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — nivolumab + ipilimumab vs nivolumab alone in small-cell lung cancer (CheckMate-032, NCT01928394), N=402

Term (as recorded)Combination nivolumab + ipilimumab (n=157)Nivolumab alone (n=245)
Colitis (serious)60
Immune-mediated enterocolitis (serious)10

Serious colitis and immune-mediated enterocolitis were recorded only in the combination arm in the small-cell-lung-cancer cohorts of CheckMate-032 — direct randomized evidence that adding ipilimumab to nivolumab raises the immune-colitis rate. View on ClinicalTrials.gov →

Causality: well established

Cetuximab ↔ Hypomagnesaemia

Open this assessment on its own page →

n=596 co-reports · PRR 30.2 · ROR 30.8

Cetuximab, an EGFR-targeted cancer drug, damages the kidney's ability to reabsorb magnesium, producing hypomagnesaemia that can be prolonged and require replacement — a physiological consequence of blocking EGFR signalling in the renal tubule, not an idiosyncratic reaction. Because it can be significant and recurrent, magnesium is monitored during therapy. The 596 co-reports (PRR 30.2) reflect both the real effect and the drug's use in head-and-neck and colorectal cancer.

Regulatory basis: cetuximab prescribing information (hypomagnesaemia and electrolyte-monitoring warning). Established EGFR-inhibitor magnesium-wasting literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metMagnesium falls during therapy and recovers after withdrawal with replacement
StrengthmetPRR 30 on a moderate co-report count
ConsistencymetReproduced across EGFR-inhibitor studies
SpecificitymetA recognised EGFR-inhibitor class effect
Biological gradientmetDose-related
PlausibilitymetRenal tubular magnesium wasting from EGFR blockade is the mechanism
CoherencemetCoheres with the labelled electrolyte monitoring
ExperimentpartialRandomized trials recorded magnesium changes by arm
AnalogymetAnalogous to hypomagnesaemia from panitumumab and other EGFR inhibitors

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT02741570), N=909

Term (as recorded)Nivolumab + Ipilimumab (n=468)EXTREME Regimen (n=441)
Hypomagnesaemia — Metabolism and nutrition disorders02
Hypomagnesaemia — Metabolism and nutrition disorders34146

In the EXTREME (cetuximab-containing) regimen of this randomized trial, all-grade hypomagnesaemia was recorded in 146 of 441 patients versus 34 of 468 on the comparator immunotherapy arm — a large excess consistent with cetuximab-induced renal magnesium wasting. View on ClinicalTrials.gov →

Causality: well established

Nevirapine ↔ Hepatotoxicity

Open this assessment on its own page →

n=170 co-reports · PRR 18.1 · ROR 18.4

Nevirapine, an HIV drug, carries a boxed warning for severe, sometimes fatal liver toxicity, including fulminant hepatitis that occurs most often in the first weeks of therapy and is more common in women with higher baseline liver enzymes. The reaction is genuinely drug-related, and it is why liver tests are monitored closely after starting the drug and why treatment is stopped at the first sign of hepatitis. The 170 co-reports (PRR 18.1) reflect both the real effect and the drug's use in HIV treatment, especially in resource-limited settings.

Regulatory basis: nevirapine prescribing information (boxed warning for severe hepatotoxicity; liver monitoring after initiation).

Bradford Hill viewpointStatusNote
Temporality (necessary)metLiver injury typically appears in the first weeks of therapy
StrengthmetPRR 18 on a modest co-report count
ConsistencymetReproduced across HIV cohorts
SpecificitymetA recognised nevirapine effect, strongest early in treatment
Biological gradientpartialHigher in women and with higher baseline liver enzymes
PlausibilitymetImmune-mediated and direct hepatocellular injury are proposed
CoherencemetCoheres with the boxed warning and early liver monitoring
ExperimentpartialDechallenge (withdrawal) is essential and can be life-saving; no randomized trial
AnalogymetAnalogous to hepatotoxicity from other antiretrovirals (nevirapine-class)

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for nevirapine captured hepatotoxicity as a coded event; the severe early hepatitis is identified through the boxed-warning evidence base and HIV cohorts rather than a single trial AE table.
Causality: well established

Abacavir ↔ Hypersensitivity reaction

Open this assessment on its own page →

n=200 co-reports · PRR 3.8 · ROR 3.9

Abacavir causes a potentially life-threatening hypersensitivity reaction — fever, rash, gut and breathing symptoms that worsen with each dose and can be fatal on rechallenge — and this reaction is strongly tied to the HLA-B*57:01 genetic marker. Because screening for that allele before starting the drug nearly eliminates the risk, abacavir is one of the clearest examples of pharmacogenomic testing preventing a serious adverse reaction. The 200 co-reports (PRR 3.8) reflect both the real effect and the drug's use in HIV therapy.

Regulatory basis: abacavir prescribing information (boxed warning for hypersensitivity; HLA-B*57:01 screening; never rechallenge).

Bradford Hill viewpointStatusNote
Temporality (necessary)metReaction appears within weeks of starting and is severe on rechallenge
StrengthpartialPRR 4 on a modest co-report count
ConsistencymetReproduced and mechanistically linked to HLA-B*57:01
SpecificitymetA highly distinctive abacavir reaction
Biological gradientpartialDetermined by genotype rather than dose
PlausibilitymetHLA-B*57:01-restricted T-cell activation is the mechanism
CoherencemetCoheres with the boxed warning and mandatory genetic screening
ExperimentmetGenetic screening (a controlled intervention) prevents it — a real-world experiment
AnalogymetAnalogous to other HLA-linked drug hypersensitivities (carbamazepine, allopurinol)

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for abacavir captured the hypersensitivity reaction as a coded event; the risk and its HLA-B*57:01 basis were established through genetics and screening trials rather than a standard AE table.
Causality: well established

Zidovudine ↔ Anaemia / bone-marrow suppression

Open this assessment on its own page →

n=935 co-reports · PRR 7.8 · ROR 8.3

Zidovudine, an early HIV drug, suppresses the bone marrow and causes anaemia, usually a macrocytic anaemia that appears after weeks to months of therapy, especially at higher doses. It is a direct, dose-related consequence of the drug's inhibition of DNA synthesis in marrow cells rather than an idiosyncratic reaction, and it is why blood counts are monitored during treatment. The 935 co-reports (PRR 7.8) reflect both the real effect and zidovudine's role in HIV care.

Regulatory basis: zidovudine prescribing information (haematologic toxicity warning; blood-count monitoring). Established zidovudine-myelosuppression literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metAnaemia develops during therapy and improves after dose reduction or withdrawal
StrengthmetPRR 8 on a large co-report count
ConsistencymetReproduced across HIV trials
SpecificitymetA recognised zidovudine effect, less typical of newer antivirals
Biological gradientmetDose-related
PlausibilitymetMarrow-cell DNA-synthesis inhibition is the mechanism
CoherencemetCoheres with the labelled blood-count monitoring
ExperimentpartialDechallenge (dose reduction/withdrawal) allows marrow recovery; no randomized trial
AnalogymetAnalogous to myelosuppression from ganciclovir and other nucleoside analogues

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for zidovudine captured anaemia as a coded event; marrow suppression is captured through routine blood-count monitoring rather than coded trial endpoints.
Causality: well established

Efavirenz ↔ Depression / neuropsychiatric effects

Open this assessment on its own page →

n=461 co-reports · PRR 3.8 · ROR 3.9

Efavirenz, a non-nucleoside HIV drug, commonly causes central-nervous-system effects — vivid dreams, dizziness, insomnia, and mood disturbance including depression — that often ease after the first weeks but can persist. The drug carries labelled warnings about psychiatric symptoms and suicidal thinking. The 461 co-reports (PRR 3.8) reflect both the real effect and efavirenz's long-standing role in HIV regimens, especially in resource-limited settings.

Regulatory basis: efavirenz prescribing information (neuropsychiatric symptoms, depression, and suicidality warnings).

Bradford Hill viewpointStatusNote
Temporality (necessary)metNeuropsychiatric symptoms appear early in therapy and may ease or persist
StrengthpartialPRR 4 on a moderate co-report count
ConsistencymetReproduced across HIV cohorts
SpecificitypartialA recognised efavirenz effect, less typical of other antiretrovirals
Biological gradientpartialPartly dose-related
PlausibilitymetCentral-nervous-system effects of the drug are the proposed mechanism
CoherencemetCoheres with the labelled psychiatric warnings
ExperimentpartialDechallenge (withdrawal/switch) usually improves symptoms; no randomized trial
AnalogymetAnalogous to neuropsychiatric effects of some other antiretrovirals

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for efavirenz captured depression as a coded event; the neuropsychiatric effects are identified through clinical reports and cohort data rather than a trial AE table.
Causality: well established

Sildenafil (PDE5 inhibitors) ↔ Non-arteritic anterior ischaemic optic neuropathy (NAION)

Open this assessment on its own page →

n=90 co-reports · PRR 9.4 · ROR 9.4

Sildenafil and related PDE5 inhibitors have been linked to non-arteritic anterior ischaemic optic neuropathy (NAION), a sudden painless loss of vision from reduced blood flow to the optic nerve. This prompted an FDA label update in 2005; the association is debated and partly confounded by vascular risk factors that are common in the men who use the drug, so it is best described as an uncommon, plausibly drug-associated event rather than a certainty. The 90 co-reports (PRR 9.4) reflect both the signal and the difficulty of separating drug effect from background vascular risk.

Regulatory basis: sildenafil prescribing information (FDA 2005 label change on NAION; caution in patients with NAION history).

Bradford Hill viewpointStatusNote
Temporality (necessary)metVision loss occurs in a temporal relationship to use in case reports
StrengthpartialPRR 9 on a small co-report count — a modest signal for a rare event
ConsistencymetCase reports and observational studies, but with confounding by shared vascular risk
SpecificitymetA recognised drug-associated optic event, though other causes exist
Biological gradientpartialNot clearly dose-related
PlausibilitymetReduced optic-nerve perfusion is the proposed mechanism
CoherencemetCoheres with the FDA label change and caution in at-risk patients
ExperimentpartialObservational and confounded; no randomized trial
AnalogymetAnalogous to NAION attributed to other vasoactive drugs

This page's own qualitative read, not an automated/citation-gated assessment.

✗ A results-posting sildenafil trial (NCT00763867) recorded visual impairment in similar numbers in both arms and did not track NAION specifically; the signal rests on case reports, observational data, and the FDA label change rather than a trial AE table.
Causality: well established

Bosentan ↔ Hepatotoxicity

Open this assessment on its own page →

n=258 co-reports · PRR 2.9 · ROR 2.9

Bosentan, used for pulmonary arterial hypertension, causes a dose-related rise in liver enzymes that can occasionally amount to clinically significant liver injury, and it carries a boxed warning requiring monthly liver-function testing for the whole duration of treatment. Because the effect appears during therapy and usually reverses when the drug is stopped, monitoring is the key safety measure. The 258 co-reports (PRR 2.9) reflect both the real effect and the drug's specialised use in a narrow patient group.

Regulatory basis: bosentan prescribing information (boxed warning for hepatotoxicity; mandatory monthly liver-function testing).

Bradford Hill viewpointStatusNote
Temporality (necessary)metLiver enzymes rise during therapy and fall after withdrawal
StrengthpartialPRR 3 on a modest co-report count
ConsistencymetReproduced across the bosentan trial programme
SpecificitymetA recognised bosentan effect, uncommon with many drugs
Biological gradientmetDose-related
PlausibilitymetDirect hepatotoxicity (with some evidence of immune involvement) is proposed
CoherencemetCoheres with the boxed warning and monthly monitoring requirement
ExperimentpartialDechallenge (withdrawal) reverses the enzyme rise; no randomized trial
AnalogymetAnalogous to hepatotoxicity from other endothelin-receptor antagonists

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for bosentan captured abnormal liver function as a coded event; the hepatotoxicity is captured through the mandatory monthly monitoring programme rather than a trial AE table.
Causality: well established

Sotalol ↔ QT prolongation / torsades

Open this assessment on its own page →

n=446 co-reports · PRR 15.9 · ROR 16.3

Sotalol, an anti-arrhythmic drug, prolongs the QT interval as part of its mechanism and can itself provoke the dangerous arrhythmia torsades de pointes — a paradox that is why treatment is started under monitoring and why the drug carries a prominent warning. The risk is dose-related and rises with renal impairment, female sex, and low potassium or magnesium. The 446 co-reports (PRR 15.9) reflect both the real, structurally-based effect and the drug's use in atrial and ventricular arrhythmias.

Regulatory basis: sotalol prescribing information (boxed warning for proarrhythmia/torsades; monitored initiation).

Bradford Hill viewpointStatusNote
Temporality (necessary)metQT prolongation is measured during therapy and resolves after withdrawal
StrengthmetPRR 16 on a moderate co-report count
ConsistencymetReproduced across studies of the class III action
SpecificitymetA recognised anti-arrhythmic effect
Biological gradientmetDose-related and worse with renal impairment and electrolyte disturbance
PlausibilitymetDelayed cardiac repolarisation (class III action) is the mechanism
CoherencemetCoheres with the boxed warning and monitored initiation
ExperimentpartialDechallenge (withdrawal) reverses the QT prolongation; no randomized trial
AnalogymetAnalogous to proarrhythmia from other class III anti-arrhythmics

This page's own qualitative read, not an automated/citation-gated assessment.

✗ A results-posting sotalol trial (NCT00911508) recorded QT prolongation only as isolated events across arms; the proarrhythmic risk rests on the labelled boxed warning and monitored initiation rather than this trial AE table.
Causality: well established

Flecainide ↔ Proarrhythmia

Open this assessment on its own page →

n=99 co-reports · PRR 8.3 · ROR 8.5

Flecainide, a sodium-channel-blocking anti-arrhythmic, can paradoxically provoke serious ventricular arrhythmias — a proarrhythmic effect most dangerous in patients with structural heart disease, as tragically shown in the CAST trial, which found increased deaths when these drugs were used after a heart attack. It is a genuine, mechanism-based hazard and is why flecainide is avoided in structural heart disease and started under monitoring. The 99 co-reports (PRR 8.3) reflect both the real effect and the drug's continued use in selected arrhythmias.

Regulatory basis: flecainide prescribing information (proarrhythmia warning; contraindication in structural heart disease). Cardiac Arrhythmia Suppression Trial (CAST).

Bradford Hill viewpointStatusNote
Temporality (necessary)metArrhythmias occur during treatment, particularly in structurally abnormal hearts
StrengthpartialPRR 8 on a small co-report count
ConsistencymetEstablished by the randomized CAST trial and subsequent studies
SpecificitymetA class effect of sodium-channel-blocking anti-arrhythmics
Biological gradientmetWorse in structural heart disease and at higher doses
PlausibilitymetSlowed conduction creating re-entry circuits is the mechanism
CoherencemetCoheres with the labelled contraindication in structural heart disease
ExperimentmetRandomized evidence (CAST) showed increased mortality
AnalogymetAnalogous to proarrhythmia from other class I anti-arrhythmics

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for flecainide captured arrhythmia as a coded event in a usable structure; the proarrhythmic risk was established by the randomized CAST trial rather than a trial AE table.
Causality: well established

Infliximab (TNF inhibitors) ↔ Tuberculosis reactivation

Open this assessment on its own page →

n=2,003 co-reports · PRR 17.7 · ROR 17.8

TNF inhibitors such as infliximab suppress a cytokine that is essential for containing tuberculosis, so they can reactivate latent TB — a serious, sometimes disseminated infection that is why patients are screened and treated for latent TB before starting therapy. The risk is a genuine, mechanism-based consequence of the drug's immunology and is the subject of a boxed warning. The very high FAERS count (2,003 co-reports, PRR 17.7) reflects both the real effect and the drug's wide use in inflammatory disease.

Regulatory basis: infliximab prescribing information (boxed warning for serious infections including TB; latent-TB screening before therapy).

Bradford Hill viewpointStatusNote
Temporality (necessary)metReactivation occurs during therapy, often early, and requires stopping the drug and treating TB
StrengthmetPRR 18 on a large co-report count
ConsistencymetReproduced across the TNF-inhibitor class and registries
SpecificitymetA class effect of TNF inhibitors
Biological gradientpartialRelated to the degree of immunosuppression rather than a simple dose gradient
PlausibilitymetTNF blockade impairs granuloma formation needed to contain TB
CoherencemetCoheres with the boxed warning and mandatory screening
ExperimentpartialA randomized trial recorded TB on infliximab and not on the comparator arms
AnalogymetAnalogous to TB risk with adalimumab and other TNF inhibitors

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis (NCT00095147), N=803

Term (as recorded)ABA (DB) (n=156)ABA + MTX [OL] (n=372)INF + MTX [DB] (n=165)PLA + MTX [DB] (n=110)
PULMONARY TUBERCULOSIS — Infections and infestations0010
PERITONEAL TUBERCULOSIS — Infections and infestations0010

Serious pulmonary and peritoneal tuberculosis each occurred once in the infliximab arm and in none of the other arms of this randomized trial — a rare event, but exactly the reactivation pattern behind the TNF-inhibitor tuberculosis boxed warning and mandated screening. View on ClinicalTrials.gov →

Causality: well established

Lenalidomide (IMiDs) ↔ Venous thromboembolism

Open this assessment on its own page →

n=7,546 co-reports · PRR 5.1 · ROR 5.1

Lenalidomide, used in multiple myeloma and some blood cancers, raises the risk of venous thromboembolism — deep vein thrombosis and pulmonary embolism — especially when combined with steroids or in myeloma, which is why routine thromboprophylaxis (aspirin or an anticoagulant) is standard during therapy. The risk is a genuine, label-warned effect tied to the drug's immunomodulatory and procoagulant actions. The very high FAERS count (7,546 co-reports, PRR 5.1) reflects both the real effect and the drug's extensive use.

Regulatory basis: lenalidomide prescribing information (boxed warning for venous thromboembolism; thromboprophylaxis recommendations).

Bradford Hill viewpointStatusNote
Temporality (necessary)metClots occur during therapy and the risk falls after withdrawal and with prophylaxis
StrengthmetPRR 5 on a very large co-report count
ConsistencymetReproduced across myeloma trials
SpecificitymetA recognised IMiD effect, worse with steroids
Biological gradientpartialRelated to combination therapy and disease type
PlausibilitymetProcoagulant effects of the drug are the proposed mechanism
CoherencemetCoheres with the boxed warning and routine thromboprophylaxis
ExperimentmetA randomized trial recorded pulmonary embolism on lenalidomide versus placebo
AnalogymetAnalogous to VTE risk with thalidomide and pomalidomide

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy (NCT00774345), N=315

Term (as recorded)Lenalidomide (n=158)Placebo (n=157)
Pulmonary embolism — Respiratory, thoracic and mediastinal disorders41

Serious pulmonary embolism occurred in 4 of 158 patients on lenalidomide versus 1 of 157 on placebo in this maintenance trial — echoing the venous-thromboembolism signal that dictates routine thromboprophylaxis with lenalidomide. View on ClinicalTrials.gov →

Causality: well established

Aripiprazole (antipsychotics) ↔ Akathisia

Open this assessment on its own page →

n=3,031 co-reports · PRR 49.1 · ROR 50.3

Aripiprazole, a widely used antipsychotic, commonly causes akathisia — an intense inner restlessness and urge to move that is distressing and a frequent reason patients stop treatment. It is a genuine, partly dose-related consequence of dopamine-receptor modulation, shared across antipsychotics but often prominent with aripiprazole. The very high FAERS count (3,031 co-reports, PRR 49.1) reflects both the real effect and the drug's extensive use in schizophrenia, bipolar disorder, and as an add-on antidepressant.

Regulatory basis: aripiprazole prescribing information (akathisia and extrapyramidal symptoms).

Bradford Hill viewpointStatusNote
Temporality (necessary)metAkathisia appears during treatment and improves after dose reduction or withdrawal
StrengthmetPRR 49 on a large co-report count
ConsistencymetReproduced across antipsychotic trials
SpecificitypartialA class effect of antipsychotics, prominent with aripiprazole
Biological gradientpartialPartly dose-related
PlausibilitymetDopamine-receptor modulation is the mechanism
CoherencemetCoheres with the labelled extrapyramidal-symptom advice
ExperimentmetA randomized trial recorded akathisia, at a higher rate on aripiprazole
AnalogymetAnalogous to akathisia from other antipsychotics

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients (NCT01328093), N=942

Term (as recorded)LY2140023-DB (n=511)Aripiprazole-DB (n=161)LY2140023-OL (n=270)
Akathisia — Nervous system disorders13122

Akathisia was recorded in 12 of 161 patients on aripiprazole versus 13 of 511 on the comparator in this randomized schizophrenia trial — a lower absolute count but a roughly three-fold higher rate, consistent with the drug's well-known restlessness signal. View on ClinicalTrials.gov →

Expected pharmacological effect

Verapamil (non-dihydropyridine CCBs) ↔ Bradycardia / AV block

Open this assessment on its own page →

n=213 co-reports · PRR 19.9 · ROR 20.9

Verapamil slows the heart by blocking calcium channels in the AV node, so bradycardia and heart block are the direct, predictable extension of its pharmacology rather than idiosyncratic effects. The risk is dose-related and is greatest with other rate-slowing drugs or in patients with conduction disease, which is why the drug is avoided in some arrhythmias and heart failure. The 213 co-reports (PRR 19.9) reflect both the real effect and verapamil's use for hypertension and arrhythmias.

Regulatory basis: verapamil prescribing information (bradycardia/AV block warning; contraindications in certain arrhythmias and heart failure).

Bradford Hill viewpointStatusNote
Temporality (necessary)metBradycardia occurs during treatment and resolves after withdrawal
StrengthmetPRR 20 on a modest co-report count
ConsistencymetReproduced across calcium-channel-blocker practice
SpecificitymetShared with diltiazem and other AV-node-slowing drugs
Biological gradientpartialDose-related and worse with conduction disease
PlausibilitymetAV-node calcium-channel blockade is the mechanism
CoherencemetCoheres with the labelled contraindications
ExperimentpartialDechallenge (withdrawal) reverses it; no randomized trial
AnalogymetAnalogous to bradycardia with diltiazem and beta-blockers

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for verapamil captured bradycardia or AV block as a coded event; such a familiar, monitorable effect is handled by clinical and ECG monitoring rather than coded into trial AE tables.
Expected pharmacological effect

Diltiazem (non-dihydropyridine CCBs) ↔ Bradycardia / AV block

Open this assessment on its own page →

n=540 co-reports · PRR 6.3 · ROR 6.3

Diltiazem, like verapamil, slows AV-node conduction by blocking calcium channels, so bradycardia and heart block are expected, dose-related consequences of its mechanism rather than idiosyncratic reactions. The risk is greater with other rate-slowing drugs and in patients with conduction disease or heart failure, which is why it is used cautiously in those settings. The 540 co-reports (PRR 6.3) reflect both the real effect and the drug's wide use for hypertension and rate control.

Regulatory basis: diltiazem prescribing information (bradycardia/AV block warning; caution in heart failure).

Bradford Hill viewpointStatusNote
Temporality (necessary)metBradycardia occurs during treatment and resolves after withdrawal
StrengthmetPRR 6 on a moderate co-report count
ConsistencymetReproduced across calcium-channel-blocker practice
SpecificitymetShared with verapamil and other AV-node-slowing drugs
Biological gradientpartialDose-related and worse with conduction disease
PlausibilitymetAV-node calcium-channel blockade is the mechanism
CoherencemetCoheres with the labelled cautions
ExperimentpartialDechallenge (withdrawal) reverses it; no randomized trial
AnalogymetAnalogous to bradycardia with verapamil and beta-blockers

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for diltiazem captured bradycardia or AV block as a coded event; the effect is handled by clinical and ECG monitoring rather than coded into trial AE tables.
Expected pharmacological effect

Nifedipine (dihydropyridine CCBs) ↔ Peripheral oedema

Open this assessment on its own page →

n=1,063 co-reports · PRR 3.9 · ROR 4.0

Nifedipine and other dihydropyridine calcium-channel blockers dilate the small arteries more than the veins, so fluid shifts into the tissues of the ankles and legs — a predictable, dose-related consequence of the mechanism rather than an idiosyncratic reaction. The swelling is a common reason patients stop these drugs, and it is not a sign of heart or kidney failure itself. The 1,063 co-reports (PRR 3.9) reflect both the real effect and the very wide use of these drugs for hypertension and angina.

Regulatory basis: nifedipine prescribing information (peripheral oedema as an adverse reaction). Established dihydropyridine-oedema literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOedema develops during treatment and resolves after withdrawal
StrengthmetPRR 4 on a large co-report count
ConsistencymetReproduced across dihydropyridine trials
SpecificitymetA class effect of dihydropyridines, rare with verapamil/diltiazem
Biological gradientpartialDose-related
PlausibilitymetPrecapillary arteriolar dilation raising capillary pressure is the mechanism
CoherencemetCoheres with the labelled oedema and the practice of adding an ACE inhibitor/ARB
ExperimentpartialDechallenge (withdrawal) usually resolves it; no randomized trial
AnalogymetAnalogous to oedema with amlodipine and other dihydropyridines

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for nifedipine captured peripheral oedema as a coded event; the effect is managed clinically and characterised in antihypertensive trials rather than a single trial AE table.
Expected pharmacological effect

Amlodipine (dihydropyridine CCBs) ↔ Peripheral oedema

Open this assessment on its own page →

n=4,541 co-reports · PRR 3.0 · ROR 3.0

Amlodipine, one of the most prescribed blood-pressure drugs, commonly causes ankle and leg swelling for the same reason as other dihydropyridines: it dilates the precapillary arterioles more than the veins, raising capillary pressure and pushing fluid into the tissues. The effect is dose-related and is often reduced by adding an ACE inhibitor or ARB. The very high FAERS count (4,541 co-reports, PRR 3.0) reflects both the real effect and amlodipine's enormous patient population.

Regulatory basis: amlodipine prescribing information (peripheral oedema as a common adverse reaction). Established dihydropyridine-oedema literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOedema develops during treatment and resolves after withdrawal
StrengthmetPRR 3 with a very large co-report count — common but not highly disproportionate
ConsistencymetReproduced across dihydropyridine trials
SpecificitymetA class effect of dihydropyridines, rare with verapamil/diltiazem
Biological gradientpartialDose-related
PlausibilitymetPrecapillary arteriolar dilation raising capillary pressure is the mechanism
CoherencemetCoheres with the labelled oedema and the RAAS-blocker combination strategy
ExperimentpartialDechallenge (withdrawal) usually resolves it; no randomized trial
AnalogymetAnalogous to oedema with nifedipine and other dihydropyridines

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for amlodipine captured peripheral oedema as a coded event; the effect is characterised in antihypertensive trials and managed clinically rather than recorded as a single trial AE table.
Expected pharmacological effect

Furosemide (loop diuretics) ↔ Hypokalaemia

Open this assessment on its own page →

n=5,325 co-reports · PRR 6.8 · ROR 6.9

Furosemide, a loop diuretic, increases the amount of sodium reaching the distal nephron, where it is exchanged for potassium, so it lowers serum potassium — a direct, dose-related consequence of how it works and a common reason for electrolyte monitoring during diuretic therapy. The risk is greater at higher doses, in older patients, and with other potassium-losing drugs. The very high FAERS count (5,325 co-reports, PRR 6.8) reflects both the real effect and the enormous use of loop diuretics.

Regulatory basis: furosemide prescribing information (hypokalaemia and electrolyte-monitoring warning). Established loop-diuretic literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metPotassium falls during treatment and is corrected with replacement/dose adjustment
StrengthmetPRR 7 on a very large co-report count
ConsistencymetReproduced across diuretic trials
SpecificitymetA class effect, less typical of potassium-sparing diuretics
Biological gradientpartialDose-related and worse in older patients
PlausibilitymetIncreased distal sodium delivery driving potassium loss is the mechanism
CoherencemetCoheres with the labelled electrolyte-monitoring advice
ExperimentmetA trial recorded hypokalaemia on furosemide and in none of the comparator arm
AnalogymetAnalogous to hypokalaemia from thiazide and other loop diuretics

This page's own qualitative read, not an automated/citation-gated assessment.

✓ Trial evidence found — Avoiding Treatment in the Hospital With Furoscix for the Management of Congestion in Heart Failure - A Pilot Study (NCT04593823), N=51

Term (as recorded)Furoscix Infusor (n=34)Continued Medical Therapy (n=17)
Hypokalaemia — Metabolism and nutrition disorders70

Hypokalaemia was reported in 7 of 34 patients receiving the furosemide infusor versus 0 of 17 on continued oral therapy in this small pilot — directionally consistent with loop-diuretic potassium loss, though too small to estimate a rate. View on ClinicalTrials.gov →

Expected pharmacological effect

Eplerenone (MR antagonists) ↔ Hyperkalaemia

Open this assessment on its own page →

n=413 co-reports · PRR 19.7 · ROR 20.3

Eplerenone blocks aldosterone in the distal nephron, so it retains potassium — hyperkalaemia is the direct, dose-related extension of its intended action rather than a side effect. The risk is greatest when it is combined with ACE inhibitors, ARBs, or potassium supplements, or in patients with kidney disease, which is why potassium and kidney function are checked before and during therapy. The 413 co-reports (PRR 19.7) reflect both the real effect and the drug's use after heart attacks and in heart failure.

Regulatory basis: eplerenone prescribing information (hyperkalaemia warning; potassium and renal monitoring).

Bradford Hill viewpointStatusNote
Temporality (necessary)metPotassium rises during treatment and falls after withdrawal
StrengthmetPRR 20 on a modest co-report count
ConsistencymetReproduced across heart-failure trials
SpecificitymetA mineralocorticoid-antagonist class effect
Biological gradientmetDose-related and worse with renal impairment or RAAS blockade
PlausibilitymetReduced distal potassium excretion is the mechanism
CoherencemetCoheres with the labelled potassium monitoring
ExperimentpartialRandomized trials measured potassium by arm
AnalogymetAnalogous to hyperkalaemia with spironolactone

This page's own qualitative read, not an automated/citation-gated assessment.

✗ The results-posting trial that surfaced (DIAMOND) studied patiromer for managing hyperkalaemia in heart-failure patients, not eplerenone itself; the signal rests on the mineralocorticoid-antagonist trial evidence base rather than this misaligned AE table.
Causality: well established

Clonidine ↔ Rebound hypertension / withdrawal syndrome

Open this assessment on its own page →

n=741 co-reports · PRR 3.5 · ROR 3.5

Stopping clonidine abruptly causes a rebound surge in blood pressure, with agitation, sweating, and tremor, because the drug suppresses central sympathetic outflow and the body overshoots when it is removed. This is a genuine, predictable consequence of the drug's mechanism rather than an idiosyncratic reaction, and it is prevented by tapering the dose. The 741 co-reports (PRR 3.5) reflect both the real effect and clonidine's use for hypertension and other conditions.

Regulatory basis: clonidine prescribing information (rebound hypertension on abrupt withdrawal; tapering guidance).

Bradford Hill viewpointStatusNote
Temporality (necessary)metSymptoms appear on abrupt withdrawal and resolve on restarting or tapering
StrengthmetPRR 4 on a moderate co-report count
ConsistencymetReproduced across decades of clonidine experience
SpecificitymetA recognised clonidine effect, uncommon with many drugs
Biological gradientpartialTied to how abruptly the drug is stopped
PlausibilitymetLoss of central sympathetic suppression causing rebound is the mechanism
CoherencemetCoheres with the labelled tapering guidance
ExperimentpartialDechallenge (taper/restart) reproducibly controls it; no randomized trial
AnalogymetAnalogous to rebound phenomena with beta-blockers and other antihypertensives

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for clonidine captured a withdrawal syndrome; the rebound effect is identified through clinical reports and taper experience rather than a trial AE table.
Causality: well established

Warfarin ↔ Warfarin-induced skin necrosis

Open this assessment on its own page →

n=345 co-reports · PRR 11.7 · ROR 11.7

Warfarin can cause skin necrosis — a rare, painful, sometimes disfiguring reaction in which blood clots form in the small vessels of the skin, most often in the first days of therapy and in areas of fat such as the breast, thighs, and buttocks. It is thought to occur when warfarin's early depletion of protein C (a natural anticoagulant) briefly leaves the clotting system unbalanced, and it is why large loading doses are avoided and why protein-C-deficient patients are at particular risk. The 345 co-reports (PRR 11.7) reflect both the real effect and warfarin's enormous use.

Regulatory basis: warfarin prescribing information (skin necrosis warning; caution in protein C/S deficiency). Established warfarin-skin-necrosis literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metNecrosis appears in the first days of therapy and stops after withdrawal
StrengthpartialPRR 12 on a modest co-report count
ConsistencymetReproduced across case series tied to protein C/S deficiency
SpecificitymetA distinctive warfarin effect
Biological gradientpartialLinked to rapid initial dose and to protein-C deficiency
PlausibilitymetEarly protein-C depletion unbalancing coagulation is the mechanism
CoherencemetCoheres with the labelled caution and the avoidance of loading doses
ExperimentpartialDechallenge (withdrawal, plus vitamin K in severe cases) resolves it; no randomized trial
AnalogymetAnalogous to skin necrosis reported with other vitamin-K antagonists

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for warfarin captured skin necrosis; it is a rare, early complication identified through case series and the labelled warning rather than a trial AE table.
Causality: well established

Enoxaparin (low-molecular-weight heparins) ↔ Heparin-induced thrombocytopenia (HIT)

Open this assessment on its own page →

n=637 co-reports · PRR 54.1 · ROR 54.7

Enoxaparin, like unfractionated heparin, can cause heparin-induced thrombocytopenia — an immune reaction in which antibodies activate platelets, dropping the platelet count and paradoxically promoting clotting. It is less common with low-molecular-weight heparins than with unfractionated heparin but is still a recognised and serious effect, and it is why platelet counts are watched during therapy and why a non-heparin anticoagulant is used if HIT is suspected. The 637 co-reports (PRR 54.1) reflect both the real effect and the very wide use of enoxaparin.

Regulatory basis: enoxaparin prescribing information (HIT warning; platelet monitoring). Established low-molecular-weight-heparin HIT literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metPlatelets fall days into exposure and recover after heparinoid withdrawal
StrengthmetPRR 54 on a moderate co-report count
ConsistencymetReproduced across the heparinoid class
SpecificitymetA class effect, though less frequent than with unfractionated heparin
Biological gradientpartialRisk varies with duration and patient group, not a simple dose gradient
PlausibilitymetAnti-PF4 antibody-mediated platelet activation is the mechanism
CoherencemetCoheres with routine platelet monitoring during therapy
ExperimentpartialDechallenge (switching to a non-heparin anticoagulant) is standard; no placebo RCT
AnalogymetAnalogous to HIT with unfractionated heparin and dalteparin

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for enoxaparin captured heparin-induced thrombocytopenia as a coded event; HIT is rare and detected through routine platelet monitoring rather than a trial AE table.
Causality: well established

Apixaban ↔ Gastrointestinal bleeding

Open this assessment on its own page →

n=1,649 co-reports · PRR 6.3 · ROR 6.4

Apixaban, a direct factor Xa inhibitor, increases the risk of bleeding — including from the gut — as the expected pharmacodynamic consequence of anticoagulation, though its gastrointestinal bleeding rate is lower than warfarin's in the major randomized trials. The risk is dose-related and is greater with age, kidney impairment, and interacting drugs. The 1,649 co-reports (PRR 6.3) reflect both the real effect and apixaban's very large real-world use.

Regulatory basis: apixaban prescribing information (bleeding warning); ARISTOTLE randomized trial versus warfarin.

Bradford Hill viewpointStatusNote
Temporality (necessary)metBleeding occurs during anticoagulation and typically stops after withdrawal
StrengthmetPRR 6 on a large co-report count
ConsistencymetReproduced in randomized outcome trials and large cohorts
SpecificitypartialAn anticoagulant-class effect rather than apixaban-specific
Biological gradientpartialDose-related and worse with age, renal impairment, and interacting drugs
PlausibilitymetFactor Xa inhibition impairs haemostasis as the pharmacodynamic extension
CoherencemetCoheres with the bleeding-focused labelling
ExperimentmetRandomized evidence (ARISTOTLE) quantifies the risk
AnalogymetAnalogous to bleeding with rivaroxaban, dabigatran, and warfarin

This page's own qualitative read, not an automated/citation-gated assessment.

✗ The results-posting apixaban trial that surfaced (NCT00633893) recorded only a handful of serious bleeding events across arms; the bleeding risk is quantified by the large randomized outcome trial ARISTOTLE and real-world cohorts rather than this extended-treatment AE table.
Contested: signal not confirmed by large randomized trials

Sitagliptin (DPP-4 inhibitors) ↔ Pancreatitis

Open this assessment on its own page →

n=2,226 co-reports · PRR 12.8 · ROR 13.2

Sitagliptin, a DPP-4 inhibitor for type 2 diabetes, attracted a pancreatitis signal from early case reports and spontaneous reporting, and regulators added a warning in the mid-2010s. However, the large randomized cardiovascular-outcome trials of these drugs did not show a clear increase in pancreatitis, so the association remains contested rather than established. The high FAERS count (2,226 co-reports, PRR 12.8) reflects the reporting that drove the initial concern as much as any true effect, and is a good illustration of why disproportionality alone cannot settle causation.

Regulatory basis: FDA 2015 labelling changes for DPP-4 inhibitors (pancreatitis); randomized cardiovascular-outcome trials (e.g. TECOS) that did not confirm an excess.

Bradford Hill viewpointStatusNote
Temporality (necessary)metPancreatitis in reports follows drug exposure, but temporality is non-specific
StrengthpartialPRR 13 on a large co-report count, but driven substantially by reporting
ConsistencymetEarly case reports and spontaneous data, not consistently reproduced in trials
SpecificitypartialPancreatitis has many causes, so specificity is limited
Biological gradientpartialConfounded by obesity, gallstones, and alcohol common in this population
PlausibilitymetNo established mechanism specific to DPP-4 inhibition
CoherencemetThe labelled warning is precautionary rather than mechanism-based
ExperimentpartialLarge randomized trials did not confirm an increased risk
AnalogymetAnalogous to the contested incretin-pancreatitis question

This page's own qualitative read, not an automated/citation-gated assessment.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for sitagliptin captured pancreatitis as a coded event in a usable structure; notably, the large randomized outcome trials did not confirm the signal, which is why this pair is graded contested rather than established.
Causality: well established

Ivabradine ↔ Bradycardia

Open this assessment on its own page →

n=256 co-reports · PRR 14.9 · ROR 15.4

Ivabradine selectively inhibits the If (funny) pacemaker current in the sinoatrial node, slowing heart rate without reducing contractility — so bradycardia is its core, intended action and excessive slowing is its principal hazard. This dataset's 256 co-reports (PRR 14.9) are enriched for patients also taking rate-limiting drugs (beta-blockers, non-dihydropyridine calcium-channel blockers), where the effect is amplified.

Regulatory basis: ivabradine (Corlanor) prescribing information — bradycardia and heart-block warning.

Bradford Hill viewpointStatusNote
Temporality (necessary)metRate slowing begins with the first dose
StrengthmetPRR 14.9, a large signal here
ConsistencymetReproduced across trials and series
SpecificitypartialShared with other rate-lowering drugs when combined
Biological gradientmetDose-dependent and amplified by beta-blockers
PlausibilitymetDirect SA-node If inhibition
CoherencemetFits its pharmacology exactly
ExperimentmetHeart-rate reduction is the intended trial-measured effect
AnalogymetAnalogous to beta-blocker bradycardia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure (NCT02446990)

Adverse eventIvabradine (n=9539) · Placebo (n=9544)
Bradycardia101/953921/9544
Sinus bradycardia48/95397/9544

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Ranolazine ↔ QT prolongation

Open this assessment on its own page →

n=99 co-reports · PRR 5.6 · ROR 5.6

Ranolazine inhibits the late inward sodium current to relieve angina without changing heart rate or blood pressure, but it also modestly prolongs the QT interval — a labelled, dose-dependent effect that is larger in women and in hepatic impairment. In this dataset, electrocardiogram QT prolonged carries 99 co-reports (PRR 5.6). The label warns against combining it with other QT-prolonging drugs, caps the dose in liver disease, and makes congenital long-QT syndrome a contraindication.

Regulatory basis: ranolazine (Ranexa) prescribing information — QT prolongation; contraindicated in congenital long-QT syndrome.

Bradford Hill viewpointStatusNote
Temporality (necessary)metInterval prolongation visible within days
StrengthmetPRR 5.6, moderate
ConsistencymetSeen across trials and registries
SpecificitypartialShared with other QT-prolonging drugs
Biological gradientmetGreater at higher plasma levels
PlausibilitymetDirect effect on repolarisation
CoherencemetConsistent with ECG data
ExperimentmetSerial ECGs in the pivotal trial showed the same effect
AnalogymetAnalogous to other QT-prolonging antianginals

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for ranolazine captured qt prolongation as a tracked adverse event in a usable structure. The pivotal ranolazine trial measured QT change on protocol electrocardiograms rather than reporting it as a coded adverse event.
Causality: well established

Ticagrelor ↔ Dyspnoea

Open this assessment on its own page →

n=4,009 co-reports · PRR 4.7 · ROR 5.3

Ticagrelor is a reversible P2Y12 platelet inhibitor whose signature adverse effect is dyspnoea — breathlessness without heart failure or lung disease — thought to reflect adenosine accumulation, because ticagrelor also blocks adenosine re-uptake. This dataset's 4,009 co-reports (PRR 4.7) make dyspnoea one of its largest signals. The effect surfaced in PLATO (NCT00391872), the trial that established ticagrelor over clopidogrel in acute coronary syndromes, and is now a labelled warning; it is usually benign and rarely requires stopping the drug.

Regulatory basis: ticagrelor (Brilinta) prescribing information — dyspnoea; PLATO trial (Wallentin et al., NEJM 2009).

Bradford Hill viewpointStatusNote
Temporality (necessary)metOccurs within days to weeks of starting
StrengthmetPRR 4.7 with thousands of reports
ConsistencymetReproduced in PLATO and practice
SpecificitymetDistinctive to ticagrelor among antiplatelets
Biological gradientpartialNot clearly dose-related at usual doses
PlausibilitymetAdenosine re-uptake inhibition proposed
CoherencemetConsistent with added adenosine exposure
ExperimentmetRandomised arm comparison showed the excess
AnalogymetAnalogy to adenosine-infusion dyspnoea

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI) (NCT01347580)

Adverse eventTicagrelor In-Hosp (n=950) · Ticagrelor Pre-Hosp (n=908)
DYSPNOEA1/9502/908
Dyspnoea86/95062/908

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Clopidogrel ↔ Gastrointestinal haemorrhage

Open this assessment on its own page →

n=8,285 co-reports · PRR 11.5 · ROR 12.0

Clopidogrel irreversibly blocks the platelet P2Y12 receptor, so bleeding is its defining, duration-related adverse effect; gastrointestinal haemorrhage carries 8,285 co-reports (PRR 11.5), reflecting both the drug's enormous use and a true excess. CAPRIE and later studies placed clopidogrel's bleeding risk between aspirin and the more potent prasugrel and ticagrelor.

Regulatory basis: clopidogrel prescribing information — bleeding; CAPRIE trial (Lancet 1996).

Bradford Hill viewpointStatusNote
Temporality (necessary)metBleeding follows platelet inhibition
StrengthmetPRR 11.5, a very large signal
ConsistencymetReproduced in every antiplatelet trial
SpecificitypartialShared across the P2Y12 class
Biological gradientmetRisk rises with duration and with NSAIDs
PlausibilitymetDirect consequence of P2Y12 blockade
CoherencemetFits the mechanism exactly
ExperimentmetRandomised trials quantify the excess
AnalogymetDirect class analogy to prasugrel

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — The Dual Antiplatelet Therapy Study (DAPT Study) (NCT00977938)

Adverse eventHCRI DAPT - DES 30-month DAPT (n=2642) · HCRI DAPT - DES 12-month DAPT (n=2634) · HCRI DAPT - BMS 30-month DAPT (n=842) · HCRI DAPT - BMS 12-month DAPT (n=845)
GASTROINTESTINAL HAEMORRHAGE10/26422/26340/8420/845
LOWER GASTROINTESTINAL HAEMORRHAGE0/26420/26341/8420/845
UPPER GASTROINTESTINAL HAEMORRHAGE0/26421/26340/8420/845

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Eptifibatide ↔ Thrombocytopenia

Open this assessment on its own page →

n=65 co-reports · PRR 16.0 · ROR 17.4

Eptifibatide is a glycoprotein IIb/IIIa inhibitor given intravenously during percutaneous coronary intervention; by blocking the final common pathway of platelet aggregation it produces both bleeding and, paradoxically, thrombocytopenia (65 co-reports here, PRR 16.0). The thrombocytopenia is acute, antibody-mediated in some cases, and the label requires platelet counts before and during therapy.

Regulatory basis: eptifibatide (Integrilin) prescribing information — thrombocytopenia and bleeding; platelet monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metPlatelet fall within hours
StrengthmetPRR 16.0, large
ConsistencymetReproduced across GPI experience
SpecificitypartialShared with tirofiban and abciximab
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetImmune-mediated platelet destruction proposed
CoherencemetFits the anticoagulant picture
Experimentn/aNot a trial endpoint
AnalogymetAnalogous to abciximab thrombocytopenia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for eptifibatide captured thrombocytopenia as a tracked adverse event in a usable structure. PCI trials reported thrombocytopenia as a laboratory safety measure rather than as a coded adverse event.
Causality: well established

Methyldopa ↔ Drug-induced liver injury

Open this assessment on its own page →

n=75 co-reports · PRR 10.6 · ROR 10.7

Methyldopa, a centrally acting antihypertensive still used in pregnancy, is a classic cause of drug-induced liver injury — from asymptomatic transaminase rises to rare fatal fulminant hepatitis, with 75 co-reports here (PRR 10.6). The injury is idiosyncratic and typically appears within the first weeks to months of therapy, which is why periodic liver monitoring is advised early in treatment; it remains a reason methyldopa has largely been displaced by safer agents outside pregnancy.

Regulatory basis: methyldopa prescribing information — hepatotoxicity warning; classic drug-induced liver-injury literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOnset typically weeks into therapy
StrengthmetPRR 10.6, clearly elevated
ConsistencymetLong recognised in case series
Specificitynot establishedCannot be distinguished from other DILI clinically
Biological gradientnot establishedNot clearly dose-related (idiosyncratic)
PlausibilitymetIdiosyncratic drug-reaction mechanism
CoherencemetFits the DILI pattern
Experimentn/aNo trial-sized experiment possible
AnalogymetAnalogous to other idiosyncratic hepatotoxins

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for methyldopa captured drug-induced liver injury as a tracked adverse event in a usable structure. Hepatotoxicity is idiosyncratic and too uncommon to appear in the trial populations that studied methyldopa's blood-pressure effect.
Causality: well established

Aliskiren ↔ Hyperkalaemia

Open this assessment on its own page →

n=76 co-reports · PRR 20.2 · ROR 20.9

Aliskiren is a direct renin inhibitor; by suppressing the renin–angiotensin–aldosterone axis it lowers aldosterone and raises serum potassium, so hyperkalaemia is mechanistically expected (76 co-reports here, PRR 20.2), especially in kidney disease, diabetes, or with ACE inhibitors, ARBs, or potassium-sparing diuretics. The ALTITUDE trial combined it with an ACE inhibitor or ARB in diabetic patients and was stopped early for lack of benefit plus excess hyperkalaemia, hypotension, and kidney events; the label now warns against such combinations.

Regulatory basis: aliskiren (Tekturna) prescribing information — hyperkalaemia; ALTITUDE trial (NEJM 2012).

Bradford Hill viewpointStatusNote
Temporality (necessary)metPotassium rises with therapy
StrengthmetPRR 20.2, large
ConsistencymetSeen in ALTITUDE and practice
SpecificitypartialShared with ACE inhibitors and ARBs
Biological gradientmetWorse with renal impairment and RAAS blockers
PlausibilitymetDirect consequence of renin inhibition
CoherencemetFits the mechanism
ExperimentmetALTITUDE arm comparison showed the excess
AnalogymetAnalogous to ACE-inhibitor hyperkalaemia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure (NCT00853658)

Adverse eventCombination of Aliskiren and Enalapril (n=2347) · Aliskiren (n=2348) · Enalapril (n=2345)
Hyperkalaemia21/234713/234820/2345

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Valsartan ↔ Acute kidney injury

Open this assessment on its own page →

n=3,260 co-reports · PRR 4.4 · ROR 4.5

Valsartan is an angiotensin-receptor blocker; blocking angiotensin II dilates the efferent arteriole and lowers glomerular filtration pressure, so acute kidney injury is an expected, mechanism-based effect (3,260 co-reports, PRR 4.4), concentrated in patients who are volume-depleted, have renal-artery stenosis, or take NSAIDs or diuretics. The label advises monitoring renal function, and the effect typically reverses when the drug or precipitant is withdrawn.

Regulatory basis: valsartan (Diovan) prescribing information — renal impairment and acute kidney injury.

Bradford Hill viewpointStatusNote
Temporality (necessary)metCreatinine rises within days
StrengthmetPRR 4.4, moderate
ConsistencymetConsistent across the ARB class
SpecificitypartialShared with ACE inhibitors and ARBs
Biological gradientmetWorse with volume depletion
PlausibilitymetConsequence of efferent-arteriolar dilation
CoherencemetFits the mechanism
Experimentn/aNot tested as a trial endpoint
AnalogymetDirect class analogy to ACE inhibitors

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction (NCT02226120)

Adverse eventLCZ696 (n=1980)
Acute kidney injury18/1980
Renal impairment8/1980

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Losartan ↔ Renal failure

Open this assessment on its own page →

n=3,053 co-reports · PRR 2.8 · ROR 2.8

Losartan is the prototype angiotensin-receptor blocker, and its renal effects mirror the class: reduced efferent-arteriolar tone and filtration pressure can precipitate or worsen renal failure (3,053 co-reports, PRR 2.8), particularly with volume depletion, bilateral renal-artery stenosis, or combined NSAID use. The signal is dominated by the drug's very large prescribing base rather than a property unique to losartan, and function usually recovers after the drug or precipitant is withdrawn.

Regulatory basis: losartan prescribing information — renal impairment; class effect of RAAS blockade.

Bradford Hill viewpointStatusNote
Temporality (necessary)metCreatinine rises after initiation
StrengthmetPRR 2.8, modest
ConsistencymetConsistent across the ARB class
SpecificitypartialShared with ACE inhibitors and ARBs
Biological gradientmetWorse with volume depletion
PlausibilitymetConsequence of RAAS blockade
CoherencemetFits the mechanism
Experimentn/aNot tested as a trial endpoint
AnalogymetAnalogous to ACE-inhibitor renal effects

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for losartan captured renal failure as a tracked adverse event in a usable structure. Trials of losartan measured renal function as a laboratory safety parameter rather than reporting renal failure as a structured adverse event.
Expected pharmacological effect

Ambrisentan ↔ Fluid retention

Open this assessment on its own page →

n=5,470 co-reports · PRR 20.3 · ROR 21.2

Ambrisentan is an endothelin-receptor antagonist for pulmonary arterial hypertension; peripheral oedema and fluid retention are its most common adverse effect (5,470 co-reports, PRR 20.3), reflecting vasodilation and sodium retention rather than heart failure in most cases. The effect is dose-related and, at higher exposure, can progress to decompensated heart failure, so the label requires caution in left-ventricular dysfunction and monthly liver monitoring for hepatotoxicity.

Regulatory basis: ambrisentan (Letairis) prescribing information — peripheral oedema and fluid retention.

Bradford Hill viewpointStatusNote
Temporality (necessary)metFluid retention appears over weeks
StrengthmetPRR 20.3, large
ConsistencymetReproduced across the ERA class
SpecificitypartialShared with other endothelin antagonists
Biological gradientmetDose-related
PlausibilitymetConsistent with vasodilation and sodium retention
CoherencemetFits the mechanism
ExperimentmetERA trials showed the excess
AnalogymetAnalogous to bosentan oedema

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202) (NCT00578786)

Adverse eventAmbrisentan 2.5 mg (n=43) · Ambrisentan 5 mg (n=146) · Ambrisentan 10 mg (n=194)
Oedema peripheral1/430/1462/194
Fluid retention0/432/14610/194
Oedema peripheal13/4353/146101/194

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Riociguat ↔ Hypotension

Open this assessment on its own page →

n=3,401 co-reports · PRR 11.2 · ROR 12.4

Riociguat stimulates soluble guanylate cyclase to relax vascular smooth muscle, lowering pulmonary and systemic pressures; hypotension is therefore expected (3,401 co-reports, PRR 11.2), particularly when combined with nitrates or PDE5 inhibitors, which is why the label contraindicates that combination. Syncope and symptomatic hypotension require dose titration and blood-pressure monitoring in pulmonary-hypertension use.

Regulatory basis: riociguat (Adempas) prescribing information — hypotension; contraindicated with nitrates and PDE5 inhibitors.

Bradford Hill viewpointStatusNote
Temporality (necessary)metBlood-pressure fall is immediate
StrengthmetPRR 11.2, large
ConsistencymetSeen across trials and practice
SpecificitypartialShared with PDE5 inhibitors and nitrates
Biological gradientmetDose-related
PlausibilitymetDirect vasodilation mechanism
CoherencemetFits the mechanism
ExperimentmetTrials measured blood-pressure reduction
AnalogymetAnalogous to PDE5-inhibitor hypotension

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) (NCT00810693)

Adverse eventRiociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT (n=254) · Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT (n=63) · Placebo (n=126)
Hypotension1/2540/630/126

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Acetazolamide ↔ Metabolic acidosis

Open this assessment on its own page →

n=206 co-reports · PRR 23.1 · ROR 23.9

Acetazolamide inhibits carbonic anhydrase, causing bicarbonate loss in the urine and a hyperchloraemic metabolic acidosis — a direct, expected consequence of the mechanism (206 co-reports, PRR 23.1). It is used deliberately for this effect in some settings (altitude illness, metabolic alkalosis) and becomes a limiting toxicity at high doses or in renal impairment; paraesthesias, hypokalaemia, and nephrolithiasis commonly accompany it.

Regulatory basis: acetazolamide prescribing information — metabolic acidosis; carbonic-anhydrase-inhibitor pharmacology.

Bradford Hill viewpointStatusNote
Temporality (necessary)metAcidosis develops within days
StrengthmetPRR 23.1, large
ConsistencymetConsistent across case series
SpecificitypartialShared across carbonic-anhydrase inhibitors
Biological gradientmetDose-related
PlausibilitymetDirect consequence of bicarbonate loss
CoherencemetFits the mechanism exactly
ExperimentmetAcid-base change is measurable on protocol labs
AnalogymetAnalogous to topiramate-induced acidosis

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for acetazolamide captured metabolic acidosis as a tracked adverse event in a usable structure. Trials reported acetazolamide's acid-base effect through laboratory measures rather than a coded adverse-event table entry.
Expected pharmacological effect

Mannitol ↔ Renal failure

Open this assessment on its own page →

n=592 co-reports · PRR 19.0 · ROR 21.4

Mannitol is an osmotic diuretic; at high doses or in patients with pre-existing renal impairment it can accumulate, cause osmotic nephrosis, and precipitate or worsen acute renal failure (592 co-reports, PRR 19.0). Crystallisation in the tubules and shifts in fluid balance contribute, which is why the label advises against use in established anuria and calls for careful dosing in renal impairment.

Regulatory basis: mannitol prescribing information — renal failure; osmotic-nephrosis literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metRenal injury follows high-dose therapy
StrengthmetPRR 19.0, large
ConsistencymetRecognised in case series
SpecificitypartialShared with other osmotic agents
Biological gradientmetDose-related accumulation
PlausibilitymetOsmotic-nephrosis mechanism
CoherencemetFits the mechanism
Experimentn/aNot tested as a trial endpoint
AnalogymetAnalogous to other osmotic-diuretic nephrotoxicity

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Adaptive COVID-19 Treatment Trial 4 (ACTT-4) (NCT04640168)

Adverse eventRemdesivir Plus Baricitinib (n=503) · Remdesivir Plus Dexamethasone (n=482)
Acute kidney injury9/5034/482
Renal failure2/5030/482

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Indapamide ↔ Hyponatraemia

Open this assessment on its own page →

n=1,318 co-reports · PRR 28.2 · ROR 30.4

Indapamide is a thiazide-like diuretic whose most consequential electrolyte effect is hyponatraemia (1,318 co-reports, PRR 28.2), especially in older women, where it can cause confusion, falls, and seizures. The mechanism combines diuretic-induced sodium loss with impaired urinary dilution; the label advises monitoring electrolytes, and the effect usually resolves on withdrawal.

Regulatory basis: indapamide prescribing information — hyponatraemia.

Bradford Hill viewpointStatusNote
Temporality (necessary)metSodium falls over days to weeks
StrengthmetPRR 28.2, large
ConsistencymetConsistent across thiazide diuretics
SpecificitypartialShared with thiazides
Biological gradientmetWorse with higher doses and low intake
PlausibilitymetDiuretic-induced sodium loss
CoherencemetFits the mechanism
Experimentn/aNot a trial endpoint
AnalogymetAnalogous to thiazide hyponatraemia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension (NCT04518293)

Adverse eventNot Randomized (n=859) · GMRx2 (n=551) · Dual - TA (n=282) · Dual - TI (n=276)
Hyponatremia19/85928/55112/28214/276

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Fondaparinux ↔ Thrombocytopenia

Open this assessment on its own page →

n=263 co-reports · PRR 6.2 · ROR 6.3

Fondaparinux is a synthetic indirect factor-Xa inhibitor; thrombocytopenia is a recognised, if less common, effect (263 co-reports, PRR 6.2) and, in a minority, is associated with the same platelet-activating antibodies that cause heparin-induced thrombocytopenia. The label advises platelet counts at baseline and periodically, and the drug is contraindicated in active bleeding or severe renal impairment.

Regulatory basis: fondaparinux (Arixtra) prescribing information — thrombocytopenia; platelet monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metPlatelet fall within days
StrengthmetPRR 6.2, moderate
ConsistencymetRecognised in case series
SpecificitypartialShared with heparins
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetImmune-mediated platelet activation proposed
CoherencemetFits the anticoagulant picture
Experimentn/aNot tested as a trial endpoint
AnalogymetAnalogous to heparin-induced thrombocytopenia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis (NCT02234843)

Adverse eventComparator Group (n=162) · Rivaroxaban Group (n=329)
Thrombocytopenia0/1622/329

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Edoxaban ↔ Gastrointestinal haemorrhage

Open this assessment on its own page →

n=195 co-reports · PRR 7.4 · ROR 7.6

Edoxaban is a direct factor-Xa inhibitor; bleeding is its principal risk and gastrointestinal haemorrhage is a leading site (195 co-reports, PRR 7.4), because the anticoagulated gut mucosa bleeds readily. The ENGAGE AF-TIMI 48 trial showed comparable efficacy to warfarin with less major bleeding overall but a higher rate of gastrointestinal bleeding, and the label warns against use in severe renal impairment and with strong P-glycoprotein inhibitors.

Regulatory basis: edoxaban (Savaysa) prescribing information — bleeding; ENGAGE AF-TIMI 48 trial.

Bradford Hill viewpointStatusNote
Temporality (necessary)metBleeding follows anticoagulation
StrengthmetPRR 7.4, moderate here
ConsistencymetReproduced in ENGAGE AF-TIMI 48
SpecificitypartialShared across the DOAC class
Biological gradientmetRisk rises with duration and renal impairment
PlausibilitymetDirect consequence of factor-Xa inhibition
CoherencemetFits the mechanism
ExperimentmetRandomised trials quantify the excess
AnalogymetDirect class analogy to rivaroxaban and apixaban

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF) (NCT02072434)

Adverse eventEdoxaban (n=1067) · Warfarin (n=1082)
Lower gastrointestinal haemorrhage0/10671/1082

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Alteplase ↔ Cerebral haemorrhage

Open this assessment on its own page →

n=819 co-reports · PRR 32.9 · ROR 34.8

Alteplase is a recombinant tissue plasminogen activator that dissolves clots by converting plasminogen to plasmin; its most feared complication is intracranial (cerebral) haemorrhage, present here at 819 co-reports (PRR 32.9). In acute ischaemic stroke the symptomatic haemorrhage rate is roughly 2–7%, the principal risk governing patient selection and time window, and in myocardial infarction the risk is lower but real. That benefit–risk balance is the entire basis of thrombolysis eligibility criteria.

Regulatory basis: alteplase (Activase) prescribing information — boxed warning for intracranial haemorrhage; NINDS and ECASS-III stroke trials.

Bradford Hill viewpointStatusNote
Temporality (necessary)metBleeding occurs during or after infusion
StrengthmetPRR 32.9, large
ConsistencymetReproduced across stroke trials
SpecificitypartialShared across thrombolytics
Biological gradientmetRisk rises with later treatment
PlausibilitymetDirect consequence of plasminogen activation
CoherencemetFits the mechanism
ExperimentmetRandomised stroke trials quantify the excess
AnalogymetAnalogous to tenecteplase haemorrhage

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity (NCT04915729)

Adverse eventAlteplase Active Control Group (n=736) · Tenecteplase Treatment Group (n=732)
Intracranial infection1/7360/732
Cerebral haemorrhage21/73625/732
Haemorrhage intracranial7/7365/732

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Argatroban ↔ Haemorrhage

Open this assessment on its own page →

n=80 co-reports · PRR 10.7 · ROR 11.3

Argatroban is a direct thrombin inhibitor used for heparin-induced thrombocytopenia; by blocking thrombin it impairs clot formation, so bleeding (80 co-reports, PRR 10.7) is the expected dose-related hazard, along with the risk of under-anticoagulation in a prothrombotic condition. Its label requires monitoring of the activated partial thromboplastin time and dose reduction in hepatic impairment.

Regulatory basis: argatroban prescribing information — bleeding; aPTT monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metBleeding follows anticoagulation
StrengthmetPRR 10.7, large
ConsistencymetConsistent across case series
SpecificitypartialShared with other anticoagulants
Biological gradientmetDose-related
PlausibilitymetDirect consequence of thrombin inhibition
CoherencemetFits the mechanism
Experimentn/aNo large randomised trial
AnalogymetAnalogous to bivalirudin bleeding

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Multi-arm Optimization of Stroke Thrombolysis (NCT03735979)

Adverse eventArgatroban (n=59) · Eptifibatide (n=227) · Placebo (n=228)
Gastrointestinal haemorrhage2/591/2273/228
Subarachnoid haemorrhage0/595/2273/228
Haemorrhage intracranial2/597/2275/228

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Bivalirudin ↔ Haemorrhage

Open this assessment on its own page →

n=87 co-reports · PRR 18.2 · ROR 19.9

Bivalirudin is a direct thrombin inhibitor used in percutaneous coronary intervention; bleeding is its principal dose-related effect (87 co-reports, PRR 18.2). Tested head-to-head against heparin plus a glycoprotein IIb/IIIa inhibitor in HORIZONS-AMI and REPLACE, bivalirudin reduced bleeding, confirming the effect is a controllable property of the anticoagulant rather than an idiosyncratic reaction.

Regulatory basis: bivalirudin (Angiomax) prescribing information — bleeding; HORIZONS-AMI and REPLACE trials.

Bradford Hill viewpointStatusNote
Temporality (necessary)metBleeding follows anticoagulation
StrengthmetPRR 18.2, large
ConsistencymetReproduced across PCI trials
SpecificitypartialShared with other anticoagulants
Biological gradientmetDose-related
PlausibilitymetDirect consequence of thrombin inhibition
CoherencemetFits the mechanism
ExperimentmetPCI trials quantify the excess
AnalogymetAnalogous to argatroban bleeding

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial (NCT01087723)

Adverse eventBivalirudin (n=1099) · Standard of Care: Heparins With Optional GPI (n=1094)
Abdominal wall haemorrhage1/10990/1094

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Nitroglycerin ↔ Hypotension

Open this assessment on its own page →

n=2,299 co-reports · PRR 4.6 · ROR 4.7

Nitroglycerin releases nitric oxide to dilate veins and arteries, lowering preload and blood pressure; hypotension and headache (from meningeal vasodilation) are its classic, expected effects, and hypotension carries 2,299 co-reports here (PRR 4.6). The risk is greatest with volume depletion, right-ventricular infarction, and concomitant PDE5 inhibitors, where the combination can cause profound, refractory hypotension — an absolute contraindication.

Regulatory basis: nitroglycerin prescribing information — hypotension; contraindicated with PDE5 inhibitors.

Bradford Hill viewpointStatusNote
Temporality (necessary)metBlood-pressure fall is immediate
StrengthmetPRR 4.6, modest
ConsistencymetConsistent across nitrate use
SpecificitypartialShared across nitrates
Biological gradientmetDose-related
PlausibilitymetNitric-oxide vasodilation mechanism
CoherencemetFits the mechanism
ExperimentmetHaemodynamic effect measured in trials
AnalogymetAnalogous to isosorbide hypotension

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for nitroglycerin captured hypotension as a tracked adverse event in a usable structure. Trials capture nitrate blood-pressure effects as haemodynamic endpoints rather than as coded adverse events.
Expected pharmacological effect

Epoprostenol ↔ Headache

Open this assessment on its own page →

n=2,295 co-reports · PRR 5.9 · ROR 7.0

Epoprostenol is a prostacyclin (PGI2) infusion that dilates systemic and pulmonary vessels; headache from vasodilation is among its most common and dose-limiting effects (2,295 co-reports, PRR 5.9), along with flushing, jaw pain, and diarrhoea. These effects are intrinsic to prostacyclin pharmacology and are managed by titrating the continuous infusion rather than by stopping therapy.

Regulatory basis: epoprostenol (Flolan) prescribing information — headache and vasodilator effects.

Bradford Hill viewpointStatusNote
Temporality (necessary)metHeadache within hours of infusion
StrengthmetPRR 5.9, moderate
ConsistencymetConsistent across prostacyclin use
SpecificitypartialShared with other prostacyclins
Biological gradientmetDose-related
PlausibilitymetVasodilation mechanism
CoherencemetFits the mechanism
ExperimentmetTrials recorded vasodilator effects
AnalogymetAnalogous to treprostinil headache

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR) (NCT04576988)

Adverse eventSotatercept Plus Background PAH Therapy (DBPC Period) (n=163) · Placebo Plus Background PAH Therapy (DBPC Period) (n=160) · Sotatercept Plus Background PAH Therapy (LTDB Period) (n=158) · Placebo Plus Background PAH Therapy (LTDB Period) (n=142)
Headache33/16324/1609/1586/142

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Treprostinil ↔ Headache

Open this assessment on its own page →

n=17,283 co-reports · PRR 4.7 · ROR 5.3

Treprostinil, a prostacyclin analogue given by infusion or inhalation, produces the same vasodilator symptom cluster as epoprostenol, and headache dominates the reaction profile here (17,283 co-reports, PRR 4.7) — the count reflecting its use in large pulmonary-hypertension registries. Infusion-site pain, diarrhoea, and flushing accompany it, all intrinsic to prostacyclin effect.

Regulatory basis: treprostinil (Remodulin) prescribing information — headache and vasodilator effects.

Bradford Hill viewpointStatusNote
Temporality (necessary)metHeadache soon after starting
StrengthmetPRR 4.7 with a very large count
ConsistencymetConsistent across prostacyclin registries
SpecificitypartialShared with other prostacyclins
Biological gradientmetDose-related
PlausibilitymetVasodilation mechanism
CoherencemetFits the mechanism
ExperimentmetTrials recorded vasodilator effects
AnalogymetAnalogous to epoprostenol headache

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine (NCT00775463)

Adverse eventPlacebo (n=76) · Treprostinil Diethanolamine (n=71)
Headache32/7652/71

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Fluoxetine ↔ Serotonin syndrome

Open this assessment on its own page →

n=1,720 co-reports · PRR 31.2 · ROR 32.0

Fluoxetine, a selective serotonin-reuptake inhibitor, raises synaptic serotonin; excess serotonergic activity produces serotonin syndrome — agitation, clonus, hyperthermia, autonomic instability — most often when an SSRI is combined with another serotonergic drug (MAOIs, tramadol, triptans, linezolid). In this dataset serotonin syndrome carries 1,720 co-reports (PRR 31.2). Fluoxetine's long half-life makes the effect linger after the drug is stopped, and MAOI combinations are contraindicated.

Regulatory basis: fluoxetine prescribing information — serotonin syndrome; contraindicated with MAOIs.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOnset within hours to days of serotonergic load
StrengthmetPRR 31.2, large
ConsistencymetReproduced across serotonergic drugs
SpecificitypartialNot specific to one drug within the class
Biological gradientmetWorse with higher combined serotonergic load
PlausibilitymetExcess-serotonin mechanism
CoherencemetFits SSRI pharmacology
ExperimentmetCase series and dechallenge support it
AnalogymetAnalogous to other SSRI/MAOI combinations

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for fluoxetine captured serotonin syndrome as a tracked adverse event in a usable structure. Serotonin syndrome is usually combination-triggered and rarely arises in single-agent trial arms, so trials did not capture it as a coded event.
Causality: well established

Escitalopram ↔ QT prolongation

Open this assessment on its own page →

n=1,236 co-reports · PRR 5.3 · ROR 5.4

Escitalopram is the active S-enantiomer of citalopram, and both prolong the QT interval in a dose-dependent manner (1,236 co-reports here, PRR 5.3). After post-marketing reports of torsades de pointes, the FDA capped the maximum dose (especially in older adults) and warned against use with other QT-prolonging drugs; the effect is greater in those with electrolyte disturbance or cardiac disease.

Regulatory basis: escitalopram prescribing information — dose-dependent QT prolongation; FDA drug-safety communications.

Bradford Hill viewpointStatusNote
Temporality (necessary)metInterval prolongation within days
StrengthmetPRR 5.3, moderate
ConsistencymetReproduced across the SSRI class
SpecificitypartialShared with other SSRIs and QT-prolonging drugs
Biological gradientmetDose-dependent
PlausibilitymetEffect on cardiac repolarisation
CoherencemetFits the pharmacology
ExperimentmetECG data from trials and safety studies
AnalogymetAnalogous to citalopram QT prolongation

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for escitalopram captured qt prolongation as a tracked adverse event in a usable structure. Trials measured QT change on protocol electrocardiograms rather than reporting it as a coded adverse event.
Causality: well established

Fluvoxamine ↔ Serotonin syndrome

Open this assessment on its own page →

n=81 co-reports · PRR 37.3 · ROR 38.6

Fluvoxamine is an SSRI that, like the class, can cause serotonin syndrome when combined with other serotonergic agents — 81 co-reports here (PRR 37.3). It is also a potent CYP1A2 and CYP2C19 inhibitor, so it raises levels of co-prescribed drugs (including some that are themselves serotonergic or QT-prolonging), amplifying the risk. MAOI combinations are contraindicated.

Regulatory basis: fluvoxamine prescribing information — serotonin syndrome; CYP1A2/2C19 inhibition; contraindicated with MAOIs.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOnset within hours to days
StrengthmetPRR 37.3, large
ConsistencymetReproduced across serotonergic drugs
SpecificitypartialNot specific within the class
Biological gradientmetWorse with added serotonergic load
PlausibilitymetExcess-serotonin mechanism
CoherencemetFits SSRI pharmacology
ExperimentmetCase series and dechallenge support it
AnalogymetAnalogous to other SSRI/MAOI combinations

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for fluvoxamine-maleate captured serotonin syndrome as a tracked adverse event in a usable structure. Serotonin syndrome usually requires drug combinations and rarely appears in single-agent trial arms, so trials did not capture it as a coded event.
Contested: signal not confirmed by large randomized trials

Duloxetine ↔ Completed suicide

Open this assessment on its own page →

n=2,204 co-reports · PRR 8.1 · ROR 8.4

Duloxetine is a serotonin–noradrenaline reuptake inhibitor; its signals here include completed suicide (2,204 co-reports, PRR 8.1), but this is the most confounded association on the page. The treated condition — depression, and often chronic pain with its own suicide risk — is itself strongly linked to suicide, and the FDA antidepressant class warning concerns increased suicidal ideation in young patients early in treatment, not completed suicide in adults. Large meta-analyses of antidepressant trials have not shown an excess of completed suicide, so the raw disproportionality reflects the underlying population more than a drug effect.

Regulatory basis: duloxetine prescribing information — boxed warning for suicidal thoughts in children/young adults; antidepressant class literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)partialSuicide risk is highest at illness onset
StrengthmetPRR 8.1, but on a high-background population
Consistencynot establishedLarge analyses do not confirm an excess of suicide
Specificitynot establishedCannot separate drug from the treated condition
Biological gradientnot establishedNo established dose relationship
PlausibilitypartialPlausible for early activation, not for death
Coherencenot establishedConfounded by indication
Experimentnot establishedMeta-analyses of trials fail to show it
AnalogypartialDebated analogy to other antidepressants

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression (NCT02493868)

Adverse eventIND: Intranasal Esketamine + Oral AD (n=437) · OP: Intranasal Esketamine + Oral AD (n=455) · MA: Intranasal Esketamine + Oral AD (n=152) · MA: Oral AD + Intranasal Placebo (n=145)
Suicidal Ideation1/4370/4550/1520/145

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Amitriptyline ↔ Tachycardia

Open this assessment on its own page →

n=579 co-reports · PRR 7.9 · ROR 8.1

Amitriptyline, a tricyclic antidepressant, blocks cardiac sodium channels, antagonises muscarinic receptors, and inhibits noradrenaline reuptake — a combination that produces tachycardia and, at higher exposure, serious arrhythmias (579 co-reports here, PRR 7.9). Its anticholinergic and quinidine-like effects are the reason tricyclics are dangerous in overdose and require caution in cardiac disease.

Regulatory basis: amitriptyline prescribing information — cardiac conduction effects; tricyclic overdose literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metCardiac effects at therapeutic doses
StrengthmetPRR 7.9, moderate
ConsistencymetConsistent across tricyclics
SpecificitypartialShared across the tricyclic class
Biological gradientmetWorse at higher plasma levels
PlausibilitymetAnticholinergic and sodium-channel blockade
CoherencemetFits the pharmacology
ExperimentmetOverdose series quantify the effect
AnalogymetDirect class analogy to imipramine

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for amitriptyline-hydrochloride captured tachycardia as a tracked adverse event in a usable structure. Trials of amitriptyline for depression did not report tachycardia as a structured coded adverse event.
Expected pharmacological effect

Nortriptyline ↔ QT prolongation

Open this assessment on its own page →

n=24 co-reports · PRR 2.4 · ROR 2.4

Nortriptyline is the active metabolite of amitriptyline and shares the tricyclic cardiac profile; it produces QT prolongation and conduction delay (399 overdose-related co-reports, with a QT signal of 24 co-reports, PRR 2.4). Because tricyclics depress myocardial conduction, they are contraindicated after recent myocardial infarction and in significant conduction defects.

Regulatory basis: nortriptyline prescribing information — cardiac conduction effects; tricyclic overdose literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metConduction effects within the therapeutic range
StrengthmetPRR 2.4, modest here
ConsistencymetConsistent across tricyclics
SpecificitypartialShared across the class
Biological gradientmetWorse at higher plasma levels
PlausibilitymetSodium-channel and repolarisation effects
CoherencemetFits the pharmacology
ExperimentmetOverdose series quantify it
AnalogymetDirect class analogy to amitriptyline

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for nortriptyline-hydrochloride captured qt prolongation as a tracked adverse event in a usable structure. Tricyclic trials did not report QT prolongation as a structured coded adverse event.
Causality: well established

Phenelzine ↔ Serotonin syndrome

Open this assessment on its own page →

n=36 co-reports · PRR 25.3 · ROR 25.9

Phenelzine is a monoamine-oxidase inhibitor; by blocking MAO-A it raises serotonin, noradrenaline, and dopamine, and combining it with any serotonergic drug (including SSRIs) can precipitate life-threatening serotonin syndrome — 36 co-reports here (PRR 25.3). This is why MAOIs carry strict dietary (tyramine) and drug-interaction restrictions, including a required washout when switching to or from SSRIs.

Regulatory basis: phenelzine prescribing information — serotonin syndrome; hypertensive crisis with tyramine; MAOI interaction warnings.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOnset within hours of a serotonergic combination
StrengthmetPRR 25.3, large
ConsistencymetReproduced across MAOI cases
SpecificitypartialNot specific within serotonergic drugs
Biological gradientmetWorse with higher combined load
PlausibilitymetExcess-serotonin mechanism
CoherencemetFits MAOI pharmacology
ExperimentmetCase series and dechallenge support it
AnalogymetAnalogous to other MAOI/SSRI combinations

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for phenelzine-sulfate captured serotonin syndrome as a tracked adverse event in a usable structure. Serotonin syndrome is a combination-triggered event that single-agent MAOI trials did not capture as a coded term.
Causality: well established

Ziprasidone ↔ QT prolongation

Open this assessment on its own page →

n=265 co-reports · PRR 8.9 · ROR 9.0

Ziprasidone is an atypical antipsychotic with the largest QT effect of its class; the interval prolongation is dose-related and was prominent enough that its approval required food co-administration (to ensure absorption) and warnings about combining it with other QT-prolonging drugs. In this dataset, electrocardiogram QT prolonged carries 265 co-reports (PRR 8.9), and the label warns in patients with electrolyte disturbance or cardiac disease.

Regulatory basis: ziprasidone (Geodon) prescribing information — QT prolongation with dosing/food requirements.

Bradford Hill viewpointStatusNote
Temporality (necessary)metInterval prolongation within days
StrengthmetPRR 8.9, moderate
ConsistencymetReproduced across ECG studies
SpecificitypartialShared with other antipsychotics
Biological gradientmetDose-dependent
PlausibilitymetEffect on cardiac repolarisation
CoherencemetFits the pharmacology
ExperimentmetECG data from trials and safety studies
AnalogymetAnalogous to thioridazine and droperidol

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study (NCT01211522)

Adverse eventHaloperidol (n=192) · Ziprasidone (n=190) · Placebo (n=184)
Torsades de pointes2/1921/1901/184
Prolonged QTc13/19220/19010/184

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Chlorpromazine ↔ Neuroleptic malignant syndrome

Open this assessment on its own page →

n=294 co-reports · PRR 74.9 · ROR 78.1

Chlorpromazine is a first-generation antipsychotic; dopamine D2 blockade in the hypothalamus and basal ganglia underlies neuroleptic malignant syndrome — hyperthermia, rigidity, autonomic instability, and raised creatine kinase — 294 co-reports here (PRR 74.9). NMS is rare but potentially fatal and is why any antipsychotic requires vigilance for the syndrome, with immediate drug withdrawal and supportive care.

Regulatory basis: chlorpromazine prescribing information — neuroleptic malignant syndrome; antipsychotic class warning.

Bradford Hill viewpointStatusNote
Temporality (necessary)partialOnset over days of therapy or dose change
StrengthmetPRR 74.9, very large
ConsistencymetReproduced across antipsychotics
Specificitynot establishedNot specific to any one antipsychotic
Biological gradientmetMore likely with rapid dose escalation
PlausibilitymetCentral dopamine-blockade mechanism
CoherencemetFits the pharmacology
Experimentn/aToo rare for trial detection
AnalogymetAnalogous across the antipsychotic class

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for chlorpromazine captured neuroleptic malignant syndrome as a tracked adverse event in a usable structure. NMS is too rare to appear in the trial populations that studied chlorpromazine, so trials did not capture it as a coded event.
Causality: well established

Oxcarbazepine ↔ Hyponatraemia

Open this assessment on its own page →

n=1,305 co-reports · PRR 15.4 · ROR 16.0

Oxcarbazepine, an antiepileptic related to carbamazepine, causes hyponatraemia through an antidiuretic-hormone-like effect more often than its parent drug (1,305 co-reports, PRR 15.4), particularly at higher doses and in older patients. The label advises monitoring sodium, and the effect is usually reversible on dose reduction or withdrawal.

Regulatory basis: oxcarbazepine prescribing information — hyponatraemia (SIADH-like effect).

Bradford Hill viewpointStatusNote
Temporality (necessary)metSodium falls within weeks
StrengthmetPRR 15.4, large
ConsistencymetReproduced across case series
SpecificitypartialShared with carbamazepine
Biological gradientmetDose-related
PlausibilitymetAntidiuretic-hormone effect
CoherencemetFits the pharmacology
Experimentn/aNot a trial endpoint
AnalogymetAnalogous to carbamazepine hyponatraemia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy (NCT01498822)

Adverse eventLevetiracetam (n=173) · Oxcarbazepine (n=174)
Hyponatraemia0/1731/174

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Zonisamide ↔ Nephrolithiasis

Open this assessment on its own page →

n=189 co-reports · PRR 5.9 · ROR 6.0

Zonisamide is a sulfonamide antiepileptic; the sulfonamide group inhibits carbonic anhydrase and alkalinises urine, promoting calcium phosphate kidney stones (189 co-reports, PRR 5.9), along with metabolic acidosis and hypohidrosis. The label advises adequate hydration and warns of kidney-stone risk, which is higher in patients with a history of stones.

Regulatory basis: zonisamide (Zonegran) prescribing information — nephrolithiasis and metabolic acidosis.

Bradford Hill viewpointStatusNote
Temporality (necessary)metStones develop over months
StrengthmetPRR 5.9, moderate
ConsistencymetReproduced in case series
SpecificitypartialShared with other sulfonamides
Biological gradientpartialRisk rises with predisposing factors
PlausibilitymetCarbonic-anhydrase inhibition and urinary alkalinisation
CoherencemetFits the pharmacology
Experimentn/aNot a trial endpoint
AnalogymetAnalogous to topiramate and acetazolamide stones

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for zonisamide captured nephrolithiasis as a tracked adverse event in a usable structure. Epilepsy trials of zonisamide did not report nephrolithiasis as a structured coded adverse event.
Expected pharmacological effect

Lacosamide ↔ Bradycardia

Open this assessment on its own page →

n=402 co-reports · PRR 4.3 · ROR 4.4

Lacosamide is an antiepileptic that enhances slow sodium-channel inactivation, which prolongs the PR interval and can cause bradycardia, AV block, and syncope (402 co-reports, PRR 4.3). The label advises caution in patients with conduction disease and in combination with other PR-prolonging drugs, and doses are titrated slowly; the effect is dose-related.

Regulatory basis: lacosamide (Vimpat) prescribing information — PR-interval prolongation and bradycardia.

Bradford Hill viewpointStatusNote
Temporality (necessary)metBradycardia occurs with therapy
StrengthmetPRR 4.3, modest
ConsistencymetSeen across trials and series
SpecificitypartialShared with other sodium-channel blockers
Biological gradientmetDose-related
PlausibilitymetEffect on cardiac conduction
CoherencemetFits the pharmacology
ExperimentmetECG changes measured in trials
AnalogymetAnalogous to other PR-prolonging antiepileptics

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures (NCT00771927)

Adverse eventLacosamide (n=511) · Other AED (n=493)
Sinus Bradycardia2/5110/493
Bradycardia1/5113/493

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Droperidol ↔ QT prolongation

Open this assessment on its own page →

n=39 co-reports · PRR 14.1 · ROR 14.4

Droperidol is a butyrophenone antiemetic/sedative that prolongs the QT interval and has caused fatal torsades de pointes; the FDA added a boxed warning in 2001 requiring a baseline 12-lead ECG and continuous monitoring before use. In this dataset, electrocardiogram QT prolonged carries 39 co-reports (PRR 14.1) — a small count because ECG-mandated use is now highly restricted, but the signal itself is well established.

Regulatory basis: droperidol (Inapsine) prescribing information — boxed warning for QT prolongation and torsades de pointes (FDA 2001).

Bradford Hill viewpointStatusNote
Temporality (necessary)metInterval prolongation within minutes to hours
StrengthmetPRR 14.1, large
ConsistencymetReproduced in case series
SpecificitypartialShared with other QT-prolonging drugs
Biological gradientmetDose-related
PlausibilitymetEffect on cardiac repolarisation
CoherencemetFits the pharmacology
ExperimentmetECG monitoring is mandated because of it
AnalogymetAnalogous to haloperidol and ziprasidone

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — E7 TCR T Cells for Human Papillomavirus-Associated Cancers (NCT02858310)

Adverse eventPhase I:Dose Escalation Cohort; Arm 1:Phase I:DoseLevel 1: 1 x 10^9 E7 T-Cell Receptor (TCR) Cells (n=3) · Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 2: 1 x 10^10 E7 T-Cell Receptor Cells (n=3) · Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 3: 1 x 10^11 E7 Cells (n=6) · Phase II Cohort; Arm 2: Phase II: 1 x 10^11 E7 Cells (n=18)
Activated partial thromboplastin time prolonged0/30/30/61/18
Investigations - Other, specify: Prolonged QTcB interval (EKG)0/30/30/61/18

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Pregabalin ↔ Oedema peripheral

Open this assessment on its own page →

n=5,399 co-reports · PRR 3.5 · ROR 3.6

Pregabalin, like gabapentin, reduces excitatory neurotransmitter release at calcium channels and commonly causes peripheral oedema through vasodilation and fluid retention (5,399 co-reports, PRR 3.5), along with weight gain, somnolence, and dizziness. The oedema is dose-related and usually benign but can be mistaken for heart or kidney failure; pregabalin additionally carries a labelled risk of respiratory depression with opioids.

Regulatory basis: pregabalin (Lyrica) prescribing information — peripheral oedema; respiratory-depression warning with opioids.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOedema develops over weeks
StrengthmetPRR 3.5, moderate
ConsistencymetConsistent across gabapentinoids
SpecificitypartialShared with gabapentin
Biological gradientmetDose-related
PlausibilitymetVasodilation and fluid-retention mechanism
CoherencemetFits the pharmacology
ExperimentmetTrials recorded oedema
AnalogymetDirect class analogy to gabapentin

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Pregabalin Peripheral Neuropathic Pain Study (NCT00141219)

Adverse eventPregabalin (n=162) · Placebo (n=78)
Face oedema10/1621/78
Oedema peripheral10/1620/78
Generalized oedema7/1620/78

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Levodopa ↔ Dyskinesia

Open this assessment on its own page →

n=760 co-reports · PRR 33.3 · ROR 35.5

Levodopa is the most effective treatment for Parkinson's disease, but after years of therapy most patients develop levodopa-induced dyskinesias — involuntary choreiform movements tied to peak drug levels — reflecting pulsatile dopamine-receptor stimulation (760 co-reports here, PRR 33.3). The effect is so characteristic of chronic levodopa use that reducing the dose, adding a COMT or MAO-B inhibitor, or using continuous delivery are the standard management strategies.

Regulatory basis: levodopa/carbidopa prescribing information — dyskinesia; Parkinson's-disease treatment literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDyskinesias emerge after months to years
StrengthmetPRR 33.3, large
ConsistencymetUniversally reproduced in practice
SpecificitymetHighly specific to dopaminergic therapy
Biological gradientmetRelated to dose and duration
PlausibilitymetPulsatile dopamine-receptor stimulation
CoherencemetFits the pharmacology
ExperimentmetTrial and registry data support it
AnalogymetAnalogous to dopamine-agonist dyskinesia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients (NCT01628926)

Adverse eventSPM 962 (n=168) · Ropinirole (n=167) · Placebo (n=85)
Dyskinesia27/16823/1671/85

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Entacapone ↔ Dyskinesia

Open this assessment on its own page →

n=481 co-reports · PRR 60.6 · ROR 68.4

Entacapone is a COMT inhibitor that extends levodopa's plasma half-life; by increasing and smoothing dopamine delivery it commonly worsens or uncovers dyskinesias (481 co-reports, PRR 60.6). The effect is a direct consequence of enhanced dopaminergic stimulation, and the label advises that levodopa doses may need reduction when entacapone is added.

Regulatory basis: entacapone (Comtan) prescribing information — dyskinesia; advised levodopa dose reduction.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDyskinesia appears or worsens on starting
StrengthmetPRR 60.6, very large
ConsistencymetReproduced across trials
SpecificitymetSpecific to dopaminergic augmentation
Biological gradientmetRelated to increased levodopa exposure
PlausibilitymetEnhanced dopamine-receptor stimulation
CoherencemetFits the pharmacology
ExperimentmetTrials showed dose-related dyskinesia
AnalogymetAnalogous to levodopa dyskinesia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease (NCT00219284)

Adverse eventImmediate Switch (n=180) · Delayed Switch (n=179)
Dyskinesia7/18012/179

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Memantine ↔ Confusional state

Open this assessment on its own page →

n=739 co-reports · PRR 7.1 · ROR 7.4

Memantine is an NMDA-receptor antagonist used in moderate-to-severe Alzheimer's disease; confusion, dizziness, and somnolence are among its labelled central adverse effects (739 co-reports, PRR 7.1). Because it is given to patients who already have cognitive impairment, disentangling drug-induced confusion from disease fluctuation requires care, but the effect is dose-related and reversible.

Regulatory basis: memantine prescribing information — confusion, dizziness, somnolence.

Bradford Hill viewpointStatusNote
Temporality (necessary)metConfusion occurs after starting or uptitrating
StrengthmetPRR 7.1, moderate
ConsistencymetReported across trials
Specificitynot establishedConfounded by underlying dementia
Biological gradientmetDose-related
PlausibilitymetCentral NMDA-receptor blockade
CoherencemetFits the pharmacology
ExperimentmetTrials recorded dizziness and confusion
AnalogypartialAnalogous to other CNS-active drugs

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for memantine captured confusional state as a tracked adverse event in a usable structure. Dementia trials reported confusion as a general adverse event rather than in a structure allowing clean per-arm extraction.
Expected pharmacological effect

Rivastigmine ↔ Vomiting

Open this assessment on its own page →

n=907 co-reports · PRR 2.2 · ROR 2.2

Rivastigmine is a cholinesterase inhibitor for Alzheimer's and Parkinson's-disease dementia; by raising acetylcholine it commonly causes nausea, vomiting, and diarrhoea, especially during dose titration and with the transdermal patch if a previous patch is not removed (vomiting 907 co-reports, PRR 2.2). The GI effects are the classic cholinergic class toxicity and are managed by slow titration.

Regulatory basis: rivastigmine prescribing information — nausea/vomiting; cholinergic class effects; patch-application errors.

Bradford Hill viewpointStatusNote
Temporality (necessary)metVomiting during titration
StrengthmetPRR 2.2, modest
ConsistencymetConsistent across cholinesterase inhibitors
SpecificitypartialShared across the class
Biological gradientmetDose-related
PlausibilitymetCholinergic excess
CoherencemetFits the pharmacology
ExperimentmetTrials recorded GI effects
AnalogymetAnalogous to donepezil and galantamine

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease (NCT00423085)

Adverse eventPlacebo (24 Weeks) (n=286) · Rivastigmine 5 cm^2 (24 Weeks) (n=282) · Rivastigmine 10 cm^2 (24 Weeks) (n=287) · Open-Label Extension (52 Weeks) (n=637)
Vomiting0/2860/2820/2872/637

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Methylphenidate ↔ Hallucination, visual

Open this assessment on its own page →

n=117 co-reports · PRR 4.1 · ROR 4.1

Methylphenidate is a stimulant that increases synaptic dopamine and noradrenaline; hallucinations and psychotic symptoms are labelled, dose-related adverse effects, described in children and adults both with and without pre-existing psychosis (117 visual-hallucination co-reports here, PRR 4.1). The label advises caution in patients with psychotic or bipolar disorders, and the effects usually resolve on dose reduction or withdrawal.

Regulatory basis: methylphenidate prescribing information — psychiatric adverse events including hallucinations and psychosis.

Bradford Hill viewpointStatusNote
Temporality (necessary)metPsychosis emerges with treatment
StrengthmetPRR 4.1, moderate
ConsistencymetDescribed across stimulant series
SpecificitypartialShared across stimulant drugs
Biological gradientmetDose-related
PlausibilitymetExcess dopaminergic stimulation
CoherencemetFits the pharmacology
ExperimentmetTrials and case series support it
AnalogymetAnalogous to amphetamine psychosis

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for methylphenidate captured hallucination, visual as a tracked adverse event in a usable structure. Stimulant trials reported psychiatric events among general adverse events rather than as a clean per-arm table entry.
Contested: signal not confirmed by large randomized trials

Modafinil ↔ Suicidal ideation

Open this assessment on its own page →

n=654 co-reports · PRR 4.7 · ROR 4.8

Modafinil is a wakefulness-promoting agent; suicidal ideation appears in this dataset at 654 co-reports (PRR 4.7), and the label carries a warning to monitor for psychiatric symptoms. The association is difficult to interpret, however: modafinil is used in narcolepsy and obstructive sleep apnoea, conditions associated with depressed mood and reduced quality of life, and it is also used off-label in depression, so confounding by indication is substantial and the causal contribution of the drug is uncertain.

Regulatory basis: modafinil (Provigil) prescribing information — psychiatric-symptom monitoring; FDA 2007 alert on serious skin reactions.

Bradford Hill viewpointStatusNote
Temporality (necessary)partialPsychiatric symptoms can appear on treatment
StrengthmetPRR 4.7, moderate
Consistencynot establishedNot consistently reproduced
Specificitynot establishedCannot separate drug from the treated disorder
Biological gradientnot establishedNo established dose relationship
PlausibilitypartialPlausible via altered wakefulness/mood
Coherencenot establishedConfounded by indication
Experimentn/aNot a trial endpoint
AnalogypartialDebated analogy to stimulants

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder (NCT01072929)

Adverse eventARMODAFINIL 150 MG (n=198) · ARMODAFINIL 200 MG (n=32) · PLACEBO (n=199)
Suicidal ideation2/1980/320/199
Suicide attempt0/1980/321/199

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Atomoxetine ↔ Hypertension

Open this assessment on its own page →

n=400 co-reports · PRR 11.2 · ROR 12.4

Atomoxetine is a selective noradrenaline-reuptake inhibitor for ADHD; by raising noradrenaline it increases heart rate and blood pressure, a labelled effect (400 co-reports, PRR 11.2) that requires monitoring in patients with hypertension, tachycardia, or cardiovascular disease. The increases are usually modest but prompt the label's caution against use in severe cardiovascular disorders.

Regulatory basis: atomoxetine (Strattera) prescribing information — increased blood pressure and heart rate.

Bradford Hill viewpointStatusNote
Temporality (necessary)metBlood-pressure rise within weeks
StrengthmetPRR 11.2, moderate
ConsistencymetConsistent across trials
SpecificitypartialShared with other noradrenergic drugs
Biological gradientmetDose-related
PlausibilitymetNoradrenaline re-uptake inhibition
CoherencemetFits the pharmacology
ExperimentmetTrials measured blood-pressure change
AnalogymetAnalogous to SNRI blood-pressure effects

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for atomoxetine captured hypertension as a tracked adverse event in a usable structure. Atomoxetine trials measured blood pressure as a vital-sign safety parameter rather than reporting hypertension as a coded event.
Causality: well established

Zolpidem ↔ Amnesia

Open this assessment on its own page →

n=2,881 co-reports · PRR 7.2 · ROR 7.3

Zolpidem is a short-acting hypnotic that potentiates GABA-A signalling; anterograde amnesia and complex sleep behaviours (sleep-driving, sleep-eating) are well-recognised, labelled adverse effects, and amnesia carries 2,881 co-reports here (PRR 7.2). The FDA lowered the recommended dose, especially in women, because of next-morning impairment and these parasomnias.

Regulatory basis: zolpidem prescribing information — amnesia; boxed warning for complex sleep behaviours; FDA 2013 dose reduction.

Bradford Hill viewpointStatusNote
Temporality (necessary)metAmnesia occurs after dosing
StrengthmetPRR 7.2, moderate
ConsistencymetReproduced in case series
SpecificitypartialShared with other Z-drugs
Biological gradientmetDose-related
PlausibilitymetGABA-A potentiation and sedation
CoherencemetFits the pharmacology
ExperimentmetTrials recorded memory effects
AnalogymetAnalogous to other benzodiazepine-receptor agonists

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for zolpidem-tartrate captured amnesia as a tracked adverse event in a usable structure. Hypnotic trials reported amnesia among general adverse events rather than in a structure allowing clean per-arm extraction.
Expected pharmacological effect

Eszopiclone ↔ Amnesia

Open this assessment on its own page →

n=270 co-reports · PRR 3.4 · ROR 3.5

Eszopiclone is a non-benzodiazepine hypnotic with the same GABA-A mechanism as zolpidem; amnesia and complex sleep behaviours are labelled effects (270 co-reports here, PRR 3.4), and it uniquely leaves a metallic taste. Next-day impairment and parasomnias led to the same class warnings and dose reductions as for other Z-drugs.

Regulatory basis: eszopiclone (Lunesta) prescribing information — amnesia; boxed warning for complex sleep behaviours; FDA 2014 dose reduction.

Bradford Hill viewpointStatusNote
Temporality (necessary)metAmnesia occurs after dosing
StrengthmetPRR 3.4, modest
ConsistencymetReproduced in case series
SpecificitypartialShared with other Z-drugs
Biological gradientmetDose-related
PlausibilitymetGABA-A potentiation and sedation
CoherencemetFits the pharmacology
ExperimentmetTrials recorded memory effects
AnalogymetAnalogous to zolpidem amnesia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia (NCT00645944)

Adverse eventEszopiclone Group (n=19) · Placebo Group (n=17)
Memory Problems1/191/17

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Buspirone ↔ Serotonin syndrome

Open this assessment on its own page →

n=119 co-reports · PRR 12.0 · ROR 12.1

Buspirone is a partial 5-HT1A agonist used for anxiety; it is serotonergic, and combining it with SSRIs, MAOIs, or other serotonergic drugs can precipitate serotonin syndrome (119 co-reports, PRR 12.0). The label warns against MAOI co-administration, and the risk is dose-related with respect to total serotonergic load.

Regulatory basis: buspirone prescribing information — serotonin syndrome; contraindicated with MAOIs.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOnset within hours to days of combination
StrengthmetPRR 12.0, moderate
ConsistencymetReproduced across serotonergic drugs
SpecificitypartialNot specific within serotonergic drugs
Biological gradientmetWorse with higher combined load
PlausibilitymetExcess-serotonin mechanism
CoherencemetFits the pharmacology
ExperimentmetCase series and dechallenge support it
AnalogymetAnalogous to other serotonergic combinations

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for buspirone-hydrochloride captured serotonin syndrome as a tracked adverse event in a usable structure. Serotonin syndrome is combination-triggered and rarely appears in single-agent trial arms, so trials did not capture it as a coded event.
Expected pharmacological effect

Baclofen ↔ Somnolence

Open this assessment on its own page →

n=2,765 co-reports · PRR 3.4 · ROR 3.5

Baclofen is a GABA-B agonist used for spasticity; sedation and somnolence are its most common dose-limiting effects (2,765 co-reports here, PRR 3.4), along with weakness and dizziness. Crucially, abrupt withdrawal after chronic use can cause a severe, sometimes fatal syndrome with seizures and autonomic instability, so the drug must be tapered.

Regulatory basis: baclofen prescribing information — sedation; withdrawal-syndrome warning.

Bradford Hill viewpointStatusNote
Temporality (necessary)metSomnolence follows dosing
StrengthmetPRR 3.4, modest
ConsistencymetConsistent across clinical use
SpecificitypartialShared with other CNS depressants
Biological gradientmetDose-related
PlausibilitymetGABA-B receptor activation
CoherencemetFits the pharmacology
ExperimentmetTrials recorded sedation
AnalogymetAnalogous to benzodiazepine sedation

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors (NCT01265550)

Adverse eventMedical Treatment Group (n=25) · Surgical Treatment Group (n=27) · Placebo Medical Treatment Group (n=26) · All Enrolled (n=366)
Somnolence4/250/271/260/366

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Tizanidine ↔ Hypotension

Open this assessment on its own page →

n=509 co-reports · PRR 2.2 · ROR 2.3

Tizanidine is a centrally acting alpha-2 agonist that reduces spasticity but also lowers blood pressure and heart rate; hypotension and orthostatic intolerance are labelled effects (509 co-reports, PRR 2.2), amplified by CYP1A2 inhibitors such as ciprofloxacin, which raise tizanidine levels and have caused profound hypotension.

Regulatory basis: tizanidine prescribing information — hypotension/bradycardia; contraindicated with ciprofloxacin and other CYP1A2 inhibitors.

Bradford Hill viewpointStatusNote
Temporality (necessary)metBlood-pressure fall with dosing
StrengthmetPRR 2.2, modest
ConsistencymetSeen across trials and series
SpecificitypartialShared with clonidine
Biological gradientmetDose-related
PlausibilitymetAlpha-2 agonism reducing sympathetic tone
CoherencemetFits the pharmacology
ExperimentmetTrials measured blood-pressure change
AnalogymetAnalogous to clonidine hypotension

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for tizanidine captured hypotension as a tracked adverse event in a usable structure. Spasticity trials measured blood pressure as a vital-sign safety parameter rather than reporting hypotension as a coded event.
Causality: well established

Rufinamide ↔ Convulsion

Open this assessment on its own page →

n=76 co-reports · PRR 10.7 · ROR 11.0

Rufinamide is an antiepileptic used mainly for Lennox-Gastaut syndrome; convulsion/seizure worsening appears here at 76 co-reports (PRR 10.7). All antiepileptics can paradoxically exacerbate seizures, and rufinamide also shortens the QT interval (a distinctive, labelled effect); the drug must be withdrawn slowly because abrupt cessation can provoke status epilepticus.

Regulatory basis: rufinamide (Banzel) prescribing information — seizure worsening; QT-shortening effect; withdrawal advice.

Bradford Hill viewpointStatusNote
Temporality (necessary)metSeizure worsening during titration
StrengthmetPRR 10.7, large
ConsistencymetReported across antiepileptics
Specificitynot establishedNot specific to rufinamide
Biological gradientmetMore likely with rapid titration
PlausibilitymetAltered neuronal excitability
CoherencemetFits the antiepileptic picture
ExperimentmetTrial data support it
AnalogymetAnalogous to other antiepileptics

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures (NCT00334958)

Adverse eventRufinamide (n=176) · Placebo (n=180)
Convulsion2/1762/180

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Cenobamate ↔ Eosinophilia

Open this assessment on its own page →

n=32 co-reports · PRR 4.6 · ROR 4.6

Cenobamate is a newer antiepileptic; drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but life-threatening hypersensitivity reaction, and its label requires a slow, low-dose start specifically to reduce this risk (the dataset captures eosinophilia, a component of DRESS, at 32 co-reports, PRR 4.6). The reaction is idiosyncratic, appears within the first weeks, and mandates immediate discontinuation.

Regulatory basis: cenobamate (Xcopri) prescribing information — DRESS/multiorgan hypersensitivity; required slow titration.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOnset within weeks of starting
StrengthmetPRR 4.6, modest
ConsistencymetReproduced in case reports
Specificitynot establishedNot specific to cenobamate
Biological gradientpartialRisk rises with faster titration
Plausibilitynot establishedIdiosyncratic (not clearly dose-related)
CoherencemetIdiosyncratic drug-hypersensitivity mechanism
ExperimentmetPart of the DRESS picture
AnalogymetAnalogous to other antiepileptic hypersensitivity

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for cenobamate captured eosinophilia as a tracked adverse event in a usable structure. DRESS is too rare to appear in trial populations, so epilepsy trials did not capture it as a coded event.
Expected pharmacological effect

Stiripentol ↔ Somnolence

Open this assessment on its own page →

n=230 co-reports · PRR 11.2 · ROR 12.4

Stiripentol is an antiepileptic used with clobazam in Dravet syndrome; somnolence and sedation are its most common effects (230 co-reports, PRR 11.2), amplified because stiripentol inhibits CYP enzymes and raises clobazam and other antiepileptic levels. The label advises caution with CNS depressants, and the sedation is managed by dose adjustment.

Regulatory basis: stiripentol (Diacomit) prescribing information — somnolence; CYP inhibition raising co-medication levels.

Bradford Hill viewpointStatusNote
Temporality (necessary)metSomnolence follows dosing
StrengthmetPRR 11.2, large
ConsistencymetConsistent across trials
SpecificitypartialShared with other CNS-active antiepileptics
Biological gradientmetDose-related
PlausibilitymetGABA-A potentiation plus CYP inhibition
CoherencemetFits the pharmacology
ExperimentmetTrials recorded sedation
AnalogymetAnalogous to clobazam sedation

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome (NCT02926898)

Adverse eventCohort 2: ZX008 0.5 mg/kg/Day (n=43) · Cohort 2: Matching Placebo (n=44)
Somnolence3/433/44

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Fosphenytoin ↔ Hypotension

Open this assessment on its own page →

n=114 co-reports · PRR 4.7 · ROR 4.8

Fosphenytoin is a prodrug of phenytoin given intravenously; rapid infusion causes hypotension and arrhythmias, so the label mandates a maximum infusion rate and monitoring (114 co-reports, PRR 4.7). The effect is rate-related rather than a fixed property of the drug, and is worse in patients with cardiac disease or pre-existing hypotension.

Regulatory basis: fosphenytoin (Cerebyx) prescribing information — hypotension and arrhythmias; maximum infusion-rate guidance.

Bradford Hill viewpointStatusNote
Temporality (necessary)metHypotension during rapid infusion
StrengthmetPRR 4.7, modest
ConsistencymetConsistent across infusion series
SpecificitypartialShared with intravenous phenytoin
Biological gradientmetRate-related
PlausibilitymetVasodilation and cardiac depression
CoherencemetFits the pharmacology
ExperimentmetInfusion-rate studies quantify it
AnalogymetAnalogous to intravenous phenytoin hypotension

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Established Status Epilepticus Treatment Trial (NCT01960075)

Adverse eventFosphenytoin (FOS) (n=125) · Valproic Acid (n=125) · Levetiracetam (n=150)
Hypotension7/1256/1254/150

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Ropinirole ↔ Hallucination

Open this assessment on its own page →

n=747 co-reports · PRR 13.8 · ROR 14.5

Ropinirole is a dopamine agonist for Parkinson's disease and restless legs; hallucinations and impulse-control disorders are class effects of dopamine agonists, and hallucinations carry 747 co-reports here (PRR 13.8). The risk rises with age, dose, and co-treatment with levodopa, and the label advises dose reduction or withdrawal if they occur.

Regulatory basis: ropinirole prescribing information — hallucinations and impulse-control disorders; dopamine-agonist class warning.

Bradford Hill viewpointStatusNote
Temporality (necessary)metHallucinations emerge after months
StrengthmetPRR 13.8, large
ConsistencymetReproduced across dopamine agonists
SpecificitypartialShared across the class
Biological gradientmetDose-related
PlausibilitymetExcess dopaminergic stimulation
CoherencemetFits the pharmacology
ExperimentmetTrials and registries support it
AnalogymetAnalogous to pramipexole hallucinations

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients (NCT01628926)

Adverse eventSPM 962 (n=168) · Ropinirole (n=167) · Placebo (n=85)
Hallucination Visual13/16810/1673/85
Hallucination3/1686/1670/85

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Pramipexole ↔ Hypersexuality

Open this assessment on its own page →

n=115 co-reports · PRR 92.0 · ROR 92.7

Pramipexole is a dopamine agonist whose stimulation of mesolimbic D3 receptors produces prominent impulse-control disorders — pathological gambling, hypersexuality, compulsive shopping and eating — with 115 hypersexuality co-reports here (PRR 92.0). These behaviours are a recognised class effect that the FDA required to be added to labelling, and they often improve on dose reduction or withdrawal.

Regulatory basis: pramipexole prescribing information — impulse-control disorders class warning; dopamine-agonist literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metEmerges after weeks to months
StrengthmetPRR 92.0, an extreme signal
ConsistencymetReproduced across dopamine agonists
SpecificitypartialShared across the class
Biological gradientmetDose-related
PlausibilitymetMesolimbic D3-receptor stimulation
CoherencemetFits the pharmacology
ExperimentmetReported in trials and registries
AnalogymetAnalogous to ropinirole impulse-control disorders

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for pramipexole captured hypersexuality as a tracked adverse event in a usable structure. Parkinson's-disease trials rarely captured compulsive behaviours as structured coded adverse events.
Causality: well established

Ketamine ↔ Cystitis

Open this assessment on its own page →

n=83 co-reports · PRR 11.3 · ROR 11.4

Ketamine is an NMDA-receptor antagonist used for anaesthesia and, increasingly, treatment-resistant depression; with chronic recreational use it causes profound ulcerative cystitis and urinary-tract damage (ketamine-induced cystitis, 83 co-reports here, PRR 11.3). The injury is dose- and duration-dependent, progressive, and can persist after cessation, sometimes requiring surgery.

Regulatory basis: ketamine prescribing information — urinary-tract effects with chronic use; ketamine-cystitis literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metCystitis after months of chronic use
StrengthmetPRR 11.3, moderate
ConsistencymetReproduced across case series
SpecificitymetFairly specific to ketamine
Biological gradientmetDose- and duration-dependent
PlausibilitymetDirect urothelial toxicity
CoherencemetFits the pharmacology
Experimentn/aNot a trial endpoint
AnalogymetAnalogous to other drug-induced cystitis

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression (NCT02493868)

Adverse eventIND: Intranasal Esketamine + Oral AD (n=437) · OP: Intranasal Esketamine + Oral AD (n=455) · MA: Intranasal Esketamine + Oral AD (n=152) · MA: Oral AD + Intranasal Placebo (n=145)
Cholecystitis Acute0/4371/4550/1520/145

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Contested: signal not confirmed by large randomized trials

Loperamide ↔ QT prolongation

Open this assessment on its own page →

n=274 co-reports · PRR 3.6 · ROR 3.6

Loperamide is an over-the-counter opioid-receptor agonist for diarrhoea; at high doses it blocks cardiac sodium and potassium channels, prolonging the QT interval and causing torsades de pointes (274 co-reports, PRR 3.6), which triggered an FDA warning. The QT signal is thus dose-dependent and confined to supratherapeutic abuse rather than normal use, so it does not represent a hazard at labelled doses.

Regulatory basis: loperamide labelling — FDA 2016 warning on cardiac arrhythmias with high doses; QT-prolongation literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metQT prolongation with high doses
StrengthmetPRR 3.6, modest
ConsistencymetReproduced across case series
SpecificitymetSpecific to high-dose use
Biological gradientmetDose-dependent
PlausibilitymetSodium/potassium-channel blockade
CoherencemetFits the pharmacology
Experimentn/aNot a trial endpoint
AnalogymetAnalogous to other QT-prolonging drugs

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — E7 TCR T Cells for Human Papillomavirus-Associated Cancers (NCT02858310)

Adverse eventPhase I:Dose Escalation Cohort; Arm 1:Phase I:DoseLevel 1: 1 x 10^9 E7 T-Cell Receptor (TCR) Cells (n=3) · Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 2: 1 x 10^10 E7 T-Cell Receptor Cells (n=3) · Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 3: 1 x 10^11 E7 Cells (n=6) · Phase II Cohort; Arm 2: Phase II: 1 x 10^11 E7 Cells (n=18)
Activated partial thromboplastin time prolonged0/30/30/61/18
Investigations - Other, specify: Prolonged QTcB interval (EKG)0/30/30/61/18

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Benztropine ↔ Dry mouth

Open this assessment on its own page →

n=89 co-reports · PRR 3.2 · ROR 3.2

Benztropine is an anticholinergic used for drug-induced parkinsonism; dry mouth, blurred vision, constipation, and urinary retention are direct consequences of muscarinic blockade (89 co-reports, PRR 3.2). The effects are dose-related and, in older patients, anticholinergic burden can cause confusion and falls, which is why use is minimised in the elderly.

Regulatory basis: benztropine prescribing information — anticholinergic adverse effects; caution in the elderly.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDry mouth follows dosing
StrengthmetPRR 3.2, modest
ConsistencymetUniversally reproduced
SpecificitymetSpecific to anticholinergic drugs
Biological gradientmetDose-related
PlausibilitymetMuscarinic-receptor blockade
CoherencemetFits the mechanism exactly
ExperimentmetWell described across the class
AnalogymetAnalogous to trihexyphenidyl effects

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Efficacy of Antidepressants in Chronic Back Pain (NCT00964886)

Adverse eventArm 1 (n=38) · Arm 2 (n=34) · Arm 3 (n=37) · Arm 4 (n=33)
dry mouth5/173/204/161/17

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Trihexyphenidyl ↔ Hallucination

Open this assessment on its own page →

n=36 co-reports · PRR 10.1 · ROR 10.5

Trihexyphenidyl is a centrally acting anticholinergic for parkinsonism; by blocking muscarinic receptors in the brain it causes confusion, hallucinations, and in overdose an anticholinergic delirium (36 co-reports, PRR 10.1). It is abused recreationally for its euphoric effects, which further increases the risk of psychosis.

Regulatory basis: trihexyphenidyl prescribing information — anticholinergic CNS effects; caution in the elderly.

Bradford Hill viewpointStatusNote
Temporality (necessary)metPsychosis emerges with dosing or overdose
StrengthmetPRR 10.1, large
ConsistencymetReproduced across anticholinergics
SpecificitypartialShared across the class
Biological gradientmetDose-related
PlausibilitymetCentral muscarinic blockade
CoherencemetFits the mechanism
ExperimentmetCase series support it
AnalogymetAnalogous to benztropine CNS effects

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for trihexyphenidyl-hydrochloride captured hallucination as a tracked adverse event in a usable structure. Anticholinergic trials reported CNS effects among general adverse events rather than as clean per-arm table entries.
Expected pharmacological effect

Varenicline ↔ Nausea

Open this assessment on its own page →

n=582 co-reports · PRR 2.6 · ROR 2.7

Varenicline is a partial nicotinic-acetylcholine-receptor agonist for smoking cessation; nausea is its commonest adverse effect (582 co-reports, PRR 2.6), accompanied by insomnia, abnormal dreams, and headache. Neuropsychiatric events led to an FDA boxed warning (later removed in 2016 after the EAGLES trial), but the gastrointestinal effects remain the typical, mechanism-related burden.

Regulatory basis: varenicline (Chantix) prescribing information — nausea; neuropsychiatric warning removed 2016 after EAGLES.

Bradford Hill viewpointStatusNote
Temporality (necessary)metNausea within days
StrengthmetPRR 2.6, modest
ConsistencymetConsistent across trials
SpecificitymetFairly specific to nicotinic agonists
Biological gradientmetDose-related
PlausibilitymetNicotinic-receptor stimulation in the gut
CoherencemetFits the pharmacology
ExperimentmetTrials consistently reported it
AnalogymetAnalogous to nicotine-related nausea

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Varenicline and Bupropion for Alcohol Use Disorder (NCT04167306)

Adverse event2) Varenicline + Placebo for Bupropion (n=96) · 1) Varenicline + Bupropion (n=101) · 3) Bupropion + Placebo for Varenicline (n=91) · 4) Placebo for Varenicline + Placebo for Bupropion (n=97)
nausea61/9638/10112/9111/97

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Naltrexone ↔ Drug withdrawal syndrome

Open this assessment on its own page →

n=595 co-reports · PRR 9.8 · ROR 9.9

Naltrexone is an opioid-receptor antagonist; in opioid-dependent patients it precipitates an acute, severe withdrawal syndrome if given before the patient is fully detoxified (595 co-reports, PRR 9.8), with agitation, abdominal cramps, vomiting, and piloerection. The label requires a period of abstinence (commonly 7–10 days) before the first dose to avoid triggering this reaction.

Regulatory basis: naltrexone prescribing information — precipitation of opioid withdrawal; required abstinence period.

Bradford Hill viewpointStatusNote
Temporality (necessary)metImmediate withdrawal on dosing
StrengthmetPRR 9.8, large
ConsistencymetReproduced across clinical experience
SpecificitymetSpecific to opioid-dependent patients
Biological gradientmetRelated to opioid load
PlausibilitymetDirect opioid-receptor blockade mechanism
CoherencemetFits the mechanism exactly
ExperimentmetClinical studies confirm it
AnalogymetAnalogous to naloxone-precipitated withdrawal

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults (NCT01218958)

Adverse eventMedisorb Naltrexone 190 mg (n=210) · Medisorb Naltrexone 380 mg (n=205) · Placebo Groups (Pooled) (n=209)
Alcohol withdrawal syndrome1/2100/2050/209

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Disulfiram ↔ Drug-induced liver injury

Open this assessment on its own page →

n=40 co-reports · PRR 24.2 · ROR 25.1

Disulfiram is used to support abstinence from alcohol by inhibiting aldehyde dehydrogenase and sensitising the patient to alcohol; it is also a recognised cause of idiosyncratic drug-induced liver injury, which carries 40 co-reports here (PRR 24.2). The injury ranges from transaminase elevation to fulminant hepatic failure, appears within weeks to months, and is why the label advises baseline and periodic liver monitoring and avoidance in pre-existing liver disease.

Regulatory basis: disulfiram prescribing information — hepatotoxicity warning; periodic liver monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOnset typically weeks into therapy
StrengthmetPRR 24.2, large
ConsistencymetReproduced across case series
Specificitynot establishedCannot be distinguished from other DILI clinically
Biological gradientnot establishedNot clearly dose-related (idiosyncratic)
PlausibilitymetIdiosyncratic drug-reaction mechanism
CoherencemetFits the DILI pattern
Experimentn/aNo trial-sized experiment possible
AnalogymetAnalogous to other idiosyncratic hepatotoxins

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma (NCT03034135)

Adverse eventGroup A (n=23)
Hepatobiliary disorders1/23

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Phentermine ↔ Tachycardia

Open this assessment on its own page →

n=21 co-reports · PRR 4.9 · ROR 4.9

Phentermine is a sympathomimetic appetite suppressant; by raising noradrenaline it increases heart rate and blood pressure, so tachycardia and palpitations are expected effects (21 co-reports, PRR 4.9). It is a Schedule IV controlled substance with a labelled warning about use in cardiovascular disease, and it is generally limited to short-term use.

Regulatory basis: phentermine prescribing information — tachycardia/palpitations; cardiovascular warnings.

Bradford Hill viewpointStatusNote
Temporality (necessary)metTachycardia follows dosing
StrengthmetPRR 4.9, modest
ConsistencymetConsistent across amphetamine-like drugs
SpecificitypartialShared with sympathomimetics
Biological gradientmetDose-related
PlausibilitymetSympathomimetic stimulation
CoherencemetFits the mechanism
ExperimentmetTrials measured heart-rate change
AnalogymetAnalogous to other sympathomimetic tachycardia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity (NCT03799198)

Adverse eventWeight Management Program (WMP) + Rx (n=100) · Weight Management Program (WMP) (n=100)
Atrial Tachycardia0/1001/100

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Semaglutide ↔ Impaired gastric emptying

Open this assessment on its own page →

n=3,558 co-reports · PRR 111.3 · ROR 117.0

Semaglutide is a GLP-1 receptor agonist; by slowing gastric emptying it can cause nausea, vomiting, and, in some patients, gastroparesis-like symptoms severe enough to risk aspiration during anaesthesia (impaired gastric emptying 3,558 co-reports, PRR 111.3). The label advises caution, and anaesthesia societies recommend holding GLP-1 agonists before surgery.

Regulatory basis: semaglutide (Ozempic/Wegovy) prescribing information — nausea/vomiting and delayed gastric emptying; anaesthesia guidance.

Bradford Hill viewpointStatusNote
Temporality (necessary)metSlowed emptying with therapy
StrengthmetPRR 111.3, an extreme signal
ConsistencymetConsistent across GLP-1 agonists
SpecificitypartialShared across the class
Biological gradientmetDose-related
PlausibilitymetGLP-1-mediated delay in gastric emptying
CoherencemetFits the mechanism
ExperimentmetTrials measured gastric emptying
AnalogymetAnalogous to liraglutide effects

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes (NCT03914326)

Adverse eventOral Semaglutide (n=4825) · Placebo (n=4825)
Impaired gastric emptying3/48250/4825

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Liraglutide ↔ Impaired gastric emptying

Open this assessment on its own page →

n=592 co-reports · PRR 20.7 · ROR 21.0

Liraglutide is a GLP-1 receptor agonist; delayed gastric emptying underlies its nausea and vomiting and can produce gastroparesis-like symptoms (592 co-reports, PRR 20.7). As with semaglutide, the effect is intrinsic to class pharmacology and has prompted guidance to hold the drug before procedures requiring an empty stomach.

Regulatory basis: liraglutide (Victoza/Saxenda) prescribing information — nausea/vomiting and delayed gastric emptying.

Bradford Hill viewpointStatusNote
Temporality (necessary)metSlowed emptying with therapy
StrengthmetPRR 20.7, large
ConsistencymetConsistent across GLP-1 agonists
SpecificitypartialShared across the class
Biological gradientmetDose-related
PlausibilitymetGLP-1-mediated delay in gastric emptying
CoherencemetFits the mechanism
ExperimentmetTrials measured gastric emptying
AnalogymetAnalogous to semaglutide effects

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for liraglutide captured impaired gastric emptying as a tracked adverse event in a usable structure. Diabetes and weight-management trials measured gastric emptying as a pharmacodynamic measure rather than reporting gastroparesis as a coded event.
Causality: well established

Metformin ↔ Vitamin B12 deficiency

Open this assessment on its own page →

n=630 co-reports · PRR 10.8 · ROR 10.8

Metformin is a first-line antidiabetic; over years of treatment it reduces ileal absorption of vitamin B12 and can lower serum levels, so vitamin B12 deficiency appears here as 630 co-reports (PRR 10.8). Deficiency develops insidiously and may present as anaemia or peripheral neuropathy, and the label advises periodic B12 monitoring in patients on long-term therapy, particularly with other risk factors.

Regulatory basis: metformin prescribing information — vitamin B12 deficiency with long-term use; periodic monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDeficiency after months to years
StrengthmetPRR 10.8, large
ConsistencymetReproduced across cohorts
SpecificitypartialShared with other biguanides
Biological gradientmetDose- and duration-related
PlausibilitymetImpaired ileal B12 absorption
CoherencemetFits the mechanism
ExperimentmetTrials recorded falls in B12 levels
AnalogymetAnalogous to other drug-induced B12 deficiency

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for metformin captured vitamin b12 deficiency as a tracked adverse event in a usable structure. Vitamin B12 deficiency develops slowly and is often subclinical, so short-term trials captured falls in B12 levels rather than clinical deficiency as a coded event.
Contested: signal not confirmed by large randomized trials

Canagliflozin ↔ Amputation

Open this assessment on its own page →

n=2,195 co-reports · PRR 535.9 · ROR 578.5

Canagliflozin is an SGLT2 inhibitor; in the CANVAS trial it was associated with an increased risk of lower-limb amputation, predominantly toe and mid-foot, prompting a boxed warning (2,195 co-reports here, PRR 535.9). The biological mechanism is uncertain and the finding was not clearly replicated across other SGLT2-inhibitor trials, so the label advises caution in patients at high amputation risk rather than attributing a proven causal mechanism.

Regulatory basis: canagliflozin (Invokana) prescribing information — boxed warning for lower-limb amputation; CANVAS trial.

Bradford Hill viewpointStatusNote
Temporality (necessary)metAmputations occurred on treatment
StrengthmetPRR 535.9, an extreme signal
ConsistencypartialSignal seen mainly in CANVAS
SpecificitypartialConcentrated in at-risk patients
Biological gradientnot establishedMechanism uncertain
PlausibilitypartialBiologically debated, not established
Coherencenot establishedNot consistently found across the class
ExperimentmetCANVAS trial showed the imbalance
AnalogypartialLimited analogy to other SGLT2 inhibitors

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for canagliflozin captured amputation as a tracked adverse event in a usable structure. Amputation was captured as a serious adverse event in CANVAS, but other SGLT2-inhibitor trials used different reporting structures.
Causality: well established

Empagliflozin ↔ Necrotising fasciitis (Fournier's gangrene)

Open this assessment on its own page →

n=251 co-reports · PRR 24.0 · ROR 24.1

Empagliflozin is an SGLT2 inhibitor; heavy glycosuria and impaired host defence make perineal necrotising fasciitis (Fournier's gangrene) a rare but life-threatening complication, carried here as 251 co-reports (PRR 24.0). The label carries a warning for necrotising fasciitis of the perineum and advises urgent treatment; the reaction is strongly disproportionate even though it is rare in absolute terms.

Regulatory basis: empagliflozin (Jardiance) prescribing information — warning for necrotising fasciitis of the perineum (Fournier's gangrene).

Bradford Hill viewpointStatusNote
Temporality (necessary)metOnset within days to weeks
StrengthmetPRR 24.0, large
ConsistencymetReproduced across SGLT2 inhibitors
SpecificitypartialShared across the class
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetGlycosuria and impaired host defence
CoherencemetFits the mechanism
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to other SGLT2-inhibitor Fournier's gangrene

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for empagliflozin captured necrotising fasciitis (fournier's gangrene) as a tracked adverse event in a usable structure. Perineal necrotising fasciitis is very rare, so the diabetes outcome trials did not capture it as a coded event.
Expected pharmacological effect

Dapagliflozin ↔ Genital infection

Open this assessment on its own page →

n=130 co-reports · PRR 5.3 · ROR 5.3

Dapagliflozin is an SGLT2 inhibitor that increases urinary glucose, creating a favourable environment for genital mycotic infections and, less often, urinary infections (candida infection 130 co-reports here, PRR 5.3). The effect is dose- and glycosuria-related, typically mild, and managed with hygiene measures and topical antifungals.

Regulatory basis: dapagliflozin (Farxiga) prescribing information — genital mycotic infections.

Bradford Hill viewpointStatusNote
Temporality (necessary)metInfection appears within weeks
StrengthmetPRR 5.3, modest
ConsistencymetConsistent across SGLT2 inhibitors
SpecificitypartialShared across the class
Biological gradientmetWorse with higher glycosuria
PlausibilitymetGlucose-rich environment favouring fungi
CoherencemetFits the mechanism
ExperimentmetTrials recorded genital infections
AnalogymetAnalogous to other SGLT2-inhibitor infections

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Phase 2b Diabetic Kidney Disease Study (NCT04170543)

Adverse eventPlacebo (n=133) · MEDI3506 30 mg (n=95) · MEDI3506 60 mg (n=89) · MEDI3506 120 mg (n=93)
Candida infection0/1330/950/891/93
Genital infection fungal1/1330/950/890/93
Oesophageal candidiasis1/1330/950/890/93

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Quinine ↔ Thrombocytopenia

Open this assessment on its own page →

n=172 co-reports · PRR 3.8 · ROR 3.9

Quinine is an antimalarial and muscle-cramp remedy; it can trigger immune thrombocytopenia through drug-dependent platelet antibodies, appearing here as 172 co-reports (PRR 3.8). The reaction can be severe and recur rapidly on re-exposure, so the label warns of thrombocytopenia and advises stopping the drug if it occurs.

Regulatory basis: quinine prescribing information — immune thrombocytopenia warning.

Bradford Hill viewpointStatusNote
Temporality (necessary)metPlatelet fall within days of exposure
StrengthmetPRR 3.8, modest
ConsistencymetReproduced across case series
SpecificitymetHighly specific to quinine
Biological gradientnot establishedNot dose-related (immune)
PlausibilitymetDrug-dependent platelet antibodies
CoherencemetFits the mechanism
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to other drug-induced immune thrombocytopenia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for quinine captured thrombocytopenia as a tracked adverse event in a usable structure. Quinine-induced thrombocytopenia is rare and idiosyncratic, so malaria and cramp trials did not capture it as a coded event.
Expected pharmacological effect

Pioglitazone ↔ Oedema peripheral

Open this assessment on its own page →

n=1,008 co-reports · PRR 4.0 · ROR 4.1

Pioglitazone is a thiazolidinedione that causes fluid retention by activating PPAR-gamma in the kidney and vasculature, producing peripheral oedema and sometimes unmasking or worsening heart failure; peripheral oedema carries 1,008 co-reports here (PRR 4.0). The effect is dose-related and greatest when the drug is combined with insulin, and the label warns against use in symptomatic heart failure.

Regulatory basis: pioglitazone prescribing information — peripheral oedema and heart-failure warning; combination with insulin.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOedema appears over weeks
StrengthmetPRR 4.0, modest
ConsistencymetReproduced across trials
SpecificitymetSpecific to thiazolidinediones
Biological gradientmetDose-related
PlausibilitymetPPAR-gamma-mediated fluid retention
CoherencemetFits the mechanism
ExperimentmetTrials recorded oedema
AnalogymetAnalogous to rosiglitazone oedema

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus. (NCT00727857)

Adverse eventPioglitazone 15 mg/Metformin 850 mg BID (n=201) · Pioglitazone 15 mg BID (n=190) · Metformin 850 mg BID (n=209)
Oedema Peripheral6/2018/1903/209

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Acarbose ↔ Gastrointestinal disorder

Open this assessment on its own page →

n=68 co-reports · PRR 4.2 · ROR 4.3

Acarbose is an alpha-glucosidase inhibitor; by delaying carbohydrate absorption it leaves undigested sugar to be fermented by colonic bacteria, producing flatulence, bloating, and diarrhoea — coded here as gastrointestinal disorder in 68 co-reports (PRR 4.2). The effects are dose-related, generally transient as the gut adapts, and minimised by starting at a low dose and titrating slowly.

Regulatory basis: acarbose prescribing information — flatulence, diarrhoea, and gastrointestinal effects.

Bradford Hill viewpointStatusNote
Temporality (necessary)metGI symptoms follow dosing
StrengthmetPRR 4.2, modest
ConsistencymetUniversally reproduced
SpecificitymetSpecific to alpha-glucosidase inhibition
Biological gradientmetDose-related
PlausibilitymetColonic fermentation of unabsorbed carbohydrate
CoherencemetFits the mechanism exactly
ExperimentmetTrials consistently reported it
AnalogymetAnalogous to other alpha-glucosidase inhibitors

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for acarbose captured gastrointestinal disorder as a tracked adverse event in a usable structure. Trials reported flatulence and diarrhoea among general adverse events, coded here as a broader gastrointestinal disorder rather than a specific per-arm term.
Causality: well established

Linagliptin ↔ Pancreatitis

Open this assessment on its own page →

n=331 co-reports · PRR 7.3 · ROR 7.4

Linagliptin is a DPP-4 inhibitor; acute pancreatitis is a labelled, if uncommon, risk (331 co-reports, PRR 7.3), and the label advises discontinuation if pancreatitis is suspected. The signal sits within the wider debate about incretin-based therapies and pancreatitis, where trial data have not consistently confirmed an excess.

Regulatory basis: linagliptin (Tradjenta) prescribing information — acute pancreatitis warning.

Bradford Hill viewpointStatusNote
Temporality (necessary)partialLatency of days to months is plausible
StrengthmetPRR 7.3, moderate
ConsistencypartialReported across DPP-4 inhibitors
Specificitynot establishedCannot exclude cholelithiasis or alcohol
Biological gradientnot establishedNo established dose relationship
PlausibilitypartialBiologically debated
Coherencenot establishedMeta-analyses are inconclusive
Experimentn/aRare in trials
AnalogypartialDebated analogy across incretin drugs

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA) (NCT01897532)

Adverse eventPlacebo (n=3485) · Linagliptin (n=3494)
Pancreatitis acute3/34857/3494
Pancreatitis3/34856/3494
Pancreatitis chronic6/34852/3494

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Exenatide ↔ Pancreatitis

Open this assessment on its own page →

n=2,012 co-reports · PRR 15.8 · ROR 16.4

Exenatide is a GLP-1 receptor agonist; pancreatitis is a labelled risk (2,012 co-reports, PRR 15.8), and post-marketing reports prompted an FDA warning and label change. Whether the drug truly increases pancreatitis, or the excess reflects the underlying diabetes, obesity, and gallstone disease of the treated population, remains debated.

Regulatory basis: exenatide (Byetta) prescribing information — acute pancreatitis warning; FDA safety communications.

Bradford Hill viewpointStatusNote
Temporality (necessary)partialLatency of weeks to months is plausible
StrengthmetPRR 15.8, large
ConsistencypartialReported across GLP-1 agonists
Specificitynot establishedCannot exclude cholelithiasis or alcohol
Biological gradientnot establishedNo established dose relationship
PlausibilitypartialBiologically debated
Coherencenot establishedMeta-analyses are inconclusive
Experimentn/aRare in trials
AnalogypartialDebated analogy across incretin drugs

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes (NCT01652716)

Adverse eventExperimental: Exenatide QWS Suspension (n=229) · Active Comparator: Exenatide BID (n=146)
Pancreatitis2/2290/146

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Cabergoline ↔ Pleural effusion

Open this assessment on its own page →

n=77 co-reports · PRR 5.5 · ROR 5.6

Cabergoline is an ergot dopamine agonist used for hyperprolactinaemia and Parkinson's disease; like other ergots it can cause fibrotic reactions, and pleural effusion appears here as 77 co-reports (PRR 5.5). Risk is greatest with prolonged high-dose therapy, and the label advises periodic echocardiography and monitoring for pleuropulmonary changes.

Regulatory basis: cabergoline prescribing information — fibrotic reactions (pleuropulmonary, pericardial, retroperitoneal); monitoring guidance.

Bradford Hill viewpointStatusNote
Temporality (necessary)metEffusion after months of therapy
StrengthmetPRR 5.5, modest
ConsistencymetReproduced across case series
SpecificitypartialShared across ergot agonists
Biological gradientmetHigher with higher cumulative dose
PlausibilitymetSerotonin-mediated fibroblast proliferation
CoherencemetFits the mechanism
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to pergolide fibrotic reactions

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for cabergoline captured pleural effusion as a tracked adverse event in a usable structure. Pleural effusion develops slowly and is uncommon, so the trials that studied cabergoline did not capture it as a coded event.
Contested: signal not confirmed by large randomized trials

Sitagliptin ↔ Pancreatic cancer

Open this assessment on its own page →

n=1,670 co-reports · PRR 17.8 · ROR 18.2

Sitagliptin is a DPP-4 inhibitor; an excess of pancreatic cancer was reported in early analyses of incretin-based therapies and appears here as 1,670 pancreatic-carcinoma co-reports (PRR 17.8), but the signal is weak and consistently disappears once the underlying diabetes, obesity, and smoking are taken into account, so causality remains unproven.

Regulatory basis: sitagliptin (Januvia) prescribing information — pancreatic-cancer reviews by FDA/EMA; no confirmed causal link.

Bradford Hill viewpointStatusNote
Temporality (necessary)partialLatency of years is plausible
StrengthmetPRR 17.8, large
Consistencynot establishedNot consistently reproduced
Specificitynot establishedCannot exclude confounding by diabetes
Biological gradientnot establishedNo clear dose relationship
PlausibilitypartialBiologically debated
Coherencenot establishedRandomised outcome trials are negative
Experimentnot establishedPooled analyses do not confirm it
AnalogypartialDebated analogy across incretin drugs

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for sitagliptin captured pancreatic cancer as a tracked adverse event in a usable structure. Pancreatic cancer has a long latency and low incidence, so the diabetes outcome trials could not detect it.
Causality: well established

Meperidine ↔ Convulsion

Open this assessment on its own page →

n=77 co-reports · PRR 3.0 · ROR 3.1

Meperidine is an opioid analgesic; its metabolite normeperidine accumulates, especially in renal impairment or with repeated dosing, and is a central nervous system excitant that causes tremor, myoclonus, and seizures (77 co-reports, PRR 3.0). This distinctive neurotoxicity is why meperidine is avoided in renal failure and in patients taking MAOIs.

Regulatory basis: meperidine prescribing information — normeperidine neurotoxicity/seizures; contraindicated with MAOIs.

Bradford Hill viewpointStatusNote
Temporality (necessary)metSeizures with drug accumulation
StrengthmetPRR 3.0, modest
ConsistencymetReproduced across case series
SpecificitymetFairly specific to meperidine
Biological gradientmetWorse with higher doses or renal impairment
PlausibilitymetNormeperidine CNS excitation
CoherencemetFits the pharmacology
Experimentn/aNot a trial endpoint
AnalogymetAnalogous to other metabolite-driven neurotoxicity

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — E7 TCR T Cells for Human Papillomavirus-Associated Cancers (NCT02858310)

Adverse eventPhase I:Dose Escalation Cohort; Arm 1:Phase I:DoseLevel 1: 1 x 10^9 E7 T-Cell Receptor (TCR) Cells (n=3) · Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 2: 1 x 10^10 E7 T-Cell Receptor Cells (n=3) · Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 3: 1 x 10^11 E7 Cells (n=6) · Phase II Cohort; Arm 2: Phase II: 1 x 10^11 E7 Cells (n=18)
Seizure0/30/30/61/18

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Hydromorphone ↔ Drug dependence

Open this assessment on its own page →

n=35,112 co-reports · PRR 63.1 · ROR 101.7

Hydromorphone is a potent mu-opioid agonist; tolerance, physical dependence, and addiction are intrinsic to chronic opioid exposure, and drug dependence carries 35,112 co-reports here (PRR 63.1). The risk is amplified with high doses, long duration, and pre-existing substance-use disorder, which is why opioid-prescribing guidelines emphasise cautious initiation and tapering.

Regulatory basis: hydromorphone prescribing information — dependence/abuse; opioid class boxed warning.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDependence develops with chronic use
StrengthmetPRR 63.1, very large
ConsistencymetUniversally reproduced
SpecificitymetShared across all mu-opioids
Biological gradientmetRises with dose and duration
PlausibilitymetMu-opioid-receptor adaptation
CoherencemetFits the mechanism exactly
ExperimentmetLong-term studies support it
AnalogymetDirect class analogy to other opioids

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Single-arm Study to Assess the Safety of Hydromorphone Hydrochloride by Intrathecal Administration (NCT01709747)

Adverse eventHydromorphone Hydrochloride (n=364)
Drug Withdrawal Syndrome1/364

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Perampanel ↔ Aggression

Open this assessment on its own page →

n=499 co-reports · PRR 28.0 · ROR 29.9

Perampanel is a non-competitive AMPA-receptor antagonist for focal epilepsy; aggression, irritability, and hostility are labelled psychiatric effects and appear here as 499 co-reports (PRR 28.0). The reactions cluster in the first weeks of treatment and are dose-related, so the label advises slow titration and monitoring for behavioural change, especially in patients with a psychiatric history.

Regulatory basis: perampanel (Fycompa) prescribing information — aggression, hostility, and irritability warnings; titration guidance.

Bradford Hill viewpointStatusNote
Temporality (necessary)metBehaviour change within weeks
StrengthmetPRR 28.0, large
ConsistencymetReproduced across trials
SpecificitymetFairly specific to perampanel
Biological gradientmetDose-related
PlausibilitymetAMPA-receptor blockade in limbic circuits
CoherencemetFits the pharmacology
ExperimentmetTrials recorded aggression
AnalogymetAnalogous to other AED behavioural effects

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures (NCT01618695)

Adverse eventCore Phase: Placebo (n=176) · Core Phase: Perampanel 4 mg (n=176) · Core Phase: Perampanel 8 mg (n=175) · Core Phase: Perampanel 12 mg (n=180)
Aggression0/1760/1760/1752/180

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Brivaracetam ↔ Aggression

Open this assessment on its own page →

n=297 co-reports · PRR 14.0 · ROR 14.4

Brivaracetam is a second-generation synaptic-vesicle-protein-2A ligand for epilepsy; aggression and irritability are recognised psychiatric effects and appear here as 297 co-reports (PRR 14.0). The reactions are typically early and can be dose-related, so the label advises monitoring for mood and behavioural changes, particularly in patients with a psychiatric history.

Regulatory basis: brivaracetam (Briviact) prescribing information — psychiatric reactions including aggression and irritability.

Bradford Hill viewpointStatusNote
Temporality (necessary)metBehaviour change within weeks
StrengthmetPRR 14.0, large
ConsistencymetReproduced across trials
SpecificitymetFairly specific to brivaracetam
Biological gradientmetDose-related
PlausibilitymetSV2A-mediated CNS effect
CoherencemetFits the pharmacology
ExperimentmetTrials recorded psychiatric events
AnalogymetAnalogous to other AED behavioural effects

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy (NCT00175916)

Adverse eventBrivaracetam (SS) (n=853)
Aggression3/853

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Tramadol ↔ Serotonin syndrome

Open this assessment on its own page →

n=624 co-reports · PRR 18.9 · ROR 19.2

Tramadol is a weak mu-opioid agonist that also inhibits serotonin and noradrenaline reuptake; excess serotonergic activity can produce serotonin syndrome — agitation, clonus, hyperthermia, and autonomic instability — carried here as 624 co-reports (PRR 18.9). Risk is greatest when tramadol is combined with SSRIs, SNRIs, MAOIs, or other serotonergic drugs, and the label warns of this interaction.

Regulatory basis: tramadol prescribing information — serotonin-syndrome interaction warning with serotonergic drugs.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOnset within hours to days
StrengthmetPRR 18.9, large
ConsistencymetReproduced across case series
SpecificitymetFairly specific to serotonergic drugs
Biological gradientmetWorse with higher doses
PlausibilitymetExcess synaptic serotonin
CoherencemetFits the mechanism
Experimentn/aNot a trial endpoint
AnalogymetAnalogous to other serotonergic drugs

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for tramadol captured serotonin syndrome as a tracked adverse event in a usable structure. Serotonin syndrome is an interaction-driven event and is not captured as a coded adverse event in analgesic trials.
Causality: well established

Isoniazid ↔ Peripheral neuropathy

Open this assessment on its own page →

n=227 co-reports · PRR 3.1 · ROR 3.2

Isoniazid is a first-line antituberculosis drug; by competing with pyridoxine it causes a dose-related peripheral neuropathy, which appears here as 227 co-reports (PRR 3.1). Risk rises with malnutrition, diabetes, alcohol use, and slow acetylator status, and the label advises pyridoxine supplementation to prevent it.

Regulatory basis: isoniazid prescribing information — peripheral neuropathy and pyridoxine supplementation.

Bradford Hill viewpointStatusNote
Temporality (necessary)metNeuropathy after weeks of therapy
StrengthmetPRR 3.1, modest
ConsistencymetReproduced across case series
SpecificitymetFairly specific to isoniazid
Biological gradientmetDose-related
PlausibilitymetPyridoxine antagonism
CoherencemetFits the mechanism
ExperimentmetTrials recorded neuropathy
AnalogymetAnalogous to other pyridoxine-antagonist drugs

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Shortening Treatment by Advancing Novel Drugs (NCT02342886)

Adverse eventDS-TB: 4 Months Moxifloxacin + PA-824 (100 mg) + Pyrazinamide (n=65) · DS-TB: 4 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide (n=71) · DS-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide (n=67) · DS-TB: 2 Months HRZE/ 4 Months HR (n=68)
Neuropathy peripheral1/650/712/674/68

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Pyrazinamide ↔ Drug-induced liver injury

Open this assessment on its own page →

n=655 co-reports · PRR 48.7 · ROR 52.3

Pyrazinamide is a first-line antituberculosis drug and the most hepatotoxic of the standard regimen; drug-induced liver injury appears at 655 co-reports here (PRR 48.7), and its use is limited by that risk. Hyperuricaemia and gout are also common because the drug raises urate, and the label advises monitoring liver enzymes, especially when combined with isoniazid and rifampicin.

Regulatory basis: pyrazinamide prescribing information — hepatotoxicity; hyperuricaemia; monitoring during combination therapy.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOnset within weeks
StrengthmetPRR 48.7, large
ConsistencymetReproduced across case series
SpecificitymetFairly specific within the regimen
Biological gradientmetDose-related
PlausibilitymetMetabolite-driven hepatocellular injury
CoherencemetFits the DILI picture
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to isoniazid hepatotoxicity

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (NCT00042289)

Adverse eventABC 300mg b.i.d. MOTHER (n=26) · ATV/COBI 300/150 mg q.d. INFANT (n=12) · ATV/COBI 300/150 mg q.d. MOTHER (n=12) · ATV/RTV 300/100mg q.d. INFANT (n=22)
Drug-induced liver injury0/260/120/120/22
Hepatitis0/260/120/120/22
Hepatitis fulminant0/260/120/120/22

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Rifampicin ↔ Drug-induced liver injury

Open this assessment on its own page →

n=346 co-reports · PRR 16.4 · ROR 16.8

Rifampicin is a first-line antituberculosis drug; drug-induced liver injury carries 346 co-reports here (PRR 16.4), usually in combination with isoniazid, and the drug also causes a flu-like syndrome and thrombocytopenia with intermittent dosing. Because it induces hepatic enzymes, it lowers levels of many co-administered drugs and requires monitoring during treatment.

Regulatory basis: rifampicin prescribing information — hepatotoxicity; CYP induction; intermittent-dosing reactions.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOnset within weeks
StrengthmetPRR 16.4, large
ConsistencymetReproduced across case series
SpecificitymetFairly specific within the regimen
Biological gradientpartialWorse in combination with isoniazid
PlausibilitymetMetabolite-driven hepatocellular injury
CoherencemetFits the DILI picture
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to isoniazid hepatotoxicity

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Assessing PA-824 for Tuberculosis (the APT Trial) (NCT02256696)

Adverse eventArm 1 (n=56) · Arm 2 (n=53) · Arm 3 (n=48)
Increased liver enzymes0/563/530/48
Drug induced liver injury1/561/530/48

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Valacyclovir ↔ Acute kidney injury

Open this assessment on its own page →

n=1,170 co-reports · PRR 3.9 · ROR 4.0

Valacyclovir is a prodrug of aciclovir; crystalluria and acute kidney injury occur when high doses are given with inadequate hydration or in renal impairment, and acute kidney injury carries 1,170 co-reports here (PRR 3.9). The label advises adequate fluid intake and dose reduction in renal impairment, and the injury usually reverses with hydration and drug withdrawal.

Regulatory basis: valacyclovir prescribing information — acute kidney injury; hydration and renal dose adjustment.

Bradford Hill viewpointStatusNote
Temporality (necessary)metRenal injury within days
StrengthmetPRR 3.9, modest
ConsistencymetConsistent across aciclovir series
SpecificitypartialShared with aciclovir
Biological gradientmetWorse with high doses and dehydration
PlausibilitymetCrystal nephropathy from drug precipitation
CoherencemetFits the mechanism
Experimentn/aNot a trial endpoint
AnalogymetAnalogous to aciclovir nephrotoxicity

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir (NCT00031486)

Adverse eventValacyclovir (n=40) · Placebo (n=47)
Renal failure acute1/400/47
Creatinine renal clearance decreased1/400/47

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Dapsone ↔ DRESS syndrome (eosinophilia)

Open this assessment on its own page →

n=354 co-reports · PRR 27.7 · ROR 28.7

Dapsone is an antimicrobial used in leprosy, dermatitis herpetiformis, and Pneumocystis prophylaxis; the dapsone hypersensitivity syndrome — a drug reaction with eosinophilia and systemic symptoms (DRESS) of fever, rash, eosinophilia, and internal-organ involvement — appears here as 354 co-reports (PRR 27.7). It typically begins weeks after starting therapy and can be fatal, so the label advises stopping the drug and urgent assessment if it is suspected.

Regulatory basis: dapsone prescribing information — dapsone hypersensitivity syndrome/DRESS; monitoring for fever, rash, and eosinophilia.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOnset weeks after starting
StrengthmetPRR 27.7, large
ConsistencymetReproduced across case series
SpecificitymetFairly specific to dapsone
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetIdiosyncratic immuno-allergic reaction
CoherencemetFits the DRESS picture
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to other drug-induced DRESS

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for dapsone captured dress syndrome (eosinophilia) as a tracked adverse event in a usable structure. DRESS is rare and idiosyncratic, so treatment trials did not capture it as a coded event.
Causality: well established

Benzocaine ↔ Methaemoglobinaemia

Open this assessment on its own page →

n=35 co-reports · PRR 46.5 · ROR 48.2

Benzocaine is a topical anaesthetic; its metabolite oxidises haemoglobin, and methaemoglobinaemia (reported here as cyanosis, 35 co-reports, PRR 46.5) is a rare but potentially fatal effect, most often with sprays used for procedures in children. The FDA issued a warning specifically about benzocaine sprays in infants, and the reaction is dose- and patient-related.

Regulatory basis: benzocaine labelling — FDA warning on methaemoglobinaemia with benzocaine sprays; oxidant-haemolysis literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOnset within an hour
StrengthmetPRR 46.5, very large
ConsistencymetReproduced across case reports
SpecificitymetHighly specific to oxidant anaesthetics
Biological gradientmetDose-related
PlausibilitymetOxidative haemoglobin modification
CoherencemetFits the mechanism
Experimentn/aNot a trial endpoint
AnalogymetAnalogous to prilocaine methaemoglobinaemia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for benzocaine captured methaemoglobinaemia as a tracked adverse event in a usable structure. Methaemoglobinaemia is rare and typically procedure-related, so trials did not report it as a coded event.
Expected pharmacological effect

Linezolid ↔ Lactic acidosis

Open this assessment on its own page →

n=1,018 co-reports · PRR 23.2 · ROR 24.0

Linezolid is an oxazolidinone antibiotic; by inhibiting mitochondrial protein synthesis it can cause lactic acidosis, which appears here as 1,018 co-reports (PRR 23.2) and is more common with courses longer than two weeks. The effect is dose- and duration-related and usually reverses on withdrawal, and the label advises monitoring for recurrent nausea, acidosis, and low bicarbonate during prolonged therapy.

Regulatory basis: linezolid (Zyvox) prescribing information — lactic acidosis with prolonged use; monitoring guidance.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOnset after 1–2 weeks
StrengthmetPRR 23.2, large
ConsistencymetReproduced across case series
SpecificitymetFairly specific to linezolid
Biological gradientmetDose- and duration-related
PlausibilitymetMitochondrial protein-synthesis inhibition
CoherencemetFits the mechanism
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to other mitochondrial-toxin lactic acidosis

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for linezolid captured lactic acidosis as a tracked adverse event in a usable structure. Lactic acidosis is uncommon and tied to prolonged courses, so short-course trials did not capture it as a coded event.
Causality: well established

Ivermectin ↔ Neurotoxicity

Open this assessment on its own page →

n=246 co-reports · PRR 17.3 · ROR 17.9

Ivermectin is an antiparasitic used for onchocerciasis, strongyloidiasis, and scabies; neurotoxicity — drowsiness, confusion, ataxia, and in heavy infection a post-treatment encephalopathy — reflects massive release of parasite antigen or drug crossing a damaged blood-brain barrier, and coma carries 246 co-reports here (PRR 17.3). Risk is greater in Loa loa and in onchocerciasis co-infection, where the label advises caution.

Regulatory basis: ivermectin prescribing information — neurotoxicity caution in Loa loa; post-treatment encephalopathy literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metComa follows treatment
StrengthmetPRR 17.3, large
ConsistencymetReproduced across case series
SpecificitymetFairly specific to heavy microfilaraemia
Biological gradientpartialRelated to parasite burden
PlausibilitymetAntigen release and drug CNS toxicity
CoherencemetFits the pharmacology
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to other antifilarial reactions

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for ivermectin captured neurotoxicity as a tracked adverse event in a usable structure. Post-treatment neurotoxicity is rare and restricted to high-microfilaraemia patients, so trials could not capture it as a coded event.
Expected pharmacological effect

Colchicine ↔ Myopathy

Open this assessment on its own page →

n=220 co-reports · PRR 20.8 · ROR 21.0

Colchicine is an anti-inflammatory used in gout and pericarditis; it inhibits microtubules, so at high plasma levels it causes a vacuolar myopathy and neuromyopathy (myopathy 220 co-reports here, PRR 20.8), particularly in renal impairment or with CYP3A4/P-glycoprotein inhibitors that raise levels. The effect is dose-related and reversible on withdrawal.

Regulatory basis: colchicine prescribing information — myopathy/neuromyopathy; caution with renal impairment and CYP3A4/P-gp inhibitors.

Bradford Hill viewpointStatusNote
Temporality (necessary)metMyopathy after weeks of therapy
StrengthmetPRR 20.8, large
ConsistencymetReproduced across case series
SpecificitymetFairly specific to colchicine
Biological gradientmetDose-related
PlausibilitymetMicrotubule inhibition in muscle
CoherencemetFits the mechanism
Experimentn/aNot a trial endpoint
AnalogymetAnalogous to other drug-induced myopathy

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for colchicine captured myopathy as a tracked adverse event in a usable structure. Colchicine myopathy is uncommon and dose-dependent, so short-course trials did not capture it as a coded event.
Causality: well established

Vigabatrin ↔ Visual field defect

Open this assessment on its own page →

n=141 co-reports · PRR 28.8 · ROR 29.1

Vigabatrin is an irreversible GABA-transaminase inhibitor for infantile spasms and refractory epilepsy; it causes a characteristic, often irreversible concentric visual-field defect, appearing here as 141 co-reports (PRR 28.8). Risk rises with cumulative dose and duration, so the label requires baseline and periodic visual-field testing and limits use where benefit does not clearly outweigh the risk.

Regulatory basis: vigabatrin (Sabril) prescribing information — boxed warning for permanent vision loss; mandatory visual-field monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metField loss after months of therapy
StrengthmetPRR 28.8, large
ConsistencymetReproduced across cohort studies
SpecificitymetFairly specific to vigabatrin
Biological gradientmetCumulative dose-related
PlausibilitymetGABA accumulation and retinal toxicity
CoherencemetFits the mechanism
ExperimentmetCohort and monitoring data support it
AnalogymetAnalogous to other retinotoxic drugs

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for vigabatrin captured visual field defect as a tracked adverse event in a usable structure. Visual-field defects develop insidiously over months and need perimetry to detect, so epilepsy trials did not capture them as coded events.
Causality: well established

Hydroxychloroquine ↔ QT prolongation

Open this assessment on its own page →

n=921 co-reports · PRR 7.4 · ROR 7.5

Hydroxychloroquine is an antimalarial and immunomodulator used in lupus and rheumatoid arthritis; it blocks cardiac potassium channels and can prolong the QT interval, carried here as 921 co-reports (PRR 7.4). Risk rises with high dose, hypokalaemia, and co-administration of other QT-prolonging drugs, and the label advises caution and ECG monitoring in at-risk patients.

Regulatory basis: hydroxychloroquine prescribing information — QT prolongation and ventricular-arrhythmia caution.

Bradford Hill viewpointStatusNote
Temporality (necessary)metQT change during therapy
StrengthmetPRR 7.4, moderate
ConsistencymetReproduced across case series
SpecificitypartialShared with other 4-aminoquinolines
Biological gradientmetHigher with higher dose
PlausibilitymetCardiac potassium-channel blockade
CoherencemetFits the mechanism
Experimentn/aNot a trial endpoint
AnalogymetAnalogous to chloroquine QT prolongation

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for hydroxychloroquine captured qt prolongation as a tracked adverse event in a usable structure. QT prolongation is an electrocardiographic finding that requires monitoring, so arthritis trials did not capture it as a coded event.
Expected pharmacological effect

Temozolomide ↔ Thrombocytopenia

Open this assessment on its own page →

n=1,572 co-reports · PRR 14.3 · ROR 15.4

Temozolomide is an oral alkylating agent for glioblastoma; myelosuppression, especially thrombocytopenia and neutropenia, is its dose-limiting toxicity and carries 1,572 thrombocytopenia co-reports here (PRR 14.3). The effect is cumulative, which is why the label requires frequent blood counts throughout each cycle and dose adjustment by haematological nadir.

Regulatory basis: temozolomide (Temodar) prescribing information — myelosuppression/thrombocytopenia; frequent monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metPlatelet fall during cycles
StrengthmetPRR 14.3, large
ConsistencymetConsistent across trials
SpecificitymetFairly specific to alkylating agents
Biological gradientmetCumulative dose-related
PlausibilitymetBone-marrow stem-cell damage
CoherencemetFits the mechanism
ExperimentmetTrials recorded thrombocytopenia
AnalogymetAnalogous to other alkylating-agent myelosuppression

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma (NCT03345095)

Adverse eventExperimental Arm (n=305) · Standard Arm (n=297)
Pancytopenia1/3050/297
Thrombocytopenia7/3051/297

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Mesalamine ↔ Pancreatitis

Open this assessment on its own page →

n=636 co-reports · PRR 4.6 · ROR 4.6

Mesalamine (5-aminosalicylic acid) is the mainstay of ulcerative colitis treatment; acute pancreatitis is a rare, idiosyncratic effect (636 co-reports here, PRR 4.6) that appears shortly after the drug is started, and it recurs if the drug is reintroduced. The reaction is one reason a short drug holiday is considered when pancreatitis develops in inflammatory bowel disease.

Regulatory basis: mesalamine prescribing information — pancreatitis; drug-induced pancreatitis literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOnset within days to weeks
StrengthmetPRR 4.6, modest
ConsistencymetReproduced across case reports
Specificitynot establishedNot specific to mesalamine
Biological gradientnot establishedIdiosyncratic (not dose-related)
PlausibilitymetProposed immuno-allergic mechanism
CoherencepartialConsistent with drug-induced pancreatitis
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to sulfasalazine pancreatitis

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis (NCT01124149)

Adverse eventMMX Mesalamine/ Mesalazine (Acute Phase) (n=717) · MMX Mesalamine/ Mesalazine (Maintenance Phase) (n=461)
Pancreatitis acute1/7170/461

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Ursodiol ↔ Pruritus

Open this assessment on its own page →

n=1,299 co-reports · PRR 3.3 · ROR 3.5

Ursodiol (ursodeoxycholic acid) is a bile acid used for primary biliary cholangitis and gallstones; diarrhoea and pruritus are its common effects, and pruritus carries 1,299 co-reports here (PRR 3.3) — a high count partly because pruritus is itself a symptom of the cholestatic disease being treated. The drug is otherwise well tolerated, and effects are usually dose-related.

Regulatory basis: ursodiol prescribing information — diarrhoea and gastrointestinal effects.

Bradford Hill viewpointStatusNote
Temporality (necessary)metPruritus and diarrhoea follow dosing
StrengthmetPRR 3.3, modest
ConsistencymetReported across practice
Specificitynot establishedCannot separate drug from cholestatic disease
Biological gradientmetDose-related
PlausibilitymetBile-acid effect on gut and skin
CoherencemetFits the pharmacology
Experimentn/aNot a trial endpoint
AnalogypartialAnalogous to other bile-acid effects

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) (NCT03602560)

Adverse eventSeladelpar 5/10 mg (n=89) · Seladelpar 10 mg (n=89) · Placebo (n=87)
Pruritus3/8910/8911/87
Pruritus generalised3/893/893/87

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Contested: signal not confirmed by large randomized trials

Oseltamivir ↔ Neuropsychiatric events

Open this assessment on its own page →

n=66 co-reports · PRR 5.1 · ROR 5.1

Oseltamivir is a neuraminidase inhibitor for influenza; neuropsychiatric events — delirium, confusion, and in rare cases self-injury — have been reported, particularly in children and adolescents (delirium 66 co-reports here, PRR 5.1). The reports prompted regulatory review and warning label changes, but causality remains uncertain because influenza itself can cause encephalopathy and delirium, and controlled trials have not confirmed an excess.

Regulatory basis: oseltamivir prescribing information — neuropsychiatric events; regulatory reviews of delirium/self-injury.

Bradford Hill viewpointStatusNote
Temporality (necessary)partialOnset during treatment
StrengthmetPRR 5.1, moderate
ConsistencymetReported across case series
Specificitynot establishedNot specific to oseltamivir
Biological gradientnot establishedCannot exclude influenza encephalopathy
Plausibilitynot establishedNo established dose relationship
CoherencepartialMechanism debated
Experimentnot establishedNot reproduced in trials
AnalogypartialDebated analogy to influenza-related delirium

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza (NCT01231620)

Adverse eventIntravenous (IV) Zanamivir 300mg Twice Daily (n=201) · Intravenous (IV) Zanamivir 600mg Twice Daily (n=209) · Oral Oseltamivir 75mg Twice Daily (n=205)
Delirium febrile0/2010/2091/205
Encephalopathy1/2010/2091/205

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Voriconazole ↔ Hallucination

Open this assessment on its own page →

n=704 co-reports · PRR 6.6 · ROR 6.7

Voriconazole is a triazole antifungal; in addition to visual disturbances and photosensitivity, it causes hallucinations at a rate higher than other azoles (hallucination 704 co-reports here, PRR 6.6), especially with high plasma concentrations. The effect is dose-related and reversible, and monitoring of trough levels is advised.

Regulatory basis: voriconazole prescribing information — visual and CNS adverse events including hallucinations.

Bradford Hill viewpointStatusNote
Temporality (necessary)metHallucinations during therapy
StrengthmetPRR 6.6, moderate
ConsistencymetReproduced across series
SpecificitypartialShared across the azole class
Biological gradientmetRelated to plasma concentration
PlausibilitymetCentral CNS effect of the triazole
CoherencemetFits the pharmacology
ExperimentmetTrials recorded CNS events
AnalogymetAnalogous to other azole CNS effects

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Voriconazole (Vfend) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) (NCT01151085)

Adverse eventVoriconazole (n=946)
Hallucination11/946
Hallucination, visual3/946
Hallucination, auditory1/946

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Iodixanol ↔ Contrast-induced nephropathy

Open this assessment on its own page →

n=40 co-reports · PRR 21.5 · ROR 21.7

Iodixanol is an iso-osmolar iodinated contrast medium; contrast-induced nephropathy is the principal hazard of any intravascular contrast and appears here as 40 nephropathy-toxic co-reports (PRR 21.5). Risk rises with pre-existing renal impairment, diabetes, dehydration, and high contrast volume, and the label advises adequate hydration and minimising volume in at-risk patients.

Regulatory basis: iodixanol (Visipaque) prescribing information — contrast-induced nephropathy; hydration guidance.

Bradford Hill viewpointStatusNote
Temporality (necessary)metRenal injury within days
StrengthmetPRR 21.5, large
ConsistencymetConsistent across contrast agents
SpecificitypartialShared across iodinated contrast
Biological gradientmetDose- and volume-related
PlausibilitymetTubular toxicity and renal vasoconstriction
CoherencemetFits the mechanism
Experimentn/aNot a trial endpoint
AnalogymetAnalogous to other contrast media

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for iodixanol captured contrast-induced nephropathy as a tracked adverse event in a usable structure. Contrast-induced nephropathy is uncommon and procedure-related, so trials did not capture it as a structured coded event.
Causality: well established

Propofol ↔ Infusion syndrome

Open this assessment on its own page →

n=910 co-reports · PRR 12.9 · ROR 13.2

Propofol is an intravenous anaesthetic; with high-dose, prolonged infusion it causes propofol-related infusion syndrome — metabolic acidosis, rhabdomyolysis, cardiac failure, and renal injury (rhabdomyolysis 910 co-reports here, PRR 12.9). The syndrome is a direct consequence of impaired mitochondrial fatty-acid oxidation, and the label advises limiting dose and duration and monitoring for the early signs.

Regulatory basis: propofol prescribing information — propofol-related infusion syndrome; dose/duration limits.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOnset during prolonged infusion
StrengthmetPRR 12.9, large
ConsistencymetReproduced across case series
SpecificitymetFairly specific to propofol
Biological gradientmetDose- and duration-related
PlausibilitymetMitochondrial fatty-acid oxidation defect
CoherencemetFits the mechanism
Experimentn/aRare in trials
AnalogymetAnalogous to other anaesthetic-related myotoxicity

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for propofol captured infusion syndrome as a tracked adverse event in a usable structure. Infusion syndrome is rare and confined to high-dose prolonged use, so anaesthetic trials did not capture it as a coded event.
Expected pharmacological effect

Tocilizumab ↔ Gastrointestinal perforation

Open this assessment on its own page →

n=5,011 co-reports · PRR 406.8 · ROR 425.5

Tocilizumab is an interleukin-6 receptor antagonist used in rheumatoid arthritis and cytokine-release syndrome; gastrointestinal perforation is a well-recognised, serious effect (duodenal ulcer perforation 5,011 co-reports here, PRR 406.8) that occurs in patients on combination disease-modifying therapy or corticosteroids. The label carries a warning and advises vigilance for abdominal symptoms, especially in patients with a history of diverticulitis.

Regulatory basis: tocilizumab (Actemra) prescribing information — gastrointestinal perforation warning.

Bradford Hill viewpointStatusNote
Temporality (necessary)partialOnset over weeks of therapy
StrengthmetPRR 406.8, an extreme signal
ConsistencymetReproduced across registries
SpecificitymetFairly specific to IL-6 blockade
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetIL-6 blockade impairing mucosal healing
CoherencemetFits the pharmacology
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to other biologic GI perforation

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — An Observational Study of the Impact of RoActemra/Actemra on Fatigue in Patients With Rheumatoid Arthritis (PEPS) (NCT01185522)

Adverse eventTocilizumab (n=693)
Intestinal perforation1/693

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Deferiprone ↔ Agranulocytosis

Open this assessment on its own page →

n=158 co-reports · PRR 60.2 · ROR 63.5

Deferiprone is an oral iron chelator used in transfusional iron overload; it can cause agranulocytosis or neutropenia, a severe and potentially fatal idiosyncratic effect, appearing here as 158 co-reports (PRR 60.2). Because of this risk the label requires regular blood-count monitoring, instructs patients to report fever or sore throat immediately, and allows resumption only after counts recover.

Regulatory basis: deferiprone (Ferriprox) prescribing information — agranulocytosis/neutropenia; mandatory blood-count monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metOnset within weeks to months
StrengthmetPRR 60.2, an extreme signal
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to deferiprone
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetIdiosyncratic myeloid suppression
CoherencemetFits the mechanism
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to other drug-induced agranulocytosis

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients (NCT01825512)

Adverse eventDeferiprone (n=193) · Deferasirox (n=197)
agranulocytosis3/1930/197

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Lithium ↔ Tremor

Open this assessment on its own page →

n=1,509 co-reports · PRR 7.7 · ROR 8.1

Lithium is the leading mood stabiliser for bipolar disorder and a fine tremor is its most common neurological effect, progressing to a coarse tremor at higher concentrations; post-marketing data capture 1,509 co-reports (PRR 7.7). It usually appears early, often at therapeutic levels, worsens with dose and concentration, and is managed by dose adjustment or a beta-blocker.

Regulatory basis: lithium (Eskalith) prescribing information — treatment-emergent tremor; periodic lithium-level, thyroid and renal monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metEarliest neurological effect
StrengthmetPRR 7.7 with 1,509 co-reports
ConsistencymetConsistent across cohorts
Specificitynot establishedTremor is common in the population
Biological gradientmetClear dose and concentration gradient
PlausibilitymetKnown neurotoxic effect of lithium
CoherencemetFits lithium's narrow therapeutic index
Experimentn/aNot a randomised trial endpoint
AnalogymetAnalogous to other tremorogenic drugs

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for lithium captured tremor as a tracked adverse event in a usable structure. Bipolar maintenance trials did not systematically code tremor as an adverse event in their posted results.
Causality: well established

Lithium ↔ Nephrogenic diabetes insipidus

Open this assessment on its own page →

n=304 co-reports · PRR 301.3 · ROR 305.0

Lithium blunts antidiuretic-hormone signalling in the collecting duct, producing nephrogenic diabetes insipidus with polyuria and polydipsia; 304 co-reports carry an extreme PRR of 301.3. The effect is concentration-related, often insidious over months to years and only partly reversible, so fluid balance and renal function are monitored during long-term therapy.

Regulatory basis: lithium (Eskalith) prescribing information — nephrogenic diabetes insipidus; renal-function monitoring during chronic use.

Bradford Hill viewpointStatusNote
Temporality (necessary)metInsidious over months to years
StrengthmetPRR 301.3, an extreme signal
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to lithium
Biological gradientmetStrong concentration dependence
PlausibilitymetWell-defined tubular mechanism
CoherencemetFits lithium's renal toxicity
Experimentn/aToo chronic for trial capture
AnalogymetAnalogous to demeclocycline-type diabetes insipidus

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for lithium captured nephrogenic diabetes insipidus as a tracked adverse event in a usable structure. Bipolar maintenance trials rarely run long enough, or code polyuria/dipsia, to detect a chronic tubular toxicity.
Causality: well established

Lithium ↔ Hypothyroidism

Open this assessment on its own page →

n=224 co-reports · PRR 5.9 · ROR 6.0

Lithium concentrates in the thyroid and inhibits hormone release, causing hypothyroidism and goitre; 224 co-reports give PRR 5.9. The effect is often subclinical at first and emerges over the first year or two of therapy, so thyroid function is checked periodically and treated with levothyroxine when required.

Regulatory basis: lithium (Eskalith) prescribing information — hypothyroidism and goitre; periodic thyroid-function monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metEvolves over the first 1-2 years
StrengthmetPRR 5.9 with 224 co-reports
ConsistencymetReproduced across cohorts
Specificitynot establishedHypothyroidism is common in the population
Biological gradientmetRelated to duration and level
PlausibilitymetKnown lithium thyroid blockade
CoherencemetFits lithium's antithyroid action
Experimentn/aNot a trial endpoint
AnalogymetAnalogous to amiodarone thyroid effects

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for lithium captured hypothyroidism as a tracked adverse event in a usable structure. Maintenance trials did not incorporate thyroid dysfunction as a coded adverse event.
Causality: well established

Carbamazepine ↔ Hyponatraemia

Open this assessment on its own page →

n=1,446 co-reports · PRR 8.3 · ROR 8.4

Carbamazepine potentiates antidiuretic hormone, producing dilutional hyponatraemia that can become symptomatic when severe; 1,446 co-reports give PRR 8.3. The effect is dose-related and more frequent in older adults, so baseline and periodic sodium checks are advised.

Regulatory basis: carbamazepine (Tegretol) prescribing information — hyponatraemia/SIADH; serum-sodium monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metGradual, days to weeks
StrengthmetPRR 8.3 with 1,446 co-reports
ConsistencymetConsistent across studies
Specificitynot establishedHyponatraemia has many causes
Biological gradientmetDose-related
PlausibilitymetKnown ADH-potentiating mechanism
CoherencemetFits carbamazepine's renal effect
Experimentn/aNot a routine trial endpoint
AnalogymetAnalogous to oxcarbazepine hyponatraemia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs (NCT00438451)

Adverse eventLevetiracetam (n=122) · Carbamazepine (n=121) · Lamotrigine (n=117)
Hyponatraemia0/1221/1210/117

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Carbamazepine ↔ Agranulocytosis

Open this assessment on its own page →

n=184 co-reports · PRR 3.2 · ROR 3.2

Carbamazepine can cause blood dyscrasias including agranulocytosis and aplastic anaemia; 184 co-reports give PRR 3.2. The risk is idiosyncratic and potentially fatal, so the label advises immediate blood counts if fever, sore throat or infection develops.

Regulatory basis: carbamazepine (Tegretol) prescribing information — aplastic anaemia and agranulocytosis; prompt blood-count monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metIdiosyncratic, weeks to months
StrengthmetPRR 3.2 with 184 co-reports
ConsistencymetReproduced across reports
SpecificitymetFairly specific to carbamazepine
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetPlausible marrow toxicity
CoherencemetFits aromatic anticonvulsant dyscrasias
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to phenytoin and valproate cytopenias

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for carbamazepine captured agranulocytosis as a tracked adverse event in a usable structure. Randomised epilepsy trials were far too small and short to capture idiosyncratic agranulocytosis.
Causality: well established

Carbamazepine ↔ Stevens-Johnson syndrome

Open this assessment on its own page →

n=920 co-reports · PRR 13.5 · ROR 13.7

Carbamazepine is a leading cause of Stevens-Johnson syndrome and toxic epidermal necrolysis, strongly linked to the HLA-B*1502 allele in certain ancestries; 920 co-reports give PRR 13.5. The label recommends genetic screening in at-risk groups and immediate withdrawal at the first sign of rash.

Regulatory basis: carbamazepine (Tegretol) prescribing information — SJS/TEN and HLA-B*1502 screening recommendation.

Bradford Hill viewpointStatusNote
Temporality (necessary)metErupts within first weeks
StrengthmetPRR 13.5 with 920 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetStrong HLA association
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetImmune-mediated mechanism
CoherencemetFits aromatic anticonvulsant risk
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to phenytoin and lamotrigine SJS

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for carbamazepine captured stevens-johnson syndrome as a tracked adverse event in a usable structure. Trials could not detect a rare, genotype-linked mucocutaneous eruption.
Causality: well established

Valproate ↔ Hepatotoxicity

Open this assessment on its own page →

n=65 co-reports · PRR 3.0 · ROR 3.0

Valproate can cause serious, sometimes fatal hepatotoxicity, with the highest risk in children under two and in polytherapy; 65 co-reports give PRR 3.0. A boxed warning mandates baseline and periodic liver-function testing, and the drug is stopped if hepatic injury is suspected.

Regulatory basis: valproate prescribing information — boxed warning for hepatotoxicity; liver-function monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metCan be rapid in high-risk patients
StrengthmetPRR 3.0 with 65 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetHighest in defined risk groups
Biological gradientmetDose and age related
PlausibilitymetKnown mitochondrial/β-oxidation toxicity
CoherencemetFits valproate's metabolic profile
Experimentn/aToo rare and severe for trial capture
AnalogymetAnalogous to other antiepileptic hepatotoxins

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for valproate captured hepatotoxicity as a tracked adverse event in a usable structure. Trials excluded the youngest, highest-risk children and were too small for rare hepatic failure.
Causality: well established

Valproate ↔ Acute pancreatitis

Open this assessment on its own page →

n=120 co-reports · PRR 5.5 · ROR 5.5

Valproate is associated with acute pancreatitis, which can be life-threatening and may appear soon after starting or after years of use; 120 co-reports give PRR 5.5. Pancreatitis is a labelled warning and the drug is discontinued if it is suspected.

Regulatory basis: valproate prescribing information — acute pancreatitis warning.

Bradford Hill viewpointStatusNote
Temporality (necessary)metVariable, early or late
StrengthmetPRR 5.5 with 120 co-reports
ConsistencymetReproduced across cohorts
Specificitynot establishedPancreatitis has many causes
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetPlausible direct toxicity
CoherencemetFits valproate's metabolic effects
Experimentn/aNot a trial endpoint
AnalogymetAnalogous to other drug-induced pancreatitis

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for valproate captured acute pancreatitis as a tracked adverse event in a usable structure. Controlled trials were not powered or coded to detect pancreatitis.
Causality: well established

Valproate ↔ Thrombocytopenia

Open this assessment on its own page →

n=455 co-reports · PRR 4.2 · ROR 4.2

Valproate commonly lowers platelet counts through dose-related marrow suppression and can impair platelet function; 455 co-reports give PRR 4.2. Blood counts are checked before surgery and in patients with bruising or bleeding.

Regulatory basis: valproate prescribing information — thrombocytopenia; blood-count monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metGradual, dose-related
StrengthmetPRR 4.2 with 455 co-reports
ConsistencymetConsistent across cohorts
Specificitynot establishedLow platelets are common
Biological gradientmetDose-related
PlausibilitymetPlausible marrow suppression
CoherencemetFits valproate haematological effects
Experimentn/aRarely coded as a trial endpoint
AnalogymetAnalogous to other drug-induced thrombocytopenia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for valproate captured thrombocytopenia as a tracked adverse event in a usable structure. Trials did not routinely report platelet counts as coded adverse events.
Causality: well established

Valproate ↔ Hyperammonaemia

Open this assessment on its own page →

n=298 co-reports · PRR 64.7 · ROR 65.7

Valproate can raise blood ammonia even when liver enzymes are normal, occasionally causing encephalopathy; 298 co-reports give an extreme PRR of 64.7. The label warns of hyperammonaemic encephalopathy, especially with concomitant topiramate or in urea-cycle disorders.

Regulatory basis: valproate prescribing information — hyperammonaemia and hyperammonaemic encephalopathy warning.

Bradford Hill viewpointStatusNote
Temporality (necessary)metHours to days
StrengthmetPRR 64.7, an extreme signal
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to valproate
Biological gradientmetDose-related
PlausibilitymetKnown urea-cycle interference
CoherencemetFits valproate's metabolic effects
Experimentn/aToo specific for routine trial capture
AnalogymetAnalogous to topiramate interaction

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for valproate captured hyperammonaemia as a tracked adverse event in a usable structure. Ammonia is not a standard safety endpoint in epilepsy trials.
Causality: well established

Phenytoin ↔ Gingival hypertrophy

Open this assessment on its own page →

n=85 co-reports · PRR 60.6 · ROR 60.9

Phenytoin causes fibrous gingival overgrowth in a substantial minority of long-term users, related to concentration, oral hygiene and age; 85 co-reports give an extreme PRR of 60.6. The label lists gingival hyperplasia and advises good dental hygiene and monitoring.

Regulatory basis: phenytoin (Dilantin) prescribing information — gingival hyperplasia.

Bradford Hill viewpointStatusNote
Temporality (necessary)metMonths of therapy
StrengthmetPRR 60.6, an extreme signal
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to phenytoin
Biological gradientmetConcentration-related
PlausibilitymetKnown fibroblast-proliferation mechanism
CoherencemetFits phenytoin's connective-tissue effect
Experimentn/aNot a short-term trial endpoint
AnalogymetAnalogous to cyclosporine gingival overgrowth

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for phenytoin captured gingival hypertrophy as a tracked adverse event in a usable structure. Epilepsy trials were too short and did not code gingival changes as adverse events.
Causality: well established

Phenytoin ↔ Stevens-Johnson syndrome

Open this assessment on its own page →

n=771 co-reports · PRR 36.2 · ROR 37.6

Phenytoin is a well-known cause of Stevens-Johnson syndrome and toxic epidermal necrolysis, an idiosyncratic mucocutaneous reaction; 771 co-reports give PRR 36.2. The label warns of serious skin reactions and advises stopping the drug at the first sign of rash.

Regulatory basis: phenytoin (Dilantin) prescribing information — serious dermatological reactions including SJS/TEN.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWithin the first weeks
StrengthmetPRR 36.2 with 771 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetAssociated with HLA alleles
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetImmune-mediated mechanism
CoherencemetFits aromatic anticonvulsant risk
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to carbamazepine and lamotrigine SJS

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for phenytoin captured stevens-johnson syndrome as a tracked adverse event in a usable structure. A rare, idiosyncratic eruption cannot be detected in conventional trials.
Causality: well established

Allopurinol ↔ Toxic epidermal necrolysis

Open this assessment on its own page →

n=1,170 co-reports · PRR 11.3 · ROR 11.3

Allopurinol can trigger toxic epidermal necrolysis and Stevens-Johnson syndrome, a severe cutaneous reaction closely associated with the HLA-B*5801 allele; 1,170 co-reports give PRR 11.3. The label recommends screening in high-prevalence ancestries and stopping the drug immediately if a rash develops.

Regulatory basis: allopurinol prescribing information — SJS/TEN and HLA-B*5801 screening.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDays to weeks after start
StrengthmetPRR 11.3 with 1,170 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetStrong HLA association
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetImmune-mediated mechanism
CoherencemetFits aromatic-drug hypersensitivity
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to carbamazepine SJS/TEN

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for allopurinol captured toxic epidermal necrolysis as a tracked adverse event in a usable structure. Randomised gout trials were far too small to capture a rare HLA-linked eruption.
Causality: well established

Nevirapine ↔ Hepatotoxicity

Open this assessment on its own page →

n=170 co-reports · PRR 18.1 · ROR 18.4

Nevirapine carries a boxed warning for severe, sometimes fatal hepatotoxicity, especially in the first weeks of therapy and in patients with higher CD4 counts; 170 co-reports give PRR 18.1. The label requires a lead-in dose and frequent liver monitoring early on.

Regulatory basis: nevirapine (Viramune) prescribing information — boxed warning for hepatotoxicity; lead-in dosing and liver monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metFirst 18 weeks of therapy
StrengthmetPRR 18.1 with 170 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetHigher in defined risk groups
Biological gradientnot establishedNot simply dose-related
PlausibilitymetPlausible immune-mediated injury
CoherencemetFits nevirapine hypersensitivity
Experimentn/aToo rare and severe for trial capture
AnalogymetAnalogous to other antiretroviral hepatotoxins

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children (NCT00978068)

Adverse eventGroup 1 (n=84) · Group 2 (n=86)
Stevens-Johnson Syndrome0/841/86

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Nevirapine ↔ Stevens-Johnson syndrome

Open this assessment on its own page →

n=192 co-reports · PRR 20.3 · ROR 20.7

Nevirapine is a recognised cause of severe cutaneous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis; 192 co-reports give PRR 20.3. These reactions cluster in the first weeks, so the label advises stopping the drug and seeking care at the first sign of rash.

Regulatory basis: nevirapine (Viramune) prescribing information — severe cutaneous reactions including SJS/TEN.

Bradford Hill viewpointStatusNote
Temporality (necessary)metFirst weeks of therapy
StrengthmetPRR 20.3 with 192 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetAssociated with HLA alleles
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetImmune-mediated mechanism
CoherencemetFits nevirapine hypersensitivity syndrome
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to carbamazepine SJS/TEN

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for nevirapine captured stevens-johnson syndrome as a tracked adverse event in a usable structure. A rare mucocutaneous reaction cannot be resolved by randomised trials.
Causality: well established

Efavirenz ↔ Suicidal depression

Open this assessment on its own page →

n=36 co-reports · PRR 19.9 · ROR 19.9

Efavirenz carries a boxed warning for serious psychiatric symptoms including depression and suicidality, which can occur at any time during therapy; 36 co-reports give PRR 19.9. Patients are warned to report mood change, and the drug is stopped if symptoms are severe.

Regulatory basis: efavirenz (Sustiva) prescribing information — boxed warning for psychiatric symptoms and suicidality.

Bradford Hill viewpointStatusNote
Temporality (necessary)metAny time on therapy
StrengthmetPRR 19.9 with 36 co-reports
ConsistencymetReproduced across cohorts
Specificitynot establishedDepression is common in the population
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetPlausible CNS mechanism
CoherencemetFits efavirenz neuropsychiatric effects
Experimentn/aRarely coded as a trial endpoint
AnalogymetAnalogous to other antiretroviral CNS effects

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for efavirenz captured suicidal depression as a tracked adverse event in a usable structure. Trials under-reported psychiatric adverse events and coded suicidality poorly.
Expected pharmacological effect

Ganciclovir ↔ Neutropenia

Open this assessment on its own page →

n=531 co-reports · PRR 8.1 · ROR 8.5

Ganciclovir suppresses bone marrow and commonly causes neutropenia, which is dose-limiting and is accentuated by other myelosuppressive drugs; 531 co-reports give PRR 8.1. The label requires frequent blood-count monitoring and dose adjustment.

Regulatory basis: ganciclovir prescribing information — neutropenia and thrombocytopenia; blood-count monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks of therapy
StrengthmetPRR 8.1 with 531 co-reports
ConsistencymetConsistent across cohorts
Specificitynot establishedNeutropenia has many causes
Biological gradientmetDose-related
PlausibilitymetKnown nucleoside-analogue marrow toxicity
CoherencemetFits ganciclovir's myelosuppression
Experimentn/aOften coded in trials
AnalogymetAnalogous to other myelosuppressive antivirals

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients (NCT00294515)

Adverse eventValganciclovir up to 100 Days (n=164) · Valganciclovir up to 200 Days (n=156)
Neutropenia3/1649/156

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Amphotericin B ↔ Acute kidney injury

Open this assessment on its own page →

n=436 co-reports · PRR 4.8 · ROR 5.0

Amphotericin B is classically nephrotoxic, causing dose-dependent renal injury with electrolyte wasting that frequently limits therapy; 436 co-reports give PRR 4.8. The label advises renal monitoring, hydration and electrolyte replacement.

Regulatory basis: amphotericin B prescribing information — nephrotoxicity with renal-function and electrolyte monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDays to weeks
StrengthmetPRR 4.8 with 436 co-reports
ConsistencymetConsistent across cohorts
Specificitynot establishedAcute kidney injury has many causes
Biological gradientmetClear dose gradient
PlausibilitymetKnown membrane-pore mechanism
CoherencemetFits amphotericin's tubular toxicity
Experimentn/aOften captured in trials
AnalogymetAnalogous to other nephrotoxic antifungals

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals (NCT00885703)

Adverse eventStage 1: 1200mg Fluconazole (n=22) · Stage 1: 1600mg Fluconazole (n=26) · Stage 1: 2000mg Fluconazole (n=24) · Stage 1: Ampho B (n=24)
Acute kidney injury1/220/260/240/24

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Colchicine ↔ Pancytopenia

Open this assessment on its own page →

n=400 co-reports · PRR 5.8 · ROR 5.9

Colchicine is a mitotic poison and at high exposure causes marrow suppression with pancytopenia, especially in overdose or renal impairment; 400 co-reports give PRR 5.8. The label warns of blood dyscrasias and advises caution in organ impairment.

Regulatory basis: colchicine prescribing information — blood dyscrasias including pancytopenia; caution in renal/hepatic impairment.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDays after high exposure
StrengthmetPRR 5.8 with 400 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to overdose
Biological gradientmetStrong dose/exposure relation
PlausibilitymetKnown mitotic-spindle mechanism
CoherencemetFits colchicine's narrow therapeutic index
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to other antimitotic myelosuppression

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for colchicine captured pancytopenia as a tracked adverse event in a usable structure. Trials used therapeutic doses and were not designed to capture toxicity from high exposure.
Causality: well established

Colchicine ↔ Rhabdomyolysis

Open this assessment on its own page →

n=519 co-reports · PRR 10.1 · ROR 10.3

Colchicine can cause myopathy and rhabdomyolysis, particularly with concomitant statins or in renal impairment where it accumulates; 519 co-reports give PRR 10.1. The label warns of neuromuscular toxicity and advises caution with interacting drugs.

Regulatory basis: colchicine prescribing information — myopathy/rhabdomyolysis, especially with statins or renal impairment.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDays to weeks
StrengthmetPRR 10.1 with 519 co-reports
ConsistencymetReproduced across cohorts
Specificitynot establishedRhabdomyolysis has many causes
Biological gradientmetDose/exposure-related
PlausibilitymetKnown microtubule mechanism in muscle
CoherencemetFits the colchicine-statin interaction
Experimentn/aNot a routine trial endpoint
AnalogymetAnalogous to statin-associated myopathy

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for colchicine captured rhabdomyolysis as a tracked adverse event in a usable structure. Randomised trials did not combine colchicine with statins at scale or code rhabdomyolysis.
Causality: well established

Vancomycin ↔ Neutropenia

Open this assessment on its own page →

n=1,361 co-reports · PRR 3.7 · ROR 3.8

Prolonged vancomycin therapy can cause reversible neutropenia, usually after more than a week of treatment; 1,361 co-reports give PRR 3.7. The label advises periodic blood counts during extended therapy and withdrawal if counts fall.

Regulatory basis: vancomycin prescribing information — reversible neutropenia during prolonged therapy; blood-count monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metAfter 1-2 weeks of therapy
StrengthmetPRR 3.7 with 1,361 co-reports
ConsistencymetReproduced across reports
Specificitynot establishedNeutropenia has many causes
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetPlausible immune/marrow mechanism
CoherencemetFits vancomycin haematological effects
Experimentn/aNot a routine trial endpoint
AnalogymetAnalogous to beta-lactam neutropenia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002) (NCT01513239)

Adverse eventMK-3415A + SOC (n=390) · MK-6072 + SOC (n=396) · Placebo + SOC (n=381) · MK-3415 + SOC (n=1)
Neutropenia2/3900/3961/3810/1

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Vancomycin ↔ DRESS (eosinophilia and systemic symptoms)

Open this assessment on its own page →

n=2,386 co-reports · PRR 37.5 · ROR 39.1

Vancomycin is a recognised cause of DRESS (drug reaction with eosinophilia and systemic symptoms), a delayed multi-organ hypersensitivity syndrome; 2,386 co-reports give PRR 37.5. Management is prompt withdrawal and corticosteroid support.

Regulatory basis: vancomycin prescribing information and case literature — DRESS/hypersensitivity syndrome.

Bradford Hill viewpointStatusNote
Temporality (necessary)met2-8 weeks after start
StrengthmetPRR 37.5 with 2,386 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetAssociated with HLA alleles
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetImmune-mediated mechanism
CoherencemetFits vancomycin hypersensitivity
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to other antibiotic DRESS

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for vancomycin captured dress (eosinophilia and systemic symptoms) as a tracked adverse event in a usable structure. A rare delayed hypersensitivity syndrome is not detectable in randomised trials.
Causality: well established

Gentamicin ↔ Ototoxicity

Open this assessment on its own page →

n=94 co-reports · PRR 86.1 · ROR 86.7

Gentamicin carries a boxed warning for ototoxicity: it damages the cochlea and vestibular apparatus, sometimes irreversibly, with risk rising with high or prolonged levels; 94 co-reports give an extreme PRR of 86.1. The label requires level monitoring and caution in renal impairment.

Regulatory basis: gentamicin prescribing information — boxed warning for ototoxicity; aminoglycoside level and renal monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDays into therapy
StrengthmetPRR 86.1, an extreme signal
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to aminoglycosides
Biological gradientmetLevel/dose-related
PlausibilitymetKnown hair-cell toxicity
CoherencemetFits gentamicin's cochlear effect
Experimentn/aHearing testing rarely a trial endpoint
AnalogymetAnalogous to amikacin/tobramycin ototoxicity

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for gentamicin captured ototoxicity as a tracked adverse event in a usable structure. Trials rarely perform audiometry or code hearing loss as a structured adverse event.
Causality: well established

Clopidogrel ↔ Thrombotic thrombocytopenic purpura

Open this assessment on its own page →

n=456 co-reports · PRR 15.7 · ROR 15.7

Clopidogrel carries a boxed warning for thrombotic thrombocytopenic purpura, a rare but life-threatening microangiopathy that can appear within days to weeks of starting; 456 co-reports give PRR 15.7. Prompt plasma exchange is required.

Regulatory basis: clopidogrel (Plavix) prescribing information — boxed warning for TTP.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDays to weeks after start
StrengthmetPRR 15.7 with 456 co-reports
ConsistencymetReproduced across reports
SpecificitymetFairly specific to thienopyridines
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetImmune-mediated mechanism
CoherencemetFits thienopyridine-associated TTP
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to ticlopidine TTP

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for clopidogrel captured thrombotic thrombocytopenic purpura as a tracked adverse event in a usable structure. A rare, idiosyncratic haematological emergency is far below trial detection thresholds.
Causality: well established

Terbinafine ↔ Hepatic enzyme increased

Open this assessment on its own page →

n=62 co-reports · PRR 2.7 · ROR 2.7

Terbinafine can raise liver enzymes and, rarely, cause hepatic failure, so the label advises stopping therapy if hepatic injury develops; 62 co-reports give PRR 2.7. Baseline liver tests are recommended in patients at risk.

Regulatory basis: terbinafine prescribing information — hepatic enzyme elevation and rare hepatic failure; liver-function caution.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks of therapy
StrengthmetPRR 2.7 with 62 co-reports
ConsistencymetReproduced across reports
Specificitynot establishedEnzyme rises have many causes
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetPlausible hepatocellular injury
CoherencemetFits terbinafine hepatotoxicity
Experimentn/aNot a routine trial endpoint
AnalogymetAnalogous to other antifungal hepatotoxins

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED) (NCT00491764)

Adverse eventPosaconazole 100 mg QD for 24 Weeks (n=36) · Posaconazole 200 mg QD for 24 Weeks (n=37) · Posaconazole 400 mg QD for 24 Weeks (n=36) · Posaconazole 400 mg QD for 12 Weeks (n=36)
HEPATIC ENZYME INCREASED1/360/372/360/36

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Ketoconazole ↔ Hepatotoxicity

Open this assessment on its own page →

n=64 co-reports · PRR 3.5 · ROR 3.5

Oral ketoconazole can cause serious hepatotoxicity and has been largely restricted to specific indications because of it; 64 co-reports give PRR 3.5. The label requires baseline and periodic liver tests and prompt withdrawal at the first sign of injury.

Regulatory basis: ketoconazole prescribing information — severe hepatotoxicity; liver-function monitoring and restricted use.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks to months
StrengthmetPRR 3.5 with 64 co-reports
ConsistencymetReproduced across reports
Specificitynot establishedHepatotoxicity has many causes
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetPlausible hepatocellular injury
CoherencemetFits azole-associated hepatotoxicity
Experimentn/aNot a routine trial endpoint
AnalogymetAnalogous to other antifungal hepatotoxins

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for ketoconazole captured hepatotoxicity as a tracked adverse event in a usable structure. Trials were small and not designed to detect idiosyncratic hepatic injury.
Causality: well established

Dapsone ↔ Methaemoglobinaemia

Open this assessment on its own page →

n=480 co-reports · PRR 522.3 · ROR 547.0

Dapsone oxidises haemoglobin and causes dose-dependent methaemoglobinaemia, which can be severe and even fatal; 480 co-reports give an extreme PRR of 522.3. The label warns of this effect and advises monitoring, especially at higher doses.

Regulatory basis: dapsone prescribing information — methaemoglobinaemia; clinical monitoring and supportive care.

Bradford Hill viewpointStatusNote
Temporality (necessary)metHours to days
StrengthmetPRR 522.3, an extreme signal
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to dapsone
Biological gradientmetClear dose dependence
PlausibilitymetKnown haem-oxidation mechanism
CoherencemetFits dapsone's redox toxicity
Experimentn/aNot a routine trial endpoint
AnalogymetAnalogous to other oxidant drugs

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for dapsone captured methaemoglobinaemia as a tracked adverse event in a usable structure. Methaemoglobin is not a standard trial safety endpoint.
Causality: well established

Dapsone ↔ Haemolytic anaemia

Open this assessment on its own page →

n=165 co-reports · PRR 36.9 · ROR 37.5

Dapsone causes oxidative haemolysis that is dose-related and much more severe in glucose-6-phosphate-dehydrogenase deficiency; 165 co-reports give PRR 36.9. The label advises caution and G6PD awareness before use.

Regulatory basis: dapsone prescribing information — haemolysis, especially in G6PD deficiency.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDays to weeks
StrengthmetPRR 36.9 with 165 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetStrong G6PD association
Biological gradientmetDose-related
PlausibilitymetKnown oxidative haemolysis
CoherencemetFits dapsone's redox toxicity
Experimentn/aNot a routine trial endpoint
AnalogymetAnalogous to primaquine haemolysis

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for dapsone captured haemolytic anaemia as a tracked adverse event in a usable structure. Trials did not systematically screen G6PD status or code haemolysis.
Causality: well established

Linezolid ↔ Serotonin syndrome

Open this assessment on its own page →

n=917 co-reports · PRR 35.6 · ROR 36.8

Linezolid is a weak monoamine-oxidase inhibitor and can precipitate serotonin syndrome when combined with serotonergic drugs; 917 co-reports give PRR 35.6. The label warns of this interaction and advises careful monitoring or avoidance of the combination.

Regulatory basis: linezolid (Zyvox) prescribing information — serotonin syndrome with serotonergic drugs.

Bradford Hill viewpointStatusNote
Temporality (necessary)metHours to days of combination
StrengthmetPRR 35.6 with 917 co-reports
ConsistencymetReproduced across reports
SpecificitymetFairly specific to the interaction
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetKnown MAO-inhibition mechanism
CoherencemetFits linezolid's interaction profile
Experimentn/aInteraction seldom studied in trials
AnalogymetAnalogous to MAOI serotonin syndrome

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for linezolid captured serotonin syndrome as a tracked adverse event in a usable structure. Trials did not systematically co-administer serotonergic drugs with linezolid.
Causality: well established

Nitrofurantoin ↔ Peripheral neuropathy

Open this assessment on its own page →

n=207 co-reports · PRR 2.8 · ROR 2.8

Nitrofurantoin can cause peripheral neuropathy that may become irreversible, particularly with prolonged use or renal impairment; 207 co-reports give PRR 2.8. The label warns of this effect and advises prompt withdrawal if numbness or paraesthesia appears.

Regulatory basis: nitrofurantoin prescribing information — peripheral neuropathy; caution in renal impairment and prolonged use.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks of therapy
StrengthmetPRR 2.8 with 207 co-reports
ConsistencymetReproduced across reports
Specificitynot establishedPeripheral neuropathy has many causes
Biological gradientmetDuration/exposure-related
PlausibilitymetPlausible axonal toxicity
CoherencemetFits nitrofurantoin neurotoxicity
Experimentn/aNot a routine trial endpoint
AnalogymetAnalogous to other drug-induced neuropathies

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for nitrofurantoin captured peripheral neuropathy as a tracked adverse event in a usable structure. Short-course urinary-tract trials were too brief to detect treatment-emergent neuropathy.
Causality: well established

Minocycline ↔ Drug-induced lupus

Open this assessment on its own page →

n=569 co-reports · PRR 29.6 · ROR 31.0

Minocycline is a well-recognised cause of drug-induced lupus, typically with arthralgia, myalgia and positive antinuclear antibodies that resolve after withdrawal; 569 co-reports give PRR 29.6. The label lists lupus-like syndrome among its hypersensitivity reactions.

Regulatory basis: minocycline prescribing information — lupus-like syndrome and autoimmune reactions.

Bradford Hill viewpointStatusNote
Temporality (necessary)metMonths of therapy
StrengthmetPRR 29.6 with 569 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to minocycline
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetPlausible immune mechanism
CoherencemetFits tetracycline-induced autoimmunity
Experimentn/aToo chronic for trial capture
AnalogymetAnalogous to hydralazine/procainamide lupus

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for minocycline captured drug-induced lupus as a tracked adverse event in a usable structure. Long-term minocycline trials for acne did not code drug-induced lupus as an adverse event.
Causality: well established

Minocycline ↔ DRESS (eosinophilia and systemic symptoms)

Open this assessment on its own page →

n=279 co-reports · PRR 20.0 · ROR 20.4

Minocycline can cause DRESS (drug reaction with eosinophilia and systemic symptoms), a severe delayed hypersensitivity syndrome with rash, fever and organ involvement; 279 co-reports give PRR 20.0. Management is withdrawal and corticosteroid support.

Regulatory basis: minocycline prescribing information — severe hypersensitivity/DRESS.

Bradford Hill viewpointStatusNote
Temporality (necessary)met2-6 weeks after start
StrengthmetPRR 20.0 with 279 co-reports
ConsistencymetReproduced across reports
SpecificitymetAssociated with HLA alleles
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetImmune-mediated mechanism
CoherencemetFits minocycline hypersensitivity
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to other antibiotic DRESS

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for minocycline captured dress (eosinophilia and systemic symptoms) as a tracked adverse event in a usable structure. A rare delayed hypersensitivity syndrome cannot be detected in randomised trials.
Contested: signal not confirmed by large randomized trials

Isotretinoin ↔ Inflammatory bowel disease

Open this assessment on its own page →

n=5,252 co-reports · PRR 494.6 · ROR 553.6

Isotretinoin has been linked to inflammatory bowel disease in case reports and some observational studies, but large cohort and meta-analytic analyses have not confirmed a causal increase; 5,252 co-reports nevertheless give PRR 494.6, a signal inflated by channeling and confounding. It is graded contested rather than established.

Regulatory basis: literature — isotretinoin and inflammatory bowel disease; label lists IBD among reported events but the association is disputed.

Bradford Hill viewpointStatusNote
Temporality (necessary)metCourses over months
StrengthmetPRR 494.6, inflated by channeling
ConsistencypartialObservational studies disagree
Specificitynot establishedAcne populations differ
Biological gradientnot establishedNo clear dose relation
PlausibilitypartialMechanism proposed but unproven
CoherencepartialCohort data argue against causality
Experimentn/aLarge cohorts did not confirm
AnalogypartialContrasted with other acne therapies

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for isotretinoin captured inflammatory bowel disease as a tracked adverse event in a usable structure. Observational designs are confounded by indication; meta-analyses of cohorts did not confirm the association.
Causality: well established

Thalidomide ↔ Peripheral neuropathy

Open this assessment on its own page →

n=1,823 co-reports · PRR 11.3 · ROR 11.8

Thalidomide carries a boxed warning for peripheral neuropathy, a dose- and duration-related axonal injury that may be irreversible and is often the dose-limiting toxicity; 1,823 co-reports give PRR 11.3. The label advises baseline and periodic neurological assessment.

Regulatory basis: thalidomide prescribing information — boxed warning for peripheral neuropathy.

Bradford Hill viewpointStatusNote
Temporality (necessary)metMonths of therapy, cumulative
StrengthmetPRR 11.3 with 1,823 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to thalidomide
Biological gradientmetStrong cumulative-dose relation
PlausibilitymetKnown axonal toxicity
CoherencemetFits thalidomide neurotoxicity
Experimentn/aNeuropathy is a coded trial endpoint
AnalogymetAnalogous to bortezomib neuropathy

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Pomalidomide for the Treatment of Bleeding in HHT (NCT03910244)

Adverse eventPlacebo (n=49) · Pomalidomide (n=95)
Neuropathy peripheral0/492/95

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Lenalidomide ↔ Deep vein thrombosis

Open this assessment on its own page →

n=4,404 co-reports · PRR 3.5 · ROR 3.6

Lenalidomide carries a boxed warning for venous thromboembolism, including deep vein thrombosis and pulmonary embolism, with risk increased by dexamethasone and in myeloma; 4,404 co-reports give PRR 3.5. The label mandates thromboprophylaxis guidance.

Regulatory basis: lenalidomide (Revlimid) prescribing information — boxed warning for venous thromboembolism; thromboprophylaxis.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks to months
StrengthmetPRR 3.5 with 4,404 co-reports
ConsistencymetReproduced across cohorts
Specificitynot establishedVTE risk is high in myeloma
Biological gradientmetDose/regimen-related
PlausibilitymetPlausible prothrombotic mechanism
CoherencemetFits IMiD-associated thrombosis
Experimentn/aVTE is often a coded trial event
AnalogymetAnalogous to thalidomide-associated VTE

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma (NCT00833833)

Adverse eventPhase 1: 2 mg Pomalidomide (n=6) · Phase 1: 3 mg Pomalidomide (n=8) · Phase 1: 4 mg Pomalidomide (n=14) · Phase 1: 5 mg Pomalidomide (n=10)
Deep vein thrombosis0/60/81/141/10

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Clonidine ↔ Blood pressure increased (rebound)

Open this assessment on its own page →

n=1,733 co-reports · PRR 4.7 · ROR 4.8

Abrupt withdrawal of clonidine causes rebound hypertension with catecholamine surge, especially after high doses or concomitant beta-blockade; 1,733 co-reports give PRR 4.7. The label warns against abrupt discontinuation and advises tapering.

Regulatory basis: clonidine (Catapres) prescribing information — rebound hypertension on abrupt withdrawal; taper guidance.

Bradford Hill viewpointStatusNote
Temporality (necessary)metHours to days after stopping
StrengthmetPRR 4.7 with 1,733 co-reports
ConsistencymetReproduced across reports
Specificitynot establishedBP readings are non-specific
Biological gradientmetHigher with higher doses
PlausibilitymetKnown withdrawal catecholamine surge
CoherencemetFits clonidine's mechanism
Experimentn/aWithdrawal not studied in trials
AnalogymetAnalogous to beta-blocker withdrawal

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for clonidine captured blood pressure increased (rebound) as a tracked adverse event in a usable structure. Trials rarely study the withdrawal phase, so rebound hypertension is not captured as an on-treatment event.
Causality: well established

Propylthiouracil ↔ Agranulocytosis

Open this assessment on its own page →

n=60 co-reports · PRR 33.3 · ROR 34.3

Propylthiouracil can cause agranulocytosis, a potentially fatal idiosyncratic effect, usually within the first weeks to months of therapy; 60 co-reports give PRR 33.3. The label advises patients to report fever or sore throat immediately for an urgent blood count.

Regulatory basis: propylthiouracil prescribing information — agranulocytosis; patient and blood-count monitoring advice.

Bradford Hill viewpointStatusNote
Temporality (necessary)metFirst weeks to months
StrengthmetPRR 33.3 with 60 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to antithyroid drugs
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetIdiosyncratic marrow suppression
CoherencemetFits thionamide agranulocytosis
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to methimazole agranulocytosis

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for propylthiouracil captured agranulocytosis as a tracked adverse event in a usable structure. Rare idiosyncratic agranulocytosis is far below the detection threshold of thyroid trials.
Causality: well established

Sotalol ↔ Prolonged QT interval

Open this assessment on its own page →

n=446 co-reports · PRR 15.9 · ROR 16.3

Sotalol prolongs the QT interval through potassium-channel blockade and can cause torsades de pointes; it carries a boxed warning for this proarrhythmia and requires initiation with ECG monitoring and attention to renal function; 446 co-reports give PRR 15.9.

Regulatory basis: sotalol prescribing information — boxed warning for QT prolongation and torsades de pointes; ECG monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metHours after dosing
StrengthmetPRR 15.9 with 446 co-reports
ConsistencymetConsistent across studies
Specificitynot establishedQT prolongation has many causes
Biological gradientmetConcentration/dose-related
PlausibilitymetKnown potassium-channel blockade
CoherencemetFits class III antiarrhythmic effect
Experimentn/aOften monitored in trials
AnalogymetAnalogous to other QT-prolonging antiarrhythmics

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial (NCT00911508)

Adverse eventLeft Atrial Ablation (n=1108) · Rate or Rhythm Control Therapy (n=1096)
ELECTROCARDIOGRAM QT PROLONGED2/11081/1096

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Dofetilide ↔ Prolonged QT interval

Open this assessment on its own page →

n=445 co-reports · PRR 25.1 · ROR 26.2

Dofetilide is a potent QT-prolonging antiarrhythmic that can cause torsades de pointes and carries a boxed warning plus mandatory initiation monitoring and renal-function checks; 445 co-reports give PRR 25.1.

Regulatory basis: dofetilide (Tikosyn) prescribing information — boxed warning for QT prolongation/torsades; mandatory in-hospital initiation.

Bradford Hill viewpointStatusNote
Temporality (necessary)metHours after initiation
StrengthmetPRR 25.1 with 445 co-reports
ConsistencymetConsistent across studies
SpecificitymetFairly specific to class III
Biological gradientmetConcentration/dose-related
PlausibilitymetKnown IKr blockade
CoherencemetFits dofetilide's mechanism
Experimentn/aMonitored in trials by design
AnalogymetAnalogous to sotalol QT effect

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial (NCT00911508)

Adverse eventLeft Atrial Ablation (n=1108) · Rate or Rhythm Control Therapy (n=1096)
ELECTROCARDIOGRAM QT PROLONGED2/11081/1096

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Haloperidol ↔ Neuroleptic malignant syndrome

Open this assessment on its own page →

n=1,630 co-reports · PRR 138.0 · ROR 147.9

Haloperidol is a leading cause of neuroleptic malignant syndrome, a life-threatening reaction of hyperthermia, rigidity and autonomic instability that can occur after any exposure; 1,630 co-reports give an extreme PRR of 138.0. Prompt recognition and withdrawal are essential.

Regulatory basis: haloperidol prescribing information — neuroleptic malignant syndrome warning.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDays after start or dose change
StrengthmetPRR 138.0, an extreme signal
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to antipsychotics
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetKnown dopaminergic blockade mechanism
CoherencemetFits haloperidol's D2 antagonism
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to other antipsychotic NMS

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study (NCT01211522)

Adverse eventHaloperidol (n=192) · Ziprasidone (n=190) · Placebo (n=184)
Neuroleptic malignant syndrome0/1920/1900/184

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Haloperidol ↔ Prolonged QT interval

Open this assessment on its own page →

n=653 co-reports · PRR 16.0 · ROR 16.4

Haloperidol prolongs the QT interval and can cause torsades de pointes, particularly with intravenous or high-dose use and co-administered QT-prolonging drugs; 653 co-reports give PRR 16.0. The label warns of this risk and advises ECG monitoring in at-risk patients.

Regulatory basis: haloperidol prescribing information — QT prolongation/torsades de pointes warning.

Bradford Hill viewpointStatusNote
Temporality (necessary)metHours after dosing
StrengthmetPRR 16.0 with 653 co-reports
ConsistencymetConsistent across reports
Specificitynot establishedQT prolongation has many causes
Biological gradientmetDose/route-related
PlausibilitymetKnown hERG blockade
CoherencemetFits haloperidol's cardiac effect
Experimentn/aMonitored in some trials
AnalogymetAnalogous to other antipsychotic QT effects

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for haloperidol captured prolonged qt interval as a tracked adverse event in a usable structure. QT effect is recognised but confounded by co-medication and the underlying agitation being treated.
Causality: well established

Haloperidol ↔ Tardive dyskinesia

Open this assessment on its own page →

n=378 co-reports · PRR 11.7 · ROR 11.8

Haloperidol, as a high-potency typical antipsychotic, carries a substantial risk of tardive dyskinesia with prolonged use; 378 co-reports give PRR 11.7. The label warns of this potentially irreversible effect and advises the lowest effective dose and periodic assessment.

Regulatory basis: haloperidol prescribing information — tardive dyskinesia warning; lowest effective dose.

Bradford Hill viewpointStatusNote
Temporality (necessary)metMonths to years of use
StrengthmetPRR 11.7 with 378 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to antipsychotics
Biological gradientmetCumulative dose-related
PlausibilitymetKnown dopaminergic supersensitivity
CoherencemetFits haloperidol's chronic effect
Experimentn/aChronic and under-coded in trials
AnalogymetAnalogous to other antipsychotic tardive syndromes

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for haloperidol captured tardive dyskinesia as a tracked adverse event in a usable structure. Tardive effects appear after chronic exposure and are rarely captured in time-limited trials.
Causality: well established

Pimozide ↔ Prolonged QT interval

Open this assessment on its own page →

n=23 co-reports · PRR 28.5 · ROR 29.9

Pimozide prolongs the QT interval and carries a boxed warning for this proarrhythmia, with ECG assessment advised before and during therapy; 23 co-reports give PRR 28.5. The label limits dose and warns against QT-prolonging co-medication.

Regulatory basis: pimozide (Orap) prescribing information — boxed warning for QT prolongation/torsades; ECG monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metHours after dosing
StrengthmetPRR 28.5, an extreme signal
ConsistencymetReproduced across reports
SpecificitymetFairly specific to pimozide
Biological gradientmetDose-related
PlausibilitymetKnown hERG blockade
CoherencemetFits pimozide's cardiac effect
Experimentn/aSmall numbers limit trial capture
AnalogymetAnalogous to other antipsychotic QT effects

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for pimozide captured prolonged qt interval as a tracked adverse event in a usable structure. QT effect is expected but the small treated population limits statistical capture.
Expected pharmacological effect

Quetiapine ↔ Hypotension

Open this assessment on its own page →

n=4,265 co-reports · PRR 2.4 · ROR 2.4

Quetiapine blocks alpha-1 adrenergic receptors and commonly causes orthostatic hypotension and dizziness, especially during dose titration; 4,265 co-reports give PRR 2.4. The label advises slow titration and caution in older adults.

Regulatory basis: quetiapine prescribing information — orthostatic hypotension and syncope; slow titration guidance.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDuring titration
StrengthmetPRR 2.4 with 4,265 co-reports
ConsistencymetConsistent across cohorts
Specificitynot establishedHypotension is common
Biological gradientmetDose/titration-related
PlausibilitymetKnown alpha-1 blockade
CoherencemetFits quetiapine's receptor profile
Experimentn/aOften coded in trials
AnalogymetAnalogous to other antipsychotic hypotension

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for quetiapine captured hypotension as a tracked adverse event in a usable structure. Hypotension is expected and reported, but co-reporting is confounded by the psychiatric population treated.
Expected pharmacological effect

Olanzapine ↔ Weight gain

Open this assessment on its own page →

n=6,832 co-reports · PRR 6.2 · ROR 6.5

Olanzapine produces marked weight gain, among the largest of the atypical antipsychotics, through appetite and metabolic effects; 6,832 co-reports give PRR 6.2. The label advises baseline weight monitoring and counselling.

Regulatory basis: olanzapine prescribing information — weight gain; metabolic monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks to months
StrengthmetPRR 6.2 with 6,832 co-reports
ConsistencymetConsistent across cohorts
Specificitynot establishedWeight gain is common
Biological gradientmetDose/duration-related
PlausibilitymetKnown appetite/metabolic mechanism
CoherencemetFits olanzapine's metabolic profile
Experimentn/aOften a coded trial endpoint
AnalogymetAnalogous to clozapine weight gain

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for olanzapine captured weight gain as a tracked adverse event in a usable structure. Weight gain is well captured in trials, though background diet and lifestyle confound comparison.
Expected pharmacological effect

Olanzapine ↔ Diabetes mellitus

Open this assessment on its own page →

n=5,404 co-reports · PRR 14.8 · ROR 15.6

Olanzapine is associated with hyperglycaemia and new-onset diabetes, sometimes without preceding weight gain; 5,404 co-reports give PRR 14.8. The label advises baseline and periodic glucose monitoring and warns of severe hyperglycaemia.

Regulatory basis: olanzapine prescribing information — hyperglycaemia/diabetes warning; glucose monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks to months
StrengthmetPRR 14.8 with 5,404 co-reports
ConsistencymetConsistent across cohorts
Specificitynot establishedDiabetes is common generally
Biological gradientmetDuration-related
PlausibilitymetPlausible insulin-resistance mechanism
CoherencemetFits olanzapine's metabolic profile
Experimentn/aMonitored in trials
AnalogymetAnalogous to clozapine dysglycaemia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for olanzapine captured diabetes mellitus as a tracked adverse event in a usable structure. Metabolic monitoring is recommended, but background diabetes prevalence confounds signal interpretation.
Causality: well established

Risperidone ↔ Neuroleptic malignant syndrome

Open this assessment on its own page →

n=2,246 co-reports · PRR 36.8 · ROR 37.4

Risperidone, like other antipsychotics, can cause neuroleptic malignant syndrome, a life-threatening hyperthermic rigid syndrome; 2,246 co-reports give PRR 36.8. The label warns of the reaction and requires immediate withdrawal if it occurs.

Regulatory basis: risperidone prescribing information — neuroleptic malignant syndrome warning.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDays after start or change
StrengthmetPRR 36.8 with 2,246 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to antipsychotics
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetKnown dopaminergic blockade
CoherencemetFits risperidone's D2 antagonism
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to haloperidol NMS

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for risperidone captured neuroleptic malignant syndrome as a tracked adverse event in a usable structure. A rare idiosyncratic emergency is not detectable in randomised psychiatric trials.
Causality: well established

Clozapine ↔ Myocarditis

Open this assessment on its own page →

n=2,231 co-reports · PRR 41.1 · ROR 41.8

Clozapine can cause myocarditis, most often in the first eight weeks of therapy, and is a leading cause of drug-induced myocarditis; 2,231 co-reports give PRR 41.1. The label advises vigilance for cardiac symptoms early in treatment and monitoring of inflammatory markers.

Regulatory basis: clozapine prescribing information — myocarditis/cardiomyopathy warning; early cardiac vigilance.

Bradford Hill viewpointStatusNote
Temporality (necessary)metFirst 8 weeks of therapy
StrengthmetPRR 41.1 with 2,231 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to clozapine
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetPlausible hypersensitivity mechanism
CoherencemetFits clozapine's cardiac toxicity
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to other drug-induced myocarditis

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for clozapine captured myocarditis as a tracked adverse event in a usable structure. A rare early cardiac reaction is not captured in randomised trials of treatment-resistant psychosis.
Expected pharmacological effect

Cyclosporine ↔ Acute kidney injury

Open this assessment on its own page →

n=1,777 co-reports · PRR 2.2 · ROR 2.2

Cyclosporine causes dose-related renal vasoconstriction and nephrotoxicity, both acutely and after chronic use; 1,777 co-reports give PRR 2.2. The label advises renal-function and level monitoring with dose adjustment.

Regulatory basis: cyclosporine prescribing information — nephrotoxicity; renal-function and trough-level monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDays to weeks
StrengthmetPRR 2.2 with 1,777 co-reports
ConsistencymetConsistent across studies
Specificitynot establishedRenal impairment is common post-transplant
Biological gradientmetLevel/dose-related
PlausibilitymetKnown vasoconstriction mechanism
CoherencemetFits cyclosporine's renal effect
Experimentn/aOften monitored in trials
AnalogymetAnalogous to tacrolimus nephrotoxicity

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) (NCT01950819)

Adverse eventEverolimus Plus@Reduced CNI (n=1014) · MPA Plus Standard@CNI (n=1012)
Acute kidney injury46/101437/1012

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Cyclosporine ↔ Gingival hypertrophy

Open this assessment on its own page →

n=231 co-reports · PRR 34.4 · ROR 34.4

Cyclosporine commonly causes gingival hyperplasia, related to dose, duration and oral hygiene; 231 co-reports give PRR 34.4. The label lists gingival hyperplasia and advises dental care and monitoring.

Regulatory basis: cyclosporine prescribing information — gingival hyperplasia.

Bradford Hill viewpointStatusNote
Temporality (necessary)metMonths of therapy
StrengthmetPRR 34.4 with 231 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to cyclosporine
Biological gradientmetDose/concentration-related
PlausibilitymetKnown fibroblast-proliferation mechanism
CoherencemetFits cyclosporine's connective-tissue effect
Experimentn/aNot a short-term trial endpoint
AnalogymetAnalogous to phenytoin gingival overgrowth

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for cyclosporine captured gingival hypertrophy as a tracked adverse event in a usable structure. Trials were too short and did not code gingival changes as adverse events.
Expected pharmacological effect

Tacrolimus ↔ Acute kidney injury

Open this assessment on its own page →

n=6,153 co-reports · PRR 5.6 · ROR 5.8

Tacrolimus, like cyclosporine, causes dose-related nephrotoxicity through renal vasoconstriction and tubular effects; 6,153 co-reports give PRR 5.6. The label advises renal-function and level monitoring with dose adjustment.

Regulatory basis: tacrolimus prescribing information — nephrotoxicity; renal-function and trough-level monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDays to weeks
StrengthmetPRR 5.6 with 6,153 co-reports
ConsistencymetConsistent across studies
Specificitynot establishedRenal impairment is common post-transplant
Biological gradientmetLevel/dose-related
PlausibilitymetKnown vasoconstriction mechanism
CoherencemetFits tacrolimus's renal effect
Experimentn/aOften monitored in trials
AnalogymetAnalogous to cyclosporine nephrotoxicity

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) (NCT01950819)

Adverse eventEverolimus Plus@Reduced CNI (n=1014) · MPA Plus Standard@CNI (n=1012)
Acute kidney injury46/101437/1012

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Sirolimus ↔ Interstitial lung disease

Open this assessment on its own page →

n=92 co-reports · PRR 3.0 · ROR 3.0

Sirolimus (mTOR inhibitor) can cause non-infectious interstitial pneumonitis and lung disease, a potentially serious complication; 92 co-reports give PRR 3.0. The label lists interstitial lung disease and advises investigation of new respiratory symptoms.

Regulatory basis: sirolimus prescribing information — interstitial lung disease/pneumonitis warning.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks to months
StrengthmetPRR 3.0 with 92 co-reports
ConsistencymetReproduced across reports
SpecificitymetFairly specific to mTOR inhibitors
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetPlausible immune-mediated mechanism
CoherencemetFits sirolimus pulmonary toxicity
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to everolimus pneumonitis

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) (NCT01950819)

Adverse eventEverolimus Plus@Reduced CNI (n=1014) · MPA Plus Standard@CNI (n=1012)
Interstitial lung disease1/10140/1012

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Azathioprine ↔ Pancytopenia

Open this assessment on its own page →

n=1,126 co-reports · PRR 4.9 · ROR 5.0

Azathioprine suppresses the marrow, and pancytopenia is a recognised toxicity, greatly amplified in thiopurine-methyltransferase deficiency; 1,126 co-reports give PRR 4.9. The label advises blood-count monitoring and thiopurine-enzyme awareness.

Regulatory basis: azathioprine prescribing information — myelosuppression/pancytopenia; blood-count monitoring and TPMT caution.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks of therapy
StrengthmetPRR 4.9 with 1,126 co-reports
ConsistencymetConsistent across cohorts
Specificitynot establishedCytopenias have many causes
Biological gradientmetMetabolism/TPMT-dependent
PlausibilitymetKnown purine-antagonist mechanism
CoherencemetFits azathioprine myelosuppression
Experimentn/aOften coded in trials
AnalogymetAnalogous to mercaptopurine myelosuppression

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis (NCT01639339)

Adverse eventPlacebo (n=224) · Belimumab 10 mg/kg (n=224) · Placebo to Belimumab 10 mg/kg (n=123) · Belimumab 10 mg/kg to Belimumab 10 mg/kg (n=132)
Pancytopenia0/2242/2240/1230/132

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Leflunomide ↔ Interstitial lung disease

Open this assessment on its own page →

n=1,346 co-reports · PRR 5.7 · ROR 5.8

Leflunomide can cause interstitial lung disease/pneumonitis, an uncommon but potentially fatal complication that has been reported early and late in therapy; 1,346 co-reports give PRR 5.7. The label warns of this risk and advises prompt withdrawal if pulmonary symptoms emerge.

Regulatory basis: leflunomide (Arava) prescribing information — interstitial lung disease/pneumonitis warning.

Bradford Hill viewpointStatusNote
Temporality (necessary)metEarly or late in therapy
StrengthmetPRR 5.7 with 1,346 co-reports
ConsistencymetReproduced across cohorts
Specificitynot establishedILD also occurs in rheumatoid disease
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetPlausible immune-mediated mechanism
CoherencemetFits leflunomide pulmonary toxicity
Experimentn/aUnder-coded in trials
AnalogymetAnalogous to methotrexate lung toxicity

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies (NCT00720798)

Adverse eventTocilizumab (n=2067)
Interstitial lung disease5/2067

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Methotrexate ↔ Pancytopenia

Open this assessment on its own page →

n=5,955 co-reports · PRR 5.9 · ROR 6.0

Methotrexate is a folate antagonist that can cause marrow suppression with pancytopenia, especially with renal impairment, low folate, or high-dose regimens; 5,955 co-reports give PRR 5.9. The label advises blood-count monitoring and folate supplementation.

Regulatory basis: methotrexate prescribing information — myelosuppression/pancytopenia; blood-count monitoring and folate.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDays to weeks
StrengthmetPRR 5.9 with 5,955 co-reports
ConsistencymetConsistent across cohorts
Specificitynot establishedCytopenias have many causes
Biological gradientmetDose and folate-dependent
PlausibilitymetKnown antifolate mechanism
CoherencemetFits methotrexate myelosuppression
Experimentn/aOften coded in trials
AnalogymetAnalogous to other antifolate toxicity

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for methotrexate captured pancytopenia as a tracked adverse event in a usable structure. Cytopenias are monitored but co-reported against the underlying disease and concomitant therapy.
Expected pharmacological effect

Hydroxyurea ↔ Febrile neutropenia

Open this assessment on its own page →

n=426 co-reports · PRR 6.5 · ROR 6.6

Hydroxyurea suppresses the marrow and can cause neutropenia with fever, which is dose-limiting in some regimens; 426 co-reports give PRR 6.5. The label advises regular blood-count monitoring and interruption for marked cytopenia.

Regulatory basis: hydroxyurea prescribing information — myelosuppression; blood-count monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks of therapy
StrengthmetPRR 6.5 with 426 co-reports
ConsistencymetConsistent across cohorts
Specificitynot establishedNeutropenic fever has many causes
Biological gradientmetDose-related
PlausibilitymetKnown ribonucleotide-reductase inhibition
CoherencemetFits hydroxyurea myelosuppression
Experimentn/aOften coded in trials
AnalogymetAnalogous to other antimetabolite cytopenias

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies (NCT02158858)

Adverse eventPhase 1 (24 mg Capsule PO Daily) (n=3) · Phase 1 (48 mg Capsule PO Daily) (n=5) · Phase 1 (120 mg Capsule PO Daily) (n=5) · Phase 1 (170 mg Capsule PO Daily) (n=3)
Febrile neutropenia1/32/51/50/3

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Bleomycin ↔ Interstitial lung disease

Open this assessment on its own page →

n=146 co-reports · PRR 8.6 · ROR 8.7

Bleomycin causes dose-related pulmonary toxicity and fibrosis, a classic dose-limiting adverse effect that can progress to fatal respiratory failure; 146 co-reports give PRR 8.6. The label warns of pulmonary toxicity and advises monitoring of respiratory status.

Regulatory basis: bleomycin prescribing information — pulmonary toxicity/fibrosis warning; cumulative-dose limitation.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks to months, cumulative
StrengthmetPRR 8.6 with 146 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to bleomycin
Biological gradientmetStrong cumulative-dose relation
PlausibilitymetKnown DNA-strand-break mechanism
CoherencemetFits bleomycin pulmonary toxicity
Experimentn/aOften monitored in trials
AnalogymetAnalogous to other drug-induced pulmonary fibrosis

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma (NCT01712490)

Adverse eventA+AVD (n=662) · ABVD (n=659)
Interstitial lung disease1/6622/659

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Cyclophosphamide ↔ Haemorrhagic cystitis

Open this assessment on its own page →

n=1,125 co-reports · PRR 46.1 · ROR 46.4

Cyclophosphamide produces acrolein, a metabolite that causes haemorrhagic cystitis, an important dose-related toxicity prevented by hydration and mesna; 1,125 co-reports give PRR 46.1. The label warns of this effect and advises preventive measures.

Regulatory basis: cyclophosphamide prescribing information — haemorrhagic cystitis warning; hydration and mesna prophylaxis.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDays after administration
StrengthmetPRR 46.1, an extreme signal
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to oxazaphosphorines
Biological gradientmetDose-related
PlausibilitymetKnown acrolein mechanism
CoherencemetFits cyclophosphamide urotoxicity
Experimentn/aOften coded in trials
AnalogymetAnalogous to ifosfamide cystitis

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for cyclophosphamide captured haemorrhagic cystitis as a tracked adverse event in a usable structure. Urotoxicity is recognised and mitigated in trials by hydration and mesna, which reduces observed rates.
Causality: well established

Doxorubicin ↔ Cardiotoxicity

Open this assessment on its own page →

n=1,221 co-reports · PRR 37.7 · ROR 38.2

Doxorubicin carries a boxed warning for cardiotoxicity: cumulative-dose-related cardiomyopathy and heart failure, with risk rising above threshold doses; 1,221 co-reports give PRR 37.7. The label advises cardiac monitoring and cumulative-dose limits.

Regulatory basis: doxorubicin prescribing information — boxed warning for cardiotoxicity; cumulative-dose limits and cardiac monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metMonths, cumulative
StrengthmetPRR 37.7 with 1,221 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to anthracyclines
Biological gradientmetStrong cumulative-dose relation
PlausibilitymetKnown free-radical mechanism
CoherencemetFits anthracycline cardiomyopathy
Experimentn/aOften monitored in trials
AnalogymetAnalogous to other anthracycline cardiotoxicity

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for doxorubicin captured cardiotoxicity as a tracked adverse event in a usable structure. Cardiac toxicity is monitored, but confounded by radiotherapy and other cardiotoxic agents.
Causality: well established

Trastuzumab ↔ Ejection fraction decreased

Open this assessment on its own page →

n=2,048 co-reports · PRR 46.5 · ROR 47.9

Trastuzumab carries a boxed warning for cardiomyopathy and left-ventricular ejection-fraction decline, particularly with anthracyclines; 2,048 co-reports give PRR 46.5. The label advises baseline and periodic cardiac monitoring.

Regulatory basis: trastuzumab (Herceptin) prescribing information — boxed warning for cardiomyopathy; ejection-fraction monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks to months
StrengthmetPRR 46.5, an extreme signal
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to HER2 agents
Biological gradientmetDose/regimen-related
PlausibilitymetPlausible HER2 cardiac mechanism
CoherencemetFits trastuzumab cardiotoxicity
Experimentn/aOften monitored in trials
AnalogymetAnalogous to anthracycline cardiotoxicity

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer (NCT01670877)

Adverse eventPart I: Neratinib Only (n=16) · Part II: Neratinib Only (ER-) (n=5) · Part II: Neratinib + Fulvestrant (ER+, Fulvestrant-naive) (n=11) · Part II: Neratinib + Fulvestrant (ER+. Prior Fulvestrant-tx) (n=24)
Ejection fraction decreased0/160/50/110/24

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Cisplatin ↔ Acute kidney injury

Open this assessment on its own page →

n=1,863 co-reports · PRR 3.3 · ROR 3.4

Cisplatin is nephrotoxic, causing dose-related tubular injury that requires hydration and electrolyte monitoring; 1,863 co-reports give PRR 3.3. The label advises renal-function and magnesium monitoring with adequate hydration.

Regulatory basis: cisplatin prescribing information — nephrotoxicity; hydration and renal/electrolyte monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDays after administration
StrengthmetPRR 3.3 with 1,863 co-reports
ConsistencymetConsistent across cohorts
Specificitynot establishedRenal injury has many causes
Biological gradientmetDose-related
PlausibilitymetKnown tubular uptake mechanism
CoherencemetFits cisplatin nephrotoxicity
Experimentn/aOften monitored in trials
AnalogymetAnalogous to other nephrotoxic cytotoxics

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) (NCT02142738)

Adverse eventPembrolizumab First Course (n=154) · SOC Chemotherapy First Course (n=150) · SOC Chemotherapy Switched Over to Pembrolizumab First Course (n=83) · Pembrolizumab Second Course (n=12)
Acute kidney injury0/1543/1500/830/12

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Oxaliplatin ↔ Peripheral neuropathy

Open this assessment on its own page →

n=4,317 co-reports · PRR 13.6 · ROR 14.3

Oxaliplatin causes a distinctive peripheral neuropathy: an acute cold-sensitive sensory component and a cumulative chronic sensory loss that can limit therapy; 4,317 co-reports give PRR 13.6. The label warns of neuropathy and advises dose modification.

Regulatory basis: oxaliplatin prescribing information — acute and cumulative peripheral neuropathy; dose modification.

Bradford Hill viewpointStatusNote
Temporality (necessary)metAcute and cumulative
StrengthmetPRR 13.6 with 4,317 co-reports
ConsistencymetConsistent across cohorts
SpecificitymetFairly specific to platinum agents
Biological gradientmetStrong cumulative-dose relation
PlausibilitymetKnown dorsal-root-ganglion toxicity
CoherencemetFits oxaliplatin neurotoxicity
Experimentn/aOften monitored in trials
AnalogymetAnalogous to cisplatin neuropathy

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer (NCT02024607)

Adverse eventNapabucasin Plus FOLFOX6 (n=115) · Napabucasin Plus FOLFOX6 Plus Bevacizumab (n=41) · Napabucasin Plus CAPOX (n=87) · Napabucasin Plus FOLFIRI (n=156)
Neuropathy peripheral35/11513/4113/875/156

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Vincristine ↔ Peripheral neuropathy

Open this assessment on its own page →

n=645 co-reports · PRR 4.9 · ROR 5.0

Vincristine is a vinca alkaloid that causes a dose-limiting peripheral sensory-motor neuropathy, with loss of deep-tendon reflexes to frank weakness; 645 co-reports give PRR 4.9. The label warns of neurotoxicity and caps the dose.

Regulatory basis: vincristine prescribing information — peripheral neuropathy; dose limitation.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDays to weeks
StrengthmetPRR 4.9 with 645 co-reports
ConsistencymetConsistent across cohorts
SpecificitymetFairly specific to vinca alkaloids
Biological gradientmetDose-related
PlausibilitymetKnown microtubule mechanism
CoherencemetFits vincristine neurotoxicity
Experimentn/aOften monitored in trials
AnalogymetAnalogous to other vinca neuropathies

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for vincristine captured peripheral neuropathy as a tracked adverse event in a usable structure. Neurotoxicity is expected, but graded clinically and confounded by other neurotoxic chemotherapy.
Causality: well established

Paclitaxel ↔ Peripheral neuropathy

Open this assessment on its own page →

n=3,933 co-reports · PRR 9.2 · ROR 9.5

Paclitaxel commonly causes a dose- and duration-dependent sensory peripheral neuropathy that may persist after treatment; 3,933 co-reports give PRR 9.2. The label lists neuropathy and advises dose reduction for severe symptoms.

Regulatory basis: paclitaxel prescribing information — peripheral neuropathy; dose modification.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks, cumulative
StrengthmetPRR 9.2 with 3,933 co-reports
ConsistencymetConsistent across cohorts
SpecificitymetFairly specific to taxanes
Biological gradientmetStrong cumulative-dose relation
PlausibilitymetKnown microtubule mechanism
CoherencemetFits paclitaxel neurotoxicity
Experimentn/aOften monitored in trials
AnalogymetAnalogous to docetaxel neuropathy

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (NCT02367781)

Adverse eventArm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) (n=473) · Arm B Without Crossover Participants (Nab-Paclitaxel+Carboplatin) (n=131) · Arm B With Crossover Participants (Nab-Paclitaxel+Carboplatin, After Crossover Atezo Monotherapy) (n=101)
NEUROPATHY PERIPHERAL56/47313/1319/101

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Docetaxel ↔ Febrile neutropenia

Open this assessment on its own page →

n=3,074 co-reports · PRR 15.2 · ROR 15.9

Docetaxel causes myelosuppression with febrile neutropenia, especially at higher doses and without growth-factor support; 3,074 co-reports give PRR 15.2. The label advises blood-count monitoring and dose adjustment.

Regulatory basis: docetaxel prescribing information — neutropenia/febrile neutropenia; blood-count monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDays after infusion
StrengthmetPRR 15.2 with 3,074 co-reports
ConsistencymetConsistent across cohorts
Specificitynot establishedFebrile neutropenia has many causes
Biological gradientmetDose-related
PlausibilitymetKnown antimitotic marrow suppression
CoherencemetFits docetaxel myelosuppression
Experimentn/aOften coded in trials
AnalogymetAnalogous to paclitaxel myelosuppression

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer (NCT00630032)

Adverse eventDocetaxel (n=398) · Ixabepilone (n=364)
Febrile neutropenia56/39827/364

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Fluorouracil ↔ Neutropenia

Open this assessment on its own page →

n=5,175 co-reports · PRR 10.8 · ROR 11.5

Fluorouracil is an antimetabolite that causes myelosuppression with neutropenia, risk being higher in DPD deficiency; 5,175 co-reports give PRR 10.8. The label advises blood-count monitoring and awareness of dihydropyrimidine-dehydrogenase deficiency.

Regulatory basis: fluorouracil prescribing information — myelosuppression; blood-count monitoring and DPD caution.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDays to weeks
StrengthmetPRR 10.8 with 5,175 co-reports
ConsistencymetConsistent across cohorts
Specificitynot establishedNeutropenia has many causes
Biological gradientmetDose/metabolism-dependent
PlausibilitymetKnown antimetabolite mechanism
CoherencemetFits fluorouracil myelosuppression
Experimentn/aOften coded in trials
AnalogymetAnalogous to capecitabine myelosuppression

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT02741570)

Adverse eventNivolumab + Ipilimumab (n=468) · EXTREME Regimen (n=441)
Neutropenia0/4682/441

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Etoposide ↔ Febrile neutropenia

Open this assessment on its own page →

n=7,715 co-reports · PRR 37.8 · ROR 42.1

Etoposide causes dose- and schedule-dependent myelosuppression, with febrile neutropenia as a common severe toxicity; 7,715 co-reports give PRR 37.8. The label advises blood-count monitoring and dose adjustment.

Regulatory basis: etoposide prescribing information — myelosuppression; blood-count monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDays after administration
StrengthmetPRR 37.8, an extreme signal
ConsistencymetConsistent across cohorts
Specificitynot establishedFebrile neutropenia has many causes
Biological gradientmetStrong dose/schedule relation
PlausibilitymetKnown topoisomerase-II mechanism
CoherencemetFits etoposide myelosuppression
Experimentn/aOften coded in trials
AnalogymetAnalogous to other epipodophyllotoxin cytopenias

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC (NCT04063163)

Adverse eventGroup A (n=389) · Group B (n=196)
Febrile neutropenia2/3893/196

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Bortezomib ↔ Peripheral neuropathy

Open this assessment on its own page →

n=6,473 co-reports · PRR 17.3 · ROR 18.6

Bortezomib causes a dose- and schedule-dependent peripheral neuropathy, often sensory and sometimes painful, that can be dose-limiting; 6,473 co-reports give PRR 17.3. The label advises monitoring and dose modification, favouring subcutaneous administration.

Regulatory basis: bortezomib prescribing information — peripheral neuropathy; dose/schedule modification.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks, cumulative
StrengthmetPRR 17.3 with 6,473 co-reports
ConsistencymetConsistent across cohorts
SpecificitymetFairly specific to proteasome inhibitors
Biological gradientmetStrong dose/schedule relation
PlausibilitymetPlausible proteasome-inhibition mechanism
CoherencemetFits bortezomib neurotoxicity
Experimentn/aOften monitored in trials
AnalogymetAnalogous to thalidomide neuropathy

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma (NCT00833833)

Adverse eventPhase 1: 2 mg Pomalidomide (n=6) · Phase 1: 3 mg Pomalidomide (n=8) · Phase 1: 4 mg Pomalidomide (n=14) · Phase 1: 5 mg Pomalidomide (n=10)
Neuropathy peripheral1/60/81/143/10

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Imatinib ↔ Fluid retention / oedema

Open this assessment on its own page →

n=287 co-reports · PRR 28.5 · ROR 29.0

Imatinib commonly causes fluid retention and periorbital or generalised oedema, occasionally with pleural effusion or severe weight gain; 287 co-reports give PRR 28.5. The label lists fluid retention and advises monitoring and dose adjustment.

Regulatory basis: imatinib (Gleevec) prescribing information — fluid retention/oedema; monitoring and dose adjustment.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks of therapy
StrengthmetPRR 28.5 with 287 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to imatinib
Biological gradientmetDose-related
PlausibilitymetPlausible kinase-inhibition mechanism
CoherencemetFits imatinib fluid retention
Experimentn/aOften coded in trials
AnalogymetAnalogous to other TKI oedema

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for imatinib captured fluid retention / oedema as a tracked adverse event in a usable structure. Fluid retention is coded in trials but confounded by disease-related oedema and other therapies.
Expected pharmacological effect

Bevacizumab ↔ Hypertension

Open this assessment on its own page →

n=5,851 co-reports · PRR 4.8 · ROR 5.0

Bevacizumab, a VEGF inhibitor, commonly raises blood pressure and can cause severe hypertension through reduced nitric-oxide signalling; 5,851 co-reports give PRR 4.8. The label advises blood-pressure monitoring and management.

Regulatory basis: bevacizumab (Avastin) prescribing information — hypertension including hypertensive crisis; BP monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks of therapy
StrengthmetPRR 4.8 with 5,851 co-reports
ConsistencymetConsistent across cohorts
Specificitynot establishedHypertension is common generally
Biological gradientmetDose-related
PlausibilitymetKnown VEGF-inhibition mechanism
CoherencemetFits bevacizumab's vascular effect
Experimentn/aOften monitored in trials
AnalogymetAnalogous to other VEGF-inhibitor hypertension

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC (NCT02364999)

Adverse eventPF-06439535 (n=356) · Bevacizumab-EU (n=358) · Total (n=714)
Hypertension60/35662/358122/714

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Erlotinib ↔ Interstitial lung disease

Open this assessment on its own page →

n=95 co-reports · PRR 4.3 · ROR 4.3

Erlotinib can cause interstitial lung disease-like events, an uncommon but potentially fatal pulmonary toxicity; 95 co-reports give PRR 4.3. The label warns of this risk and advises prompt interruption of treatment for new respiratory symptoms.

Regulatory basis: erlotinib (Tarceva) prescribing information — interstitial lung disease warning.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks of therapy
StrengthmetPRR 4.3 with 95 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to EGFR inhibitors
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetPlausible pulmonary toxicity mechanism
CoherencemetFits erlotinib ILD
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to gefitinib ILD

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for erlotinib captured interstitial lung disease as a tracked adverse event in a usable structure. An uncommon pulmonary toxicity is not reliably captured in randomised oncology trials.
Expected pharmacological effect

Cetuximab ↔ Rash

Open this assessment on its own page →

n=2,273 co-reports · PRR 3.5 · ROR 3.7

Cetuximab, an EGFR inhibitor, characteristically causes an acneiform rash that reflects target engagement and can be dose-limiting and socially distressing; 2,273 co-reports give PRR 3.5. The label advises management with topical therapy and dose adjustment.

Regulatory basis: cetuximab (Erbitux) prescribing information — acneiform rash; management guidance.

Bradford Hill viewpointStatusNote
Temporality (necessary)metFirst weeks of therapy
StrengthmetPRR 3.5 with 2,273 co-reports
ConsistencymetConsistent across cohorts
SpecificitymetFairly specific to EGFR inhibitors
Biological gradientmetDose-related
PlausibilitymetKnown EGFR skin mechanism
CoherencemetFits cetuximab's on-target effect
Experimentn/aOften coded in trials
AnalogymetAnalogous to other EGFR-inhibitor rash

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT02741570)

Adverse eventNivolumab + Ipilimumab (n=468) · EXTREME Regimen (n=441)
Rash1/4680/441

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Sorafenib ↔ Hypertension

Open this assessment on its own page →

n=1,148 co-reports · PRR 5.5 · ROR 5.8

Sorafenib, a multikinase inhibitor with anti-VEGF activity, commonly raises blood pressure and can cause severe hypertension; 1,148 co-reports give PRR 5.5. The label advises blood-pressure monitoring and management during therapy.

Regulatory basis: sorafenib (Nexavar) prescribing information — hypertension; BP monitoring and management.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks of therapy
StrengthmetPRR 5.5 with 1,148 co-reports
ConsistencymetConsistent across cohorts
Specificitynot establishedHypertension is common generally
Biological gradientmetDose-related
PlausibilitymetKnown VEGF-inhibition mechanism
CoherencemetFits sorafenib's vascular effect
Experimentn/aOften monitored in trials
AnalogymetAnalogous to bevacizumab hypertension

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer (NCT01234337)

Adverse eventSorafenib (Nexavar, BAY43-9006) + Capecitabine (n=260) · Placebo + Capecitabine (n=267)
Hypertension69/26016/267

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Flutamide ↔ Hepatic function abnormal

Open this assessment on its own page →

n=24 co-reports · PRR 13.8 · ROR 14.1

Flutamide carries a warning for severe hepatic injury, including hepatic failure, and requires liver-function monitoring with prompt withdrawal if injury develops; 24 co-reports give PRR 13.8. The label advises baseline and periodic liver tests.

Regulatory basis: flutamide prescribing information — hepatotoxicity; liver-function monitoring and prompt withdrawal.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks to months
StrengthmetPRR 13.8, an extreme signal
ConsistencymetReproduced across reports
SpecificitymetFairly specific to flutamide
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetPlausible hepatocellular injury
CoherencemetFits flutamide hepatotoxicity
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to other antiandrogen hepatotoxicity

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer (NCT02918968)

Adverse eventEnzalutamide 160mg 1st Line AAT (n=102) · Enzalutamide 160mg 2nd Line AAT (n=85) · Flutamide 375mg 1st Line AAT (n=104) · Flutamide 375mg 2nd Line AAT (n=48)
Hepatic function abnormal1/1022/851/1040/48

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Ribavirin ↔ Haemolytic anaemia

Open this assessment on its own page →

n=339 co-reports · PRR 12.8 · ROR 12.9

Ribavirin causes dose-dependent oxidative haemolysis, which is its principal toxicity and can be severe, particularly with renal impairment; 339 co-reports give PRR 12.8. The label carries a boxed warning for haemolytic anaemia and advises haemoglobin monitoring.

Regulatory basis: ribavirin prescribing information — boxed warning for haemolytic anaemia; haemoglobin monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks of therapy
StrengthmetPRR 12.8 with 339 co-reports
ConsistencymetConsistent across cohorts
Specificitynot establishedAnaemia has many causes
Biological gradientmetClear dose dependence
PlausibilitymetKnown oxidative haemolysis
CoherencemetFits ribavirin's mechanism
Experimentn/aOften monitored in trials
AnalogymetAnalogous to other oxidative haemolysis

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for ribavirin captured haemolytic anaemia as a tracked adverse event in a usable structure. Haemolytic anaemia is monitored in trials and confounded by interferon and underlying liver disease.
Causality: well established

Amantadine ↔ Livedo reticularis

Open this assessment on its own page →

n=50 co-reports · PRR 33.5 · ROR 33.6

Amantadine causes livedo reticularis, a net-like mottling of the skin from dermal venule changes, that is usually benign and reversible; 50 co-reports give PRR 33.5. The label lists livedo reticularis among its adverse reactions.

Regulatory basis: amantadine prescribing information — livedo reticularis.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks of therapy
StrengthmetPRR 33.5 with 50 co-reports
ConsistencymetReproduced across reports
SpecificitymetFairly specific to amantadine
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetPlausible vascular mechanism
CoherencemetFits amantadine's dermatological effect
Experimentn/aNot a routine trial endpoint
AnalogymetAnalogous to other drug-induced livedo

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for amantadine captured livedo reticularis as a tracked adverse event in a usable structure. A benign dermatological sign is not coded as an adverse event in Parkinson's trials.
Expected pharmacological effect

Levodopa ↔ Hallucination

Open this assessment on its own page →

n=656 co-reports · PRR 15.4 · ROR 16.2

Levodopa commonly causes visual hallucinations and other dopaminergic psychiatric effects, especially in older patients and with higher doses; 656 co-reports give PRR 15.4. The label lists hallucinations and advises dose adjustment and caution.

Regulatory basis: levodopa/carbidopa prescribing information — hallucinations; dose adjustment guidance.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks to months
StrengthmetPRR 15.4 with 656 co-reports
ConsistencymetConsistent across cohorts
Specificitynot establishedPsychosis occurs in Parkinson's disease
Biological gradientmetDose-related
PlausibilitymetKnown dopaminergic mechanism
CoherencemetFits levodopa's CNS effects
Experimentn/aOften coded in trials
AnalogymetAnalogous to dopamine-agonist hallucinations

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients (NCT01628926)

Adverse eventSPM 962 (n=168) · Ropinirole (n=167) · Placebo (n=85)
Hallucination3/1686/1670/85

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Pramipexole ↔ Somnolence

Open this assessment on its own page →

n=557 co-reports · PRR 3.8 · ROR 3.9

Pramipexole commonly causes somnolence and can produce sudden-onset sleep attacks, a hazard for driving; 557 co-reports give PRR 3.8. The label warns of somnolence and advises caution with driving.

Regulatory basis: pramipexole prescribing information — somnolence and sudden sleep onset; driving caution.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDays to weeks
StrengthmetPRR 3.8 with 557 co-reports
ConsistencymetReproduced across cohorts
Specificitynot establishedSomnolence is common
Biological gradientmetDose-related
PlausibilitymetKnown dopaminergic mechanism
CoherencemetFits pramipexole's CNS effects
Experimentn/aOften coded in trials
AnalogymetAnalogous to other dopamine-agonist sedation

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Special Survey on Parkinson's Disease Patients Treated Long-term Use of Pramipexole (NCT00615914)

Adverse eventPramipexole (n=1553)
Somnolence3/1553

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Pioglitazone ↔ Fracture (ankle)

Open this assessment on its own page →

n=94 co-reports · PRR 3.0 · ROR 3.0

Pioglitazone increases fracture risk, particularly of the distal upper limb and foot, in a dose- and duration-related manner; 94 co-reports give PRR 3.0. The label warns of increased fractures and advises consideration of fracture risk.

Regulatory basis: pioglitazone prescribing information — increased risk of fracture warning.

Bradford Hill viewpointStatusNote
Temporality (necessary)metMonths of therapy
StrengthmetPRR 3.0 with 94 co-reports
ConsistencymetReproduced across trials
Specificitynot establishedFractures are common
Biological gradientmetDuration-related
PlausibilitymetPlausible PPAR-gamma bone mechanism
CoherencemetFits thiazolidinedione bone loss
Experimentn/aSometimes pooled in trials
AnalogymetAnalogous to rosiglitazone fracture risk

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for pioglitazone captured fracture (ankle) as a tracked adverse event in a usable structure. Fracture risk emerged from pooled analyses, and background trauma confounds individual reporting.
Causality: well established

Warfarin ↔ Skin necrosis

Open this assessment on its own page →

n=345 co-reports · PRR 11.7 · ROR 11.7

Warfarin can cause skin necrosis, a rare but serious complication from transient protein-C deficiency, typically in the first days of therapy and in certain deficiencies; 345 co-reports give PRR 11.7. The label warns of this risk and advises close early monitoring.

Regulatory basis: warfarin prescribing information — skin necrosis warning.

Bradford Hill viewpointStatusNote
Temporality (necessary)metFirst days of therapy
StrengthmetPRR 11.7 with 345 co-reports
ConsistencymetReproduced across reports
SpecificitymetFairly specific to vitamin-K antagonists
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetKnown protein-C depletion mechanism
CoherencemetFits warfarin's paradoxical prothrombotic phase
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to other coumarin skin necrosis

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for warfarin captured skin necrosis as a tracked adverse event in a usable structure. A rare early complication is not captured in trials of anticoagulation.
Causality: well established

Zoledronic acid ↔ Osteonecrosis of the jaw

Open this assessment on its own page →

n=2,708 co-reports · PRR 64.0 · ROR 68.6

Zoledronic acid is a potent bisphosphonate associated with osteonecrosis of the jaw, especially after invasive dental work and with prolonged therapy; 2,708 co-reports give an extreme PRR of 64.0. The label warns of ONJ and advises dental care before starting.

Regulatory basis: zoledronic acid prescribing information — osteonecrosis of the jaw warning; dental precautions.

Bradford Hill viewpointStatusNote
Temporality (necessary)metMonths to years
StrengthmetPRR 64.0, an extreme signal
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to antiresorptives
Biological gradientmetDuration-related
PlausibilitymetKnown bone-turnover suppression
CoherencemetFits bisphosphonate ONJ
Experimentn/aOften coded once recognised in trials
AnalogymetAnalogous to denosumab ONJ

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for zoledronic acid captured osteonecrosis of the jaw as a tracked adverse event in a usable structure. ONJ is under-recognised and requires dental triggers, so trial capture depends on coding practice.
Expected pharmacological effect

Zoledronic acid ↔ Hypocalcaemia

Open this assessment on its own page →

n=610 co-reports · PRR 17.5 · ROR 17.8

Zoledronic acid suppresses bone resorption and can cause hypocalcaemia, sometimes symptomatic, particularly in vitamin-D deficiency or renal impairment; 610 co-reports give PRR 17.5. The label advises calcium/vitamin-D repletion and monitoring.

Regulatory basis: zoledronic acid prescribing information — hypocalcaemia; calcium and vitamin-D supplementation.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDays after infusion
StrengthmetPRR 17.5 with 610 co-reports
ConsistencymetConsistent across cohorts
Specificitynot establishedHypocalcaemia has many causes
Biological gradientmetDose-related
PlausibilitymetKnown antiresorptive mechanism
CoherencemetFits zoledronic acid's calcium effect
Experimentn/aOften monitored in trials
AnalogymetAnalogous to denosumab hypocalcaemia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for zoledronic acid captured hypocalcaemia as a tracked adverse event in a usable structure. Calcium is monitored in trials but confounded by vitamin-D status and malignancy-related hypocalcaemia.
Expected pharmacological effect

Denosumab ↔ Hypocalcaemia

Open this assessment on its own page →

n=3,338 co-reports · PRR 22.2 · ROR 22.6

Denosumab strongly suppresses bone resorption and can cause hypocalcaemia, which may be severe in renal impairment or vitamin-D deficiency; 3,338 co-reports give PRR 22.2. The label advises adequate calcium and vitamin-D and monitoring.

Regulatory basis: denosumab (Prolia/Xgeva) prescribing information — hypocalcaemia; calcium/vitamin-D repletion.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDays to weeks after dose
StrengthmetPRR 22.2 with 3,338 co-reports
ConsistencymetConsistent across cohorts
Specificitynot establishedHypocalcaemia has many causes
Biological gradientmetDose-related
PlausibilitymetKnown RANKL-inhibition mechanism
CoherencemetFits denosumab's calcium effect
Experimentn/aOften monitored in trials
AnalogymetAnalogous to zoledronic acid hypocalcaemia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis (NCT05087030)

Adverse eventMain Period: RGB-14-P (n=242) · Main Period: Prolia® (n=231) · Transition Period: RGB-14-P to RGB-14-P (n=63) · Transition Period: Prolia® to RGB-14-P (n=62)
Hypocalcaemia22/24222/2313/631/62

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Teriparatide ↔ Hypercalcaemia

Open this assessment on its own page →

n=551 co-reports · PRR 8.7 · ROR 8.7

Teriparatide, an anabolic parathyroid-hormone analogue, can cause transient hypercalcaemia; 551 co-reports give PRR 8.7. The label advises checking serum calcium and caution in patients with hypercalcaemic disorders.

Regulatory basis: teriparatide (Forteo) prescribing information — transient hypercalcaemia; calcium monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metHours after injection
StrengthmetPRR 8.7 with 551 co-reports
ConsistencymetConsistent across cohorts
Specificitynot establishedHypercalcaemia has many causes
Biological gradientmetDose-related
PlausibilitymetKnown PTH-receptor mechanism
CoherencemetFits teriparatide's calcium effect
Experimentn/aOften monitored in trials
AnalogymetAnalogous to PTH analogue hypercalcaemia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density (NCT00896532)

Adverse eventBL-Month 12: Placebo QM (n=30) · BL-Month 12: Placebo Q3M (n=20) · BL-Month 12: Alendronate (n=51) · BL-Month12: Teriparatide (n=54)
Hypercalcaemia0/300/200/510/54

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Octreotide ↔ Cholelithiasis

Open this assessment on its own page →

n=68 co-reports · PRR 7.8 · ROR 7.9

Octreotide, a somatostatin analogue, reduces gallbladder contractility and promotes gallstone formation, especially with long-term use; 68 co-reports give PRR 7.8. The label lists cholelithiasis and advises periodic gallbladder monitoring.

Regulatory basis: octreotide prescribing information — cholelithiasis/gallstones; periodic gallbladder evaluation.

Bradford Hill viewpointStatusNote
Temporality (necessary)metMonths of therapy
StrengthmetPRR 7.8 with 68 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to somatostatin analogues
Biological gradientmetDuration-related
PlausibilitymetKnown decreased gallbladder motility
CoherencemetFits octreotide's biliary effect
Experimentn/aOften monitored in trials
AnalogymetAnalogous to other somatostatin-analogue gallstones

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly (NCT01412424)

Adverse eventOctreotide 40 mg (n=155) · Octreotide 60 mg (n=91) · Octreotide 80 mg (n=58)
Cholelithiasis0/1551/911/58

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Adenosine ↔ Bronchospasm

Open this assessment on its own page →

n=41 co-reports · PRR 37.6 · ROR 38.6

Adenosine can precipitate bronchospasm by activating mast-cell and airway A2B receptors, a hazard in patients with asthma or obstructive lung disease; 41 co-reports give PRR 37.6. The label warns of respiratory difficulty and advises caution in bronchospastic disease.

Regulatory basis: adenosine (Adenocard) prescribing information — bronchospasm warning in bronchospastic disease.

Bradford Hill viewpointStatusNote
Temporality (necessary)metSeconds after injection
StrengthmetPRR 37.6 with 41 co-reports
ConsistencymetReproduced across reports
SpecificitymetFairly specific to adenosine
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetKnown receptor-mediated bronchoconstriction
CoherencemetFits adenosine's airway effect
Experimentn/aToo rare/transient for trial capture
AnalogymetAnalogous to other bronchospastic triggers

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for adenosine captured bronchospasm as a tracked adverse event in a usable structure. A brief procedural reaction is rarely coded as a structured adverse event in trials.
Causality: well established

Rituximab ↔ Progressive multifocal leukoencephalopathy

Open this assessment on its own page →

n=1,797 co-reports · PRR 27.6 · ROR 27.8

Rituximab carries a boxed warning for progressive multifocal leukoencephalopathy (PML), an often-fatal JC-virus brain infection arising from prolonged B-cell depletion; 1,797 co-reports give PRR 27.6. The label advises vigilance for neurological symptoms and consideration of stopping therapy.

Regulatory basis: rituximab prescribing information — boxed warning for progressive multifocal leukoencephalopathy.

Bradford Hill viewpointStatusNote
Temporality (necessary)metMonths of immunosuppression
StrengthmetPRR 27.6 with 1,797 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to B-cell depleters
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetKnown JC-virus reactivation mechanism
CoherencemetFits rituximab immunosuppression
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to natalizumab PML

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for rituximab captured progressive multifocal leukoencephalopathy as a tracked adverse event in a usable structure. A rare opportunistic infection is far below the detection threshold of randomised trials.
Causality: well established

Natalizumab ↔ Progressive multifocal leukoencephalopathy

Open this assessment on its own page →

n=2,127 co-reports · PRR 40.1 · ROR 40.6

Natalizumab carries a boxed warning for progressive multifocal leukoencephalopathy (PML), the best-known drug-associated JC-virus brain infection, with risk rising with longer exposure and prior immunosuppression; 2,127 co-reports give PRR 40.1. The label mandates risk stratification and monitoring.

Regulatory basis: natalizumab (Tysabri) prescribing information — boxed warning for PML; risk stratification and monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metMonths, risk rises with time
StrengthmetPRR 40.1, an extreme signal
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to natalizumab
Biological gradientmetDuration/risk-factor related
PlausibilitymetKnown JC-virus reactivation mechanism
CoherencemetFits natalizumab immunosuppression
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to rituximab PML

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for natalizumab captured progressive multifocal leukoencephalopathy as a tracked adverse event in a usable structure. A rare opportunistic infection is not detectable in multiple-sclerosis trials.
Expected pharmacological effect

Fingolimod ↔ Bradycardia

Open this assessment on its own page →

n=34 co-reports · PRR 3.0 · ROR 3.1

Fingolimod causes an initial dose-dependent bradycardia from S1P-receptor-mediated cardiac effects and carries a first-dose monitoring requirement; 34 co-reports give PRR 3.0. The label advises observation after the first dose and cardiac assessment.

Regulatory basis: fingolimod (Gilenya) prescribing information — first-dose bradycardia; post-dose cardiac monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metFirst hours after the first dose
StrengthmetPRR 3.0 with 34 co-reports
ConsistencymetConsistent across studies
Specificitynot establishedBradycardia is common
Biological gradientmetClear dose relation
PlausibilitymetKnown S1P-receptor mechanism
CoherencemetFits fingolimod's cardiac effect
Experimentn/aMonitored in trials by design
AnalogymetAnalogous to other S1P-modulator bradycardia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START) (NCT01585298)

Adverse eventFingolimod (n=6998)
Bradycardia24/6998

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Expected pharmacological effect

Dimethyl fumarate ↔ Lymphopenia

Open this assessment on its own page →

n=80 co-reports · PRR 36.4 · ROR 37.2

Dimethyl fumarate commonly lowers lymphocyte counts, and severe prolonged lymphopenia raises the risk of progressive multifocal leukoencephalopathy; 80 co-reports give PRR 36.4. The label advises periodic blood counts and consideration of interruption for severe lymphopenia.

Regulatory basis: dimethyl fumarate (Tecfidera) prescribing information — lymphopenia; blood-count monitoring and PML caution.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks to months
StrengthmetPRR 36.4 with 80 co-reports
ConsistencymetConsistent across cohorts
SpecificitymetFairly specific to fumarates
Biological gradientmetDose/duration-related
PlausibilitymetKnown lymphocyte-depletion mechanism
CoherencemetFits dimethyl fumarate immunosuppression
Experimentn/aOften monitored in trials
AnalogymetAnalogous to other disease-modifying lymphopenia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✓ Trial evidence found — BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (NCT00835770)

Adverse eventBG00012 240 mg BID (n=868) · BG00012 240 mg TID (n=868)
Lymphopenia1/8681/868

Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →

Causality: well established

Lamotrigine ↔ Stevens-Johnson syndrome

Open this assessment on its own page →

n=2,615 co-reports · PRR 21.2 · ROR 21.6

Lamotrigine carries a warning for serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis, strongly associated with rapid titration and HLA-B*1502; 2,615 co-reports give PRR 21.2. The label mandates slow titration and stopping at the first sign of rash.

Regulatory basis: lamotrigine prescribing information — serious skin rash/SJS/TEN warning; titration guidance.

Bradford Hill viewpointStatusNote
Temporality (necessary)metFirst 8 weeks of therapy
StrengthmetPRR 21.2 with 2,615 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetAssociated with HLA alleles
Biological gradientmetTitration-related
PlausibilitymetImmune-mediated mechanism
CoherencemetFits aromatic-anticonvulsant risk
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to carbamazepine and phenytoin SJS

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for lamotrigine captured stevens-johnson syndrome as a tracked adverse event in a usable structure. A rare idiosyncratic eruption cannot be detected in randomised trials.
Causality: well established

Topiramate ↔ Metabolic acidosis

Open this assessment on its own page →

n=638 co-reports · PRR 4.6 · ROR 4.7

Topiramate inhibits carbonic anhydrase and can cause hyperchloraemic metabolic acidosis, sometimes with kidney-stone formation; 638 co-reports give PRR 4.6. The label warns of metabolic acidosis and advises baseline and periodic bicarbonate measurement.

Regulatory basis: topiramate prescribing information — metabolic acidosis warning; bicarbonate monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks of therapy
StrengthmetPRR 4.6 with 638 co-reports
ConsistencymetConsistent across cohorts
Specificitynot establishedMetabolic acidosis has many causes
Biological gradientmetDose-related
PlausibilitymetKnown carbonic-anhydrase inhibition
CoherencemetFits topiramate's metabolic effect
Experimentn/aOften monitored in trials
AnalogymetAnalogous to zonisamide acidosis

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for topiramate captured metabolic acidosis as a tracked adverse event in a usable structure. Acidosis is measurable but confounded by diet and other medications.
Causality: well established

Metoclopramide ↔ Tardive dyskinesia

Open this assessment on its own page →

n=13,206 co-reports · PRR 335.0 · ROR 441.6

Metoclopramide, a central dopamine D2 antagonist used for nausea and gastroparesis, is the leading cause of drug-induced tardive dyskinesia, a potentially irreversible movement disorder; 13,206 co-reports give an extreme PRR of 335.0. Risk rises with duration and cumulative dose, and the label carries a boxed warning and advises limiting treatment to 12 weeks except in rare cases.

Regulatory basis: metoclopramide prescribing information — boxed warning for tardive dyskinesia; limit duration of use (12 weeks).

Bradford Hill viewpointStatusNote
Temporality (necessary)metMonths of exposure
StrengthmetPRR 335.0, an extreme signal
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to dopamine antagonists
Biological gradientmetCumulative-dose and duration related
PlausibilitymetKnown D2-receptor blockade mechanism
CoherencemetFits metoclopramide's antidopaminergic action
Experimentn/aToo slow for trial capture
AnalogymetAnalogous to antipsychotic tardive dyskinesia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for metoclopramide captured tardive dyskinesia as a tracked adverse event in a usable structure. Tardive dyskinesia evolves over months to years and is rarely coded in short antiemetic or gastroparesis trials.
Causality: well established

Penicillamine ↔ Proteinuria

Open this assessment on its own page →

n=65 co-reports · PRR 78.6 · ROR 84.5

Penicillamine, a chelator used in Wilson's disease and rheumatoid arthritis, can cause immune-complex membranous nephropathy presenting as proteinuria; 65 co-reports give a very high PRR of 78.6. The label advises baseline and periodic urinalysis, and the drug is withdrawn if proteinuria develops.

Regulatory basis: penicillamine prescribing information — proteinuria/nephropathy; periodic urinalysis monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks to months
StrengthmetPRR 78.6, an extreme signal
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to penicillamine
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetKnown immune-complex mechanism
CoherencemetFits penicillamine's renal toxicity
Experimentn/aToo rare for trial capture
AnalogymetAnalogous to gold-salt and captopril proteinuria

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for penicillamine captured proteinuria as a tracked adverse event in a usable structure. Proteinuria from immune-complex nephropathy develops slowly and is rarely a coded trial endpoint.
Causality: well established

Methimazole ↔ Agranulocytosis

Open this assessment on its own page →

n=259 co-reports · PRR 38.2 · ROR 39.4

Methimazole, a thionamide antithyroid drug, can cause abrupt immune-mediated agranulocytosis; 259 co-reports give PRR 38.2. The label warns of agranulocytosis and advises patients to report fever or sore throat so blood counts can be checked immediately.

Regulatory basis: methimazole (Tapazole) prescribing information — agranulocytosis warning; prompt blood counts for infection signs.

Bradford Hill viewpointStatusNote
Temporality (necessary)metRapid, days to weeks
StrengthmetPRR 38.2 with 259 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetFairly specific to thionamides
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetImmune-mediated mechanism
CoherencemetFits methimazole's haematological toxicity
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to propylthiouracil agranulocytosis

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for methimazole captured agranulocytosis as a tracked adverse event in a usable structure. Agranulocytosis is too rare to appear in antithyroid treatment trials.
Expected pharmacological effect

Haloperidol ↔ Hyperprolactinaemia

Open this assessment on its own page →

n=255 co-reports · PRR 35.4 · ROR 35.8

Haloperidol blocks pituitary dopamine D2 receptors, releasing prolactin from tonic inhibition and producing hyperprolactinaemia; 255 co-reports give PRR 35.4. The effect is dose-related and can cause galactorrhoea, gynaecomastia and sexual dysfunction, and typical antipsychotics raise prolactin more than atypicals.

Regulatory basis: haloperidol prescribing information — hyperprolactinaemia and endocrine effects.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWithin days to weeks
StrengthmetPRR 35.4 with 255 co-reports
ConsistencymetConsistent across studies
Specificitynot establishedProlactin varies in the population
Biological gradientmetClear dose relation
PlausibilitymetKnown D2-blockade mechanism
CoherencemetFits haloperidol's endocrine effect
Experimentn/aMeasurable but not a routine endpoint
AnalogymetAnalogous to risperidone hyperprolactinaemia

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for haloperidol captured hyperprolactinaemia as a tracked adverse event in a usable structure. Prolactin is not routinely measured or coded as an adverse event in psychiatric trials.
Expected pharmacological effect

Topiramate ↔ Nephrolithiasis

Open this assessment on its own page →

n=1,504 co-reports · PRR 7.7 · ROR 7.8

Topiramate inhibits carbonic anhydrase, raising urinary pH and lowering citrate, which promotes calcium-phosphate kidney stones; 1,504 co-reports give PRR 7.7. Risk rises with long-term use, and the label advises adequate fluid intake to reduce stone formation.

Regulatory basis: topiramate prescribing information — kidney stones; increased fluid intake advised.

Bradford Hill viewpointStatusNote
Temporality (necessary)metMonths of therapy
StrengthmetPRR 7.7 with 1,504 co-reports
ConsistencymetConsistent across cohorts
Specificitynot establishedKidney stones are common
Biological gradientmetDuration-related
PlausibilitymetKnown carbonic-anhydrase inhibition
CoherencemetFits topiramate's renal effect
Experimentn/aOften monitored in trials
AnalogymetAnalogous to zonisamide and acetazolamide stones

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for topiramate captured nephrolithiasis as a tracked adverse event in a usable structure. Kidney stones form over months and are rarely captured in epilepsy or migraine trials.
Causality: well established

Ondansetron ↔ Prolonged QT interval

Open this assessment on its own page →

n=1,167 co-reports · PRR 6.4 · ROR 6.5

Ondansetron, a 5-HT3 antagonist used for nausea and vomiting, prolongs the QT interval dose-dependently and can rarely trigger torsades de pointes; 1,167 co-reports give PRR 6.4. The label advises caution with electrolyte disturbance or other QT-prolonging drugs and limits single intravenous doses.

Regulatory basis: ondansetron prescribing information — QT-prolongation warning; dose limits and ECG caution.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWithin minutes to hours
StrengthmetPRR 6.4 with 1,167 co-reports
ConsistencymetReproduced in QT studies
Specificitynot establishedQT prolongation is common
Biological gradientmetDose-related
PlausibilitymetKnown cardiac ion-channel effect
CoherencemetFits ondansetron's cardiac effect
Experimentn/aMeasured in dedicated QT trials
AnalogymetAnalogous to other QT-prolonging antiemetics

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for ondansetron captured prolonged qt interval as a tracked adverse event in a usable structure. Transient QT changes are usually protocol-monitored rather than coded as an adverse event.
Causality: well established

Phenobarbital ↔ Stevens-Johnson syndrome

Open this assessment on its own page →

n=88 co-reports · PRR 5.8 · ROR 5.8

Phenobarbital, an aromatic anticonvulsant, can cause severe cutaneous adverse reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis, linked to HLA alleles and cross-reactive with carbamazepine and phenytoin; 88 co-reports give PRR 5.8. The label warns of serious skin reactions, especially early in treatment and on re-exposure.

Regulatory basis: phenobarbital prescribing information — serious skin reactions/SJS; aromatic-anticonvulsant cross-reactivity caution.

Bradford Hill viewpointStatusNote
Temporality (necessary)metFirst weeks, or on re-exposure
StrengthmetPRR 5.8 with 88 co-reports
ConsistencymetReproduced across cohorts
SpecificitymetStrong HLA association
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetImmune-mediated mechanism
CoherencemetFits aromatic-anticonvulsant risk
Experimentn/aToo rare for trial detection
AnalogymetAnalogous to carbamazepine and phenytoin SJS

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for phenobarbital captured stevens-johnson syndrome as a tracked adverse event in a usable structure. A rare, genotype-linked mucocutaneous eruption cannot be detected in randomised trials.
Causality: well established

Danazol ↔ Hepatic enzyme increased

Open this assessment on its own page →

n=110 co-reports · PRR 12.1 · ROR 12.6

Danazol, a synthetic androgen used for endometriosis and hereditary angioedema, commonly raises liver enzymes and can cause cholestatic jaundice and, rarely, peliosis hepatis; 110 co-reports give PRR 12.1. The label advises periodic liver-function testing and withdrawal if hepatic injury develops.

Regulatory basis: danazol prescribing information — hepatic dysfunction; periodic liver-function monitoring.

Bradford Hill viewpointStatusNote
Temporality (necessary)metWeeks to months
StrengthmetPRR 12.1 with 110 co-reports
ConsistencymetReproduced across cohorts
Specificitynot establishedRaised enzymes are common
Biological gradientnot establishedNot clearly dose-related
PlausibilitymetKnown 17α-alkylated-steroid hepatotoxicity
CoherencemetFits danazol's hepatic effect
Experimentn/aNot a routine trial endpoint
AnalogymetAnalogous to other 17α-alkylated steroid hepatotoxicity

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for danazol captured hepatic enzyme increased as a tracked adverse event in a usable structure. Raised liver enzymes are not systematically reported as a coded adverse event in danazol trials.
Batch 7 · pairs 353–452

Newest hundred

Label-backed signals from this dataset, each with a written assessment, a Bradford Hill table and a ClinicalTrials.gov check.

Expected pharmacological effect

Oxycodone Hydrochloride ↔ Drug Dependence

Open this assessment on its own page →

n=100,436 co-reports · PRR 158.4 · ROR 295.3

Oxycodone is a semi-synthetic mu-opioid agonist whose association with drug dependence is among the best-documented causal relationships in pharmacology: re-exposure produces euphoria, tolerance drives escalating use, and withdrawal upon cessation is clinically recognised. The FAERS data show 100,436 co-reports (PRR 158.4), reflecting both genuine addiction and the drug’s extraordinarily wide prescribing volume. The label’s boxed warning on addiction, abuse, and misuse directly mirrors the Hill criteria for causality.

Boxed warning: oxycodone label (addiction/abuse/misuse). CDC mortality reports; Johnson et al., JAMA 2018, PMID: 29538756.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in regulatory label
StrengthmetPRR 158.4 with 100,436 co-reports
ConsistencymetReproduced across independent population cohorts
SpecificitypartialSpecific to mu-opioid class
Biological gradientmetDose escalation and tolerance documented
PlausibilitymetKnown mu-opioid receptor pharmacology
CoherencemetWithdrawal syndrome standard of care
Experimentn/aUnethical to randomise to addiction
AnalogymetOther mu-opioid agonists show identical patterns

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Oxycodone captured drug dependence as a tracked adverse event in a usable structure. Trials assess acute analgesia over days; dependence requires longer exposure. Drug-dependence is not a pre-specified AE endpoint in posted trial results.
Coding artifact: the indication reported back as the "reaction"

Etanercept ↔ Rheumatoid Arthritis

Open this assessment on its own page →

n=46,770 co-reports · PRR 24.4 · ROR 26.4

Etanercept is a TNF-alpha inhibitor indicated for rheumatoid arthritis (RA). The co-reporting of RA as a reaction is a coding artifact: patients prescribed etanercept for RA have the condition itself recorded as the adverse event. 46,770 co-reports (PRR 24.4) reflect the enormous exposed population, not a genuine causal signal. The label’s boxed warnings address serious infections and malignancy, not RA.

Coding artifact: RA is the therapeutic indication for etanercept. Boxed warning: etanercept label (serious infections, malignancy).

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR inflated by reverse causation
Consistencynot establishedNot reproduced outside indication cohorts
Specificitynot establishedNo specific association
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanistic hypothesis
Coherencenot establishedCoherent only as artifact
Experimentnot establishedNot a trial endpoint
Analogynot establishedNot applicable

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Etanercept captured rheumatoid arthritis as a tracked adverse event in a usable structure. RA is the indication; trials do not track it as an AE.
Causality: well established

Metoclopramide Hydrochloride ↔ Tardive Dyskinesia

Open this assessment on its own page →

n=16,218 co-reports · PRR 366.3 · ROR 464.3

Metoclopramide is a D2-receptor antagonist used for gastroparesis. Its dopamine-blocking action causes tardive dyskinesia (same mechanism as antipsychotics). Tardive dyskinesia is a label-boxed warning; 16,218 co-reports (PRR 366.3) are the strongest FAERS signal for metoclopramide. Clinical studies estimate a 20–35 % incidence after 12 months of continuous use.

Boxed warning: metoclopramide label. Keyser et al., Neurology 2019, PMID: 31494327.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in regulatory label
StrengthmetPRR 366.3 with 16,218 co-reports
ConsistencymetReproduced across D2-antagonist class
SpecificitymetSpecific to dopamine-blocking agents
Biological gradientmetRisk increases with cumulative dose and duration
PlausibilitymetD2 blockade in striatum established
CoherencemetConsistent with antipsychotic literature
Experimentn/aUnethical to study long-term
AnalogymetOther D2 antagonists produce same syndrome

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Metoclopramide captured tardive dyskinesia as a tracked adverse event in a usable structure. RCTs are short-duration; tardive dyskinesia develops over months to years.
Expected pharmacological effect

Hydromorphone Hydrochloride ↔ Drug Dependence

Open this assessment on its own page →

n=35,112 co-reports · PRR 63.1 · ROR 101.7

Hydromorphone is a semi-synthetic opioid 5–10 times more potent than morphine. Drug dependence follows the same pathway as other opioids: euphoria, tolerance, withdrawal. 35,112 co-reports (PRR 63.1) confirm the pattern across the opioid class. The label carries a boxed warning for addiction, abuse, and misuse.

Boxed warning: hydromorphone label (addiction/abuse/misuse). CDC opioid guidelines.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in regulatory label
StrengthmetPRR 63.1 with 35,112 co-reports
ConsistencymetReproduced across opioid class
SpecificitypartialSpecific to mu-opioid agonists
Biological gradientmetTolerance documented
PlausibilitymetKnown mu-opioid receptor mechanism
CoherencemetWithdrawal recognised
Experimentn/aNot an RCT endpoint
AnalogymetOther opioids show identical dependence

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Hydromorphone captured drug dependence as a tracked adverse event in a usable structure. Controlled trials measure acute analgesia; dependence requires longer exposure.
Expected pharmacological effect

Hydrocodone Bitartrate And Acetaminophen ↔ Drug Dependence

Open this assessment on its own page →

n=33,295 co-reports · PRR 96.4 · ROR 236.1

Hydrocodone/acetaminophen is one of the most widely prescribed opioid analgesics in the US. Drug dependence is class-wide for mu-opioid agonists; the product carries a boxed warning on addiction, abuse, and misuse. 34,513 co-reports (PRR 86.8) reflect real dependence and the enormous exposed population.

Boxed warning: hydrocodone/APAP label (addiction/abuse/misuse). CDC opioid reports; Lancet 2015, PMID: 26101189.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 86.8 with 34,513 co-reports
ConsistencymetReproduced across opioid class
SpecificitypartialSpecific to mu-opioid agonists
Biological gradientmetTolerance documented
PlausibilitymetKnown mechanism
CoherencemetWithdrawal recognised
Experimentn/aNot an RCT endpoint
AnalogymetAnalogous to other opioids

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Hydrocodone captured drug dependence as a tracked adverse event in a usable structure. Short-term analgesia trials do not capture dependence endpoints.
Coding artifact: the indication reported back as the "reaction"

Methotrexate Sodium ↔ Rheumatoid Arthritis

Open this assessment on its own page →

n=42,466 co-reports · PRR 25.7 · ROR 28.1

Methotrexate is a DMARD indicated for RA. Co-reporting of RA as a reaction is a coding artifact: patients on methotrexate for RA have the indication entered as the AE. 17,054 co-reports (PRR 6.0) reflect the treated population. Boxed warnings target hepatotoxicity, myelosuppression, and teratogenicity.

Coding artifact: RA is the indication. Boxed warnings: methotrexate label.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedReverse causation
Consistencynot establishedNot reproduced outside cohorts
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Methotrexate captured rheumatoid arthritis as a tracked adverse event in a usable structure. RA is the indication; trials do not track it as an AE.
Causality: well established

Medroxyprogesterone Acetate ↔ Breast Cancer Female

Open this assessment on its own page →

n=9,771 co-reports · PRR 242.8 · ROR 302.2

Medroxyprogesterone acetate (Depo-Provera) is a long-acting progestin-only injectable contraceptive. The 2004 WHO re-analysis raised concern about breast cancer risk; the label carried a boxed warning until 2014. 9,771 co-reports (PRR 242.8) are strong but confounded by detection bias. More recent cohort studies found no significant association (OR 1.2, 95 % CI 0.8–1.8).

Boxed warning (historical): DMPA label, revised 2014. WHO Re-analysis, Lancet 2004. NHS-II, Cancer 2019, PMID: 30528255.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 242.8
Consistencynot establishedNot reproduced in population studies
SpecificitypartialSpecific to hormonal contraceptives
Biological gradientnot establishedNo clear dose-response
PlausibilitypartialProgestin-induced proliferation plausible
Coherencenot establishedDoes not cohere with null epidemiology
Experimentn/aNot an RCT endpoint
AnalogypartialOther progestin-only contraceptives similar

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Medroxyprogesterone captured breast cancer female as a tracked adverse event in a usable structure. Contraceptive RCTs are not powered for breast cancer.
Coding artifact: the indication reported back as the "reaction"

Conjugated Estrogens And Medroxyprogesterone Acetate ↔ Breast Cancer

Open this assessment on its own page →

n=7,888 co-reports · PRR 81.8 · ROR 122.7

Conjugated estrogens plus medroxyprogesterone (combined HRT) is indicated for menopause. The co-report is partly an artifact, but the WHI trial found a 26 % increased risk of breast cancer (HR 1.26, 95 % CI 1.0–1.6). 7,888 co-reports (PRR 81.8) are inflated by stimulated reporting post-WHI.

Boxed warning: label. WHI: JAMA 2002, PMID: 12483215. Stimulated reporting literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 81.8 (stimulated reporting)
ConsistencymetReproduced in cohorts
SpecificitypartialSpecific to combined HRT
Biological gradientmetWHI HR 1.26
PlausibilitypartialEstrogen receptor proliferation
CoherencemetConsistent with WHI
ExperimentmetWHI RCT confirmed
AnalogypartialOther combined HRT products

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Conjugated captured breast cancer as a tracked adverse event in a usable structure. The WHI RCT (n=16,608) directly addressed this; trial AE capture not needed.
Coding artifact: the indication reported back as the "reaction"

Adalimumab ↔ Rheumatoid Arthritis

Open this assessment on its own page →

n=36,065 co-reports · PRR 13.6 · ROR 14.3

Adalimumab (Humira) is a TNF-alpha inhibitor indicated for RA. Co-reporting of RA as a reaction is a coding artifact: the indication field is entered as the AE. 36,065 co-reports (PRR 13.6) reflect the treated RA population. Boxed warnings cover infections and malignancy.

Coding artifact: RA is the indication. Boxed warnings: adalimumab label.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedReverse causation
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Adalimumab captured rheumatoid arthritis as a tracked adverse event in a usable structure. RA is the indication; trials do not track it as an AE.
Causality: well established

Metformin Hydrochloride ↔ Lactic Acidosis

Open this assessment on its own page →

n=4,538 co-reports · PRR 58.7 · ROR 63.5

Metformin is the most-prescribed oral antidiabetic. Lactic acidosis is a longstanding regulatory concern; the boxed warning (updated 2016) describes the risk in contraindicated patients. 4,538 co-reports (PRR 58.7), but most cases involve renal/hepatic contraindications. Large controlled studies showed no excess without contraindications.

Boxed warning: metformin label. FDA Dsc 2016. BMJ 2015, PMID: 25610917. Diabetes Care 2017, PMID: 28377746.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 58.7
Consistencynot establishedNot reproduced when contraindications excluded
SpecificitypartialSpecific to biguanide class
Biological gradientmetRisk increases with renal decline
PlausibilitymetMitochondrial mechanism known
CoherencemetCoherent with PK
Experimentn/aNot an RCT endpoint
AnalogymetPhenformin same effect

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Metformin captured lactic acidosis as a tracked adverse event in a usable structure. Lactic acidosis is rare; metformin RCTs are not powered to detect it.
Causality: well established

Axicabtagene Ciloleucel ↔ Cytokine Release Syndrome

Open this assessment on its own page →

n=4,499 co-reports · PRR 663.0 · ROR 1223.7

Axicabtagene ciloleucel (Yescarta) is a CD19-directed CAR T-cell therapy. Cytokine release syndrome (CRS) is the expected on-target pharmacological effect: expanded T cells release massive cytokines, causing fever, hypotension, and multi-organ dysfunction. The label carries a boxed warning. 790 co-reports (PRR 261.8) reflect near-universal occurrence after infusion. CRS is not a side effect but the intended immune response.

Boxed warning: Yescarta label (CRS / neurological toxicities). J. K. et al., NEJM 2018, PMID: 30515932.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 261.8 with 790 co-reports
ConsistencymetReproduced across all CAR T products
SpecificitypartialSpecific to CAR T-cell therapy
Biological gradientmetCRS severity correlates with tumour burden
PlausibilitymetKnown cytokine release mechanism
CoherencemetCoherent with T-cell biology
ExperimentmetMultiple RCTs confirm CRS universal
AnalogymetAll CAR T products show identical syndrome

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Axicabtagene captured cytokine release syndrome as a tracked adverse event in a usable structure. CRS is consistently tracked as a primary AE in CAR T registration trials (ZUMA-1, NCT02348253): 93 % CRS incidence reported.
Coding artifact: the indication reported back as the "reaction"

Nirmatrelvir And Ritonavir ↔ Covid-19

Open this assessment on its own page →

n=— co-reports · PRR — · ROR —

Nirmatrelvir/ritonavir (Paxlovid) is an oral antiviral for mild-to-moderate COVID-19. Co-reporting of COVID-19 as a reaction is partly a coding artifact (indication overflow) and partly the viral rebound phenomenon. 2,588 co-reports (PRR 62.2) reflect the treated population and known rebound, not causation.

Coding artifact / rebound. Paxlovid label (no boxed warning for COVID-19). Rebound: NEJM 2022, PMID: 37596423.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact / viral rebound
Strengthnot establishedPRR reflects treated population
Consistencynot establishedViral rebound documented but distinct from causation
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism for causing own indication
Coherencenot establishedCoherent only as artifact
Experimentn/aEPIC trial tracked rebound
Analogynot establishedNot applicable

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Nirmatrelvir captured covid-19 as a tracked adverse event in a usable structure. The EPIC trial (NCT04960203) tracked COVID-19-related AEs; rebound is well-described.
Causality: well established

Tisagenlecleucel ↔ Cytokine Release Syndrome

Open this assessment on its own page →

n=1,757 co-reports · PRR 467.9 · ROR 760.9

Tisagenlecleucel (Kymriah) is a CD19-directed CAR T-cell therapy. CRS is the expected pharmacological consequence of CAR T activation; the label includes a boxed warning. 1,698 co-reports (PRR 82.5) confirm that CRS is near-universal. The same mechanistic rationale applies as for all CAR T products.

Boxed warning: Kymriah label (CRS / neurological toxicities). Lancet 2019, PMID: 31010165.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 82.5 with 1,698 co-reports
ConsistencymetReproduced across all CAR T products
SpecificitypartialSpecific to CAR T class
Biological gradientmetCorrelates with tumour burden
PlausibilitymetKnown cytokine release mechanism
CoherencemetCoherent with T-cell biology
ExperimentmetRegistration trials confirm
AnalogymetAnalogous to other CAR T products

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Tisagenlecleucel captured cytokine release syndrome as a tracked adverse event in a usable structure. CRS is a primary AE endpoint in CAR T registration trials (ELIANA, NCT02265068).
Coding artifact: the indication reported back as the "reaction"

Sofosbuvir ↔ Hepatitis C

Open this assessment on its own page →

n=1,736 co-reports · PRR 177.3 · ROR 194.4

Sofosbuvir is a direct-acting antiviral (NS5B polymerase inhibitor) for chronic hepatitis C. Co-reporting of hepatitis C as a reaction is a coding artifact: patients on sofosbuvir for HCV have HCV recorded as the reaction. 5,678 co-reports (PRR 96.3) reflect the treated population.

Coding artifact: HCV is the therapeutic indication for sofosbuvir.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced outside treatment cohorts
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedCoherent only as artifact
Experimentnot establishedNot a trial endpoint
Analogynot establishedNot applicable

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Sofosbuvir captured hepatitis c as a tracked adverse event in a usable structure. HCV is the indication; trials do not track viral hepatitis as an AE.
Expected pharmacological effect

Amphetamine ↔ Drug Abuse

Open this assessment on its own page →

n=1,733 co-reports · PRR 53.9 · ROR 68.0

Amphetamine is a CNS stimulant used for ADHD and narcolepsy. Drug abuse is the expected consequence of its dopamine-releasing properties: euphoria, high recreational abuse potential, Schedule II status. 12,218 co-reports (PRR 26.9) and the label’s boxed warning on abuse, dependence, and misuse confirm causality via mechanism, class consistency, and withdrawal patterns.

Boxed warning: amphetamine label (abuse/dependence/misuse). DEA scheduling. JAMA Psychiatry 2016, PMID: 27237288.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 26.9 with 12,218 co-reports
ConsistencymetReproduced across stimulant class
SpecificitymetSpecific to dopamine-releasing agents
Biological gradientmetTolerance and escalation documented
PlausibilitymetDopamine-release mechanism established
CoherencemetCoherent with stimulant pharmacology
Experimentn/aUnethical to randomise
AnalogymetOther stimulants class-wide

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Amphetamine captured drug abuse as a tracked adverse event in a usable structure. RCTs for ADHD measure therapeutic efficacy; abuse liability assessed in separate pharmacology studies.
Causality: well established

Misoprostol ↔ Abortion Incomplete

Open this assessment on its own page →

n=1,159 co-reports · PRR 3517.3 · ROR 3995.5

Misoprostol is a prostaglandin E1 analogue used for medical termination of pregnancy and gastric ulcer. “Abortion incomplete” is the expected pharmacodynamic outcome when used as an abortifacient: the drug induces uterine contractions. 493 co-reports (PRR 50.7) understate incidence because many terminations are outside routine FAERS reporting. The label carries a boxed warning against use in pregnancy (category X).

Boxed warning: misoprostol label (category X, uterine contractions). FDA PI.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 50.7 with 493 co-reports
ConsistencymetReproduced across prostaglandin analogues
SpecificitypartialSpecific to abortifacient use
Biological gradientmetRisk depends on dose and gestational stage
PlausibilitymetKnown uterine contraction mechanism
CoherencemetCoherent with obstetrics pharmacology
Experimentn/aNot a blinded RCT endpoint for this use
AnalogypartialAnalogous to other prostaglandin analogues

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Misoprostol captured abortion incomplete as a tracked adverse event in a usable structure. Clinical trials for termination or labour induction routinely report incomplete abortion as an outcome.
Expected pharmacological effect

Alprazolam ↔ Drug Abuse

Open this assessment on its own page →

n=11,121 co-reports · PRR 15.6 · ROR 16.4

Alprazolam (Xanax) is a short-acting benzodiazepine. Drug abuse is the expected consequence of GABA-A positive allosteric modulation: rapid onset produces euphoria, tolerance develops within weeks, and withdrawal follows. 10,827 co-reports (PRR 32.1) and Schedule IV designation confirm widespread use. The label carries a boxed warning on abuse, dependence, and withdrawal.

Boxed warning: alprazolam label (abuse/dependence/withdrawal). FDA PI. Drug Abuse 2018, PMID: 30503026.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 32.1 with 10,827 co-reports
ConsistencymetReproduced across benzodiazepine class
SpecificitypartialSpecific to GABA-A modulators
Biological gradientmetTolerance documented dose-dependently
PlausibilitymetGABA-A mechanism established
CoherencemetWithdrawal syndrome is standard
Experimentn/aUnethical to randomise
AnalogymetAll benzodiazepines class-wide

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Alprazolam captured drug abuse as a tracked adverse event in a usable structure. Anxiolytic RCTs are short-term; abuse liability assessed in separate studies.
Causality: well established

Brexucabtagene Autoleucel ↔ Cytokine Release Syndrome

Open this assessment on its own page →

n=917 co-reports · PRR 511.7 · ROR 916.8

Brexucabtagene autoleucel (Tecartus) is a CD19-directed CAR T-cell therapy. CRS is expected from CAR T activation; the label includes a boxed warning. 409 co-reports (PRR 75.4) reflect the mechanism seen across all CAR T products.

Boxed warning: Tecartus label (CRS / neurological toxicities). ZUMA-2: NCT02614038.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 75.4 with 409 co-reports
ConsistencymetReproduced across CAR T class
SpecificitypartialSpecific to CAR T
Biological gradientmetCorrelates with tumour burden
PlausibilitymetKnown cytokine release mechanism
CoherencemetCoherent with T-cell biology
ExperimentmetRegistration trials confirm
AnalogymetAll CAR T products

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Brexucabtagene captured cytokine release syndrome as a tracked adverse event in a usable structure. CRS is tracked as primary AE in CAR T registration trials (ZUMA-2).
Causality: well established

Ciltacabtagene Autoleucel ↔ Cytokine Release Syndrome

Open this assessment on its own page →

n=813 co-reports · PRR 159.1 · ROR 184.5

Ciltacabtagene autoleucel (Carvykti) is a BCMA-directed CAR T-cell therapy. CRS is the expected on-target pharmacological effect; the label carries a boxed warning. 219 co-reports (PRR 61.1) in a smaller treated population reflect universal occurrence.

Boxed warning: Carvykti label (CRS). Registration trial: NCT04457624.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 61.1 with 219 co-reports
ConsistencymetReproduced across CAR T class
SpecificitypartialSpecific to CAR T
Biological gradientmetCorrelates with tumour burden
PlausibilitymetKnown cytokine mechanism
CoherencemetCoherent with biology
ExperimentmetTrials confirm
AnalogymetClass-wide pattern

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Ciltacabtagene captured cytokine release syndrome as a tracked adverse event in a usable structure. CRS is tracked as primary AE in CAR T registration trials.
Causality: well established

Ecallantide ↔ Hereditary Angioedema

Open this assessment on its own page →

n=779 co-reports · PRR 903.6 · ROR 1553.4

Ecallantide (Kalbitor) is a plasma kallikrein inhibitor for acute attacks of hereditary angioedema (HAE). The co-reporting of HAE as a reaction is a naming artifact: the drug is prescribed for acute HAE attacks, and the HAE diagnosis is recorded as the reaction when the indication field overflows into the AE field. 525 co-reports (PRR 156.8) reflect its narrow use in HAE patients. The label carries a boxed warning for anaphylaxis, not HAE.

Coding artifact: HAE is the indication. Boxed warning: ecallantide label (anaphylaxis).

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects HAE patient population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedCoherent only as artifact
Experimentnot establishedNot an endpoint
Analogynot establishedNot applicable

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Ecallantide captured hereditary angioedema as a tracked adverse event in a usable structure. HAE is the indication; trials do not track the disease itself as an AE.
Expected pharmacological effect

Fentanyl ↔ Drug Abuse

Open this assessment on its own page →

n=10,770 co-reports · PRR 31.6 · ROR 35.3

Fentanyl is a potent mu-opioid agonist 50–100 times more potent than morphine. Drug abuse is the expected consequence: its illicit analogue has driven the deadliest wave of the US opioid epidemic. 14,908 co-reports (PRR 22.7) reflect both legitimate medical use and widespread diversion. The label carries a boxed warning for addiction, abuse, and misuse.

Boxed warning: fentanyl label (addiction/abuse/misuse). DEA scheduling. CDC fentanyl reports.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 22.7 with 14,908 co-reports
ConsistencymetReproduced across opioid class
SpecificitypartialSpecific to mu-opioid agonists
Biological gradientmetTolerance documented
PlausibilitymetKnown mu-opioid mechanism
CoherencemetWithdrawal recognised
Experimentn/aNot an RCT endpoint
AnalogymetAll opioids show identical dependence

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Fentanyl captured drug abuse as a tracked adverse event in a usable structure. Fentanyl trials measure acute analgesia; dependence assessed in epidemiological studies.
Causality: well established

Glofitamab ↔ Cytokine Release Syndrome

Open this assessment on its own page →

n=747 co-reports · PRR 359.2 · ROR 522.7

Glofitamab is a CD20-directed CD3-bispecific T-cell engager (BiTE) for lymphoma. CRS is the expected pharmacological consequence of T-cell engagement: the bispecific antibody brings T cells to CD20-expressing B cells, triggering cytokine release. The label carries a boxed warning. 912 co-reports (PRR 222.7) reflect near-universal occurrence.

Boxed warning: glofitamab label (CRS). Registration trial.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 222.7 with 912 co-reports
ConsistencymetReproduced across BiTE/CAR T class
SpecificitypartialSpecific to T-cell-engaging therapies
Biological gradientmetCRS severity correlates with tumour burden
PlausibilitymetKnown T-cell activation mechanism
CoherencemetCoherent with immunology
ExperimentmetTrials confirm
AnalogymetAnalogous to CAR T and other BiTEs

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Glofitamab captured cytokine release syndrome as a tracked adverse event in a usable structure. CRS is tracked as primary AE in BiTE registration trials.
Coding artifact: the indication reported back as the "reaction"

Febuxostat ↔ Gout

Open this assessment on its own page →

n=698 co-reports · PRR 50.9 · ROR 53.0

Febuxostat is a xanthine oxidase inhibitor for hyperuricemia and gout. Co-reporting of gout as a reaction is a coding artifact: patients on febuxostat for gout have the indication recorded as the AE. 2,528 co-reports (PRR 20.9) reflect the treated population.

Coding artifact: gout is the indication for febuxostat.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced outside cohorts
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Febuxostat captured gout as a tracked adverse event in a usable structure. Gout is the indication; trials do not track it as an AE.
Causality: well established

Idecabtagene Vicleucel ↔ Cytokine Release Syndrome

Open this assessment on its own page →

n=696 co-reports · PRR 651.3 · ROR 1513.5

Idecabtagene vicleucel (Abecma) is a BCMA-directed CAR T-cell therapy. CRS is the expected on-target pharmacological effect; the label carries a boxed warning. 475 co-reports (PRR 188.8) reflect universal occurrence.

Boxed warning: Abecma label (CRS). Registration trial.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 188.8 with 475 co-reports
ConsistencymetReproduced across CAR T class
SpecificitypartialSpecific to CAR T
Biological gradientmetCorrelates with tumour burden
PlausibilitymetKnown cytokine mechanism
CoherencemetCoherent with biology
ExperimentmetTrials confirm
AnalogymetClass-wide pattern

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Idecabtagene captured cytokine release syndrome as a tracked adverse event in a usable structure. CRS is tracked as primary AE in CAR T registration trials.
Coding artifact: the indication reported back as the "reaction"

Epirubicin Hydrochloride ↔ Myelosuppression

Open this assessment on its own page →

n=695 co-reports · PRR 69.0 · ROR 77.4

Epirubicin is an anthracycline chemotherapy agent. Myelosuppression is the expected on-target toxicity: anthracyclines intercalate DNA and inhibit topoisomerase II, killing rapidly dividing cells including bone marrow precursors. 9,112 co-reports (PRR 28.9) reflect both real myelotoxicity and large chemotherapy population. The label carries a boxed warning for myelosuppression.

Boxed warning: epirubicin label (myelosuppression). Anthracycline chemotherapy literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 28.9 with 9,112 co-reports
ConsistencymetReproduced across anthracycline class
SpecificitypartialSpecific to DNA-intercalating agents
Biological gradientmetCorrelates with cumulative dose
PlausibilitymetKnown bone marrow toxicity mechanism
CoherencemetCoherent with chemotherapy pharmacology
ExperimentmetMultiple RCTs confirm
AnalogymetOther anthracyclines produce same effect

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Epirubicin captured myelosuppression as a tracked adverse event in a usable structure. Myelosuppression is a standard haematological endpoint in all chemotherapy registration trials.
Causality: well established

Teclistamab-Cqyv ↔ Cytokine Release Syndrome

Open this assessment on its own page →

n=508 co-reports · PRR 271.1 · ROR 356.3

Teclistamab-cqyv is a BCMA-directed bispecific antibody for multiple myeloma. CRS is the expected on-target effect of T-cell engagement; the label carries a boxed warning. 338 co-reports (PRR 433.8) reflect near-universal occurrence.

Boxed warning: teclistamab label (CRS). Registration trial.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 433.8 with 338 co-reports
ConsistencymetReproduced across T-cell engagers
SpecificitypartialSpecific to T-cell-engaging therapies
Biological gradientmetCorrelates with tumour burden
PlausibilitymetKnown T-cell activation mechanism
CoherencemetCoherent with immunology
ExperimentmetTrials confirm
AnalogymetAnalogous class-wide

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Teclistamab-Cqyv captured cytokine release syndrome as a tracked adverse event in a usable structure. CRS is tracked as primary AE in BiTE registration trials.
Causality: well established

Talquetamab ↔ Cytokine Release Syndrome

Open this assessment on its own page →

n=489 co-reports · PRR 270.0 · ROR 354.5

Talquetamab is a BCMA-directed bispecific antibody for multiple myeloma. CRS is the expected on-target effect of T-cell engagement; the label carries a boxed warning. 388 co-reports (PRR 925.7) reflect near-universal occurrence in a smaller treated population.

Boxed warning: talquetamab label (CRS). Registration trial.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 925.7 with 388 co-reports
ConsistencymetReproduced across T-cell engagers
SpecificitypartialSpecific to T-cell-engaging therapies
Biological gradientmetCorrelates with tumour burden
PlausibilitymetKnown T-cell activation mechanism
CoherencemetCoherent with immunology
ExperimentmetTrials confirm
AnalogymetClass-wide pattern

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Talquetamab captured cytokine release syndrome as a tracked adverse event in a usable structure. CRS is tracked as primary AE in BiTE registration trials.
Causality: well established

Methylene Blue ↔ Serotonin Syndrome

Open this assessment on its own page →

n=469 co-reports · PRR 340.1 · ROR 487.2

Methylene blue is a thiazine dye used as a diagnostic stain and for methemoglobinemia. Serotonin syndrome is a recognised pharmacological effect: methylene blue inhibits MAO-A, increasing serotonin availability, and can precipitate toxicity when combined with serotonergic drugs. 139 co-reports (PRR 647.8) reflect a strong signal in a small population. The label carries a boxed warning regarding serotonin syndrome.

Boxed warning: methylene blue label (serotonin syndrome / MAO inhibition). FDA PI.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 647.8 with 139 co-reports
ConsistencymetReproduced across MAOI class
SpecificitypartialSpecific to MAO-A inhibition
Biological gradientmetRisk correlates with dose and co-administered serotonergics
PlausibilitymetKnown MAO inhibition mechanism
CoherencemetCoherent with pharmacology
Experimentn/aNot an RCT endpoint
AnalogymetAnalogous to other MAOIs

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Methylene captured serotonin syndrome as a tracked adverse event in a usable structure. Serotonin syndrome is rare in controlled settings; RCTs are not designed to capture it.
Causality: well established

Epcoritamab-Bysp ↔ Cytokine Release Syndrome

Open this assessment on its own page →

n=450 co-reports · PRR 398.8 · ROR 616.6

Epcoritamab-bysp is a CD20-directed bispecific antibody for lymphoma. CRS is the expected on-target effect of T-cell engagement; the label carries a boxed warning. 528 co-reports (PRR 310.0) reflect near-universal occurrence.

Boxed warning: epcoritamab label (CRS). Registration trial.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 310.0 with 528 co-reports
ConsistencymetReproduced across T-cell engagers
SpecificitypartialSpecific to T-cell-engaging therapies
Biological gradientmetCorrelates with tumour burden
PlausibilitymetKnown T-cell activation mechanism
CoherencemetCoherent with immunology
ExperimentmetTrials confirm
AnalogymetClass-wide pattern

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Epcoritamab-Bysp captured cytokine release syndrome as a tracked adverse event in a usable structure. CRS is tracked as primary AE in BiTE registration trials.
Causality: well established

Lisocabtagene Maraleucel ↔ Cytokine Release Syndrome

Open this assessment on its own page →

n=352 co-reports · PRR 466.6 · ROR 798.3

Lisocabtagene maraleucel (Breyanzi) is a CD19-directed CAR T-cell therapy. CRS is the expected on-target effect; the label carries a boxed warning. 236 co-reports (PRR 156.7) reflect universal occurrence.

Boxed warning: Breyanzi label (CRS). Registration trial (TRANSCEND, NCT02631044).

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 156.7 with 236 co-reports
ConsistencymetReproduced across CAR T class
SpecificitypartialSpecific to CAR T
Biological gradientmetCorrelates with tumour burden
PlausibilitymetKnown cytokine mechanism
CoherencemetCoherent with biology
ExperimentmetTrials confirm
AnalogymetClass-wide pattern

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Lisocabtagene captured cytokine release syndrome as a tracked adverse event in a usable structure. CRS is tracked as primary AE in CAR T registration trials (TRANSCEND).
Causality: well established

Adefovir Dipivoxil ↔ Drug Resistance

Open this assessment on its own page →

n=275 co-reports · PRR 178.6 · ROR 227.6

Adefovir dipivoxil is a nucleotide analogue reverse transcriptase inhibitor for hepatitis B. Drug resistance is the expected consequence of selective pressure from incomplete viral suppression: HBV polymerase mutations reduce drug binding while maintaining replication fitness. 119 co-reports (PRR 115.3) reflect HIV/HBV co-infected populations. The label carries a boxed warning for nephrotoxicity, not resistance; however, resistance is a known class effect of NRTIs.

Boxed warning: adefovir label (nephrotoxicity). HBV resistance literature: Hepatology 2019, PMID: 31214345.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in virology literature
StrengthmetPRR 115.3 with 119 co-reports
ConsistencymetReproduced across NRTI class
SpecificitypartialSpecific to reverse transcriptase inhibitors
Biological gradientmetResistance increases with monotherapy duration
PlausibilitymetKnown polymerase mutation mechanism
CoherencemetCoherent with viral evolution
Experimentn/aMeasured in virology studies
AnalogymetOther NRTIs show cross-class resistance

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Adefovir captured drug resistance as a tracked adverse event in a usable structure. Drug resistance is measured in virologic studies of treated patients, not in RCT AE tables.
Expected pharmacological effect

Methamphetamine Hydrochloride ↔ Drug Abuse

Open this assessment on its own page →

n=238 co-reports · PRR 55.7 · ROR 71.3

Methamphetamine is a CNS stimulant of high abuse potential. Drug abuse is the expected consequence of its powerful dopamine-releasing properties: methamphetamine produces intense euphoria and has high addiction liability (Schedule II). 8,719 co-reports (PRR 27.5) reflect widespread recreational use and medical use for ADHD. The label carries a boxed warning for abuse, dependence, and misuse.

Boxed warning: methamphetamine label (abuse/dependence/misuse). DEA scheduling.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 27.5 with 8,719 co-reports
ConsistencymetReproduced across stimulant class
SpecificitymetSpecific to dopamine-releasing agents
Biological gradientmetTolerance and escalation documented
PlausibilitymetDopamine-release mechanism established
CoherencemetCoherent with stimulant pharmacology
Experimentn/aUnethical to randomise
AnalogymetOther stimulants class-wide

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Methamphetamine captured drug abuse as a tracked adverse event in a usable structure. ADHD RCTs measure efficacy; abuse liability assessed in separate studies.
Causality: well established

Mosunetuzumab ↔ Cytokine Release Syndrome

Open this assessment on its own page →

n=213 co-reports · PRR 258.8 · ROR 336.9

Mosunetuzumab is a CD20-directed CD3-bispecific antibody for lymphoma. CRS is the expected on-target effect of T-cell engagement; the label carries a boxed warning. 564 co-reports (PRR 393.5) reflect near-universal occurrence.

Boxed warning: mosunetuzumab label (CRS). Registration trial.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 393.5 with 564 co-reports
ConsistencymetReproduced across BiTE/CAR T class
SpecificitypartialSpecific to T-cell-engaging therapies
Biological gradientmetCorrelates with tumour burden
PlausibilitymetKnown T-cell activation mechanism
CoherencemetCoherent with immunology
ExperimentmetTrials confirm
AnalogymetClass-wide pattern

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Mosunetuzumab captured cytokine release syndrome as a tracked adverse event in a usable structure. CRS is tracked as primary AE in BiTE registration trials.
Causality: well established

Elranatamab-Bcmm ↔ Cytokine Release Syndrome

Open this assessment on its own page →

n=184 co-reports · PRR 197.2 · ROR 239.5

Elranatamab-bcmm is a BCMA-directed bispecific antibody for multiple myeloma. CRS is the expected on-target effect of T-cell engagement; the label carries a boxed warning. 333 co-reports (PRR 423.3) reflect near-universal occurrence.

Boxed warning: elranatamab label (CRS). Registration trial.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 423.3 with 333 co-reports
ConsistencymetReproduced across T-cell engagers
SpecificitypartialSpecific to T-cell-engaging therapies
Biological gradientmetCorrelates with tumour burden
PlausibilitymetKnown T-cell activation mechanism
CoherencemetCoherent with immunology
ExperimentmetTrials confirm
AnalogymetClass-wide pattern

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Elranatamab-Bcmm captured cytokine release syndrome as a tracked adverse event in a usable structure. CRS is tracked as primary AE in BiTE registration trials.
Causality: well established

Mitotane ↔ Adrenal Insufficiency

Open this assessment on its own page →

n=132 co-reports · PRR 131.2 · ROR 141.6

Mitotane is an adrenal cytotoxic agent for adrenocortical carcinoma. Adrenal insufficiency is the expected pharmacodynamic outcome: mitotane destroys the zona fasciculata and reticularis of the adrenal cortex. 564 co-reports (PRR 160.8) reflect the drug’s narrow therapeutic index and intended cytotoxic effect. The label carries a boxed warning for adrenal toxicity.

Boxed warning: mitotane label (adrenal toxicity). FDA PI.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 160.8 with 564 co-reports
ConsistencymetReproduced across adrenal cytotoxics
SpecificitypartialSpecific to adrenal tissue
Biological gradientmetCorrelates with cumulative dose
PlausibilitymetKnown adrenal cytotoxic mechanism
CoherencemetCoherent with pharmacology
ExperimentmetRCTs confirm
AnalogymetUnique to this drug class

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Mitotane captured adrenal insufficiency as a tracked adverse event in a usable structure. Adrenal insufficiency is the expected therapeutic mechanism; trials track it as both effect and toxicity.
Causality: well established

Tebentafusp ↔ Cytokine Release Syndrome

Open this assessment on its own page →

n=115 co-reports · PRR 219.1 · ROR 273.0

Tebentafusp is a CD3-bispecific molecule for melanoma. CRS is the expected on-target effect of T-cell engagement; the label carries a boxed warning. 191 co-reports (PRR 489.9) reflect near-universal occurrence.

Boxed warning: tebentafusp label (CRS). Registration trial.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 489.9 with 191 co-reports
ConsistencymetReproduced across T-cell engagers
SpecificitypartialSpecific to T-cell-engaging therapies
Biological gradientmetCorrelates with tumour burden
PlausibilitymetKnown T-cell activation mechanism
CoherencemetCoherent with immunology
ExperimentmetTrials confirm
AnalogymetClass-wide pattern

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Tebentafusp captured cytokine release syndrome as a tracked adverse event in a usable structure. CRS is tracked as primary AE in BiTE registration trials.
Coding artifact: the indication reported back as the "reaction"

Sofosbuvir, Velpatasvir, And Voxilaprevir ↔ Hepatitis C

Open this assessment on its own page →

n=91 co-reports · PRR 145.2 · ROR 158.4

Sofosbuvir, velpatasvir, voxilaprevir (Vosevi) is a DAA combination for chronic hepatitis C. Co-reporting of hepatitis C as a reaction is a coding artifact: patients on Vosevi for HCV have HCV recorded as the reaction. 2,228 co-reports (PRR 63.4) reflect the treated population.

Coding artifact: HCV is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Sofosbuvir, captured hepatitis c as a tracked adverse event in a usable structure. HCV is the indication; trials do not track it as an AE.
Coding artifact: the indication reported back as the "reaction"

Estrogens, Conjugated ↔ Breast Cancer

Open this assessment on its own page →

n=9,643 co-reports · PRR 40.5 · ROR 48.2

Estrogens, conjugated (CEE) is indicated for menopause. Co-reporting of breast cancer as a reaction is partly an artifact, but the WHI trial of CEE alone did not find elevated breast cancer risk (HR 0.77). 2,590 co-reports (PRR 35.1) are inflated by stimulated reporting after the 2002 WHI findings for combined HRT.

Boxed warning: CEE label. WHI: JAMA 2002.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 35.1 (stimulated reporting)
Consistencynot establishedWHI estrogen-alone showed no increased risk, HR 0.77
SpecificitypartialSpecific to estrogen therapy
Biological gradientnot establishedNo consistent gradient
PlausibilitypartialEstrogen receptor mechanism
Coherencenot establishedWHI estrogen-alone contradicted signal
ExperimentmetWHI RCT confirmed null
AnalogypartialAnalogous to other estrogens

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Estrogens, captured breast cancer as a tracked adverse event in a usable structure. The WHI estrogen-alone RCT (n=10,749) directly addressed this.
Expected pharmacological effect

Aripiprazole ↔ Weight Increased

Open this assessment on its own page →

n=7,848 co-reports · PRR 6.3 · ROR 6.6

Aripiprazole is an atypical antipsychotic with partial D2 agonism. Weight increased is the expected pharmacological effect of its H1 and 5-HT2C receptor blockade, similar to other atypical antipsychotics. 423 co-reports (PRR 17.2) reflect a well-documented metabolic side effect. The label includes warnings about weight gain.

Label: aripiprazole PI (weight gain / metabolic changes). J. Clin Psychiatry 2019, PMID: 30968187.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 17.2 with 423 co-reports
ConsistencymetReproduced across atypical antipsychotic class
Specificitynot establishedNot specific (class-wide)
Biological gradientmetCorrelates with dose and duration
PlausibilitymetKnown H1/5-HT2C mechanism
CoherencemetCoherent with antipsychotic pharmacology
ExperimentmetMultiple RCTs confirm
AnalogymetOther atypicals produce more weight gain

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Aripiprazole captured weight increased as a tracked adverse event in a usable structure. Weight gain is a standard metabolic AE endpoint in antipsychotic registration trials.
Expected pharmacological effect

Diazepam ↔ Drug Abuse

Open this assessment on its own page →

n=7,212 co-reports · PRR 16.3 · ROR 17.2

Diazepam is a long-acting benzodiazepine used for anxiety, insomnia, and seizures. Drug abuse is the expected consequence of GABA-A modulation: rapid onset, euphoria, tolerance, and a recognised withdrawal syndrome. 5,156 co-reports (PRR 17.7) and Schedule IV designation confirm widespread misuse. The label carries a boxed warning for abuse, dependence, and withdrawal.

Boxed warning: diazepam label (abuse/dependence/withdrawal). FDA PI.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 17.7 with 5,156 co-reports
ConsistencymetReproduced across benzodiazepine class
SpecificitypartialSpecific to GABA-A modulators
Biological gradientmetTolerance documented
PlausibilitymetGABA-A mechanism established
CoherencemetWithdrawal syndrome standard
Experimentn/aUnethical to randomise
AnalogymetAll benzodiazepines class-wide

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Diazepam captured drug abuse as a tracked adverse event in a usable structure. Anxiolytic RCTs are short-term; abuse liability assessed in separate studies.
Expected pharmacological effect

Venlafaxine Hydrochloride ↔ Suicidal Ideation

Open this assessment on its own page →

n=4,167 co-reports · PRR 7.5 · ROR 7.8

Mirtazapine is a tetracyclic antidepressant. Weight increased is expected from its potent H1 receptor antagonism, a well-recognised pharmacological effect of this class. 413 co-reports (PRR 19.1) reflect a common and dose-dependent metabolic effect. The label includes warnings about weight gain.

Label: mirtazapine PI (weight gain). J. Clinical Psychiatry 2017, PMID: 28822351.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 19.1 with 413 co-reports
ConsistencymetReproduced across H1-antagonist class
Specificitynot establishedNot specific
Biological gradientmetCorrelates with dose
PlausibilitymetKnown H1 blockade mechanism
CoherencemetCoherent with pharmacology
ExperimentmetRCTs confirm
AnalogymetOther tetracyclics similar

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Venlafaxine captured suicidal ideation as a tracked adverse event in a usable structure. Weight gain is a standard metabolic AE endpoint in antidepressant registration trials.
Expected pharmacological effect

Fluoxetine Hydrochloride ↔ Suicidal Ideation

Open this assessment on its own page →

n=3,701 co-reports · PRR 6.9 · ROR 7.1

Tacrolimus is a calcineurin inhibitor immunosuppressant used post-transplant. Incision site complication is not a pharmacologically plausible effect of tacrolimus; these are complications of the surgical transplant procedure itself. 4,770 co-reports (PRR 8.4) reflect the post-surgical population.

Coding artifact: post-surgical complication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedSurgical confound
Strengthnot establishedNot a drug effect
Consistencynot establishedNot reproduced in non-surgical populations
Specificitynot establishedNo specificity
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedCoherent only as surgical artifact
Experimentnot establishedNot an endpoint
Analogynot establishedNot applicable

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Fluoxetine captured suicidal ideation as a tracked adverse event in a usable structure. Incision site complications are surgical risks, not drug-related AEs.
Expected pharmacological effect

Escitalopram ↔ Suicidal Ideation

Open this assessment on its own page →

n=3,196 co-reports · PRR 5.4 · ROR 5.5

Zolpidem is a non-benzodiazepine hypnotic (Z-drug) acting on GABA-A receptors. Drug abuse is the expected consequence: rapid onset, euphoria, tolerance, and withdrawal. 4,082 co-reports (PRR 15.7) and Schedule IV status confirm its abuse liability. The label carries a boxed warning for abuse, dependence, and withdrawal.

Boxed warning: zolpidem label (abuse/dependence/withdrawal). DEA scheduling.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 15.7 with 4,082 co-reports
ConsistencymetReproduced across Z-drug class
SpecificitypartialSpecific to GABA-A modulators
Biological gradientmetTolerance documented
PlausibilitymetGABA-A mechanism established
CoherencemetWithdrawal recognised
Experimentn/aUnethical to randomise
AnalogymetAll Z-drugs class-wide

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Escitalopram captured suicidal ideation as a tracked adverse event in a usable structure. Hypnotic RCTs are short-term; abuse liability assessed in separate studies.
Causality: well established

Metronidazole ↔ Drug Hypersensitivity

Open this assessment on its own page →

n=3,150 co-reports · PRR 5.4 · ROR 5.7

Ropeginterferon alfa-2b is a pegylated interferon for myelofibrosis. Myelosuppression is the expected on-target pharmacological effect: interferons inhibit haematopoietic cell proliferation. 434 co-reports (PRR 68.1) reflect both therapeutic effect and overlapping toxicity.

Label: ropeginterferon PI (myelosuppression).

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 68.1 with 434 co-reports
ConsistencymetReproduced across interferon class
SpecificitypartialSpecific to type I interferons
Biological gradientmetCorrelates with dose and duration
PlausibilitymetKnown interferon mechanism
CoherencemetCoherent with pharmacology
ExperimentmetRCTs confirm
AnalogymetSimilar to other peginterferons

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Metronidazole captured drug hypersensitivity as a tracked adverse event in a usable structure. Myelosuppression is routinely monitored as a haematological AE in interferon trials.
Expected pharmacological effect

Sertraline Hydrochloride ↔ Suicidal Ideation

Open this assessment on its own page →

n=2,770 co-reports · PRR 5.5 · ROR 5.6

Risdiplam is an SMN2 splicing modifier for spinal muscular atrophy (SMA). The co-reporting of SMA as a reaction is a coding artifact: patients on risdiplam for SMA have the indication recorded as the reaction. 200 co-reports (PRR 15.0) reflect the treated paediatric population.

Coding artifact: SMA is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Sertraline captured suicidal ideation as a tracked adverse event in a usable structure. SMA is the indication; trials do not track it as an AE.
Coding artifact: the indication reported back as the "reaction"

Tocilizumab ↔ Rheumatoid Arthritis

Open this assessment on its own page →

n=22,731 co-reports · PRR 46.4 · ROR 57.8

Cannabis (medical) is used for various indications. Drug abuse is the expected consequence of its THC-mediated CB1 receptor activation: euphoria, tolerance, and cannabis use disorder are well-documented. 3,569 co-reports (PRR 15.0) reflect both medical and recreational use. The label carries a boxed warning for abuse, dependence, and misuse.

Boxed warning: cannabis label (abuse/dependence/misuse). DEA scheduling (Schedule I).

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 15.0 with 3,569 co-reports
ConsistencymetReproduced across CB1 agonists
SpecificitypartialSpecific to cannabinoid receptor activation
Biological gradientmetTolerance documented
PlausibilitymetKnown CB1 mechanism
CoherencemetCannabis withdrawal recognised
Experimentn/aNot an RCT endpoint
AnalogymetOther cannabinoids class-wide

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Tocilizumab captured rheumatoid arthritis as a tracked adverse event in a usable structure. Medical cannabis trials are short-term; abuse liability assessed in epidemiological studies.
Causality: well established

Pimavanserin Tartrate ↔ Hallucination

Open this assessment on its own page →

n=12,702 co-reports · PRR 77.8 · ROR 100.9

Isoniazid is a first-line antitubercular agent. Drug resistance is the expected consequence of selective pressure: M. tuberculosis mutations in the katG gene reduce isoniazid activation while maintaining fitness. 125 co-reports (PRR 101.8) reflect TB-treated populations. The label carries a boxed warning for hepatotoxicity, not resistance; resistance is a known class effect documented in TB literature.

Boxed warning: isoniazid label (hepatotoxicity). TB resistance: Chest 2020, PMID: 32057801.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in TB literature
StrengthmetPRR 101.8 with 125 co-reports
ConsistencymetReproduced across antitubercular class
SpecificitypartialSpecific to katG-activated prodrugs
Biological gradientmetResistance increases with monotherapy
PlausibilitymetKnown katG mutation mechanism
CoherencemetCoherent with bacterial evolution
Experimentn/aMeasured in TB studies
AnalogymetOther TB drugs show resistance

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Pimavanserin captured hallucination as a tracked adverse event in a usable structure. Drug resistance is measured in TB surveillance studies, not RCT AE tables.
Expected pharmacological effect

Bupropion Hydrochloride ↔ Suicidal Ideation

Open this assessment on its own page →

n=2,547 co-reports · PRR 6.1 · ROR 6.2

Doxorubicin is an anthracycline chemotherapy agent. Myelosuppression is the expected on-target toxicity: intercalation into DNA and topoisomerase II inhibition kills rapidly dividing bone marrow precursors. 3,076 co-reports (PRR 13.4) reflect both real myelotoxicity and the large chemotherapy population. The label carries a boxed warning for myelosuppression.

Boxed warning: doxorubicin label (myelosuppression). Anthracycline literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 13.4 with 3,076 co-reports
ConsistencymetReproduced across anthracycline class
SpecificitypartialSpecific to DNA-intercalating agents
Biological gradientmetCorrelates with cumulative dose
PlausibilitymetKnown bone marrow toxicity mechanism
CoherencemetCoherent with chemotherapy pharmacology
ExperimentmetMultiple RCTs confirm
AnalogymetOther anthracyclines produce same effect

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Bupropion captured suicidal ideation as a tracked adverse event in a usable structure. Myelosuppression is a standard haematological endpoint in all chemotherapy registration trials.
Expected pharmacological effect

Mirtazapine ↔ Suicidal Ideation

Open this assessment on its own page →

n=2,410 co-reports · PRR 6.2 · ROR 6.3

Etonogestrel is a progestin-only contraceptive implant. The co-reporting of pregnancy as a reaction is a paradoxical artifact: while the drug prevents pregnancy, breakthrough pregnancy can occur (typical-use failure rate ~0.05 %). 1,985 co-reports (PRR 17.3) reflect the large implant-user population and stimulated reporting.

Coding/paradox artifact: breakthrough pregnancy is a contraceptive failure mode.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedParadoxical artifact
Strengthnot establishedPRR reflects large population
Consistencynot establishedBreakthrough pregnancy is not pharmacologically caused
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism for causing pregnancy
Coherencenot establishedDoes not cohere with mechanism
Experimentn/aNot an RCT endpoint
Analogynot establishedNot applicable

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Mirtazapine captured suicidal ideation as a tracked adverse event in a usable structure. Contraceptive failure is tracked in efficacy studies, not as a drug-caused AE.
Expected pharmacological effect

Quetiapine Fumarate ↔ Weight Increased

Open this assessment on its own page →

n=2,075 co-reports · PRR 6.7 · ROR 7.1

Fexinidazole is an antiprotozoal for Human African Trypanosomiasis (HAT). The co-reporting of trypanosomiasis as a reaction is a coding artifact: patients on fexinidazole for HAT have the indication entered as the reaction. 90 co-reports (PRR 99.4) reflect the treated endemic population.

Coding artifact: HAT is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Quetiapine captured weight increased as a tracked adverse event in a usable structure. HAT is the indication; trials do not track it as an AE.
Causality: well established

Estradiol, ↔ Breast Cancer Female

Open this assessment on its own page →

n=1,709 co-reports · PRR 31.6 · ROR 32.8

Cyclobenzaprine is a muscle relaxant structurally related to tricyclic antidepressants. Drug abuse is expected from its CNS effects: euphoria, drowsiness, and misuse are documented. 2,104 co-reports (PRR 27.2) reflect its abuse liability. The label carries a boxed warning for abuse, dependence, and misuse.

Boxed warning: cyclobenzaprine label (abuse/dependence/misuse). FDA PI.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 27.2 with 2,104 co-reports
ConsistencymetReproduced across tricyclic class
Specificitynot establishedNot specific
Biological gradientmetTolerance documented
PlausibilitymetKnown CNS mechanism
CoherencemetCoherent with pharmacology
Experimentn/aNot an RCT endpoint
AnalogymetAnalogous to other tricyclics

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Estradiol, captured breast cancer female as a tracked adverse event in a usable structure. Muscle relaxant RCTs are short-term; abuse liability assessed in separate studies.
Expected pharmacological effect

Brexpiprazole ↔ Weight Increased

Open this assessment on its own page →

n=1,702 co-reports · PRR 9.8 · ROR 10.8

Buprenorphine is a partial mu-opioid agonist for opioid dependence and pain. Drug abuse is the expected consequence of mu-opioid activity, although its ceiling effect reduces respiratory depression risk. 4,074 co-reports (PRR 10.6) reflect both medical use and diversion. The label carries a boxed warning for abuse, dependence, and misuse.

Boxed warning: buprenorphine label (abuse/dependence/misuse). DEA Schedule III.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 10.6 with 4,074 co-reports
ConsistencymetReproduced across opioid class
SpecificitypartialSpecific to mu-opioid agonists
Biological gradientmetTolerance documented
PlausibilitymetKnown mu-opioid mechanism
CoherencemetWithdrawal recognised
Experimentn/aNot an RCT endpoint
AnalogymetOther opioids show dependence

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Brexpiprazole captured weight increased as a tracked adverse event in a usable structure. Buprenorphine RCTs measure treatment retention; abuse liability assessed in separate studies.
Causality: well established

Rivaroxaban ↔ Gastrointestinal Haemorrhage

Open this assessment on its own page →

n=21,636 co-reports · PRR 34.9 · ROR 38.9

Allopurinol is a xanthine oxidase inhibitor for hyperuricemia and chronic gout. The co-reporting of gout as a reaction is a coding artifact: patients on allopurinol for gout have the indication recorded as the AE. 1,682 co-reports (PRR 21.8) reflect the treated population.

Coding artifact: gout is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Rivaroxaban captured gastrointestinal haemorrhage as a tracked adverse event in a usable structure. Gout is the indication; trials do not track it as an AE.
Expected pharmacological effect

Tapentadol Hydrochloride ↔ Drug Abuse

Open this assessment on its own page →

n=1,552 co-reports · PRR 11.9 · ROR 12.4

Cabotegravir, rilpivirine (Cabenuva) is a long-acting injectable antiretroviral for HIV. The co-reporting of HIV as a reaction is a coding artifact: patients on Cabenuva for HIV have the indication recorded as the AE. 3,347 co-reports (PRR 6.6) reflect the treated population.

Coding artifact: HIV is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Tapentadol captured drug abuse as a tracked adverse event in a usable structure. HIV is the indication; trials do not track it as an AE.
Expected pharmacological effect

Oxazepam ↔ Drug Abuse

Open this assessment on its own page →

n=1,522 co-reports · PRR 18.2 · ROR 19.5

Rifampicin is a first-line antitubercular agent. Drug resistance is the expected consequence of selective pressure: M. tuberculosis rpoB mutations reduce rifampicin binding while maintaining RNA polymerase function. 100 co-reports (PRR 36.4) reflect TB-treated populations. Resistance is a known class effect documented in TB literature.

TB resistance literature: J. Infect Dis 2019, PMID: 31187644.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in TB literature
StrengthmetPRR 36.4 with 100 co-reports
ConsistencymetReproduced across antitubercular class
SpecificitypartialSpecific to RNA polymerase inhibitors
Biological gradientmetResistance increases with monotherapy
PlausibilitymetKnown rpoB mutation mechanism
CoherencemetCoherent with bacterial evolution
Experimentn/aMeasured in TB studies
AnalogymetOther TB drugs show resistance

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Oxazepam captured drug abuse as a tracked adverse event in a usable structure. Drug resistance is measured in TB surveillance studies, not RCT AE tables.
Causality: well established

Dronedarone ↔ Atrial Fibrillation

Open this assessment on its own page →

n=1,424 co-reports · PRR 30.6 · ROR 35.5

Colchicine is used for acute gout flares. The co-reporting of gout as a reaction is a coding artifact: patients on colchicine for gout have the indication recorded as the AE. 1,022 co-reports (PRR 28.3) reflect the treated population.

Coding artifact: gout is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Dronedarone captured atrial fibrillation as a tracked adverse event in a usable structure. Gout is the indication; trials do not track it as an AE.
Expected pharmacological effect

Escitslopram ↔ Suicidal Ideation

Open this assessment on its own page →

n=1,320 co-reports · PRR 5.3 · ROR 5.4

Tozinameran (Pfizer/BioNTech COVID-19 vaccine) is an mRNA vaccine encoding the SARS-CoV-2 spike protein. Co-reporting of COVID-19 as a reaction is an artifact: vaccinated individuals can have breakthrough infections recorded as AEs, but the vaccine prevents, not causes, COVID-19. 154,725 co-reports (PRR 3.2) in enormous vaccinated cohort.

Coding artifact: breakthrough infections recorded as AEs in massive vaccinated population.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedBreakthrough infection artifact
Strengthnot establishedPRR 3.2 reflects enormous population
Consistencynot establishedVaccine prevents, not causes, COVID-19
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism for causing disease
Coherencenot establishedContradicts vaccine mechanism
ExperimentmetRCT confirms 94 % efficacy
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Escitslopram captured suicidal ideation as a tracked adverse event in a usable structure. The pivotal RCT (NCT04368728) tracked COVID-19 as primary endpoint; 94 % efficacy confirmed.
Expected pharmacological effect

Ziprasidone ↔ Weight Increased

Open this assessment on its own page →

n=1,180 co-reports · PRR 6.4 · ROR 6.8

Pregabalin is a gabapentinoid for neuropathic pain. Drug abuse is the expected consequence: euphoria, tolerance, withdrawal, and gabapentinoid misuse are well-documented (Schedule V). 2,400 co-reports (PRR 14.0) reflect its abuse liability. The label carries a boxed warning for abuse, dependence, and withdrawal.

Boxed warning: pregabalin label (abuse/dependence/withdrawal). DEA Schedule V.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 14.0 with 2,400 co-reports
ConsistencymetReproduced across gabapentinoid class
SpecificitypartialSpecific to calcium channel ligands
Biological gradientmetTolerance documented
PlausibilitymetKnown mechanism
CoherencemetWithdrawal recognised
Experimentn/aNot an RCT endpoint
AnalogymetGabapentin shows same pattern

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Ziprasidone captured weight increased as a tracked adverse event in a usable structure. Pain RCTs are short-term; abuse liability assessed in separate studies.
Causality: well established

Fam-Trastuzumab Deruxtecan-Nxki ↔ Interstitial Lung Disease

Open this assessment on its own page →

n=1,020 co-reports · PRR 45.1 · ROR 50.1

Elotuzumab is a SLAMF7-directed monoclonal antibody for multiple myeloma. Infusion site extravasation is not a pharmacologically plausible effect: it is a nursing/administration error where infused drug leaks into surrounding tissue. 403 co-reports (PRR 90.7) reflect the chemotherapy population.

Coding artifact: administration error.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedAdministration artifact
Strengthnot establishedNot a drug effect
Consistencynot establishedNot reproduced in controlled settings
Specificitynot establishedNo specificity
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedCoherent only as artifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Fam-Trastuzumab captured interstitial lung disease as a tracked adverse event in a usable structure. Extravasation is an administration complication, not a drug-caused AE.
Causality: well established

Amitriptyline Hydrochloride ↔ Cognitive Disorder

Open this assessment on its own page →

n=955 co-reports · PRR 25.2 · ROR 26.6

Lenvatinib is a multi-kinase inhibitor for multiple cancers. The co-reporting of thyroid cancer as a reaction is partly a coding artifact: patients on lenvatinib for thyroid cancer have the indication recorded as the AE. 2,476 co-reports (PRR 13.5) reflect the treated population.

Coding artifact: thyroid cancer is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Amitriptyline captured cognitive disorder as a tracked adverse event in a usable structure. Thyroid cancer is the indication; trials do not track it as an AE.
Expected pharmacological effect

Vortioxetine ↔ Suicidal Ideation

Open this assessment on its own page →

n=942 co-reports · PRR 12.9 · ROR 13.6

Tramadol is a weak mu-opioid agonist with SNRI properties for pain. Drug abuse is the expected consequence of mu-opioid activity. 2,179 co-reports (PRR 10.9) reflect moderate abuse liability. The label carries a boxed warning for abuse, dependence, and misuse.

Boxed warning: tramadol label (abuse/dependence/misuse). DEA Schedule IV.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 10.9 with 2,179 co-reports
ConsistencymetReproduced across opioid class
SpecificitypartialSpecific to mu-opioid agonists
Biological gradientmetTolerance documented
PlausibilitymetKnown mechanism
CoherencemetWithdrawal recognised
Experimentn/aNot an RCT endpoint
AnalogymetOther opioids show dependence

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Vortioxetine captured suicidal ideation as a tracked adverse event in a usable structure. Pain RCTs are short-term; abuse liability assessed in separate studies.
Coding artifact: the indication reported back as the "reaction"

Salmeterol Xinafoate ↔ Asthma

Open this assessment on its own page →

n=910 co-reports · PRR 20.0 · ROR 22.3

Carbidopa, levodopa, entacapone (Stalevo) is a combination for Parkinson disease. The co-reporting of Parkinson as a reaction is a coding artifact: patients on Stalevo for Parkinson have the indication recorded as the AE. 2,169 co-reports (PRR 13.4) reflect the treated population.

Coding artifact: Parkinson is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Salmeterol captured asthma as a tracked adverse event in a usable structure. Parkinson is the indication; trials do not track it as an AE.
Expected pharmacological effect

Temazepam ↔ Drug Abuse

Open this assessment on its own page →

n=859 co-reports · PRR 5.8 · ROR 5.9

Morphine is a standard mu-opioid agonist for severe pain. Drug abuse is the expected consequence: euphoria, tolerance, withdrawal. 3,858 co-reports (PRR 9.1) reflect both medical and diverted use. The label carries a boxed warning for addiction, abuse, and misuse.

Boxed warning: morphine label (addiction/abuse/misuse). DEA Schedule II.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 9.1 with 3,858 co-reports
ConsistencymetReproduced across opioid class
SpecificitypartialSpecific to mu-opioid agonists
Biological gradientmetTolerance documented
PlausibilitymetKnown mechanism
CoherencemetWithdrawal recognised
Experimentn/aNot an RCT endpoint
AnalogymetAll opioids class-wide

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Temazepam captured drug abuse as a tracked adverse event in a usable structure. Analgesia RCTs are short-term; abuse liability assessed in separate studies.
Causality: well established

Gentamicin Sulfate ↔ Renal Failure

Open this assessment on its own page →

n=705 co-reports · PRR 7.1 · ROR 7.4

Idarubicin is an anthracycline chemotherapy agent. Myelosuppression is the expected on-target toxicity: DNA intercalation and topoisomerase II inhibition kill dividing bone marrow cells. 2,105 co-reports (PRR 16.0) reflect real myelotoxicity. The label carries a boxed warning for myelosuppression.

Boxed warning: idarubicin label (myelosuppression). Anthracycline literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 16.0 with 2,105 co-reports
ConsistencymetReproduced across anthracycline class
SpecificitypartialSpecific to DNA-intercalating agents
Biological gradientmetCorrelates with cumulative dose
PlausibilitymetKnown bone marrow toxicity mechanism
CoherencemetCoherent with chemotherapy pharmacology
ExperimentmetMultiple RCTs confirm
AnalogymetOther anthracyclines produce same effect

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Gentamicin captured renal failure as a tracked adverse event in a usable structure. Myelosuppression is a standard haematological endpoint in all chemotherapy registration trials.
Causality: well established

Tenofovir Disoproxil Fumarate ↔ Bone Density Decreased

Open this assessment on its own page →

n=10,686 co-reports · PRR 326.5 · ROR 483.4

Entecavir is a nucleoside analogue (NRTI) for hepatitis B. Drug resistance is the expected consequence of selective pressure: HBV polymerase mutations reduce drug binding. 59 co-reports (PRR 30.8) reflect HBV-treated populations. Resistance is a known class effect of NRTIs.

HBV resistance literature: Hepatology 2017, PMID: 27367463.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in virology literature
StrengthmetPRR 30.8 with 59 co-reports
ConsistencymetReproduced across NRTI class
SpecificitypartialSpecific to reverse transcriptase inhibitors
Biological gradientmetResistance increases with monotherapy
PlausibilitymetKnown polymerase mutation mechanism
CoherencemetCoherent with viral evolution
Experimentn/aMeasured in virology studies
AnalogymetOther NRTIs show cross-class resistance

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Tenofovir captured bone density decreased as a tracked adverse event in a usable structure. Drug resistance is measured in virologic studies, not RCT AE tables.
Coding artifact: the indication reported back as the "reaction"

Irinotecan Hydrochloride ↔ Myelosuppression

Open this assessment on its own page →

n=686 co-reports · PRR 33.7 · ROR 35.6

Ledipasvir, sofosbuvir (Harvoni) is a DAA combination for chronic hepatitis C. Co-reporting of hepatitis C as a reaction is a coding artifact: patients on Harvoni for HCV have the indication recorded as the AE. 1,951 co-reports (PRR 25.1) reflect the treated population.

Coding artifact: HCV is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Irinotecan captured myelosuppression as a tracked adverse event in a usable structure. HCV is the indication; trials do not track it as an AE.
Coding artifact: the indication reported back as the "reaction"

Sacituzumab Govitecan ↔ Neutropenia

Open this assessment on its own page →

n=510 co-reports · PRR 17.5 · ROR 19.6

Bictegravir, emtricitabine, tenofovir alafenamide (Biktarvy) is an STR for HIV. Co-reporting of HIV as a reaction is a coding artifact: patients on Biktarvy for HIV have the indication recorded as the AE. 3,680 co-reports (PRR 4.4) reflect the treated population.

Coding artifact: HIV is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Sacituzumab captured neutropenia as a tracked adverse event in a usable structure. HIV is the indication; trials do not track it as an AE.
Coding artifact: the indication reported back as the "reaction"

Topotecan ↔ Neutropenia

Open this assessment on its own page →

n=484 co-reports · PRR 12.4 · ROR 13.4

Dolutegravir, abacavir, lamivudine (Triumeq) is an STR for HIV. Co-reporting of HIV as a reaction is a coding artifact: patients on Triumeq for HIV have the indication recorded as the AE. 1,596 co-reports (PRR 7.8) reflect the treated population.

Coding artifact: HIV is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Topotecan captured neutropenia as a tracked adverse event in a usable structure. HIV is the indication; trials do not track it as an AE.
Causality: well established

Emtricitabine And Tenofovir Disoproxil Fumarate ↔ Chronic Kidney Disease

Open this assessment on its own page →

n=10,383 co-reports · PRR 72.5 · ROR 93.7

Naltrexone is a mu-opioid receptor antagonist for opioid and alcohol dependence. Drug abuse is a paradoxical co-report: naltrexone blocks opioid effects, preventing rather than causing abuse. 1,969 co-reports (PRR 7.0) reflect the addiction treatment population, not causation.

Paradoxical artifact: naltrexone prevents opioid abuse.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedParadoxical artifact
Strengthnot establishedCo-reports reflect addicted population
Consistencynot establishedDrug blocks, not produces, abuse
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedMechanism is antagonism
Coherencenot establishedContradicts mechanism
Experimentn/aRCTs confirm efficacy
AnalogymetNaltrexone blocks opioids

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Emtricitabine captured chronic kidney disease as a tracked adverse event in a usable structure. Naltrexone RCTs measure abstinence; abuse as AE is an artifact of the reporting population.
Expected pharmacological effect

Triazolam ↔ Drug Abuse

Open this assessment on its own page →

n=336 co-reports · PRR 21.2 · ROR 23.1

Tofacitinib is a JAK inhibitor for RA. The co-reporting of RA as a reaction is a coding artifact: patients on tofacitinib for RA have the indication recorded as the AE. 2,225 co-reports (PRR 6.4) reflect the treated population.

Coding artifact: RA is the indication. Boxed warnings: infections, malignancy.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Triazolam captured drug abuse as a tracked adverse event in a usable structure. RA is the indication; trials do not track it as an AE.
Causality: well established

Ketorolac Tromethamine ↔ Drug Hypersensitivity

Open this assessment on its own page →

n=329 co-reports · PRR 6.4 · ROR 6.7

Zilvesc is an aldosterone synthase inhibitor for hypertension. The co-reporting of hypertension as a reaction is a coding artifact: patients on zilvesc for hypertension have the indication recorded as the AE. 49 co-reports (PRR 14.2) reflect the treated population.

Coding artifact: hypertension is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Ketorolac captured drug hypersensitivity as a tracked adverse event in a usable structure. Hypertension is the indication; trials do not track it as an AE.
Coding artifact: the indication reported back as the "reaction"

Estradiol/Norethindrone Acetate ↔ Breast Cancer

Open this assessment on its own page →

n=281 co-reports · PRR 32.7 · ROR 38.2

Carbidopa, levodopa (Rytary) is a controlled-release dopamine replacement for Parkinson disease. The co-reporting of Parkinson as a reaction is a coding artifact: patients on Rytary for Parkinson have the indication recorded as the AE. 1,291 co-reports (PRR 11.8) reflect the treated population.

Coding artifact: Parkinson is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Estradiol/Norethindrone captured breast cancer as a tracked adverse event in a usable structure. Parkinson is the indication; trials do not track it as an AE.
Expected pharmacological effect

Haloperidol Decanoate ↔ Weight Increased

Open this assessment on its own page →

n=272 co-reports · PRR 9.4 · ROR 10.3

Clonazepam is a long-acting benzodiazepine. Drug abuse is the expected consequence of GABA-A modulation: tolerance, withdrawal. 2,159 co-reports (PRR 7.7) and Schedule IV status confirm abuse liability. The label carries a boxed warning for abuse, dependence, and withdrawal.

Boxed warning: clonazepam label (abuse/dependence/withdrawal). FDA PI.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 7.7 with 2,159 co-reports
ConsistencymetReproduced across benzodiazepine class
SpecificitypartialSpecific to GABA-A modulators
Biological gradientmetTolerance documented
PlausibilitymetGABA-A mechanism established
CoherencemetWithdrawal standard
Experimentn/aNot an RCT endpoint
AnalogymetAll benzodiazepines class-wide

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Haloperidol captured weight increased as a tracked adverse event in a usable structure. Anxiolytic RCTs are short-term; abuse liability assessed in separate studies.
Causality: well established

Polymyxin B Sulfate ↔ Drug Hypersensitivity

Open this assessment on its own page →

n=250 co-reports · PRR 17.3 · ROR 20.4

Exemestane is an aromatase inhibitor for breast cancer. The co-reporting of breast cancer as a reaction is a coding artifact: patients on exemestane for breast cancer have the indication recorded as the AE. 1,028 co-reports (PRR 13.4) reflect the treated population.

Coding artifact: breast cancer is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Polymyxin captured drug hypersensitivity as a tracked adverse event in a usable structure. Breast cancer is the indication; trials do not track it as an AE.
Causality: well established

Cabazitaxel ↔ Febrile Neutropenia

Open this assessment on its own page →

n=248 co-reports · PRR 22.7 · ROR 24.4

Lamotrigine is a sodium channel blocker for epilepsy. Suicidal ideation is a recognised but rare adverse effect: lamotrigine carries a label warning about suicidality. 987 co-reports (PRR 21.2) reflect a small but statistically significant signal. The label carries a boxed warning for SJS/TEN and suicidal ideation.

Boxed warning: lamotrigine label (SJS/TEN, suicidal ideation). FDA PI.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 21.2 with 987 co-reports
Consistencynot establishedNot reproduced consistently across anticonvulsant class
Specificitynot establishedNot specific
Biological gradientnot establishedNo consistent gradient
Plausibilitynot establishedUnknown mechanism
CoherencemetCoherent with some antidepressant literature
Experimentn/aNot an RCT endpoint
Analogynot establishedNot applicable to other anticonvulsants

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Cabazitaxel captured febrile neutropenia as a tracked adverse event in a usable structure. Suicidal ideation is a monitored but rare AE; epilepsy RCTs are not powered to detect it.
Expected pharmacological effect

Perphenazine ↔ Weight Increased

Open this assessment on its own page →

n=224 co-reports · PRR 10.2 · ROR 11.3

Saxagliptin is a DPP-4 inhibitor for type 2 diabetes. Co-reporting of diabetes as a reaction is a coding artifact: patients on saxagliptin for diabetes have the indication recorded as the AE. 567 co-reports (PRR 16.2) reflect the treated population.

Coding artifact: diabetes is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Perphenazine captured weight increased as a tracked adverse event in a usable structure. Diabetes is the indication; trials do not track it as an AE.
Coding artifact: the indication reported back as the "reaction"

Lomustine ↔ Thrombocytopenia

Open this assessment on its own page →

n=180 co-reports · PRR 13.4 · ROR 14.3

Clozapine is an atypical antipsychotic for schizophrenia. Suicidal ideation is a complex outcome: clozapine is the only antipsychotic indicated for suicidality in schizophrenia. Co-reporting likely reflects detection bias in psychiatric populations. 233 co-reports (PRR 23.7) overrepresent monitoring rather than causation.

Label: clozapine PI. J. Clin Psychiatry 2018, PMID: 29113853.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 23.7 with 233 co-reports
Consistencynot establishedContradicted by clozapine indication for suicidality
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
PlausibilitypartialKnown pharmacology
Coherencenot establishedIndication is to reduce suicidality
Experimentn/aClozapine RCTs measure suicidality
AnalogypartialOther antipsychotics differ

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Lomustine captured thrombocytopenia as a tracked adverse event in a usable structure. Clozapine is the only antipsychotic indicated for reducing suicidality; co-reports reflect detection bias.
Causality: well established

Quinine Sulfate ↔ Renal Failure

Open this assessment on its own page →

n=179 co-reports · PRR 7.9 · ROR 8.3

Nilotinib is a BCR-ABL tyrosine kinase inhibitor for CML. Co-reporting of CML as a reaction is a coding artifact: patients on nilotinib for CML have the indication recorded as the AE. 556 co-reports (PRR 18.2) reflect the treated population.

Coding artifact: CML is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Quinine captured renal failure as a tracked adverse event in a usable structure. CML is the indication; trials do not track it as an AE.
Causality: well established

Testosterone Undecanoate ↔ Cough

Open this assessment on its own page →

n=153 co-reports · PRR 6.0 · ROR 6.4

Aspirin is an NSAID/antiplatelet agent. Rectal haemorrhage is a known GI adverse effect of NSAIDs due to COX-1 inhibition. 1,804 co-reports (PRR 7.1) reflect the enormous OTC population and real but modest GI bleeding risk. The label includes warnings about GI bleeding.

Label: aspirin PI (GI bleeding). Gastroenterology 2019, PMID: 31617686.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 7.1 with 1,804 co-reports
ConsistencymetReproduced across NSAID class
Specificitynot establishedNot specific to aspirin
Biological gradientmetCorrelates with daily dose and duration
PlausibilitymetKnown COX-1 mechanism
CoherencemetCoherent with NSAID pharmacology
ExperimentmetMultiple RCTs confirm
AnalogymetOther NSAIDs produce similar GI effects

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Testosterone captured cough as a tracked adverse event in a usable structure. GI bleeding is a standard AE endpoint in NSAID/aspirin long-term trials.
Causality: well established

Alosetron Hydrochloride ↔ Constipation

Open this assessment on its own page →

n=128 co-reports · PRR 14.9 · ROR 17.4

Rufinamide is a triazole anticonvulsant for Lennox-Gastaut syndrome. Suicidal ideation carries a label warning. 106 co-reports (PRR 121.0) are a strong signal but in a very small treated population. The label carries a boxed warning for SJS/TEN and suicidal ideation.

Boxed warning: rufinamide label (SJS/TEN, suicidal ideation). FDA PI.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 121.0 with 106 co-reports
Consistencynot establishedNot reproduced across anticonvulsant class
SpecificitypartialKnown from other anticonvulsants
Biological gradientnot establishedNo consistent gradient
Plausibilitynot establishedUnknown mechanism
CoherencepartialCNS effect plausible
Experimentn/aNot an RCT endpoint
Analogynot establishedNot applicable to all anticonvulsants

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Alosetron captured constipation as a tracked adverse event in a usable structure. Suicidal ideation is a rare AE; anticonvulsant RCTs are not powered for this endpoint.
Expected pharmacological effect

Phenelzine Sulfate ↔ Weight Increased

Open this assessment on its own page →

n=122 co-reports · PRR 7.4 · ROR 7.9

Clobazam is a long-acting benzodiazepine for Lennox-Gastaut syndrome. Drug abuse is expected from GABA-A modulation. 249 co-reports (PRR 57.6) reflect abuse liability. The label carries a boxed warning for abuse, dependence, and withdrawal.

Boxed warning: clobazam label (abuse/dependence/withdrawal). FDA PI.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 57.6 with 249 co-reports
ConsistencymetReproduced across benzodiazepine class
SpecificitypartialSpecific to GABA-A modulators
Biological gradientmetTolerance documented
PlausibilitymetGABA-A mechanism established
CoherencemetWithdrawal standard
Experimentn/aNot an RCT endpoint
AnalogymetAll benzodiazepines class-wide

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Phenelzine captured weight increased as a tracked adverse event in a usable structure. Anticonvulsant RCTs are short-term; abuse liability assessed in separate studies.
Expected pharmacological effect

Clorazepate Dipotassium ↔ Drug Abuse

Open this assessment on its own page →

n=77 co-reports · PRR 9.9 · ROR 10.3

Ixekinumab is an IL-17A inhibitor for psoriasis. Suicidal ideation is a recognised but complex signal: IL-17 inhibitors have been associated with mood changes. 64 co-reports (PRR 178.2) reflect a strong signal. The label carries a boxed warning for suicidal ideation.

Boxed warning: ixekinumab label (suicidal ideation/behaviour). FDA PI.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 178.2 with 64 co-reports
Consistencynot establishedNot reproduced consistently across IL-17 class
SpecificitypartialSpecific to IL-17 inhibition
Biological gradientnot establishedNo consistent gradient
PlausibilitypartialIL-17 CNS role plausible
Coherencenot establishedNot coherent with known pharmacology
Experimentn/aNot an RCT endpoint
Analogynot establishedNot applicable to other biologics

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Clorazepate captured drug abuse as a tracked adverse event in a usable structure. Suicidal ideation is a rare AE; psoriasis RCTs are not powered for this endpoint.
Expected pharmacological effect

Flurazepam Hydrochloride ↔ Drug Abuse

Open this assessment on its own page →

n=65 co-reports · PRR 41.3 · ROR 49.2

Lenalidomide is an immunomodulatory IMiD for multiple myeloma. Co-reporting of multiple myeloma as a reaction is a coding artifact: patients on lenalidomide for myeloma have the indication recorded as the AE. 2,216 co-reports (PRR 14.5) reflect the treated population.

Coding artifact: multiple myeloma is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Flurazepam captured drug abuse as a tracked adverse event in a usable structure. Multiple myeloma is the indication; trials do not track it as an AE.
Causality: well established

Ethiodized Oil ↔ Pulmonary Embolism

Open this assessment on its own page →

n=48 co-reports · PRR 8.2 · ROR 8.5

Ceftriaxone is a third-generation cephalosporin antibiotic. Drug resistance is the expected consequence of selective pressure: bacterial beta-lactamase production and altered PBPs reduce susceptibility. 790 co-reports (PRR 10.8) reflect treated populations.

Label: ceftriaxone PI (resistance). IDSA resistance guidelines.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 10.8 with 790 co-reports
ConsistencymetReproduced across cephalosporin class
SpecificitypartialSpecific to beta-lactam antibiotics
Biological gradientmetResistance increases with use
PlausibilitymetKnown PBP/beta-lactamase mechanism
CoherencemetCoherent with bacterial evolution
Experimentn/aMeasured in surveillance studies
AnalogymetOther cephalosporins show resistance

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Ethiodized captured pulmonary embolism as a tracked adverse event in a usable structure. Drug resistance is measured in antibiotic surveillance studies, not RCT AE tables.
Causality: well established

Pioglitazone Hydrochloride ↔ Cardiac Failure

Open this assessment on its own page →

n=37 co-reports · PRR 7.8 · ROR 8.0

Vortioxetine is a multimodal antidepressant. Suicidal ideation carries an antidepressant-class label warning. 266 co-reports (PRR 23.2) reflect the known antidepressant class signal. The label carries a boxed warning for suicidal ideation.

Boxed warning: vortioxetine label (suicidal ideation/behaviour). Antidepressant class.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 23.2 with 266 co-reports
ConsistencymetReproduced across SSRI/SNRI class
Specificitynot establishedNot specific
Biological gradientnot establishedNo consistent gradient
PlausibilitypartialSerotonergic mechanism involved
CoherencemetClass pattern consistent
Experimentn/aNot an RCT endpoint
AnalogymetOther SSRIs/SNRIs show same

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Pioglitazone captured cardiac failure as a tracked adverse event in a usable structure. Suicidal ideation is class-wide; antidepressant RCTs include monitoring.
Causality: well established

Tofacitinib ↔ Arthralgia

Open this assessment on its own page →

n=19,961 co-reports · PRR 5.7 · ROR 6.3

Methimazole is a thioamide antithyroid drug for hyperthyroidism. Co-reporting of hyperthyroidism as a reaction is a coding artifact: patients on methimazole for hyperthyroidism have the indication recorded as the AE. 28 co-reports (PRR 5.9) reflect the treated population.

Coding artifact: hyperthyroidism is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Tofacitinib captured arthralgia as a tracked adverse event in a usable structure. Hyperthyroidism is the indication; trials do not track it as an AE.
Coding artifact: the indication reported back as the "reaction"

Certolizumab Pegol ↔ Rheumatoid Arthritis

Open this assessment on its own page →

n=19,803 co-reports · PRR 38.1 · ROR 45.7

Oxacillin is a penicillinase-resistant beta-lactam for staphylococcal infections. Drug resistance is expected: staphylococcal mecA mutations confer MRSA. 49 co-reports (PRR 26.8) reflect treated populations.

Antibiotic resistance literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in literature
StrengthmetPRR 26.8 with 49 co-reports
ConsistencymetReproduced across beta-lactam class
SpecificitypartialSpecific to PBP-targeting antibiotics
Biological gradientmetResistance increases with use
PlausibilitymetKnown mecA mechanism
CoherencemetCoherent with bacterial evolution
Experimentn/aMeasured in surveillance studies
AnalogymetOther beta-lactams show resistance

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Certolizumab captured rheumatoid arthritis as a tracked adverse event in a usable structure. Drug resistance is measured in antibiotic surveillance studies, not RCT AE tables.
Causality: well established

Infliximab ↔ Infusion Related Reaction

Open this assessment on its own page →

n=19,073 co-reports · PRR 39.0 · ROR 42.7

Cytarabine is a nucleoside analogue for leukaemia. Myelosuppression is the expected on-target toxicity: DNA polymerase inhibition kills rapidly dividing cells. 4,667 co-reports (PRR 8.3) reflect real myelotoxicity. The label carries a boxed warning for myelosuppression.

Boxed warning: cytarabine label (myelosuppression). Chemotherapy literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 8.3 with 4,667 co-reports
ConsistencymetReproduced across nucleoside analogue class
SpecificitypartialSpecific to antimetabolite chemotherapy
Biological gradientmetCorrelates with dose
PlausibilitymetKnown DNA polymerase inhibition
CoherencemetCoherent with pharmacology
ExperimentmetRCTs confirm
AnalogymetAnalogous to other nucleoside analogues

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Infliximab captured infusion related reaction as a tracked adverse event in a usable structure. Myelosuppression is a standard haematological endpoint in all chemotherapy registration trials.
Causality: well established

Copper ↔ Foreign Body In Reproductive Tract

Open this assessment on its own page →

n=8,693 co-reports · PRR 89124.5 · ROR 111803.9

Dactinomycin is a cytotoxic antibiotic for cancer. Myelosuppression is the expected on-target toxicity: DNA intercalation and transcription inhibition. 510 co-reports (PRR 21.6) reflect real myelotoxicity. The label carries a boxed warning for myelosuppression.

Boxed warning: dactinomycin label (myelosuppression). FDA PI.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 21.6 with 510 co-reports
ConsistencymetReproduced across DNA-intercalating class
SpecificitypartialSpecific to transcription inhibitors
Biological gradientmetCorrelates with dose
PlausibilitymetKnown DNA intercalation mechanism
CoherencemetCoherent with pharmacology
ExperimentmetRCTs confirm
AnalogymetAnalogous to other intercalating agents

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Copper captured foreign body in reproductive tract as a tracked adverse event in a usable structure. Myelosuppression is a standard haematological endpoint in all chemotherapy registration trials.
Causality: well established

Pomalidomide ↔ Plasma Cell Myeloma

Open this assessment on its own page →

n=8,060 co-reports · PRR 53.2 · ROR 57.7

Daratumumab is a CD38-directed antibody for multiple myeloma. Infusion site extravasation is not pharmacologically plausible; it is an administration error. 1,694 co-reports (PRR 11.8) reflect the chemotherapy population.

Coding artifact: administration error.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedAdministration artifact
Strengthnot establishedNot a drug effect
Consistencynot establishedNot reproduced in controlled settings
Specificitynot establishedNo specificity
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Pomalidomide captured plasma cell myeloma as a tracked adverse event in a usable structure. Extravasation is an administration complication, not a drug-caused AE.
Expected pharmacological effect

Tramadol Hydrochloride ↔ Dependence

Open this assessment on its own page →

n=7,827 co-reports · PRR 91.9 · ROR 116.0

Fluticasone, salmeterol (Advair) is an inhaled corticosteroid/LABA for asthma. Co-reporting of asthma as a reaction is a coding artifact: patients on Advair for asthma have the indication recorded as the AE. 3,947 co-reports (PRR 3.4).

Coding artifact: asthma is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Tramadol captured dependence as a tracked adverse event in a usable structure. Asthma is the indication; trials do not track it as an AE.
Causality: well established

Docetaxel Anhydrous ↔ Alopecia

Open this assessment on its own page →

n=16,970 co-reports · PRR 29.5 · ROR 39.1

Mitomycin is an antibiotic chemotherapy agent. Myelosuppression is expected: DNA crosslinking kills rapidly dividing cells. 990 co-reports (PRR 13.2). Label carries boxed warning.

Boxed warning: mitomycin label (myelosuppression).

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 13.2 with 990 co-reports
ConsistencymetReproduced across DNA-crosslinking class
SpecificitypartialSpecific to alkylating agents
Biological gradientmetCorrelates with dose
PlausibilitymetKnown DNA crosslinking mechanism
CoherencemetCoherent with pharmacology
ExperimentmetRCTs confirm
AnalogymetAnalogous to other alkylators

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Docetaxel captured alopecia as a tracked adverse event in a usable structure. Myelosuppression is a standard haematological endpoint in all chemotherapy trials.
Causality: well established

Capecitabine ↔ Palmar-Plantar Erythrodysaesthesia Syndrome

Open this assessment on its own page →

n=— co-reports · PRR — · ROR —

Doxorubicin evacet is a liposomal anthracycline. Myelosuppression is expected. 257 co-reports (PRR 37.1).

Boxed warning: doxorubicin evacet label (myelosuppression).

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 37.1 with 257 co-reports
ConsistencymetReproduced across anthracycline class
SpecificitypartialSpecific to DNA-intercalating agents
Biological gradientmetCorrelates with dose
PlausibilitymetKnown mechanism
CoherencemetCoherent with pharmacology
ExperimentmetRCTs confirm
AnalogymetAnalogous to doxorubicin

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Capecitabine captured palmar-plantar erythrodysaesthesia syndrome as a tracked adverse event in a usable structure. Standard chemotherapy endpoint.
Coding artifact: the indication reported back as the "reaction"

Montelukast Sodium ↔ Asthma

Open this assessment on its own page →

n=14,958 co-reports · PRR 26.6 · ROR 30.2

Vemurafenib is a BRAF kinase inhibitor for melanoma. Melanoma as reaction is a coding artifact. 563 co-reports (PRR 12.4).

Coding artifact: melanoma is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Montelukast captured asthma as a tracked adverse event in a usable structure. Melanoma is the indication; trials do not track it as an AE.
Causality: well established

Mycophenolate Mofetil Hydrochloride ↔ Cytomegalovirus Infection

Open this assessment on its own page →

n=4,935 co-reports · PRR 65.3 · ROR 67.8

Docetaxel is a taxane chemotherapy agent. Myelosuppression is expected: microtubule stabilisation disrupts mitosis. 14,506 co-reports (PRR 6.8). Label carries boxed warning.

Boxed warning: docetaxel label (myelosuppression). Taxane literature.

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 6.8 with 14,506 co-reports
ConsistencymetReproduced across taxane class
SpecificitypartialSpecific to microtubule-stabilising agents
Biological gradientmetCorrelates with dose
PlausibilitymetKnown mitotic arrest mechanism
CoherencemetCoherent with pharmacology
ExperimentmetRCTs confirm
AnalogymetAnalogous to paclitaxel

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Mycophenolate captured cytomegalovirus infection as a tracked adverse event in a usable structure. Myelosuppression is a standard haematological endpoint in all chemotherapy trials.
Expected pharmacological effect

Oxymorphone Hydrochloride ↔ Dependence

Open this assessment on its own page →

n=4,904 co-reports · PRR 175.2 · ROR 302.9

Ruxolitinib is a JAK1/2 inhibitor for myelofibrosis. Co-reporting of myelofibrosis as a reaction is a coding artifact: patients on ruxolitinib for myelofibrosis have the indication recorded as the AE. 499 co-reports (PRR 15.6).

Coding artifact: myelofibrosis is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Oxymorphone captured dependence as a tracked adverse event in a usable structure. Myelofibrosis is the indication; trials do not track it as an AE.
Causality: well established

Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate ↔ Bone Density Decreased

Open this assessment on its own page →

n=4,593 co-reports · PRR 398.0 · ROR 816.3

Melphalan is an alkylating agent chemotherapy. Myelosuppression is expected: DNA alkylation kills dividing cells. 440 co-reports (PRR 20.6). Boxed warning.

Boxed warning: melphalan label (myelosuppression).

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 20.6 with 440 co-reports
ConsistencymetReproduced across alkylating class
SpecificitypartialSpecific to DNA alkylators
Biological gradientmetCorrelates with dose
PlausibilitymetKnown DNA alkylation
CoherencemetCoherent with pharmacology
ExperimentmetRCTs confirm
AnalogymetAnalogous to other alkylators

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Elvitegravir, captured bone density decreased as a tracked adverse event in a usable structure. Standard chemotherapy haematological endpoint.
Coding artifact: the indication reported back as the "reaction"

Golimumab ↔ Rheumatoid Arthritis

Open this assessment on its own page →

n=14,419 co-reports · PRR 35.9 · ROR 43.0

Tretinoin is a vitamin A derivative for APL. Co-reporting of APL as a reaction is a coding artifact: patients on tretinoin for APL have the indication recorded as the AE. 371 co-reports (PRR 12.6).

Coding artifact: APL is the indication.

Bradford Hill viewpointStatusNote
Temporality (necessary)not establishedIndication artifact
Strengthnot establishedPRR reflects treated population
Consistencynot establishedNot reproduced
Specificitynot establishedNot specific
Biological gradientnot establishedNo gradient
Plausibilitynot establishedNo mechanism
Coherencenot establishedArtifact
Experimentnot establishedNot an endpoint
Analogynot establishedN/A

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Golimumab captured rheumatoid arthritis as a tracked adverse event in a usable structure. APL is the indication; trials do not track it as an AE.
Causality: well established

Acetaminophen ↔ Infusion Related Reaction

Open this assessment on its own page →

n=13,947 co-reports · PRR 12.4 · ROR 12.8

Fludarabine is a purine nucleoside analogue for CLL. Myelosuppression is expected: DNA synthesis inhibition. 610 co-reports (PRR 14.8). Boxed warning.

Boxed warning: fludarabine label (myelosuppression).

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 14.8 with 610 co-reports
ConsistencymetReproduced across nucleoside analogue class
SpecificitypartialSpecific to purine analogues
Biological gradientmetCorrelates with dose
PlausibilitymetKnown DNA synthesis inhibition
CoherencemetCoherent with pharmacology
ExperimentmetRCTs confirm
AnalogymetAnalogous to other purine analogues

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Acetaminophen captured infusion related reaction as a tracked adverse event in a usable structure. Standard chemotherapy haematological endpoint.
Causality: well established

Onabotulinumtoxina ↔ Product Preparation Error

Open this assessment on its own page →

n=3,647 co-reports · PRR 58.4 · ROR 61.2

Carmustine is a nitrosourea alkylating agent. Myelosuppression is expected: DNA alkylation and crosslinking. 275 co-reports (PRR 17.4). Boxed warning.

Boxed warning: carmustine label (myelosuppression).

Bradford Hill viewpointStatusNote
Temporality (necessary)metDocumented in label
StrengthmetPRR 17.4 with 275 co-reports
ConsistencymetReproduced across alkylating class
SpecificitypartialSpecific to DNA alkylators
Biological gradientmetCorrelates with dose
PlausibilitymetKnown DNA crosslinking
CoherencemetCoherent with pharmacology
ExperimentmetRCTs confirm
AnalogymetAnalogous to other nitrosoureas

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for Onabotulinumtoxina captured product preparation error as a tracked adverse event in a usable structure. Standard chemotherapy haematological endpoint.
Coding artifact: the indication reported back as the "reaction"

Seven large, high-PRR pairs that are really "what the drug treats"

Etanercept ↔ Rheumatoid arthritis: n=46,770 · PRR 24.4 Etanercept ↔ Psoriasis: n=25,095 · PRR 8.2 Dupilumab ↔ Dermatitis atopic: n=45,026 · PRR 444.6 Adapalene ↔ Acne: n=39,434 · PRR 125.0 Vedolizumab ↔ Colitis ulcerative: n=15,612 · PRR 132.3 Furosemide ↔ Cardiac failure congestive: n=12,088 · PRR 9.1 Levetiracetam ↔ Seizure: n=15,976 · PRR 25.4

This is the single most common pattern the widened scan surfaced, and it is a data-quality lesson rather than a safety signal: in each pair above, the "reaction" term is the disease the drug is prescribed to treat. Etanercept and dupilumab treat the exact conditions ("rheumatoid arthritis," "dermatitis atopic") listed as their top disproportionality signals; adapalene is a topical acne medication whose top "reaction" is acne; furosemide treats congestive heart failure; levetiracetam treats seizures. FAERS case-report forms often record the condition under treatment in the same reaction-term field used for genuine adverse events — sometimes because the report concerns lack of effect, disease progression despite treatment, or simply because the submitter filled in the indication by habit. A disproportionality algorithm cannot distinguish "the drug caused this" from "the patient had this, which is why they were prescribed the drug" from the term alone. This pattern alone accounts for a large share of the roughly 136,000 pairs the widened scan flagged, and is exactly why this page's selection criterion is the outside literature, not the PRR rank.

Methodological note, not a regulatory finding: a known FAERS data-quality pattern (indication/disease-under-treatment recorded in the reaction field), distinct from a true adverse-event signal.

No per-pair Hill table here — one would be identical for all seven and isn't informative. In Hill terms, every pair in this group fails the same two viewpoints for the same reason: specificity (the "reaction" is definitionally the condition the drug is used for, not a distinguishable outcome) and, in most cases, temporality (the condition usually precedes the prescription, not the reverse). That double failure is what the pattern is — it isn't a borderline call on any one viewpoint.

Extended scan: 24 more pairs, briefer read

The 453 cards above were selected for having an independent regulatory or trial basis. Widening further down the same volume-sorted candidate list surfaces mostly three patterns: genuinely well-established, mechanistically expected drug effects; indication/disease-under-treatment recorded as the "reaction"; and a few real but more nuanced or lower-confidence cases. Rather than pad this page with full essays for pairs that are mostly re-confirming the same two or three lessons above, here is the rest of the top-volume scan in one line each, graded honestly — including where this page's confidence is genuinely lower.

PairDataGradeRead
Dupilumab ↔ Pruritusn=58,692
PRR 7.9
Indication-adjacentPruritus is the core symptom of the atopic dermatitis dupilumab treats; this likely reflects residual/breakthrough itch, not a new drug-caused symptom. Dupilumab's own distinctive labeled reactions are conjunctivitis and injection-site effects.
Etanercept ↔ Injection site painn=56,795
PRR 7.9
ExpectedMild, transient injection-site pain/erythema is the most commonly labeled reaction to self-injected biologics generally — a local, not systemic, effect.
Adapalene ↔ Dry skin / skin burningn=45,426 / 41,912
PRR 61–168
Expected, labeledTopical retinoids accelerate epidermal turnover; dryness, peeling, and burning during the first weeks are the expected, labeled on-target local effect.
Albuterol ↔ Dyspnoea / Asthman=42,640 / 24,781CircularAlbuterol is a rescue bronchodilator prescribed specifically for these symptoms; almost certainly the underlying disease recorded as a "reaction." (Paradoxical bronchospasm is a separate, real, much rarer phenomenon not captured by this generic pairing.)
Proton-pump inhibitors (omeprazole, esomeprazole) ↔ Acute kidney injury / CKDn=23,910 + 36,748 + 16,270
PRR 8.6–43.0
Plausible, actively studiedPPI-associated acute interstitial nephritis is real and biopsy-documented, in product labeling. A longer-term link to incident chronic kidney disease has been reported in large cohort studies (e.g. Lazarus et al., JAMA Intern Med 2016) but remains debated given likely confounding by indication/comorbidity.
Adalimumab ↔ Psoriasisn=24,917
PRR 6.8
Established, paradoxicalAnti-TNF-induced paradoxical psoriasis is a published phenomenon: patients treated with adalimumab for Crohn's disease or RA (not psoriasis) can develop new psoriasiform lesions, usually reversible on stopping — distinct from simple indication-coding since psoriasis isn't the indication for most of these patients.
Methotrexate ↔ Joint swelling / Drug intolerancen=24,834 / 24,385Indication-adjacent / vagueJoint swelling is methotrexate's own target symptom in RA (likely treatment failure/flare); "drug intolerance" is too non-specific a term to assess alone.
Tiotropium ↔ Incorrect route of administrationn=23,320
PRR 282.5
Device/usability errorTiotropium ships in more than one inhaler device (e.g. HandiHaler vs. Respimat) with different handling instructions; this almost certainly reflects documented device-confusion/medication-error reports — a real usability issue, not a pharmacological ADR.
Rivaroxaban ↔ Gastrointestinal haemorrhagen=21,636
PRR 34.9
Well established, expectedBleeding is the direct, mechanistically expected consequence of inhibiting Factor Xa — the central, labeled risk of every oral anticoagulant and the basis of formal bleeding-risk scoring tools.
Abatacept ↔ Arthralgian=21,293
PRR 8.2
Indication-adjacent, ambiguousJoint pain is both abatacept's target symptom (RA) and a reported infusion-associated reactogenicity symptom; the term alone can't distinguish the two.
Infliximab ↔ Condition aggravatedn=19,722Vague termToo non-specific a MedDRA term to assess; likely a mix of disease progression and treatment failure across infliximab's many indications.
Infliximab ↔ Infusion related reactionn=19,073
PRR 39.0
Well established, expectedAcute infusion reactions are a recognized, labeled class effect of infused monoclonal antibodies; infliximab's chimeric (part-mouse) structure makes it more immunogenic than fully humanized biologics, the proposed reason for its comparatively high rate.
Hydromorphone ↔ Emotional distressn=17,705
PRR 39.0
Nonspecific, lower confidenceNo established, specific causal literature for this term; may reflect genuine opioid-related mood effects, co-occurring distress from the underlying painful condition, or a reporting-form artifact. Lower confidence than the rest of this page.
Metformin ↔ Lactic acidosisn=17,141
PRR 67.6
Established, historically overstatedBiologically plausible via metformin's effect on hepatic lactate metabolism and long-labeled, but recent cohort data suggest real-world incidence in patients with normal renal function is much lower than once feared; risk concentrates in renal impairment.
Lenalidomide ↔ Plasma cell myeloman=17,121
PRR 38.5
CircularMultiple myeloma is lenalidomide's primary indication; almost certainly disease status/progression being recorded, not a new drug-caused cancer.
Docetaxel ↔ Alopecian=16,970
PRR 29.5
Well established, expectedHair loss from cytotoxic chemotherapy directly reflects killing rapidly-dividing hair-follicle cells — universally expected and pre-counseled, not a new safety concern.
Natalizumab ↔ MS relapsen=16,902
PRR 37.4
Circular; real signal lies elsewhereLikely breakthrough disease/treatment failure, not a drug-caused event. Natalizumab's actual serious, mechanistically distinct signal is PML (progressive multifocal leukoencephalopathy), a rare JC-virus brain infection risk with its own boxed warning and REMS — not what this pairing captures.
Acetaminophen ↔ Toxicity to various agentsn=16,635
PRR 5.1
Vague term, real mechanism elsewhereToo generic a term to assess directly, but acetaminophen hepatotoxicity in overdose is one of the most mechanistically well-understood drug injuries (NAPQI accumulation depleting hepatic glutathione) and the leading cause of acute liver failure in the U.S.
Adalimumab ↔ Injection site haemorrhagen=16,243Expected, minor, proceduralNeedle-related bruising/bleeding at a self-injection site is a mechanical event common to any subcutaneous injectable, not specific to adalimumab's pharmacology.
Levetiracetam ↔ Seizuren=15,976
PRR 25.4
Circular; real signal lies elsewhereLikely breakthrough seizure/treatment failure, not a drug-caused event. Levetiracetam's genuine, distinctive labeled signal is behavioral/psychiatric: irritability, aggression, and mood change are what clinicians specifically counsel on.
Pimavanserin (Nuplazid) ↔ Hallucinationn=12,702
PRR 77.8
ContestedApproved for hallucinations/delusions in Parkinson's disease psychosis, so some of this is the condition itself. 2018 investigative reporting on a death/AE cluster prompted an FDA safety review, which did not change its approval status, finding available data did not establish a new causal problem beyond the drug's high-background-mortality target population.
Pembrolizumab ↔ Malignant neoplasm progressionn=12,012
PRR 26.7
Circular / expected in oncologyReflects the expected natural history of cancer in non-responders, not a drug-caused event. Pembrolizumab's genuine, mechanistically distinct signals are immune-related adverse events (colitis, pneumonitis, endocrinopathies) from checkpoint activation — real, labeled, and not shown here.
Exenatide ↔ Nausean=12,043
PRR 6.2
Well established, expectedNausea is the single most common GLP-1-receptor-agonist class effect, driven directly by the drug's intended delayed-gastric-emptying mechanism; dose-related and usually improves over weeks.
Leflunomide ↔ Abdominal discomfortn=12,046
PRR 15.6
Well established, expectedGI symptoms are among leflunomide's most commonly labeled effects; leflunomide also carries a distinct, more serious labeled hepatotoxicity warning, a better-established signal than this nonspecific GI term.

These 24 were drawn from the same volume-sorted, loosened-threshold scan (n ≥ 150, PRR ≥ 4, signal-flagged, deduplicated by reaction term and capped at two per drug) as the 453 full cards above. Several raw top-40 entries were left out as exact duplicates of a pair already covered above (e.g. a second oxycodone-combination dependence entry).

What this page is not. It is not an exhaustive review of any drug's full safety profile, and the causality grades above are this editorial summary's qualitative read of the published regulatory and clinical literature for each specific pair — not an automated score, and not a substitute for the prescribing information or a clinician's judgment. The underlying scan (loosened to PRR ≥ 5, n ≥ 30 co-reports, signal-flagged pairs only) found far more candidates than are written up here; these full write-ups are the ones with an independent, verifiable regulatory or clinical-trial basis, not the full candidate list. See the Evidence Matrix and vaccine signal-pairs page for the equivalent assessment applied to vaccine–event pairs on this site.